,ticker,content
0,VRTX,tuesday vertex pharmaceutical vrtx get upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength ibd proprietary rating track share price movement worst best score score show stock price performance trail week hold other stock database year market history reveal market biggest winner tend have rs rating north launch largest climb see vertex pharmaceutical continue show renew price strength clear threshold look winning stock try simple routinevertex pharmaceutical be try complete consolidation entry see stock break heavy volume revenue growth fall last quarter ep grow previous report company earn rank peer medical biom biotech industry group ligand pharmaceutical lgnd supernus pharmaceutical supn enanta pharmaceutical enta be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
1,VRTX,friday vertex pharmaceutical vrtx get upgrade ibd smartselect composite rating new rating show stock be outpace stock come most important stock pick criterium winning stock often have higher score early stage new price run so good item have checklist look best stock buy watch vertex pharmaceutical be currently form flat base entry see stock break heavy trade least average see ibd help make more money stocksone weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term company post rise earning sale growth come previous quarter vertex pharmaceutical hold rank peer medical biom biotech industry group supernus pharmaceutical supn be rank stock group related company be now outperform stock see stock just come ibd top stock list
2,VRTX,vertex pharmaceutical vrtx smash first quarter expectation late thursday reiterate guidance announce triple pill regimen cystic fibrosis head phase study have several potential triple pill combination allow vertex have multiple shot goal jmp security analyst liisa bayko say ahead report vertex expect treat cystic fibrosis patient triple pill regimen hour trading stock market today vertex share rise stock end regular session share be form flat base buy point biotech stock collectively wrapped regular session nearly first quarter vertex report adjust profit cent share sale adjust earning rise sale dip metric beat analyst estimate adjust income cent share sale get free access ibd digital april
3,VRTX,get premium stock list pass fail stock rating more start herecystic fibrosis drug sale rise quarter chief executive jeffrey leiden credit growth increase number patient eligible vertex medicine symdeko regimen tezacaftor kalydeco be approve quarter continue make significant progress goal develop new better medicine treatment cystic fibrosis other serious disease leiden say prepared statement year vertex reiterate guidance total cystic fibrosis drug sale analyst consensus have modeled adjust income share total revenue vertex also say send triple pill combination phase study test drug know vx tezacaftor ivacaftor group patient specific genetic mutation associate cystic fibrosis successful vertex use week effectiveness datum week safety datum seek approval first group patient vertex seek approval second group week effectiveness datum week safety datum firm also announce datum study drug call vx tezacaftor vx vx patient show average improve ability forcefully expel air percentage point baseline vx vx regimen respectively triple pill regimen be give patient daily majority adverse event be mild moderate severity discussion food drug administration vertex say plan run further study vx determine proper dose do not believe be material concern once daily pill be nice have far have first triple rbc analyst brian abraham say note client have outperform rating vertex stock related trade stock most penny stock fail make investor richlook next nvidia start simple buy stock ahead earning report
4,VRTX,general market stabilize return confirm uptrend friday investor be eyee potential breakout top stock stock market today recent market weakness many top stock idea be currently shape right side potential formation xif market build latest bout strength more more breakout emerge lead chinese stock zto express zto be handily outperform stock market monday leaderboard member zto express be quietly shape second stage flat base buy point accord marketsmith chart analysis share advanced almost midday monday ipo leader zoom past standard buy point quickly moved next trading session early entry be also justified note annotate leaderboard chart late june share pull back find support day move average line stock be now rebound level chinese express delivery service boast ibd composite rating highest possible rating be blend key fundamental technical metric design gauge stock leadership ability get newsletter deliver inbox more info product service privacy policy term usevertex pharmaceutical vrtx be move right side cup shape base so far feature handle action yield buy point accord marketsmith chart analysis share soar june competitor galapago glpg release weak test result own cystic fibrosis drug biotech company develop cystic fibrosis drug orkambi kalydeco symdeko most recent quarter earning growth measure revenue decline vs year period due significantly lower collaborative revenue analyst expect company earning grow surge oil price have lead plentiful number strong energy stock marathon oil mro be striking distance base base buy point stock break past cup handle entry never look back share remain buy point new entry emerge marathon be buy point find support day line lastly fertilizer stock cf industry cf break cup handle buy point be buy range top stock relative strength line hit new high post signify strong market outperformance tip make investment decision be sure check current market condition use ibd stock checkup see stock get pass rating most important fundamental technical criterium get ongoing chart analysis alert buy sell signal check leaderboard swingtrader get instant access more trading idea exclusive stock list ibd proprietary rating only related facebook twitter ipo headline top stock relative strength shouldn discount top stock buy zonesjpmorgan citigroup well fargo kick earning season investing action top stock near buy point call too low ignore
5,VRTX,vertex pharmaceutical vrtx share rocket month high friday rival galapago glpg release disappointing result cystic fibrosis treatment lead partner abbvie abbv opt additional study stock market today vertex pop share galapago tumble abbvie stock lift broadly biotech stock rise galapago test drug glpg cystic fibrosis treatment patient specific genetic mutation patient have already receive vertex drug orkambi galapago goal show drug be part triple regimen cystic fibrosis fall short day patient treat glpg show improvement lung function receive placebo fail hit statistical significance also trail vertex datum drug vx vx show benefit respectively get newsletter deliver inbox more info product service privacy policy term use bar remain high raymond james analyst laura chico say report vertex already advance phase pivotal study triple regimen see few competitor be able challenge vertex intermediate term chico keep outperform rating biotech company stock improvement vs placebo have be competitive credit suisse analyst vamil divan say report glpg be also be test part triple regimen contain pair other drug galapago divan be now bearish study call falcon thursday datum raise significant concern falcon competitiveness entire cystic fibrosis franchise say galapago be partner abbvie cystic fibrosis effort abbvie be take knee cystic fibrosis raymond james chico note press release galapago say abbvie decide not proceed previously contemplated second triple regimen therapy now galapago be review future cf cystic fibrosis collaboration abbvie biotech company say release datum release galapago remove major overhang vertex stock rbc capital market analyst brian abraham say report expect vertex be dominant cystic fibrosis player foreseeable future abraham expect biotech company hit year cystic fibrosis treatment sale share earning have price target vertex stock leerink analyst geoffrey porge have price target vertex note galapago cystic fibrosis treatment result sweat chloride reduction be also materially lower vertex result experimental triple regimen sweat chloride be indicator cystic fibrosis none be particularly surprising say report however serve reminder difficulty do complex multicompound drug development project high wall vertex future value cystic fibrosis get instant access more trading idea exclusive stock list ibd proprietary rating only related chart read basic buy point mark time real invest stock free new apps aim term retirement investing strategy etfs
6,VRTX,stock surge start gate friday aim end trading june well second quarter positive note nike nke be market early pacer turnaround north american sale send dow jone component soar well fargo wfc spearhead rally bank stock slew dividend hike buyback increase follow federal reserve second round stress test vertex pharmaceutical vrtx gap open competitor report mixed clinical trial result dow jone industrial average nike american express axp jpmorgan jpm top list nasdaq composite stride ahead vertex jump highest vertex nike top gain bank lead well fargo suntrust bank sti also drive early gain get newsletter deliver inbox more info product service privacy policy term usein economic news growth personal income accelerate consumer spending growth slow commerce department report income rise april advance line estimate spending slow sharply jump april half increase expect consensus forecast core price index energy food be unchanged growth line expectation june chicago purchasing manager index university michigan consumer sentiment weekly oil rig census be also set release session friday mark last session tough june volatile quarter investor struggle navigate shift trade policy fed evolve strategy june dow lose thursday doesn recover loss friday session index be month start year be so far look third straight monthly advance nasdaq have gain also work third month view quarter show tech small cap run show chip be left advance nasdaq have logged gain start quarter smallcap russell have gain meanwhile philadelphia semiconductor index have slip advanced quarter thursday dow have struggle remain positive show gain quarter industry jewelry office supply auto international oil group post large double digit gain quarter mortgage service foreign bank solar energy industry group book deepest loss nike bolt higher report north american sale have turn quarter slide revenue earning growth top analyst consensus target company announce share buyback gain send nike share buy range follow rebound support week move average create buy range level rebound buy zone coincide buy area buy point also earning front kb home kbh surge constellation brand stz drop follow quarter result veeva system veev rise morgan stanley reaffirm overweight rating raise stock price target gain lift ibd stock back day move aveage stock have undercut buy point week also breaking support week line heavy trade vertex rocket open biotech galapago glpg report cystic fibrosis treatment glpg show mixed result phase trial left vertex current treatment dominant position space vertex share have be consolidate march well fargo vault rise raise quarterly dividend cent cent announce plan add share buyback program other bank rise fed stress test report suntrust jump citigroup gain market hong kong shanghai rally friday hong kong hang seng end shanghai composite take gain hang seng nevertheless take loss june fourth monthly decline year shanghai composite lose june give year date loss tokyo nikkei manage gain friday market europe picked china rally frankfurt dax lead afternoon trade cac paris rally london ftse gain get instant access more trading idea exclusive stock list ibd proprietary rating only related big picture nasdaq rebound key future rise bank rally stress test nike spikesbeer giant buy earning due fed favorite inflation gauge tap action plannike stock leap strong earning north america sale recovery buybackamazon pillpack deal roil health care stock
7,VRTX,vertex pharmaceutical vrtx be get breathe room analyst say thursday rival proteostasis pti tumble disappointing result study testing cystic fibrosis drug proteostasis test drug pti patient also take vertex drug orkambi regimen show improvement blood glucose sweat chloride indicator cystic fibrosis weight gain patient didn experience major improvement breathe not easy look leerink analyst geoffrey porge say note vertex share have dip quarter date competitive worry sell reverse competitive threat fade say vertex rise much intraday end regular session fraction share proteostasis crash stock market today galapago glpg rival see share lose proteostasis news get newsletter deliver inbox more info product service privacy policy term usea number cystic fibrosis drug work correct malfunctioning protein make cftr gene pti be know cftr corrector vertex have portfolio corrector work different patient base own genetic mutation vertex proteostasis galapago partner abbvie abbv be work combination drug treat cystic fibrosis study proteostasis be look determine best dose pti double triple pill study leerink analyst joseph schwartz say key metric test look improve be force expiratory volume second proteostasis study best result come milligram dose pti top orkambi improve force expiratory volume second percentage point lag vertex newly approve drug symdeko medicine regimen improve patient ability forcefully expel air leerink porge say now proteostasis competitive threat appear modest say proteostasis corrector bound different site cftr protein vertex medicine failure match high effectiveness bar establish vertex be testament difficult development path competitor small molecule therapy cystic fibrosis say galapago likely have datum later month study second generation corrector top orkambi result proteostasis suggest medicinal chemistry vertex indeed be durable competitive advantage company cystic fibrosis indication say galapago be successful vertex retrace back range june july related chart read basic buy point mark time real tame volatile swing trade half positionlook next nvidia start simple routine
8,VRTX,acceleron pharma xlrn stock jump tuesday celgene celg report second many week blood disease drug call close bell stock market today acceleron share rise earlier pop much celgene advanced share biotech company broadly dip less stoke more confidence celgene rbc capital market analyst brian abraham say firm biggest cancer drug revlimid soon face patent cliff celgene be work other angle cancer drug acquire juno therapeutic be partner bluebird bio blue view positive development recent success juno drug call jcar bluebird drug call bb begin re instill investor confidence pipeline revlimid not substantially reflect share current level say report client get newsletter deliver inbox more info product service privacy policy term study call believe test treatment patient beta thalassemia be dependent regular blood transfusion patient don produce enough protein carry oxygen body show highly statistically significant improvement red blood cell response goal be reduce red blood cell transfusion burden least researcher also look absolute reduction least transfusion unit week week study addition also meet key secondary goal study side effect be consistent previously report datum biotech company say news release firm now plan ask regulator europe approve drug first half news be largely expect week celgene acceleron release positive datum study late stage test look drug ability improve red blood cell response patient be call myelodysplastic syndrome analyst have varied model market credit suisse analyst martin call peak sale disorder leerink analyst geoffrey porge see peak sale used rbc abraham model just small fraction peak sale revlimid still help celgene fill future revlimid shape hole see couple other positive pipeline development jcar bb putt company celgene track reach probability adjust sale current pipeline say piper jaffray analyst edward tenthoff be more bearish partner acceleron downgrade acceleron stock neutral rating cut price target tenthoff acknowledge say acceleron be not buy valuation see sale european official likely approve biggest opportunity drug be myelodysplastic syndrome replace current less effective therapy tail be short tenthoff say crispr therapeutic crsp vertex pharmaceutical vrtx be work potentially curative treatment beta thalassemia therapy get approval say not patient be appropriate able afford gene therapy crispr form gene editing anticipate significant competitive pressure impact acceleron market share say related do spot major market top easy look heavy trade stock most penny stock fail make investor richlook next nvidia start simple routine
9,VRTX,stock future point solid early gain friday bank receive positive report card federal reserve nike nke swoosh higher fiscal fourth quarter report other hot performer friday premarket session include jpmorgan jpm kb home kbh well fargo wfc thursday rebound major index be week nasdaq be tack second straight weekly slip dow be set extend lose streak week market hang back bit personal income spending number come start bell friday china market remain sharp focus yuan descend critical level vs dollar constellation brand stz greenbrier gbx be notable name set report friday morning future trade fair value nasdaq future jump dow future strengthen fair value nike surge nearly late banking rally spur release federal reserve most recent round stress test lift jpmorgan jpm nearly goldman sachs gs more get newsletter deliver inbox more info product service privacy policy term federal reserve put kibosh plan morgan stanley ms goldman sachs fat return capital shareholder instead fed hold bank payout level prior year say company effect need save more money well fargo share receive largest boost big bank fed stress test report san francisco base bank spend year hot seat regard practice financial crisis receive approval fed balance sheet capital spending plan result company late thursday raise quarterly dividend cent cent announce plan throw additional share buyback program share rise nearly hour trade citibank rise boost dividend cent launch share buyback jpmorgan climb friday premarket trade hike quarterly payout cent say buy back stock nike be dow heavy hitter hour scramble nearly report north american sale have turn quarter slide revenue earning growth top analyst consensus target company announce share buyback nike share end thursday test week move average create buy range level new buy zone coincide buy area buy point nike retail wingman foot locker fl also gain rise late trade share end thursday buy range cup base buy point kb home narrow gain early friday follow fiscal second quarter result handily top analyst consensus view delivery new order backlog rise low single digit stock be try pull month decline vertex pharmaceutical have vault more lead nasdaq thursday hour trade be inactive early friday be immediately apparent news vertex late thursday earlier company announce canadian regulator approve cystic fibrosis treatment symdeko positive phase trial result stock cut key level support week complicate month base formation get instant access more trading idea exclusive stock list ibd proprietary rating only related nasdaq find support day line stock play successful defensenasdaq lead bounce gain amazon com roil pharmacy stocksbeer giant buy earning due fed favorite inflation gauge tap action planbank set big buyback dividend hike fed curb morgan goldman payout
10,VRTX,minute dow jone industrial average component merck mrk be do battle fellow drugmaker bristol myer squibb bmy drug cancer next biotech giant amgen amgn sanofi sny be tussle court fate cholesterol bust drug meanwhile company gilead science gild be rake coal congress charge day treat hepatitis brave contentious new world pharmaceutical biotechnology company realm science be try develop landmark medicine cure cancer hepatitis other life threaten illness do delicate dance wall street regulator balancing public health issue demand shareholder investor find tricky navigate sector company rise fall drop hat bookmark page stay top latest news biopharma sector get newsletter deliver inbox more info product service privacy policy term useview more biotech pharma stock newsrelated best stock buy watch
11,VRTX,nike fuel big rally dow jone friday major stock index look poise end second quarter high note biotech stock nasdaq outperformed name vertex vrtx celgene celg biomarin bmrn nicely share vertex soar compete cystic fibrosis drug galapago glpg didn do well mid stage trial dow be midday nasdaq composite rise respectively volume nyse nasdaq be tracking lower thursday level stock market result today nike nke be hand winner dow company report strong earning late thursday share surge head report nike be still buy range entry get support day move average also dow american express axp rise more flatten yield curve hasn be good news financial recent week sector outperformed nicely friday federal reserve give go ahead several bank increase dividend initiate share buyback american express increase dividend cent also announce plan buy back stock elsewhere share constellation brand stz slump earning miss large cap name be solid technical setup ahead result not more constellation gap day move average be well session lows ibd viper energy partner vnom continue low volume ascent rise back day move average only high current cup shape base be too short be valid base ibd name illumina ilmn extend gain pay visit day line thursday share be health care name continue show relative strength entry china base name package delivery firm zto express zto continue show good action week move average recent share be get instant access more trading idea exclusive stock list ibd proprietary rating only also tesla sale trade war job fed minute investing action planvideo game stock be potential medium company acquisition targetsnovartis surge decision spin alcon eye device unit
12,VRTX,nike power healthy advance dow jone industrial average late afternoon trading friday extend own gain prime entry et stock blue chip index shave advance still gain surpass gain nasdaq composite stock today nike nke gap open jump more reach time high stock have break week flat base gain have now reach so nike share be extend stock make mild gain ahead friday earning inspire big blast higher week athletic apparel shoe giant get high nearly then stock pull back way day move average current general market decline stock show support day line week move average weekly chart proper base be show sign bullish institutional support see day move average red line ibd daily chart marketsmith late thursday nike report first quarter double digit ep revenue gain year year basis quarters last time have go way back second quarter fiscal end november nike post ep jump rise sale time nike expressed confidence digital commerce strategy return growth north america strong revenue sale growth be mother outstanding earning increase accord ibd decade research top growth stock factor growth stock be current quarterly profit ibd slim point investment system get newsletter deliver inbox more info product service privacy policy term usewatch nike composite rating currently scale ibd stock checkup climb come day many company stock dow jone industrial rise point more dow jone component unitedhealth group unh gain dull turnover health insurance giant look poise snap session lose streak stay north side day move average unitedhealth be year date gain first stage late february saucer style base have now reach unite health earning share be see rise share year small cap underperform friday be still smash large cap year date performance smallcap give back modest gain trade nearly still hold solid gain be so far year meanwhile apple aapl remain buy zone follow second straight rally iphone ipad digital service giant rise be now point well form double bottom base apple clear proper entry just day report accelerate growth quarterly sale earning share please read recent stock market today column reason continue hold apple share current downdraft equity apple relative price strength rating improve scale accord ibd stock checkup mean past month largest company market value exchange have outperformed company ibd database week apple rs rating be other lead stock rise heavy volume include follow rpm international rpm specialty paint coating firm clear entry point month saucer base follow news go take several initiative boost operate financial performance activist fund elliott management be key investor medina ohio company vertex pharmaceutical vrtx expert treat cystic fibrosis rally nearly volume run more triple usual level stock have now take serious step form right side potential cuplike saucer style base saucer decline head toe be just deep short cup base however tend stretch many month wear holder rather shake read investor corner concept saucer base important chart pattern growth investor use gain edge wall street other financial market treasury show small move yield benchmark year bond edge basis point month bill yielded basis point june west texas intermediate crude oil future rally barrel hit fresh year date high wti future be now jan please follow saito chung twitter ibd_dchung more commentary growth stock chart action buy point sell signal financial market get instant access more trading idea exclusive stock list ibd proprietary rating only related buy stock free ibd latest investor corneripo be top growth stock head second half find next netflix google cisco system home depot start simple routine
13,VRTX,analyst remain bullish thursday food drug administration delay application crispr therapeutic crsp begin gene editing study sickle cell disease share tumble close earlier fall much vertex pharmaceutical vrtx be partner technology lose meanwhile share biotech company broadly pop stock market today late wednesday fda place clinical hold crispr application begin study drug ctx treatment sickle cell disease biotech company note hold be due certain question fda part review clinical hold be myriad reason chardan analyst gbola amusa say report client note ctx be first gene editing medicine base technology call crispr approach clinical study get newsletter deliver inbox more info product service privacy policy term use overall implication clinical hold depend be base gene editing component other element ctx production process clinical trial design straightforward need clarification say issue crispr technology also impact publicly trade biotech company edita medicine edit intellium therapeutic ntla be used crispr base gene editing re look use treat other disease also be positive biotech company used other mode gene editing sangamo therapeutic sgmo cellectis cll homology medicine fixx alternatively fda favor gene editing approach like bluebird bio blue also possible fda be hold company disease specific issue case impact other program crispr crispr be also work cancer drug call ctx analyst expect seek fda approval begin study year rapid resolution hold mitigate negative impact ctx program gene editing space amusa say expect crispr get better visibility fda concern come month crispr also seek approval europe begin study ctx blood disease call beta thalassemia already european official clear application piper jaffray analyst edward tenthoff say note client first man ctx datum serve important driver say set potential rapid approval beta thalassemia sickle cell disease blockbuster sale potential related chart read basic buy point mark time real trade stock most penny stock fail make investor richnew option strategy limit risk earning
14,VRTX,dow jone future be little change thursday morning future nasdaq future gene editing specialist crispr therapeutic crsp crash fda put hold sickle cell disease treatment vertex pharmaceutical vrtx meanwhile amazon com amzn enter buy range wednesday trading action suggest investor want keep fang stock friend zone now amazon passionless move come salesforce com crm have own flaw push past buy point micron technology mu fail close entry second straight session dow jone industrial average rise wednesday stock market trading rebound tuesday sell end blue chip index just day line advanced well nasdaq composite rally best level more month dow jone future be slightly fair value future edge higher nasdaq future rise president trump reportedly implement steel tariff vs european union thursday such move pressure stock market steel other domestic steelmaker rally overnight get newsletter deliver inbox more info product service privacy policy term biotechs announce late wednesday fda have put clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question be provide fda part review ind crispr therapeutic stock fall late trade hour lows crispr be not yet active thursday morning share rise wednesday new close high crispr be danger round trip buy point cup handle base vertex pharmaceutical best know cystic fibrosis treatment edge lower late vertex stock rise wednesday session close just day line day average amazon stock rise wednesday close cup base buy point first time be passion move relatively small percentage gain very light volume want see stock power buy zone strong price gain volume least normal investor also want amazon clear april record high online sale giant spiked follow first quarter earning report actually amazon be well way form short flat base still need few more day carve pattern amazon stock edge higher thursday premarket salesforce stock rise wednesday move back flat base buy point robust volume follow strong earning late tuesday closer look raise concern salesforce stock close lower half daily range hit intraday also left salesforce close top brief consolidation past week share rise slightly early thursday micron stock not only fail close buy range wednesday fail close higher micron clear cup base buy point second straight session rise intraday stock reversed lower end micron have run so far powerful action especially major average move sideway also didn give chance weak holder exit be investor be do now micron stock fall early thursday morgan stanley downgrade memory chip maker lower price target also big picture be still trade war play stock italy populist just take fed stock market be thatdow jone stock apple microsoft intel nike visa be buy invest shake shack la quinta show pattern see iposlululemon ulta beauty workday earning tap investing action plan
15,VRTX,vertex pharmaceutical vrtx have relative strength rs rating upgrade monday ibd proprietary rating identify price action worst best score rating show stock price performance trail week compare other stock database decade market research reveal best stock typically have rs rating north early stage move look best stock buy watch start ibd big cap stock break earlier have fall back prior entry consolidation stock re watch break past buy point then retreat more original entry price consider fail base best stock form new base also keep mind latest consolidation be later stage base make riskier establish new position add share exist earning growth decline last quarter revenue gain moved higher company hold rank peer medical biom biotech industry group bioverativ bivv ligand pharmaceutical lgnd be also group highest rate stock related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
16,VRTX,vertex pharmaceutical vrtx slide week low friday food drug administration call additional test compound used potential cystic fibrosis treatment result potential drug regimen likely win enter market leerink analyst geoffrey porge say note client add fda requirement be also blessing vertex be rivale galapago glpg abbvie abbv treatment fda stance do provide reassurance vertex competitive position say fda be clearly signale be shortcut least traditional good drug development indication stock market today vertex dip close earlier stock fall much share be form flat base buy point galapago slip fraction abbvie rise get free access ibd digital april
17,VRTX,get premium stock list pass fail stock rating more start herevertex galapago be separately work bring drug regimen treat cystic fibrosis market vertex think treat cystic fibrosis patient treatment thursday vertex say send second regimen phase testing third potential combination be be hold vertex do additional study drug involved regiment know test moniker vx phase testing regimen vx tezacaftor other test drug vx vx improve patient ability forcefully expel air however give very little monotherapy dose range work have be do vx fda request additional clinical trial prior phase start needham analyst alan carr write report client guidance timing first quarter initiation seem feasible once daily regimen used vx be nice have far have first drug regimen rbc analyst brian abraham say note combination phase study be also daily regimen require single dose vertex kalydeco evening further delay vx regimen doesn mean other combination win pass muster fda analyst say vertex have total potential combo pivotal study piper jaffray analyst edward tenthoff say note see vertex year ahead galapago leerink porge now expect vertex first drug regimen be market first quarter previously predict late launch regimen change be not particularly meaningful forecast vertex primary competitor galapago seem closer pivotal trial be month say further galapago also be require run additional study go pivotal testing porge reduce sale view still see rapid revenue growth almost also cut price target vertex reiterate outperform rating vertex remain most uncomplicated growth story large cap biotech say expect recover recent weakness target price come month related chart read basic buy point mark time real invest stock free new apps aim term retirement investing strategy etfs
18,VRTX,last week rally lead nasdaq composite signale stock market be look healthier stock sector be likely lead fang stock apple aapl facebook fb amazon amzn netflix nflx google parent alphabet googl generally have be perform well salesforce com crm other software stock have be winner payment stock be pocket strength many retail name lululemon lulu tjx tjx have be strong energy stock chevron cvx marathon oil mro be do well be subject up down crude oil price biotechs be try make recovery biogen biib skyrocket friday positive alzheimer drug news meanwhile chip be still well high bad sign stock market rally financial be lows jpmorgan chase jpm citigroup well fargo wfc kick earning season friday dow future rise vs fair value future climb nasdaq future be fair value keep mind dow jone future other overnight action doesn always translate actual trading next regular session china shanghai composite roar higher monday tumble bear market recent week hong kong hang seng advanced japan nikkei european market show modest gain intraday last week holiday shorten week stock market average be volatile ultimately rally nasdaq composite rally dow jone friday post job post china tariff rally be particularly significant haven already read latest big picture column get newsletter deliver inbox more info product service privacy policy term stock market come pressure trump trade war tariff threat past several week president donald trump friday impose tariff worth chinese good quickly match beij trump also threaten tariff virtually chinese import now wall street have decide trump trade impact have be price stock look nasdaq composite last several month tech heavy index look break june rally few week then erased gain rebound again last week day move average index dow jone have be consolidate late january somewhat better shape stock even top stock tend track broader stock market sector rotation china internet software stock energy name have left many individual stock chart look more volatile amazon stock especially netflix stock have be biggest stock market winner facebook stock scandalous spring be record high slightly extend buy point apple stock be buy range double bottom entry dow jone component have pull back day line be work new consolidation alphabet googl be buy point low volume last month hit resistance old high software account top group industry ibd track more be top buy hold individual software stock have be challenge salesforce top stock rank enterprise software group stage low volume early then promptly undercut buy point didn trigger loss trigger automatic sell end follow quarterly earning salesforce stock be back buy range be now modestly extend meanwhile stock do trigger loss sell rule workday wday red hat rht other round trip double digit gain such qualys qlys software stock watch okta okta april cybersecurity ipo be find support day move average first time late april solid gain heavy volume offer buy opportunity alternatively okta continue consolidate few week form new base buy point collaboration software maker atlassian team break last october anyone hold atlassian stock then be sit pretty then stock have stage few fail breakout still moved generally follow day atlassian stock be once again find day support need least week form proper base lululemon athletica canada goose goos be trendy apparel retail stock have boom specialty discounter such tjx be fare well too tjx rival ross store rost stock buy range currently dollar general dg be set buy point improve job market trump tax cut have fuel consumer wallet confidence most retailer also aren expose trump trade war europe china other energy stock be tricky play tend rise fall crude price refiner tend benefit wider crack spread crude gasoline price eog resource eog recent ibd stock day break early run couple week crude future rally eog stock pull back buy point find support day line june crude also backed multiyear high eog resource know apple oil be set new base crude hit best level marathon oil ibd stock day also break early run marathon oil stock also pull back day line never undercut buy point share be now flat base base base formation biogen shot nearly friday race cup base entry vertex pharmaceutical vrtx also be close buy point biogen vertex pharma have relative strength line improve be downtrend several month relative strength line track stock performance vs indexnotable biotech etfs include ishare nasdaq biotech ibb triple lever direxion daily biotech bull labu also be approach possible buy point rs line have make much headway past year payment stock have be pocket strength mastercard dow jone component visa have be consolidate record high few week find support day week line square sq have also be act well paypal pypl be close record high recent fizzle rs line have be go sideway late get instant access more trading idea exclusive stock list ibd proprietary rating only also stock have rs line high include ipo breakoutdon discount top stock buy leader qualys rebound sell many top growth stock be form basis now ibd stock day near new buy point run
19,VRTX,italy political chaos president donald trump tariff weigh dow jone nasdaq moved multus month high stock rally friday strong fed friendly job report lululemon lulu momo momo vmware vmw soar earning workday wday dollar store sell result walt disney retreat solo box office lag abc cancele roseanne racist tweet roseanne barr italy political chaos roil global market start week president trump thursday announce slap tariff european union canada mexico retaliate fed safe job report boost stock friday dow jone pare weekly loss index rise nasdaq climb best level mid march facebook fb amazon amzn enter buy zone google parent alphabet googl rebound add job jobless rate fall match lowest level hourly wage rise slightly view annual gain be line institute supply management manufacturing index unexpectedly rise strong new order surge momo momo provide mobile base social networking platform china report revenue vs year earlier beating expectation profit jump cent top estimate cent momo end quarter monthly active user vs year earlier analyst expect upside acquisition mobile date app tantan nearly momo stock soar salesforce com crm report earning revenue top expectation increase full year revenue outlook range hike come recent mulesoft acquisition be dilutive margin cash flow defer revenue increase just shy estimate salesforce forecast july quarter profit analyst estimate share rise workday earn cent share year revenue rise top view billing rise miss estimate maker cloud base software human relation payroll didn announce new large contract financial software new market share fall friday lululemon report cent ep revenue total comp share sky-rocket friday already double past year pvh pvh parent tommy hilfiger calvin klein line post ep sale growth pvh stock fall friday edge week pursemaker michael kor kor also top cent ep revenue growth share tumble guess ge match share loss view beat sale estimate growth share crash weak full year guidance solo star war story have lowest start ever disney star war movie han solo origin story only bring day holiday weekend vs projection be sign star war fatigue disney wo continue abc cancele hit show roseanne star roseanne barr tweet racial slur valerie jarrett obama administration official dollar store dollar general dg dollar tree dltr crash quarterly result miss estimate dollar general cite significant weather related headwind dollar tree cite headwind related increase freight cost colder normal spring weather many part country earlier easter holiday warehouse club costco cost earning top estimate rise cost pressured gross margin share pull back buy point vmware vmw late thursday say adjust earning be share year top estimate share revenue rise top estimate vmware soar friday move buy zone abercrombie fitch anf stock tank friday doubt remodel store pay trendy apparel firm handily beating estimate guide full year revenue growth view meanwhile rival american eagle outfitter aeo also slip report thursday be double beat management guide higher ep share dick sporting good spiked higher earning profit rise cent share revenue grow better view cent ep sale online sale grow consolidated comp adjust calendar shift slip dick lift full year outlook better consensus fiat chrysler fcau honda motor hmc post stronger expect auto sale ford beat expectation sale decline toyota motor tm nissan nsany see new vehicle sale shrink analyst estimate general motor gm longer report monthly sale datum grow sale annualize pace auto sale be estimate be april rate last nissan nsany sale decline last month follow plunge april be slash car production mexico consumer continue pile suvs truck japanese automaker hope improve profitability rather focus market share ciena cien report second straight quarterly decline gross margin send optical gear maker stock company raise revenue growth outlook fiscal pagseguro pag stock swung back forth worry trucker strike impact brazil economy report earning revenue top view company have step marketing next generation mobile payment device sell small merchant box box stock fall guidance disappoint profit revenue edge past analyst estimate large deal momentum continue online datum storage file sharing service provider crispr therapeutic crsp tumble thursday food drug administration place clinical hold application begin human study gene editing drug ctx ctx be be develop collaboration vertex pharmaceutical vrtx treat sickle cell disease alibaba baba be investing zto express zto bolster delivery logistical capability share express delivery company surge record high universal display oled stock jump nearly news report apple aapl switch oled display next year new iphone gain quickly evaporate analyst pour cold water speculation analog device adi stock surge buy zone chipmaker beat fiscal second quarter target guide higher current quarter thank strong industrial communication chip sale medman large marijuana producer retailer begin trading canadian security exchange tuesday make latest big pot producer country go public private placement give medman imply valuation ulta beauty ulta report ep jump gain revenue estimate same store sale rise beauty product chain see ep forecast see same store sale slow marvell technology mrvl edge wall street target fiscal first quarter offer mixed guidance current quarter company credit momentum internet thing datum center mobile market beat
20,VRTX,astrazeneca azn bristol myer squibb bmy vertex pharmaceutical vrtx be likeliest target biopharma detonation event tax reform spur widespread merger acquisition group analyst say friday leerink analyst seamus fernandez call come consolidation inevitable product make like abbvie abbv roche rhhby amgen amgn dow jone stock merck mrk celgene celg biogen biib shire shpg be soon face new competition generic rival follow unprecedented period innovation new product launch large biopharma say note client several largest company likely experience substantial growth slowdown next year get newsletter deliver inbox more info product service privacy policy term usecelgene biogen astrazeneca be most accretive potential acquirer base short term financial fernandez say average accretion be respectively bristol astrazeneca vertex make most sense long term strategically say appear be best position longer term revenue growth base look consensus expectation last major consolidation period biopharma occur last decade be deal greater value largest be dow jone stock pfizer pfe acquisition warner lambert premium pfizer also paid biggest premium pharmacia fork acquire firm merck paid premium buy schering plough deal combine pfizer astrazeneca allergan agn abbvie shire have fail fernandez see next cycle seller market pfizer be struggle late entry immuno oncology market merck have strong immuno oncology drug keytruda lack robust late stage pipeline roche face biosimilar competition top drug avastin herceptin rituxan novartis nvs be still experience challenge sandoz unit abbvie be strong term key drug humira soon see competition europe strategically astrazeneca be strong fit abbvie pfizer roche merck fernandez say bristol fit abbvie pfizer meanwhile possible abbvie swing vertex financial lens astrazeneca vertex biogen bristol be most compelling target ability enhance long term sale say amgen be acquirer target fund buy something fernandez say assume amgen be look make deal value less vertex rise top list potential target outlasting regeneron pharmaceutical regn shire vertex look more interesting say related chart read basic buy point mark time real opportunitylong term retirement investing strategy buy stock ahead earning report
21,VRTX,long costly process big pharma biotech stock abbvie abbv vertex pharmaceutical vrtx abbot laboratory get food drug administration approval new drug lead clinical research organization cro pra health science prah help drugmaker get new treatment market conduct clinical trial base
22,VRTX,big cap biotechs amgen amgn biogen biib have fall pressure year variety reason include revenue concern patent issue weak guidance smaller counterpart have rally fuel strong drug sale new drug news well merger acquisition take supernus pharmaceutical supn soar friday pad gain past buy point cup handle base clear thursday wednesday leap biotech report result top view thank strong sale trokendi xr migraine treatment seizure drug oxtellar xr follow gain thursday supernus be ibd sector leader stock biotech have fall industry group track ibd week now try push past resistance day move average so be good time keep eye biotech exchange trade fund get newsletter deliver inbox more info product service privacy policy term biggest bunch be ishare nasdaq biotechnology ibb asset rise friday continue consolidate day day move average line biogen celgene celg amgen gilead science gild vertex pharmaceutical vrtx make top holding account just stock portfolio supernus be holding ibb year date deficit accord morningstar inc lag gain etf be oldest biotech fund february launch average market cap company portfolio be next be year old spdr biotech xbi track biotechnology select industry index fund be also consolidate day day line ytd gain be average market cap xbi holding skews much smaller ibb top holding avexis avxs spark therapeutic once sarepta therapeutic srpt intercept pharmaceutical icpt immunomedic immu represent stock portfolio other nonleveraged biotech play include be idea prefer leverage play target double triple performance inverse performance underlie index be aware tend be more volatile nonleveraged counterpart usually have higher expense ratio also be interested way profit surge sector trump bump way apple earning buffett news breakoutdow top gainer intel also power semiconductor stock play
23,VRTX,payer likely win balk yearly price vertex pharmaceutical vrtx new drug regimen treat cystic fibrosis patient analyst say tuesday regulator approve therapy regimen dub symdeko have wholesale acquisition price be vertex drug know orkambi treat homozygous patient meaning have specific genetic mutation cause lung condition symdeko also treat patient have genetic mutation symdeko have better effectiveness tolerability orkambi needham analyst alan carr say eventually vertex plan have triple drug regimen firm say treat genetic mutation responsible cystic fibrosis symdeko effectiveness tolerability profile have modest moderate improvement orkambi carr say note client assume modest amount switch orkambi symdeko well use patient do not tolerate orkambi approval be expect come day fda be set discuss combination drug tezacaftor ivacaftor latter be brand kalydeco early trading stock market today vertex rise much share end regular trading day leerink analyst geoffrey porge note symdeko label doesn respiratory event require monitoring blood pressure low lung function patient issue have limit orkambi penetration less addressable population say label advantage double effectiveness symdeko increase homozygous penetration rate provide robust top line growth vertex clinical development period triple therapy say vertex guide sale bracketing consensus porge say model growth kalydeco growth number homozygous patient treat orkambi symdeko ibd take market broadly go correction last week be still far high head investor corner keep tab top sell rule price increase symdeko orkambi wasn fully expect consensus porge say note orkambi launch be discount kalydeco gain approval consensus estimate rise account symdeko premium do not expect much resistance premium payer physician patient give considerable advantage symdeko orkambi say now investor be look triple drug regimen vertex plan begin phase testing first half year potential combination treat homozygous patient population know heterozygous piper jaffray analyst edward tenthoff say note ultimately anticipate patient specific genetic mutation be consolidated triplerx vertex be also work crispr therapeutic crsp gene editing treat disease include cystic fibrosis tenthoff write duo plan begin trial year blood disease know beta thalassemia sickle cell disease first man potentially curative datum be driver vertex share year say related biotechs spring back market correction benefit lackluster datum present rivalsis teva pharma restructure plan actually more reasonable
24,VRTX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
25,VRTX,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
26,VRTX,flexion therapeutic flxn have relative strength rs rating upgrade thursday welcome improvement still shy higher score prefer see look best stock buy watch be sure pay attention relative price strength unique rating identify market leadership used worst best score identify stock price action trail week compare other publicly trade company year market history reveal market biggest winner typically have higher rs rating launch largest climb see flexion therapeutic continue rebound clear threshold see ibd help make more money not currently ideal time invest see stock go form base break company report earning growth last quarter sale growth come next quarterly number be expect flexion therapeutic hold rank peer medical biom biotech industry group halozyme therapeutic halo supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
27,VRTX,look best stock buy watch focus rise relative price strength stock fit bill be therapeutic cort have relative strength rs rating upgrade thursday look best stock buy watch factor watch closely be relative price strength proprietary rating track technical performance used worst best score identify stock price action last week match other publicly trade company year market history reveal best stock typically have rs rating north early stage move look best stock buy watch start herewhile now be not ideal time invest see stock manage form chart pattern break earning growth decrease last quarter sale rise next quarterly number be expect company hold rank peer medical biom biotech industry group halozyme therapeutic halo supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
28,VRTX,vertex pharmaceutical vrtx have triple pill treatment cystic fibrosis early analyst say thursday biotech initiate first phase study test drug involved pivotal trial be short sweet leerink analyst geoffrey porge say note client vertex announce late wednesday begin trial combine drug know vx tezacaftor ivacaftor treat group cystic fibrosis patient timing be month ahead expectation even more importantly trial be shorter company prior pivotal study cystic fibrosis combination porge say total vertex plan enroll patient trial goal be improve patient ability forcefully expel air week treatment safety be evaluate week treatment then vertex file application approval porge expect trial enroll very quickly suggest regulatory submission occur early first half mean vertex start selling treatment early fourth quarter earlier expectation first quarter get ibd market prep tech report newsletter free goal be bring best triple combination patient rapidly possible first phase study combination tezacaftor ivacaftor be significant step goal vertex chief medical officer jeffrey chodakewitz say statement triple regimen treat patient cystic fibrosis vertex have say abbvie abbv galapago glpg also be work triple combination analyst say duo be lag vertex vertex be also plan test regimen vx tezacaftor ivacaftor group patient different genetic mutation regimen vx tezacaftor vx be test group patient different mutation porge keep outperform rating price target vertex stock rbc analyst brian abraham maintain outperform rating vertex abraham also expect trial move quickly expect approval end stock market today vertex lose fraction close related sangamo therapeutic make double digit gain gilead dealthese biotechs spring back market correction analystwhy payer win balk price tag vertex new drug
29,VRTX,index dow jone industrial average nasdaq tumble week alphabet googl caterpillar cat mmm earning treasury yield spook investor stock market average pare loss strong earning amazon amzn facebook fb boee ba visa other index dow jone nasdaq find support day move average rebound close week fractional loss year treasury hit first time year hit week pull back short term yield continue rise faster long term rate squeeze yield spread alphabet googl expense ongoing chip weakness also hit stock amazon amzn facebook fb boee ba visa rally strong result intel intc microsoft msft initially hit buy point friday pull back amazon first quarter earning sky-rocket more double ep estimate revenue rise fifth straight quarter accelerate sale growth revenue amazon web service rise aw account most amazon overall operate profit amazon share shot record high friday pare gain advance ebay ebay stock drop report result fall short consensus estimate end quarter global active buyer facebook fb stock surge post first quarter result blow past expectation dash fear exodus user advertiser social medium giant twitter twtr report strong earning guidance share fall ceo make cautious comment slow growth get free access ibd digital april
30,VRTX,get premium stock list pass fail stock rating more start hereboee ba easily beat forecast raise full year guidance aerospace giant say aircraft completion center china be nearly finished downplay china trade war fear fellow dow jone stock unite technology utx report stronger expect earning sale industrial giant also raise full year adjust ep sale forecast lockheed martin lmt top first quarter estimate defense contractor raise ep revenue target maker didn raise cash flow expectation northrop grumman noc also report earning estimate northrop say didn submit bid air force gps iii contract leave lockheed likely lone bidder raytheon rtn raise full year earning forecast consensus earning revenue top estimate general dynamic gd beat earning meet revenue view share defense contractor sell sharply week software kingpin earn cent share year year sale fiscal third quarter analyst expect cent microsoft msft have be shift business desktop pc software cloud compute infrastructure application such office azure microsoft commercial cloud revenue rise fiscal software giant initially reclaim recent buy point friday pare gain intel intc earning rise sale grow well analyst view chip giant guide higher current quarter sale indicate third straight quarter top line growth share initially jump year high friday reversed close slightly lower texas instrument txn advanced micro device amd stm xilinx xlnx get boost upbeat earning report chip gear maker teradyne ter tumble warning weak demand equipment test mobile device western digital wdc make disk drife memory chip tumble friday beating fiscal view philadelphia semiconductor index fought support day move average google parent alphabet googl report earning revenue top view sharp rise capital spending margin pressure higher traffic acquisition cost spark sell internet search giant capex jump year period include real estate purchase manhattan traffic cost google pay partner website generate advertising revenue jump google have hike spending youtube video content cloud compute smart home consumer appliance artificial intelligence project paypal pypl top earning revenue expectation total payment volume rise year year vs estimate company raise revenue adjust ep guidance management point momentum partnership visa international bank technology platform such baidu bidu exxon mobil xom miss earning view output slip recent surge oil price chevron cvx fall short revenue conocophillip cop crushed estimate hess hes report shallower expect loss royal dutch shell rdsa report highest profit oil price crash energy information administration say crude inventory rise barrel vs drop analyst expect domestic production rise barrel day barrel increase crude oil future briefly top barrel highest level late trade little change week general motor gm ford motor fiat chrysler fcau beat quarterly estimate ford not invest traditional sedan north america go forward almost phase passenger car consumer migrate suvs light truck gm still see small car opportunity home abroad even too shift focus larger more profitable vehicle casino operator la vegas sand lvs top first quarter result estimate help strong demand global gaming hub macau singapore macau also help result wynn resort wynn overall macau sale disappoint analyst wynn resort also approve dividend increase earning report wynn be first steve wynn resign ceo sell stake follow allegation sexual misconduct mgm resort mgm narrowly beat stock tumble decline traffic location mgm be more focuse sand wynn amgen amgn alexion pharmaceutical alxn broadly top view amgen sale adjust profit outlook be bit soft midpoint sale alexion blockbuster soliris miss estimate share pop promising study new drug alxn biogen biib sale lag sluggish spinraza multiple sclerosis drug revenue prothena prta tank monday scrap rare disease drug fail phase study eli lilly lly broadly beat consensus diabetes drug chemotherapy help offset short sale psoriasis drug taltz glaxosmithkline gsk sale adjust profit lag abbvie abbv bristol myer squibb bmy top profit view raise full year guidance bristol sale miss estimate shire shpg say consider raise takeover bid japan takeda vertex pharmaceutical vrtx top view sale decline vs last year vertex say ll move triple pill regimen phase study domino dpz deliver ep gain revenue leap blow view share rise thursday chipotle grill cmg stock vault month high ep unexpectedly jump same store sale also top starbucks sbux be par earning ep rise cent rise sale outdo analyst prediction new oriental education edu earn cent share revenue grow total student enrollment rise year year ibd stock tal education tal ep jump cent share revenue soar student enrollment balloon vs year earlier new oriental tal share pop respective earning day be slightly lower week intraday friday pultegroup phm tuesday crushed view ep jump cent home sale revenue leap homebuilder stock be generally muted due rise interest rate horton dhi biggest builder thursday best view ep surge revenue swell homebuilder stock rally solid gain help cool treasury yield new home sale rise march annualize sale pace unit month high meanwhile exist home price rise february vs year earlier china search engine leader baidu bidu report profit blow past estimate lift share baidu still own majority iqiyi iq hold ipo march video stream iqiyi account roughly parent revenue share iqiyi fall release earning tandem baidu visa report ep gain revenue rise beating fiscal view credit debit card giant raise full year revenue outlook share leap thursday mmm meet ep view revenue rise just consensus dow jone giant slash full year ep target stock plunge caterpillar cat report strong earning sale share heavy construction equipment maker reversed sharply lower tuesday warning operate margin hit high watermark year servicenow now report profit revenue estimate customer now spend annually metric be year year edward lifescience ew top sale adjust profit view share tank sale transcatheter heart valve replacement lag illumina ilmn beat consensus adjust profit rise share sale swell align technology algn report adjust earning share revenue handily beating view cent respectively td ameritrade amtd deliver impressive ep revenue growth fall short lofty expectation share fall week trade financial etfc continue rise last week strong result first solar fslr hit year high earning top expectation due sale several solar project expand production proofpoint pfpt cybersecurity firm top adjust first quarter earning revenue view guide low profit share fall friday advanced protection solution nearly double make new add booking prior quarter
31,VRTX,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
32,VRTX,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
33,VRTX,important metric look stock be higher relative strength rating alnylam pharmaceutical alny now clear threshold jump friday look best stock buy watch factor watch closely be relative price strength proprietary rating identify market leadership show stock price action last week measure other stock major index decade market research reveal stock go make biggest gain typically have better rs rating begin biggest price move look best stock buy watch start herewhile stock be not proper buy point right now see manage form break proper base company bottom line growth decline prior quarter revenue rise prior report look next report company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
34,VRTX,keep list stock watch date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock add remove list include planet fitness ticker
35,VRTX,build watch list focus stock higher rs rating pharmaceutical adms just meet criterium new score look best stock buy watch factor watch closely be relative price strength unique rating track technical performance used worst best score show stock price performance trail week match other stock decade market research reveal best stock tend have rs rating north early stage move see ibd help make more money not currently ideal time buy share see stock manage establish enter buy range heavy volume earning growth drop most recent quarter revenue gain moved higher next quarterly number be expect company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
36,VRTX,acceleron pharma xlrn see positive improvement relative strength rs rating thursday rise re research best stock buy watch be sure pay attention relative price strength unique rating measure technical performance used worst best score identify stock price action last week match other stock history show top perform stock often have better rs rating early stage move see acceleron pharma continue rebound hit benchmark look best stock buy watch start hereacceleron pharma be not currently show potential buy point see stock go build chart pattern kick new price move ep growth decrease last quarter sale rise company be expect report latest number company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
37,VRTX,welcome move exact science exas see relative strength rating improve thursday try find best stock buy watch be sure pay attention relative price strength proprietary rating measure technical performance show stock price action last week measure other stock database decade market research show market biggest winner tend have rs rating north begin biggest climb see exact science continue rebound hit benchmark look best stock buy watch start hereexact science be not currently show potential entry point see stock go build promising consolidation kick new climb earning growth picked last quarter revenue gain fall keep eye company next round number apr exact science hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
38,VRTX,thursday ironwood pharma irwd earn positive adjustment relative strength rs rating look best stock buy watch factor watch closely be relative price strength ibd unique rs rating identify technical performance show stock price action last week compare other stock major index year market history reveal top perform stock tend have rs rating early stage move look winning stock try simple routineironwood pharma be work consolidation buy point see break heavy volume ironwood pharma post earning growth latest quarterly report sale growth come company be expect report latest number ironwood pharma earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
39,VRTX,important metric look stock be higher relative strength rating cellectis cll clear benchmark thursday jump thursday try find best stock buy watch keep close eye relative price strength exclusive rating investor business daily track market leadership worst best score rating show stock price performance trail week hold other stock database decade market research show stock go make biggest gain often have rs rating least begin biggest run look winning stock try simple routinewhile cellectis be not ideal buy point right now see be able form break proper chart pattern cellectis post negative growth sale earning last quarter company be expect release next quarterly number company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
40,VRTX,intrexon xon have relative strength rs rating upgrade thursday re research best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily track price movement worst best score grade show stock price movement trail week stack other stock database year market history reveal top perform stock often have rs rating least launch biggest climb look best stock buy watch start hereintrexon be not currently potential buy zone see stock go form base spark new run top bottom line growth moved higher last quarter earning be compare prior report revenue increase company be expect report latest number intrexon hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
41,VRTX,build watch list focus stock higher rs rating exact science exas just meet criterium new score look best stock buy watch factor watch closely be relative price strength proprietary rating measure technical performance used worst best score indicate stock price action trail week match rest market history show stock go make biggest gain tend have better rs rating begin biggest run look best stock buy watch start hereexact science be now consider extend buy range clear buy point third stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line earning growth increase last quarter revenue gain fall look next report apr exact science earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
42,VRTX,important metric look stock be higher relative strength rating therapeutic cort clear benchmark tuesday jump tuesday look best stock buy watch factor watch closely be relative price strength ibd proprietary rs rating track market leadership used worst best score indicate stock price action trail week match rest market history show best stock tend have rs rating least begin biggest climb look best stock buy watch start herecorcept therapeutic be not currently show potential entry point see stock go build base launch new move earning growth slow most recent quarter sale moved higher look next report company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
43,VRTX,tuesday intellium therapeutic ntla reach important technical milestone relative strength rs rating jump percentile improvement rise day look best stock buy watch factor watch closely be relative price strength ibd proprietary rs rating measure market leadership used worst best score show stock price performance trail week match other publicly trade company decade market research reveal best stock typically have rs rating north launch biggest price move see ibd help make more money intellium therapeutic be not ideal buy range right now see manage form break proper chart pattern company post earning growth last quarter sale growth come keep eye company next round number intellium therapeutic hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
44,VRTX,welcome move intrexon xon see relative strength rating rise tuesday try find best stock buy watch be sure pay attention relative price strength ibd proprietary rs rating measure technical performance show stock price movement last week compare other stock database year market history reveal market biggest winner often have higher rs rating launch biggest price move see intrexon continue rebound hit benchmark see ibd help make more money stocksintrexon be not currently show potential entry point see stock go form sound pattern kick new price move top bottom line growth moved higher last quarter earning be compare prior report revenue increase next quarterly result be expect company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
45,VRTX,relative strength rs rating revance therapeutic rvnc jump new percentile tuesday increase try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily measure market leadership worst best score rating show stock price behavior trail week stack other stock database year market history show best perform stock typically have rs rating north early stage move look winning stock try simple routinerevance therapeutic be try complete consolidation entry see break heavy trade keep mind later stage consolidation entail more risk company show ep growth last quarter sale increase next quarterly number be expect company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
46,VRTX,audente therapeutic bold see welcome improvement relative strength rs rating tuesday rise look best stock buy watch factor watch closely be relative price strength ibd unique rs rating measure technical performance used worst best score indicate stock price action trail week match other stock database decade market research reveal best stock typically have rs rating north begin new climb look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock be able form chart pattern break regard fundamental company have post quarters accelerate earning growth top line growth have be different story come latest report company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
47,VRTX,tuesday regenxbio rgnx earn positive adjustment relative strength rs rating look best stock buy watch keep close eye relative price strength exclusive rating investor business daily identify price action worst best score rating show stock price behavior last week compare other stock database year market history show market biggest winner typically have rs rating begin new run look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock be able offer clear proper buy point sale growth fall last quarter bottom line grow previous report company be expect report latest earning sale number regenxbio hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
48,VRTX,welcome move pharmaceutical adms see relative strength rating improve wednesday look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify share price performance worst best score rating show stock price performance trail week stack other stock database year market history show stock go make biggest gain typically have rs rating early stage move see pharmaceutical continue show renew price strength clear threshold see ibd help make more money now be not ideal time invest see stock manage offer clear proper buy point earning growth fall last quarter sale moved higher look next report pharmaceutical earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
49,VRTX,tuesday agio pharmaceutical agio get upgrade relative strength rs rating re research best stock buy watch be sure pay attention relative price strength ibd unique rating identify market leadership worst best score grade show stock price movement last week compare other stock database history reveal best perform stock often have rs rating early stage move see ibd help make more money stocksagio pharmaceutical have climb more past entry second stage cup handle meaning now proper buy zone look stock offer new chance get week tight pullback day week move average company post negative growth top bottom line last quarter agio pharmaceutical be expect report next quarterly number company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
50,VRTX,global blood therapeutic gbt have relative strength rs rating upgrade tuesday look best stock buy watch factor watch closely be relative price strength ibd proprietary rs rating track market leadership show stock price action last week compare other stock database history reveal stock go make biggest gain typically have rs rating begin new price run see ibd help make more money stocksglobal blood therapeutic be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average global blood therapeutic post earning growth latest quarterly report revenue gain come keep eye company next round number company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
51,VRTX,spark therapeutic once see positive improvement relative strength rs rating tuesday rise look best stock buy watch factor watch closely be relative price strength unique rating track technical performance used worst best score identify stock price action trail week match other stock database decade market research reveal market biggest winner tend have higher rs rating begin new climb look winning stock try simple routinespark therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week move average take look top bottom line number company have post quarters increase earning growth sale growth have not follow same trajectory come most recent report spark therapeutic be expect release next quarterly number company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
52,VRTX,tuesday momenta pharmaceutical mnta hit important technical milestone relative strength rs rating enter percentile upgrade increase day look best stock buy watch keep close eye relative price strength exclusive rating investor business daily track share price movement worst best score grade show stock price performance trail week hold other stock database decade market research reveal best stock tend have rs rating begin new run look best stock buy watch start heremomenta pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase next quarterly number be expect company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
53,VRTX,amag pharmaceutical amag have relative strength rs rating upgrade monday re research best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily track price performance worst best score rating show stock price performance trail week stack other stock database year market history reveal best stock often have rs rating north launch biggest price move look best stock buy watch start herewhile not currently ideal time invest see stock be able form consolidation break company top line growth fall last quarter bottom line grow prior report keep eye company next round number amag pharmaceutical hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
54,VRTX,relative strength rs rating acorda therapeutic acor enter higher percentile tuesday get lift re research best stock buy watch be sure pay attention relative price strength proprietary rating identify technical performance show stock price action last week measure other stock database year market history show stock go make biggest gain tend have rs rating north early stage move see acorda therapeutic continue show renew price strength hit benchmark see ibd help make more money stocksacorda therapeutic be build cup handle entry see clear price volume least higher normal company see earning sale growth rise last quarter earning share increase revenue rise company be expect report latest earning sale number apr acorda therapeutic earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
55,VRTX,glaxosmithkline gsk partner innoviva inva be try buck market correction finish new base biotech stock recently receive new european union approval relvar ellipta asthma drug innoviva develop gsk last month london base gsk california base innoviva announce european commission approve label upgrade relvar ellipta
56,VRTX,aimmune therapeutic aimt have relative strength rs rating upgrade thursday try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily identify market leadership worst best score rating show stock price behavior last week stack other stock database decade market research reveal best stock typically have rs rating north begin biggest climb look best stock buy watch start hereaimmune therapeutic have climb more past entry first stage cup handle meaning now proper buy range look stock create new buy opportunity week tight pullback day week line aimmune therapeutic show earning growth most recent report sale growth come aimmune therapeutic earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx chemocentryx ccxi halozyme therapeutic halo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
57,VRTX,relative strength rs rating momenta pharmaceutical mnta jump new percentile wednesday rise try find best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily identify market leadership worst best score grade show stock price movement last week stack other stock database year market history reveal market biggest winner tend have rs rating launch biggest climb see ibd help make more money stocksmomenta pharmaceutical be not currently show potential buy point see stock go form chart pattern kick new climb earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx chemocentryx ccxi halozyme therapeutic halo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
58,VRTX,pharmaceutical adms have relative strength rs rating upgrade wednesday welcome improvement still better score look re research best stock buy watch keep close eye relative price strength ibd proprietary rs rating track market leadership show stock price action last week measure other stock database history reveal best stock typically have higher rs rating begin largest climb see pharmaceutical continue rebound clear threshold look best stock buy watch start hereadamas pharmaceutical be not currently offer proper buy opportunity see stock go form sound pattern launch new move earning growth slow most recent quarter sale moved higher pharmaceutical hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx chemocentryx ccxi halozyme therapeutic halo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
59,VRTX,tuesday acorda therapeutic acor earn upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure price movement worst best score grade show stock price performance trail week stack other stock database decade market research reveal best perform stock tend have higher rs rating launch biggest climb see acorda therapeutic continue show renew price strength hit benchmark see ibd help make more money stocksacorda therapeutic be work cup handle entry see stock clear price heavy trade top bottom line growth moved higher last quarter earning be compare prior report revenue increase acorda therapeutic earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx chemocentryx ccxi halozyme therapeutic halo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
60,VRTX,monday pharmaceutical adms receive positive adjustment relative strength rs rating re research best stock buy watch be sure pay attention relative price strength ibd unique rating track share price performance worst best score score show stock price movement trail week stack other stock database decade market research show market biggest winner tend have better rs rating begin biggest price move look winning stock try simple routinewhile not currently ideal time buy share see stock go form base break ep growth fall company most recent report top line rise company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
61,VRTX,consider name put watch list look stock higher rs rating therapeutic cort just meet criterium new score look best stock buy watch keep close eye relative price strength ibd unique rating measure share price action worst best score rating show stock price performance trail week stack other stock database history show best stock typically have rs rating early stage move look best stock buy watch start herewhile not currently ideal time invest see stock go form base break company bottom line growth decline prior quarter sale rise previous report company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
62,VRTX,relative strength rs rating alk enter higher percentile friday get lift look best stock buy watch factor watch closely be relative price strength ibd unique rating track price movement worst best score score show stock price movement trail week hold other stock database year market history reveal best stock often have rs rating early stage move see continue rebound clear threshold see ibd help make more money now be not ideal time invest see stock manage form consolidation break earning grow last quarter prior report revenue also increase company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
63,VRTX,consider name put watch list look stock higher rs rating supernus pharmaceutical supn just meet criterium new score look best stock buy watch factor watch closely be relative price strength proprietary rating track technical performance used worst best score show stock price performance trail week match other publicly trade company history reveal best perform stock tend have better rs rating launch biggest run see ibd help make more money stockssupernus pharmaceutical be work consolidation entry see clear price volume least higher normal supernus pharmaceutical post earning growth most recent report revenue increase supernus pharmaceutical hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
64,VRTX,regenxbio rgnx have relative strength rs rating upgrade thursday re research best stock buy watch keep close eye relative price strength ibd unique rating track market leadership worst best score rating show stock price performance trail week stack other stock database year market history show market biggest winner tend have rs rating least launch largest run look best stock buy watch start hereregenxbio have climb more past entry first stage consolidation meaning now proper buy range look stock offer new chance get week tight pullback day week line company top line growth fall last quarter bottom line grow previous report company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
65,VRTX,stock slip tuesday start bell threaten put damper market day bounce strong early move abc handful china base stock dow jone industrial average nasdaq composite open global stock china market picked rally retook lose ground ahead lunar new year holiday begin friday hong kong hang seng index pop shanghai composite rally shanghai exchange close thursday wednesday hong kong exchange be close friday monday japan tokyo stock exchange reopen monday holiday nikkei stumbling europe market remain mixed afternoon trade frankfurt dax cac paris be respectively london ftse hold gain dow microsoft msft drop head early downside share have be find support week line just clear flat base december apple aapl edge stock retook day line powerful rally monday have be struggle regain hold psychologically important level support feb mega cap mmm take early lead dow jone stock rise stock be look add third day rebound support day move average medical system supply name post deepest loss stock amazon com amzn announce plan expand medical supply business hospital supply chain henry schein hsic dive patterson pdco drop more open trade
66,VRTX,vertex pharmaceutical snap top nasdaq food drug administration approve company symdeko treat cystic fibrosis vertex say begin shipping drug week vertex share have pull back more buy point trigger automatic sell rule share have be testing support week move average drug wholesaler spiked premarket action news report say company be talk walgreen boot alliance wba regard possible takeover walgreen own company hold market capitalization more market sell have pull back buy point trigger automatic sell rule stock open back entry tuesday market correction mean move be not valid walgreen share rise early trade share be trading deep yearlong consolidation competitor cardinal health cah mckesson mck drop respectively early trade armour uaa grab gain mixed fourth quarter report revenue come stronger expect share end monday november low september peak china base name be early leader ibd name weibo wb board fourth quarter beat weibo share be testing support week move average fall more buy point trigger automatic sell rule sina sina rolled ahead generally strong fourth quarter report sina hold control stake weibo also fall more cup base buy point make also subject automatic sell rule vipshop hold vip swung higher online retailer turn fourth quarter report late monday top analyst earning revenue target raise first quarter revenue guidance expectation crude oil trade lower post gain monday just enough snap day downtrend benchmark crude be early action trading barrel other commodity natural gas pop look rebound fall hard recent session copper rise more nearly post gain monday dollar pull back euro slip month low vs yen bond gain ground trimming year yield basis point bitcoin slip monday high bitcoin blockchain related stock be generally quiet also be interested big picture stock jump again hurdle remainwhy stock market sell do nowthese defense stock stand market correctionnike microsoft lead dow stock hold market correction
67,VRTX,look best stock buy watch focus rise relative price strength stock fit bill be acceleron pharma xlrn have relative strength rs rating upgrade tuesday look best stock buy watch factor watch closely be relative price strength ibd proprietary rs rating identify technical performance used worst best score indicate stock price action trail week match other stock year market history show best stock often have rs rating north early stage move look best stock buy watch start hereacceleron pharma be build cup handle buy point see stock break volume least average company bottom line growth decline company most recently report quarter sale grow prior report acceleron pharma earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx chemocentryx ccxi halozyme therapeutic halo be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
68,VRTX,more year half begin late june red hat rht be sort stock aggressive growth investor ignore stock form consolidation gain first breakout be fifth be different story red hat clear
69,VRTX,thursday spark therapeutic once receive positive adjustment relative strength rs rating look best stock buy watch be sure pay attention relative price strength ibd unique rs rating track technical performance used worst best score indicate stock price action trail week compare rest market decade market research show best stock often have rs rating north early stage move see spark therapeutic continue show renew price strength hit benchmark look best stock buy watch start herewhile spark therapeutic be not proper buy point right now see go form break proper base term fundamental company have post quarters accelerate earning growth revenue gain have be less impressive come last quarter spark therapeutic hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term userelated biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
70,VRTX,wednesday regenxbio rgnx hit important technical milestone see relative strength rs rating jump percentile improvement day try find best stock buy watch be sure pay attention relative price strength ibd unique rating identify price movement worst best score score show stock price behavior trail week compare other stock database history reveal best stock typically have rs rating least begin biggest run look winning stock try simple be not currently show potential buy point see stock go build sound pattern launch new move earning growth increase last quarter revenue gain fall company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx chemocentryx ccxi be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
71,VRTX,celgene celg vertex pharmaceutical vrtx incyte incy be worth watch broader market correction see biotech stock lose collective previous day analyst say tuesday biotech stock rebound stock market today diving monday bmo capital market analyst brian belski say note client investor be reap sow intent purpose majority client market pundit especially increasingly boisterous set naysayer have be predict bull market imminent demise day presidential election say doesn mean bull market be dead belski say rbc analyst brian abraham agree see opportune entry point certain biotechs stock datum approval expect thing be look celgene few misstep second half include major miss sale psoriatic arthritis drug otezla third quarter abraham say sale drug rebound fourth quarter believe market cap reduction more reflect believe fourth quarter number guidance point reassure stabilization key revlimid otezla sale say ibd take bull market be good time review stock selling smart once begin stall uptrend too late catch head investor corner brush stock selling rule cancer drug revlimid be celgene biggest drug analyst have worry generic rival take sale start contend celgene recently announce plan acquire remainder juno therapeutic juno didn already own add juno coffer put celgene car space compete novartis nvs gilead science gild latter acquisition kite pharma car therapy immune system identify fight cancer even juno celgene look poise generate enough cash flow buy back virtually entire enterprise value revlimid go completely generic abraham say outside abraham see number catalyst include additional datum revlimid treat lymphoma late stage datum drug partner acceleron pharma xlrn blood disorder celgene rise tuesday abraham say vertex be victim bad timing vertex recently report strong datum triple combination regimen cystic fibrosis datum come just broader market be begin turn stock fall hard past day vertex rebound tuesday rise strong effectiveness drug know vx vx triple regimen head phase study support likelihood vertex expand tough treat population cystic fibrosis patient say also enable multiple additional shot goal set bar be difficult match beat significant lead time likely render mid year competitive datum galapago glpg overhang vertex share much less impactful raise price target vertex macro weakness be mask improve fundamental abraham argue incyte be set read datum phase trial know echo first half study combine incyte immuno oncology drug epacadostat dow stock merck mrk keytruda late stage melanoma drug class know immuno oncology treatment epacadostat work block interaction involve ido enzyme immune system keytruda be call pd inhibitor have similar interaction pd protein instinet analyst christopher marai expect trial read positively be similar regimen bristol myer squibb bmy drug opdivo yervoy bristol be also combine drug treat other cancer include advanced lung cancer so epacadostat become part standard care metastatic melanoma broad adoption augment current pd use say note client lead peak worldwide sale north melanoma alone epacadostat rbc abraham say eventually nearly value epacadostat soon be go incyte share see share jakafi treat bone marrow disorder share olumiant rheumatoid arthritis drug co develop eli lilly lly suggest downside upcoming epacadostat datum be negative be now likely only share fundamental upside now potentially more say make upside downside level much more interesting incyte advanced tuesday related allergan pop consensus top quarter strong migraine biotech stock dive more be sell overdo crispr small biotechs cure disease
72,VRTX,aldr see positive improvement relative strength rs rating tuesday rise look best stock buy watch factor watch closely be relative price strength ibd unique rs rating measure technical performance used worst best score indicate stock price performance trail week match rest market year market history show best stock tend have rs rating north early stage move look best stock buy watch start herealder be work consolidation entry see stock break heavy trading top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
73,VRTX,intra cellular therapy itci see positive improvement relative strength rs rating monday increase look best stock buy watch factor watch closely be relative price strength proprietary rating identify market leadership show stock price movement last week measure other stock database year market history show best stock tend have better rs rating early stage move look winning stock try simple routineintra cellular therapy be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week line earning growth increase company most recent report revenue fall intra cellular therapy earn rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
74,VRTX,build watch list focus stock higher rs rating exact science exas just meet criterium new score try find best stock buy watch be sure pay attention relative price strength ibd proprietary rating measure market leadership worst best score grade show stock price behavior trail week compare other stock database year market history reveal top perform stock typically have better rs rating early stage move look winning stock try simple routineexact science have climb more past entry third stage flat base meaning now proper buy range look stock create new chance get week tight pullback day week line sale growth fall last quarter earning share grow prior report exact science earn rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
75,VRTX,welcome move alk see relative strength rating rise monday re research best stock buy watch be sure pay attention relative price strength unique rating measure technical performance used worst best score indicate stock price performance last week compare rest market history show market biggest winner often have better rs rating early stage move see continue rebound clear threshold see ibd help make more money stocksalkerme break earlier have fall back prior entry cup handle stock re tracking climb buy point then fall more original entry price consider fail base best stock form new pattern also understand latest pattern be later stage base involve more risk earning grow last quarter prior report revenue also increase company earn rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
76,VRTX,ligand pharmaceutical lgnd be biotech worth doesn market single drug yet expect approach sale stock be breaking reason be ligand operate unique business model acquire early stage technology necessary drug development then license platform biotechs pharmas dow jone stock merck mrk pfizer pfe well amgen amgn novartis nvs total ligand have more program development north partner firm say fourth quarter conference call february craig hallum capital group analyst matt hewitt praise model feb report client give larger ever expand portfolio current potential future royalty generate asset broad pipeline partnership model inherently gear deliver very high profit margin believe be tremendous value creation motion ligand say shareholder seem agree hewitt assessment ligand stock have pop more begin year outperform broader biotech group have rise roughly same time period thursday share jump early morning trade break second stage week flat base share end regular session ligand share have be run last week jump least day stretch straight trading session meanwhile biotech group have be red past session stock have ibd composite rating best possible meaning perform top stock term key growth metric biotech group rank third vertex pharmaceutical vrtx halozyme therapeutic halo have rating ligand demonstrated dominance fourth quarter total revenue grow top consensus roth capital partner analyst scott henry write recent note client royalty main driver sale increase line expectation henry say upside revenue drive adjust earning share spiking vs year earlier quarter beating analyst view cent better expect sale amgen kyproli novartis promacta lead revenue charge ligand get royalty sale promacta oral medicine increase number platelet blood royalty sale multiple myeloma drug kyproli total ligand be tie dozen commercial product have technology platform biotechs pharmas use develop drug firm also have handful early stage drug plan license interested company further development ligand goal be create diversify company more licensing opportunity lower impact individual patent expiry firm say protect scenario now face biotech leader celgene celg see patent cancer drug revlimid begin expire mid use ibd marketsmith free march
77,VRTX,see stock buy point get chart pattern recognition run custom screen start nowamong recent success ligand announce week have partner drug hold firm roivant science diabetes drug lgd roivant company metavant develop drug have strong phase datum second half be major partnership have potential generate substantial medical value type type diabetes patient ligand chief executive john higgin say prepared statement lgd be successfully develop license roivant have potential be ligand largest financial asset possibility annual royalty continue late offer upside guidance royalty revenue sale related captisol compound used pharma development related milestone license fee analyst say ligand tend promise deliver come annual guidance roth capital henry say expect be more same revenue earning share target view conservative surpass company guidance henry expect kyproli promacta sale moderate call kyproli sale grow promacta sale increase sustain movement drug provide upside guidance say ligand be bullish drug ceo higgin call kyproli promacta become blockbuster promacta have be market year so see level growth be particularly impressive say earning call promacta become molecule analyst project continue strong growth say kyproli give recently report sale number drug appear also be track exceed worldwide sale ligand partner currently have handful drug late stage testing include brexanolone postpartum depression drug sage therapeutic sage slew other phase trial partner program be preclinical be phase study firm expect benefit current trend include new tax law reduce ligand project tax rate more third higgin say earning call ligand also get boost bump fda drug approval recent study massachusett institute technology find success rate drug program advance approval have increase believe be attribute many factor include better decision advance program more favorable regulatory environment say be very meaningful ligand have program stage development related tame volatile swing trade half trade stock most penny stock fail make investor richlook best stock buy watch start here
78,VRTX,december big cap column sport headline large cap stock ponder stock be alphabet googl facebook fb vertex pharmaceutical vrtx do stock do ve be best way play buy buy hold ibd style rule swing trading
79,VRTX,welcome move supernus pharmaceutical supn see relative strength rating improve thursday try find best stock buy watch keep close eye relative price strength proprietary rating measure market leadership show stock price movement last week compare other stock database decade market research show market biggest winner typically have rs rating north launch biggest climb see supernus pharmaceutical continue show renew price strength hit benchmark look winning stock try simple routinesupernus pharmaceutical be try complete consolidation buy point see break heavy trading supernus pharmaceutical report earning growth last quarter sale growth come supernus pharmaceutical hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
80,VRTX,thursday amag pharmaceutical amag reach important technical milestone see relative strength rs rating jump percentile improvement day look best stock buy watch keep close eye relative price strength ibd unique rating measure market leadership worst best score rating show stock price movement last week stack other stock database decade market research show best stock tend have rs rating north early stage move see ibd help make more money stocksamag pharmaceutical be still buy range clear buy point cup handle once stock move higher initial entry consider proper buy zone earning growth increase last quarter top line fall company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
81,VRTX,vertex pharmaceutical vrtx beat fourth quarter sale expectation more have select pair cystic fibrosis treatment send late stage testing company say late wednesday vertex report adjust income cent share sale rise respective vs year earlier period metric beat consensus adjust profit cent share sale total sale vertex bring revenue cystic fibrosis treatment grow year year biggest drug orkambi increase kalydeco also know ivacaftor tack growth chief executive jeffrey leiden call outstanding year vertex written statement look vertex scientific expertise financial strength position advance key pipeline program cf include triple combination regimen bring forth potential new medicine multiple other serious disease hour trading stock market today vertex pop close regular session triple pill treatment be expect treat cystic fibrosis patient say jeffrey chodakewitz vertex executive vice president chief medical officer vertex plan send combo used drug know vx vx late stage testing year look forward conclude discussion regulator initiate phase development first half year goal bring triple regimen patient quickly possible chodakewitz say written statement excitement have be build surround potential triple pill target underlie genetic cause disease total vertex have potential combination be consider vertex have now narrow potential combination combination vx tezacaftor ivacaftor begin phase trial first half study investigate regimen effect patient group different genetic mutation ibd take vertex wasn always cystic fibrosis focuse company earliest day be focuse hepatitis gilead science launch massively successful drug call sovaldi do vertex escape crisis head new america more pending additional datum first half year vertex also plan send combination vx tezacaftor drug call vx phase testing once daily treatment group patient different genetic mutation vertex select treatment base ongoing study show absolute improvement patient ability forcefully expel air second treat vx vx regimen show improvement percentage point respectively week treatment cystic fibrosis patient triple combination be generally well tolerate study vertex say majority adverse event mild moderate severity discontinuation rate due adverse event be low vertex isn only firm seek make triple regimen treat cystic fibrosis abbvie abbv galapago glpg have also team make triple pill analyst have say duo be several year most see vertex triple get approval time frame february vertex expect get approval regimen tezacaftor ivacaftor treatment cystic fibrosis patient age older specific genetic mutation european regulator make determination second half vertex say issue guidance cystic fibrosis drug sale anticipate approval tezacaftor ivacaftor regimen feb analyst expect vertex offer outlook share adjust earning sale vertex be also plan move forward crispr therapeutic crsp used gene therapy treat blood disease know beta thalassemia sickle cell disease trial be expect begin year europe related biotech growth testing buy zone get new drug approvalwhich biotech stock surprise upside earning biotechs outperform hyper competition
82,VRTX,index nasdaq composite dow industrial suffering worst weekly loss year not surprising top rate growth stock retreat vertex pharmaceutical vrtx apple aapl supplier qorvo qrvo atlassian team ipg photonic ipgp paylocity pcty cypress semiconductor cy break recently past week so have slip modestly buy point stock be worth keep watch list case retake buy point preferably robust price gain strong volume keep mind market uptrend be pressure investor be cautious new purchase quick cut loss want consider take profit winning stock future selling hard once again likely many stock future come further pressure open vertex pharmaceutical clear buy point late january close level jan average volume share biotech dip just entry retook buy point feb jump strong volume follow strong earning vertex choose cystic fibrosis treatment late stage testing stock fall friday market sell vertex fall morning trade stock market today vertex relative strength line track stock performance vs index have be lag rs line be blue line chart lag rs line reflect stock sideway action month shallow consolidation broader market rally strongly vertex be member leaderboard ibd premium service offer annotate chart handful stock mostly growth name buy zone chipmaker qorvo get estimate revenue apple rise further thank big new contract apple iphone announce last week qorvo stock have be trend lower early november rs line have fall week low late last month qorvo shot thursday apple iphone wind vaulting cup handle base buy point capped rally session friday share retreat apple plunge weak iphone sale guide low current quarter revenue other apple chipmaker also sell qorvo share be morning trade apple rise modestly day test qorvo rs line be well high recent consolidation late peak do shoot last week stock jump short term high ibd take recent breakout be struggle other have weather recent market retreat facebook lead top stock hold buy zone atlassian make collaboration software business clear buy point jan close level jan rise high jan session strong volume jan close bell atlassian give weak earning guidance top fiscal second quarter estimate share fall jan back entry then share have be hover just buy point friday share fall light volume atlassian share fall morning trade monday rs line be lag not much strong retake buy point not only claim short term high also approach november peak ipg photonic shot jan part surge start run right side short cup handle base push stock top buy zone entry fiber laser maker rs line almost hit new high daily chart do hit new high weekly chart ipg share then moved sideway move slightly extend buy point then share begin pull back jan light volume close buy range thursday friday stock slide back entry volume be normal ipg share lose monday morning rs line be now lag stock have drift lower several week market fared better paylocity be cloud base provider payroll human resource software mostly small mid size business stock clear cup handle buy point jan volume be only normal rs line clear short term high be still bottom consolidation share keep rise reverse lower thursday friday share slide volume be normal palocity dip intraday paylocity be strong field paycom payc have fall back buy zone ahead earning tuesday night workday wday target larger enterprise be lead stock cite ibd take be still buy zone cypress semi close buy point jan light volume lag rs line session later stock fall back entry cypress moved back buy zone jan again light trade then pull just entry once again cypress report stronger expect fourth quarter earning sale late thursday give bullish guidance share fall just cent friday cypress lose monday morning strong retake buy point likely push rs line short term high be interested stock fall broadly be true correction do see big flaw ibd stock chart anatomy chart breaking buy sell zone
83,VRTX,alk have relative strength rs rating upgrade thursday welcome improvement still shy better score prefer see look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify share price action worst best score rating show stock price movement last week hold other stock database history reveal top perform stock typically have rs rating early stage move see continue rebound hit benchmark see ibd help make more money not currently ideal time jump see stock manage form chart pattern break see earning sale growth rise last quarter earning share increase revenue rise hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx therapeutic cort be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
84,VRTX,look best stock buy watch focus rise relative price strength stock fit bill be spark therapeutic once have relative strength rs rating upgrade thursday look best stock buy watch factor watch closely be relative price strength unique rating track market leadership show stock price action last week measure other stock major index decade market research show market biggest winner tend have rs rating begin biggest run look best stock buy watch start herewhile spark therapeutic be not proper entry right now see be able form break proper chart pattern take look top bottom line number spark therapeutic have post quarters accelerate earning growth revenue gain have be less impressive come latest report spark therapeutic hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx therapeutic cort be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
85,VRTX,look best stock buy watch focus rise relative price strength stock fit bill be regenxbio rgnx see welcome improvement relative strength rs rating wednesday upgrade look best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily track price movement worst best score rating show stock price movement trail week hold other stock database history reveal market biggest winner tend have higher rs rating begin new run look best stock buy watch start hereregenxbio be not currently show potential entry point see stock go build sound pattern ignite new run earning growth picked last quarter revenue gain fall regenxbio hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
86,VRTX,relative strength rs rating aldr enter new percentile wednesday increase look best stock buy watch factor watch closely be relative price strength proprietary rating identify technical performance used worst best score indicate stock price performance last week match rest market year market history reveal market biggest winner typically have rs rating least launch biggest climb look best stock buy watch start herealder be try complete consolidation buy point see break volume least average top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
87,VRTX,look best stock buy watch focus rise relative price strength stock fit bill be aimmune therapeutic aimt see welcome improvement relative strength rs rating wednesday increase ibd unique rating identify market leadership worst best score score show stock price behavior last week stack other stock database year market history reveal best stock often have better rs rating early stage move look winning stock try simple routineaimmune therapeutic have rise more past entry first stage cup handle meaning now proper buy range look stock create new chance pick share week tight pullback day week line company show earning growth most recent report sale growth come aimmune therapeutic hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
88,VRTX,dow jone industrial average nasdaq open firm gain thursday market look pull positive ground week dow jone industrial average scramble start bell aid early show strength unite technology utx caterpillar cat nasdaq composite advanced vertex pharmaceutical vrtx chalk biggest gain nasdaq stock also swung energy name hold index strongest early gain chesapeake energy chk technipfmc fti lead advance track top stock market trend free ibd market be broadly mixed hong kong picked late day sell shanghai shenzhen reopen week long holiday hong kong hang seng dive shanghai composite rally japan tokyo nikkei tumble rac second loss week europe market be increase pressure afternoon trade cac paris slip frankfurt dax ftse london show decline dow unite technology rally lead index caterpillar show gain apple also advanced aim reverse straight decline stock have manage hold support week move average facebook fb jump amazon com amzn pop netflix nflx lag fang stock tech leader early action gain share be consolidate jan high extend flat base early january avis budget car bolt higher report expectation fourth quarter result late wednesday stamp com stmp post early advance score big fourth quarter earning beat revenue also top analyst target management hoist full year guidance well expectation gain hoist ibd stock back support converge week move average base pattern begin october roku roku stab lower investor look past strong fourth quarter performance focus first quarter revenue guidance be consensus estimate trade chip stock be relatively tame exception tower semiconductor tsem topple more fourth quarter report also motion early earning report pandora medium plummet repligen rgen surge apply optoelectronic aaoi take dive china base stock be largely quiet thursday volatile session home market jd com jd edge premarket trade online retail heavyweight have be consolidate jan high late january attempt fail trigger automatic sell rule thursday economic news open labor department report first time unemployment claim drop sharply week end feb be steepest decline claim prior week undercut consensus estimate application conference board lead economic indicator january be due et kansa city federal reserve regional manufacturing survey energy information administration report weekly natural gas withdrawal oil inventory et respectively be interested stock future find support stock just report big picture investor be still nervous factor sprout universal display first solar investing action plana walmart get whack amazon retailer fashion new
89,VRTX,alk see ibd smartselect composite rating rise friday day new score tell company be now outperform stock term most important fundamental technical stock pick criterium be now buy range clear entry cup handle see ibd help make more money stock sport ep rating meaning recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company post earning growth sale growth climb prior quarter mark consecutive report increase revenue gain hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related company be now outperform stock
90,VRTX,friday alk get positive adjustment relative strength rs rating ibd unique rs rating identify market leadership show stock price movement last week compare other stock major index decade market research show best stock tend have higher rs rating launch biggest price move look best stock buy watch start herealkerme be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average top bottom line growth moved higher last quarter earning be compare prior report revenue increase company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
91,VRTX,thursday acorda therapeutic acor receive upgrade relative strength rs rating ibd proprietary rs rating identify technical performance show stock price action last week compare other stock database year market history show best stock often have rs rating north begin biggest run look best stock buy watch start hereacorda therapeutic be work consolidation buy point see break heavy volume company see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
92,VRTX,puma biotechnology pbyi see positive improvement relative strength rs rating thursday increase exclusive rating investor business daily measure price movement worst best score grade show stock price movement trail week compare other stock database year market history reveal stock go make biggest gain tend have rs rating north launch biggest price move look best stock buy watch start herepuma biotechnology be now consider extend buy range clear buy point first stage double bottom see stock form new pattern follow buy opportunity week tight pullback day week move average puma biotechnology post ep growth latest quarterly report sale increase keep eye company next round number mar company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
93,VRTX,puma biotechnology pbyi see positive improvement relative strength rs rating thursday increase exclusive rating investor business daily measure price movement worst best score grade show stock price movement trail week compare other stock database year market history reveal stock go make biggest gain tend have rs rating north launch biggest price move look best stock buy watch start herepuma biotechnology be now consider extend buy range clear buy point first stage double bottom see stock form new pattern follow buy opportunity week tight pullback day week move average puma biotechnology post ep growth latest quarterly report sale increase keep eye company next round number mar company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
94,VRTX,important metric look stock be higher relative strength rating radius health rdus just hit mark jump wednesday ibd unique rating track price action worst best score score show stock price behavior last week compare other stock database history show stock go make biggest gain tend have rs rating north early stage move look winning stock try simple routineradius health be not currently offer proper buy opportunity see stock go build sound pattern launch new move radius health show earning growth latest quarterly report revenue increase keep eye company next round number feb company hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
95,VRTX,stock watch week be technology health care stock be near clear buy point form long basis gilead science gild take interactive break monday morning take faltered vertex pharmaceutical vrtx have be form long base clear buy point friday pull back monday wellness software firm mindbody mb be hover buy point gilead science rise heavy volume monday stock market trading clear buy point cup base go back september share surge friday jeffery upgrade gilead buy hold raise price target gilead science be rally hepatitis drug optimism rival abbvie abbv report strong hep sale friday ibd take look actionable high quality growth stock investor business daily do work check leaderboard market team curate analyze list top notch name take free trial leaderboard take interactive rise high clear cup handle buy point consolidation be take shape early november share reversed close gaming software company stock have be somewhat rangebound past few week trading day line buy point meanwhile vertex pharmaceutical break past entry late friday trading session rise market surge more new high volume be normal see volume rise least average monday vertex reversed lower lose back entry volume be modestly normal action come ahead earning wednesday vertex have be consolidate last july biotech have be steady rise december wellness service software company mindbody sank monday work consolidation form november shortest base group mindbody lose support day line several time build base have be able quickly recover stock have now form handle lower buy point slightly be important note major index have continue surge higher base build technology health care stock have relative strength line be lag rs line measure stock price performance vs stock break want see rs line hit short term high not time high vertex rs line have rise very short term level so have gilead rs line be interested facebook google breakout internet stock enter buy zonethese stock composite rating have earning apple stock chart be tell ahead earning guidance leader top buy point breakout be not create equaleven big week stock leader issue key sell signalsthese ibd tech stock be buy rangestock buy watch top ipos big small cap growth stock
96,VRTX,important metric look stock be higher relative strength rating therapeutic cort now clear threshold jump tuesday look best stock buy watch factor watch closely be relative price strength proprietary rating identify technical performance show stock price movement last week measure other stock database decade market research show top perform stock tend have better rs rating begin biggest run look winning stock try simple routinewhile now be not ideal time jump see stock be able form base break earning growth drop last quarter revenue rise company earn rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
97,VRTX,health care industry make headline new partnership amazon amzn berkshire hathaway brkb jpmorgan chase jpm well new buyout drugmaker sanofi sny lead biotech stock vertex pharmaceutical vrtx be testing new buy zone tuesday amazon berkshire jpmorgan say create independent company
98,VRTX,therapeutic cort have relative strength rs rating upgrade wednesday welcome improvement still shy better score look try find best stock buy watch be sure pay attention relative price strength ibd proprietary rs rating track market leadership used worst best score identify stock price action last week stack other stock database decade market research show best stock typically have rs rating least early stage move see therapeutic continue show renew price strength clear threshold look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock manage offer clear proper buy point earning growth decrease company latest report sale rise therapeutic hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
99,VRTX,welcome move pharmaceutical adms see relative strength rating rise tuesday look best stock buy watch be sure pay attention relative price strength proprietary rating track technical performance show stock price movement last week measure other stock database decade market research show market biggest winner tend have better rs rating begin largest run see pharmaceutical continue rebound clear threshold look winning stock try simple routineadamas pharmaceutical be not currently potential buy zone see stock go form promising consolidation spark new run earning growth decline most recent report revenue moved higher company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
100,VRTX,welcome move pharmaceutical adms see relative strength rating rise tuesday look best stock buy watch be sure pay attention relative price strength proprietary rating track technical performance show stock price movement last week measure other stock database decade market research show market biggest winner tend have better rs rating begin largest run see pharmaceutical continue rebound clear threshold look winning stock try simple routineadamas pharmaceutical be not currently potential buy zone see stock go form promising consolidation spark new run earning growth decline most recent report revenue moved higher company hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
101,VRTX,monday flexion therapeutic flxn clear important technical benchmark see relative strength rs rating jump percentile improvement day re research best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily measure market leadership worst best score grade show stock price behavior trail week compare other stock database year market history reveal best stock tend have rs rating least early stage move look best stock buy watch start hereflexion therapeutic be not currently offer proper buy opportunity see stock go build sound pattern launch new move company post earning growth last quarter sale growth come look next report mar flexion therapeutic earn rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
102,VRTX,portola pharmaceutical ptla have relative strength rs rating upgrade thursday welcome improvement still shy higher score look proprietary rating track technical performance used worst best score show stock price performance last week compare rest market year market history show best stock tend have rs rating north launch biggest climb see portola pharmaceutical continue show renew price strength hit benchmark look best stock buy watch start hereportola pharmaceutical be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth rise last quarter sale fall look next report feb portola pharmaceutical hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
103,VRTX,wednesday dermira derm receive upgrade relative strength rs rating ibd unique rating identify market leadership worst best score rating show stock price movement last week hold other stock database year market history reveal stock go make biggest gain often have rs rating north begin largest price move see dermira continue show renew price strength hit benchmark look best stock buy watch start heredermira be not currently show potential buy point see stock go build base launch new move earning growth decline last quarter revenue moved higher look next report feb dermira earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
104,VRTX,la jolla pharmaceutical ljpc see positive improvement relative strength rs rating wednesday rise ibd unique rating identify market leadership worst best score rating show stock price movement trail week stack other stock database decade market research reveal stock go make biggest gain typically have rs rating least launch biggest price move look best stock buy watch start herewhile not currently ideal time invest see stock be able form chart pattern break la jolla pharmaceutical report ep growth latest quarterly report sale growth come next quarterly result be expect feb company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
105,VRTX,important metric look stock be higher relative strength rating flexion therapeutic flxn now clear threshold jump wednesday unique rating measure technical performance used worst best score identify stock price action trail week match other publicly trade company year market history reveal top perform stock typically have rs rating north early stage move look best stock buy watch start hereflexion therapeutic be not currently potential buy zone see stock go build promising consolidation kick new price move flexion therapeutic post earning growth most recent report sale growth come next quarterly result be expect mar flexion therapeutic hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
106,VRTX,radius health rdus have relative strength rs rating upgrade tuesday welcome improvement still higher score look exclusive rating investor business daily track market leadership worst best score rating show stock price movement trail week hold other stock database history reveal best stock typically have rs rating north early stage move see radius health continue show renew price strength clear threshold look winning stock try simple routinewhile stock be not ideal buy range right now see manage form break proper base company post earning growth last quarter sale growth come keep eye company next round number feb company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
107,VRTX,welcome move acorda therapeutic acor see relative strength rating rise tuesday ibd proprietary rs rating track technical performance show stock price action last week compare other stock database decade market research reveal stock go make biggest gain tend have rs rating early stage move see acorda therapeutic continue show renew price strength hit benchmark look winning stock try simple routineacorda therapeutic be work consolidation entry see clear price volume least average sale growth fall last quarter bottom line grow prior report next quarterly result be expect feb acorda therapeutic earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
108,VRTX,momenta pharmaceutical mnta have relative strength rs rating upgrade monday welcome improvement still better score look exclusive rating investor business daily track share price action worst best score rating show stock price behavior last week compare other stock database year market history show market biggest winner often have better rs rating early stage move see momenta pharmaceutical continue rebound clear threshold look winning stock try simple routinenow be not ideal time jump isn proper buy zone see stock be able establish enter buy range heavy volume momenta pharmaceutical report negative growth sale earning last quarter company be expect report next quarterly number feb company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
109,VRTX,innoviva inva see welcome improvement relative strength rs rating monday upgrade exclusive rating investor business daily measure price movement worst best score score show stock price performance last week stack other stock database year market history reveal market biggest winner tend have rs rating least begin new run look best stock buy watch start herewhile now be not ideal time invest see stock go establish enter buy range heavy volume top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase innoviva earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
110,VRTX,puma biotechnology pbyi have relative strength rs rating upgrade monday welcome improvement still shy better score look ibd unique rating track share price action worst best score score show stock price behavior trail week compare other stock database decade market research show best perform stock tend have better rs rating early stage move see puma biotechnology continue rebound hit benchmark see ibd help make more money stockspuma biotechnology have moved more past entry first stage double bottom meaning now proper buy zone look stock offer new chance pick share week tight pullback day week move average company post earning growth most recent report sale growth come look next report mar company hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
111,VRTX,thursday gilead science gild hit important performance benchmark see relative strength rs rating jump percentile improvement day ibd proprietary rating track share price action worst best score score show stock price performance last week hold other stock database year market history show best stock often have rs rating north early stage move see ibd help make more money stocksgilead science be not currently potential buy zone see stock go form sound pattern spark new run company post negative growth sale earning last quarter gilead science hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
112,VRTX,revance therapeutic rvnc have relative strength rs rating upgrade monday try find best stock buy watch keep close eye relative price strength exclusive rating investor business daily track market leadership worst best score score show stock price behavior last week stack other stock database decade market research show stock go make biggest gain often have rs rating north begin biggest run see ibd help make more money stocksrevance therapeutic be work consolidation entry see stock clear price heavy trading later stage pattern investor be aware be less likely lead significant gain revance therapeutic report earning growth last quarter sale growth come company hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
113,VRTX,relative strength rs rating aldr climb new percentile monday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price action worst best score score show stock price movement trail week compare other stock database year market history show market biggest winner typically have rs rating north early stage move see continue show renew price strength hit benchmark look best stock buy watch start herealder be build consolidation entry see clear price heavy trading company see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
114,VRTX,consider name put watch list look stock higher rs rating flexion therapeutic flxn just meet criterium new score unique rating measure technical performance used worst best score identify stock price action trail week match other stock decade market research show top perform stock often have rs rating north begin biggest price move see ibd help make more money stocksflexion therapeutic be not currently offer proper buy opportunity see stock go build sound pattern spark new run flexion therapeutic show earning growth most recent report sale rise next quarterly number be expect mar company hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
115,VRTX,important metric look stock be higher relative strength rating exact science exas clear benchmark wednesday jump wednesday ibd proprietary rs rating track technical performance used worst best score indicate stock price performance trail week match other publicly trade company decade market research reveal market biggest winner often have rs rating launch biggest price move see ibd help make more money stocksexact science be now consider extend buy range clear buy point third stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line earning growth moved company most recent report revenue fall exact science hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
116,VRTX,thursday gw pharmaceutical gwph clear noteworthy technical benchmark see relative strength rs rating jump percentile improvement day ibd proprietary rs rating track technical performance used worst best score identify stock price action trail week match other publicly trade company year market history show stock go make biggest gain typically have rs rating north early stage move look winning stock try simple routinewhile gw pharmaceutical be not proper entry right now see manage form break proper base term fundamental company have post quarters accelerate earning growth revenue gain have also moved higher same time frame company earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
117,VRTX,thursday acorda therapeutic acor earn positive adjustment relative strength rs rating ibd unique rating measure market leadership worst best score grade show stock price behavior trail week compare other stock database decade market research reveal best stock tend have rs rating early stage move look winning stock try simple routineacorda therapeutic be work consolidation buy point see stock clear price heavy trade revenue growth fall last quarter bottom line grow previous report company be expect report latest performance number feb acorda therapeutic hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx biogen biib be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
118,VRTX,wednesday acorda therapeutic acor earn positive adjustment relative strength rs rating exclusive rating investor business daily identify market leadership worst best score rating show stock price performance last week stack other stock database decade market research reveal stock go make biggest gain typically have rs rating least begin largest price move see acorda therapeutic continue show renew price strength hit benchmark see ibd help make more money stocksacorda therapeutic be try complete consolidation buy point see stock clear price volume least higher normal earning growth picked last quarter revenue gain fall company be expect report latest earning sale number feb acorda therapeutic hold rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
119,VRTX,relative strength rs rating regenxbio rgnx jump new percentile wednesday increase exclusive rating investor business daily measure market leadership worst best score score show stock price behavior last week compare other stock database history show market biggest winner often have rs rating north begin biggest price move see ibd help make more money stock be not ideal entry right now see go form break proper base earning grow last quarter prior report revenue also increase look next report mar regenxbio hold rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
120,VRTX,wednesday acceleron pharma xlrn hit important technical milestone relative strength rs rating move percentile upgrade increase day exclusive rating investor business daily measure market leadership worst best score rating show stock price movement trail week hold other stock database year market history show stock go make biggest gain tend have rs rating least begin new run look winning stock try simple pharma be not currently offer proper buy opportunity see stock go build promising consolidation launch new move earning share growth fall last quarter sale rise keep eye company next round number mar company earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
121,VRTX,relative strength rs rating therapeutic cort jump new percentile wednesday increase proprietary rating measure technical performance used worst best score show stock price action last week match other stock history show top perform stock typically have rs rating north begin biggest run look best stock buy watch start herecorcept therapeutic be not currently offer proper buy opportunity see stock go form sound pattern kick new climb earning growth drop most recent report revenue gain moved higher therapeutic hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
122,VRTX,wednesday regenxbio rgnx receive upgrade relative strength rs rating proprietary rating measure market leadership show stock price action last week compare other stock database history reveal best perform stock typically have rs rating north begin new climb look best stock buy watch start herewhile stock be not ideal buy range right now see be able form break proper consolidation regenxbio see earning sale growth rise last quarter earning share increase revenue rise keep eye company next round number mar regenxbio hold rank peer medical biom biotech industry group bioverativ bivv halozyme therapeutic halo vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
123,VRTX,retrophin rtrx see ibd smartselect composite rating jump thursday day new rating show stock be outpace stock come most important stock pick criterium top perform stock tend have better grade begin launch significant move so be sure keep mind look best stock buy watch retrophin be currently form consolidation entry see stock break volume least average be aware thinly trade stock average daily dollar volume less liquid stock be more prone large daily weekly fluctuation take fewer share buy sell move share price look winning stock try simple routineone weak spot be company ep rating track quarterly annual earning growth look improve better show top stock accumulation distribution rating show heavy buy institutional investor last week company post earning share growth mean now generate straight quarters rise ep gain sale growth fall previous quarter retrophin hold rank peer medical biom biotech industry group halozyme therapeutic halo vertex pharmaceutical vrtx bioverativ bivv be top highly rate stock group related company be now outperform stock
124,VRTX,tech stock turn solid performance tuesday help strong earning netflix nflx nasdaq composite marked third straight record close high nasdaq end gain nasdaq add price action be quieter dow jone industrial average
125,VRTX,biotech internet related large cap help nasdaq composite forge solid gain monday general electric ge be try put skid sharp day slide suck nearly worth company market value meanwhile oil gas share continue advance drove energy price remain strong wti crude oil future reversed small early loss edge higher barrel diamondback energy fang ibd leaderboard play jump more extend gain past buy point nearly ge focus front page story latest ibd weekly have market cap share outstanding end devastate bear market ge trade low share equivalent market value time nasdaq lead gain tech heavyweight alphabet googl intel intc microsoft msft lift gain dow jone industrial average lag nearly apple aapl largest company nasdaq dow component fall volume be dull iphone giant get new downgrade be not trigger sell signal share be clear fine second stage cup handle oct slightly more recent entry megacap tech recently hop day move average week justify follow buy holder nice profit cushion stock russell rise nearly volume rise nasdaq be sharply nyse accord preliminary datum ge part stock dow industrial be now trading day move average too have be fall hard last year exclude brief flash crash august last time ge fall hard important long term level be way back march tail end market severe slide top november notice rally early january year fail keep ge share day move average long healthy stock trade day move average turn lead day move average higher ge opposite be occur technically speaking ge find buyer value investing crowd however note ge feature ibd ge face unenviable task decide maintain position power aviation health care market sell more part become leaner meaner ge attractiveness dividend play have definitely lose luster board approve haircut quarterly dividend cent share november dow jone industrial average fellow component verizon communication vz make ibd dividend leader screen telecom giant have annualize yield terrific year earning stability factor scale rise nearly fast turnover move past cent high handle long saucer base present timely buy point street expect verizon post rise fourth quarter profit cent share lift revenue result come tuesday market open check ibd earning calendar other company set report result meanwhile fellow dow component intel intc goldman sachs gs continue do well gain former be still form new base latter appear be build shallow new base much longer saucer handle furnished past nov elsewhere stock market today biotechs help lead upside follow news french pharma giant sanofi sny be buy biogen biib spinoff bioverativ bivv more celgene celg confirm rumor buy juno therapeutic juno least company ibd biotech industry group hold solid composite rating higher trade least share include ligand pharmaceutical lgnd vertex pharmaceutical vrtx hold awesome score respectively ligand run nearly afternoon trading extend gain buy point week flat base so bit extend price vertex report result jan close be try clear stubborn resistance build long flat base also be view saucer pattern standard buy point be follow saito chung twitter ibd_dchung more analysis growth stock chart financial market related stock buy zonewhere be stock market head read column first dayfind great growth stock ibd stock break have amazing earning outlook
126,VRTX,monday vanda pharmaceutical vnda hit important technical milestone see relative strength rs rating jump percentile improvement day proprietary rating identify technical performance used worst best score indicate stock price performance last week match other stock database year market history reveal best stock tend have higher rs rating begin new climb look winning stock try simple routinevanda pharmaceutical be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average earning share growth decline company latest report revenue rise company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
127,VRTX,supernus pharmaceutical supn have relative strength rs rating upgrade monday welcome improvement still shy better score prefer see ibd unique rating track price action worst best score grade show stock price performance last week compare other stock database decade market research show stock go make biggest gain tend have rs rating north begin biggest run see supernus pharmaceutical continue rebound clear threshold look winning stock try simple routinesupernus pharmaceutical be try complete consolidation entry see break heavy volume supernus pharmaceutical show ep growth most recent report sale growth come look next report mar supernus pharmaceutical hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
128,VRTX,amag pharmaceutical amag have relative strength rs rating upgrade monday ibd unique rs rating measure market leadership used worst best score indicate stock price performance last week match other publicly trade company history reveal stock go make biggest gain often have rs rating north launch biggest climb look winning stock try simple routineamag pharmaceutical be work cup handle buy point see break heavy trade amag pharmaceutical post ep growth last quarter revenue gain come amag pharmaceutical earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
129,VRTX,monday aldr get upgrade relative strength rs rating ibd unique rating track share price movement worst best score score show stock price behavior last week stack other stock database year market history show stock go make biggest gain often have better rs rating launch biggest climb look best stock buy watch start herealder be work consolidation entry see stock break volume least average earning growth fall last quarter sale moved higher company hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
130,VRTX,relative strength rs rating amgen amgn moved new percentile monday get lift ibd unique rating track price action worst best score score show stock price movement last week compare other stock database history reveal market biggest winner tend have rs rating north launch largest run see amgen continue rebound hit benchmark see ibd help make more money stocksamgen break earlier have fall back prior entry saucer handle stock re watch clear buy point then decline more original entry price consider fail base best stock form new consolidation also keep mind latest consolidation be later stage base such basis be more prone failure company post earning growth last quarter sale growth come amgen earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
131,VRTX,alk see positive improvement relative strength rs rating monday rise unique rating measure market leadership used worst best score identify stock price performance trail week stack other stock database decade market research show top perform stock typically have higher rs rating early stage move see continue show renew price strength hit benchmark look winning stock try simple routinealkerme break earlier have fall back prior entry cup handle stock re tracking clear buy point then retreat more original entry price consider fail base stock set new chart pattern entry price also keep mind most recent pattern be later stage base such basis be more prone failure company see earning sale growth rise last quarter earning share increase revenue rise hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
132,VRTX,vertex pharmaceutical vrtx chief executive jeffrey leiden call year biotechnology company look likely end year balance sheet rapidly approach approval key cystic fibrosis treatment company stock price reflect success year share have almost double year date rise outperform investor business daily company biotech industry group have climb more january year begin leiden tell ibd layer part strategy begin goal expand number eligible patient vertex cystic fibrosis cf drug expand pipeline outside lung disease sector strengthen financial stance leiden say goal come fruition expect continue same trajectory vertex send potential triple pill regimen treat cystic fibrosis pivotal trial next year dife deeper treat other disease crispr therapeutic crsp moderna therapeutic so really look start year approve bit less half patient cystic fibrosis end year medicine believe be able get patient say know very significant expansion patient population think treat here leiden have say vertex plan examine company strategy outside cystic fibrosis medication ibd major accomplishment do vertex have leiden expand medicine cystic fibrosis say have very important accomplishment food drug administration approval kalydeco patient residual function mutation have previously be decline fda so more patient very importantly be breakthrough respect regulatory science be think first approval ever medicine new patient population base just datum cellular datum really testament think work fda get appreciate trust strength cell base assay predict effectiveness europe successfully obtain reimbursement orkambi particular also kalydeco number country particularly ireland italy also netherlands expand number patient be now reimburse medicine ibd take vertex be crisis point pull blockbuster hepatitis drug market mount competition gilead science gild see pivot cystic fibrosis transform company visit new america third be obviously positive phase datum tezacaftor ivacaftor treat cystic fibrosis datum be highly positive different trial be able very quickly submit regulatory application fda european medicine agency expect approval medicine first quarter next year first half third quarter europe go pick large number patient today be not take cftr corrector target certain gene mutation particularly patient have difficulty tolerate orkambi so re talk thousand additional patient be eligible tezacaftor ivacaftor next year final way most important long run be announce phase phase datum different triple regimen so call next generation regimen datum tell re go be able reach patient cf single triple combination medicine datum be strong enough re confident ll be able start pivotal trial final trial medicine first half next year expand pipeline cf be something haven talk much yet ll be hearing lot more new program be very serious disorder sickle cell disease alpha antitrypsin disease inherited disorder cause lung liver ailment be move forward really nicely thankfully faster expect hope get least maybe medicine clinic next year ll start talk more re medicine be very much cf medicine treat underlie cause disease re re really excited re able move forward ultimately want be serious disease company not just cf company term financial strength company likely end year close more balance sheet base increase number patient treat cf really important not want build big balance sheet give financial wherewithal invest internal research program make more new medicine also go do business development deal allow enhance pipeline even further ibd expect see vertex leiden look same goal expand access cf medicine develop pipeline cf produce more financial strength think thing look be first tezacaftor ivacaftor approval europe very very important allow patient get access medicine second expand access even further orkambi particularly europe couple country re still negotiating france want try finish negotiation reimbursement europe next year start pivotal trial triple regimen first half next year very important milestone company patient final be watch first program get clinic outside cf seem be furthest now be sickle cell disease alpha antitrypsin disease ibd make prediction broader biotech group leiden think really most exciting time biotech year ve be do reason new therapeutic technology gene editing gene therapy be really come maturity now cell base therapy re go see become viable therapy next year unbelievably exciting re see already immunotherapy car cell ll see soon gene editing gene therapy so be lot new therapeutic modality allow other attack disease be hard attack side equation other side equation be re just now get much better understand biology disease meaning re get better pick target most drug failure today be make drug target target picked wrong target so better understand biology industry be understand biology much better higher probability success so think take advance together re go see pretty significant kind acceleration breakthrough therapy related galapago pop vertex detriment compete vertex pop analyst question rival have viable drug biotech firm top third quarter view only pop
133,VRTX,gilead science gild see positive improvement relative strength rs rating monday increase exclusive rating investor business daily identify market leadership worst best score grade show stock price performance last week stack other stock database decade market research show best stock often have better rs rating early stage move see gilead science continue show renew price strength hit benchmark look best stock buy watch start herewhile stock be not proper buy point right now see manage form break proper base gilead science post negative growth top bottom line last quarter gilead science be expect release next quarterly number feb gilead science earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
134,VRTX,la jolla pharmaceutical ljpc have relative strength rs rating upgrade monday ibd unique rating track market leadership worst best score grade show stock price behavior trail week stack other stock database history show best perform stock tend have rs rating least begin new run see ibd help make more money stocksla jolla pharmaceutical break earlier have fall back prior entry consolidation stock re tracking clear buy point then decline more original entry price consider fail base stock set new base entry price also keep mind latest consolidation be later stage base make riskier establish new position add share exist la jolla pharmaceutical post ep growth latest quarterly report revenue gain come next quarterly result be expect feb la jolla pharmaceutical hold rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
135,VRTX,alexion pharmaceutical alxn pop tuesday vertex pharmaceutical vrtx be list top biotech stock pick hyper competition pricing pressure uncertain merger activity likely dominate year leerink analyst geoffrey porge peg vertex alexion leader rival struggle mount competition rely pricing hike sustain top line growth have strong management team attractive franchise garner takeover interest analysis lead believe best perform stock foreseeable future be participate category high barrier entry rely volume growth rather positive price contribution say note client close bell stock market today alexion climb finish vertex rise finish vertex share end alexion meanwhile broader biotech group wrapped year vertex be second best performer top biotechs market cap easily lead amgen amgn gilead science gild celgene celg end year respective flat alnylam pharmaceutical alny lead top rocket vertex have monopolized cystic fibrosis category drug know kalydeco orkambi porge say nearest competitor galapago glpg be time disadvantage product haven show same effectiveness vertex lucrative commercial opportunity cystic fibrosis present high barrier entry therapeutic indication have preclude emergence clear viable threat vertex cystic fibrosis franchise say ibd take median tenure chief executive large cap biotechs fall just year plunge year have impact merger acquisition analyst say last week head ibd industry theme closer look first quarter vertex be likely gain approval combination drug know tezacaftor ivacaftor treat cystic fibrosis patient gain traction patient discontinue treatment orkambi due tolerability year also be key vertex triple pill regimen treat cystic fibrosis say vertex be plan begin pivotal trial first half most analyst expect triple pill gain approval alexion meanwhile have see revenue growth drug know soliris past year treatment pair blood disorder increase sale be mostly due volume increase little price contribution porge say october food drug administration approve soliris treat muscle disease help continue sale trend say alexion be also work follow drug know alxn favorable dose schedule potentially better effectiveness porge expect alxn prove superior soliris treat blood disease know paroxysmal nocturnal hemoglobinurium phase testing result high conversion rate alxn soliris likely approve catalyst also extend terminal cash flow horizon alexion key franchise mid mid patent alxn expire say further alexion say late tuesday board director agree work activist investor elliott management identify new board member november alexion say have search underway fill open board seat be look candidate range background skill expertise related vertex chief talk company year biotech stock feel lovewhy biotech see upside second quarter
136,VRTX,omero omer see welcome improvement relative strength rs rating friday upgrade proprietary rating track market leadership show stock price action last week compare other stock database history reveal best perform stock tend have better rs rating early stage move see omero continue show renew price strength clear threshold look winning stock try simple routinewhile omero be not ideal entry right now see go form break proper consolidation earning grow last quarter prior report revenue also increase omero earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
137,VRTX,thursday la jolla pharmaceutical ljpc earn positive adjustment relative strength rs rating ibd proprietary rs rating track technical performance used worst best score identify stock price action trail week match other publicly trade company decade market research reveal best stock typically have rs rating begin biggest price move see ibd help make more money stocksla jolla pharmaceutical be build consolidation buy point see stock clear price heavy volume la jolla pharmaceutical report earning growth last quarter revenue increase next quarterly result be expect feb company hold rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
138,VRTX,median tenure chief executive large cap biotech company be just year plunge year key transition period amgen amgn celgene celg biogen biib vertex pharmaceutical vrtx analyst say wednesday new chief executive also tend hold less power biotech chief have dual title ceo board chairman compare pharma chief leerink analyst geoffrey porge write note client believe investor understandably find hard have confidence new executive give lack track record recent history group be unlikely inspire confidence say investor be also likely view executive have less power broker merger acquisition contribute expectation relatively modest deal activity improve cash position most large cap porge say biotech company be operated chief executive long tenure mostly scientific background proven track record familiarity investor porge say number ceo be founder scientist carefully choose successor ibd take large cap biotechs be frustrated smaller play newer medicine start take share analyst say trend continue head ibd industry theme breakdown mean biggest stock collapse median large cap biotech ceo tenure past year follow uptick year year meanwhile pharma company see rotation ceo business law degree median duration experience year however imbalance reversed early median biotech ceo tenure have decline match pharma year porge say median ceo tenure large cap pharmaceutical be year ceo pharmas have maintain dual role chief executive chairman time biotech ceo have dual role just time be likely result high prevalence physician scientist founder often have senior business leader chairman position porge say see pro con company combine chief executive chairman position hat believe lack strong authority leadership position biotech company be certainly suggestive lack immediate opportunity change company industry structure say investor be dissatisfied company performance be also likely find divide title arrangement more vulnerable challenge change entrench ceo chairman related company be now outperform stock stock rise apple bitcoin fall play pay big tax reform impact tax bracket rate
139,VRTX,index other major average have first week be worst show year apple aapl guide lower many suspect amazon amzn boee ba deliver strong result facebook fb tout strong ad rate alibaba baba miss earning paypal pypl crash former parent ebay ebay moved cut ty move amazon jpmorgan chase jpm berkshire hathaway brkb team tackle health care cost hit insurer pharmacy benefit manager bitcoin meltdown continuedx hot start major average suffer worst weekly loss year dow nasdaq rise bond yield worldwide pressured stock unitedhealth unh cvs health cvs many other insurer fall amazon jpmorgan berkshire health care joint venture amazon boee facebook be earning winner alibaba be notable loser apple aapl do bitcoin plummet loss accelerate facebook joined chorus regulator worldwide crack cryptocurrency apple aapl earning share rise year year sale fiscal first quarter narrowly beat expectation apple sell iphone vs consensus unit average selling price due new iphone iphone model fuel overall result march quarter apple expect sale base midpoint guidance official estimate share fall friday new month low commerce leader report adjust earning share smash consensus big benefit tax cut help revenue rise also beating revenue amazon web service rise sale echo line smart speaker far exceed expectation amazon amzn say share gain hit new high intraday facebook fb report robust earning revenue growth top forecast user growth cool user time spend facebook fall even latest big news feed change executive say conference call ad rate be soar ease analyst revenue fear share hit record high thursday alphabet googl share fall google parent report adjust earning be share year earlier miss view traffic acquisition cost google pay partner website carry ad soar google expect rise tac moderate google rise tac have be link contract renewal apple well internet search shift mobile phone revenue rise top consensus adjust ep exclude impact tax reform result additional expense amazon jeff bezos jpmorgan jamie dimon berkshire warren buffett say new nonprofit company be aim reduce cost employee be successful own firm think be expand service corporate america health insurer pharmacy benefit manager sell unitedhealth largest health insurer also pbm sank drugstore pbm cvs health cvs be buy insurer aetna aet lose pure play pbm express script esrx retreat paypal pypl report strong earning line guidance former parent ebay ebay report line earning stronger expect gross merchandise volume real news be ebay stunned wall street news replace paypal handle payment own site partnership adyen move add revenue stream share ebay soar nearly thursday paypal lose week close buy point day line chinese commerce giant revenue soar best gain least quarters beating view earning share climb slightly miss forecast alibaba buy stake ant financial former unit run payment service alipay replace deal alibaba get ant financial pretax profit alibaba provide intellectual property not cash move clear hurdle possible ant financial ipo alibaba share week tumble recent buy point add job january better expect average hourly wage surge vs year earlier far view best ism manufacturing index continue point raid employment gain fast growth wage gain be good news spur federal reserve raise rate more aggressively year software leader report adjust earning share cent year year sale fiscal second quarter analyst expect cent microsoft get lift cloud compute business include azure office dynamic current quarter microsoft guide earning share cent sale view share hit record high intraday thursday amd amd broadcom avgo qorvo qrvo offer investor positive financial news amd beat wall street target december quarter guide estimate higher current quarter broadcom give preliminary sale earning guidance fiscal first quarter top view qorvo rocket disclose big contract major customer apple aapl next generation iphone qorvo deliver better expect result fiscal guide well wall street target current quarter boee ba report ep share exclude share benefit tax cut way boee beat analyst view revenue climb also top view boee also guide ep revenue forecast higher tax cut spur more investment make case new midmarket jet more compelling boee also get missile defense contract pentagon up up order new jet give venerable jumbo jet new lifeline meanwhile lockheed martin lmt ep jump revenue rise defense giant guide ep view higher boee share rise week lockheed hit new high video game publisher electronic art ea see stock surge record high report big gain online service associate sport game franchise fifa madden nfl boost live service be reveal part ea line december quarter earning report video game hardware software firm nintendo ntdoy post better expect december quarter result thank continue success switch console related software take interactive software announce major delay highly anticipate wild west action game red dead redemption now set release oct instead spring visa mastercard top analyst forecast person break plastic more often spend holiday visa also buyback follow american express axp just suspend buyback visa also hike quarterly cash dividend cent share homebuilder stock continue struggle even big builder report better expect earning prior week surprise miss nvr nvr housing demand price be strong concern be grow rise labor material cost mortgage rate low be rise america largest homebuilder horton dhi beat ep revenue wednesday share meet resistance day line pultegroup phm stock keep fall slide gross margin even earning sale top view smaller meritage home mth also beat smaller home mho holding mdc miss ep slew biotechs drugmaker report earning include pfizer pfe eli lilly lly vertex pharmaceutical vrtx astrazeneca azn merck mrk top wall street fourth quarter earning expectation pfizer come sale adjust profit cent share lilly total sale grow firm bring adjust income share vertex report sale adjust profit cent share astrazeneca report core earning share sale merck result be mixed top line miss view adjust income cent share beat cent amgen amgn report sale adjust earning share lag consensus merger news sanofi sny announce acquire ablynx ablx exxon mobil xom fall well short consensus fellow dow industrial component chevron cvx also miss ep view share plunge day line chevron undercut recent buy point separately crude production continue hit fresh longtime high crude supply rise first time week crude future remain year high ferrari race gap buy zone report strong earning thursday meanwhile auto sale slump january big decline ford fiat chrysler fcau gm gm sale edge higher miss view toyota tm sale sky-rocket strong truck sale
140,VRTX,major stock index be modestly higher head close briefly turn negative follow federal reserve policy meeting central bank left key lend rate unchanged make slightly more hawkish comment inflation meeting future trader see chance quarter point hike march meeting decision statement trader now see chance accord datum cme group fedwatch intraday gain dow jone industrial average fade end gain strong earning guidance dow component boee ba help fuel gain stock apple aapl be fractionally higher even bmo capital market lower rating market perform outperform cut apple price target apple earning report be due thursday close persistent concern iphone demand meanwhile nasdaq rise rise volume nyse nasdaq be pace be lower tuesday level stock market today video game maker electronic art ea take interactive lead nasdaq gain electronic art gap consolidation report strong earning guidance late tuesday take also break active trading ahead feb earning report economic news adp employment report reveal jump january private payroll nicely consensus estimate datum come ahead friday job report be expect show increase same month nonfarm payroll unemployment rate hold steady ibd china name sina sina alibaba baba outperformed gain sina have accumulation distribution rating hold buy point double bottom base note be light volume alibaba meanwhile be hold well recent buy point result former member ibd leaderboard be due thursday open result ibd name paypal pypl be due today close stock be slightly extend low volume buy point rise nearly earning facebook fb vertex pharmaceutical vrtx be also due close related boee beat earning forecast give strong earning come uncertain time social medium giant feel chipper broadcom jump outlook amd pop earningsstock buy way be stock market likely head read column day
141,VRTX,stock open lower thursday overseas market lose ground inflation gauge jump unexpectedly barrage earning news fuel busy early trade dow jone industrial average dig hole nike nke slip bottom index visa post only early gain better nasdaq composite drop paypal pypl tractor supply tsco vodafone vod putt nasdaq largest open decline dip bolster qorvo qrvo ebay ebay vertex vrtx now thick earning season microsoft msft facebook fb qualcomm qcom unite parcel service up be many notable name react quarter result early thursday apple aapl alphabet googl amazon com amzn visa be set report today close bell visa lead dow ahead quarterly report nike dive open trade microsoft edge cloud compute business drive fourth quarter result well ahead analyst target company report late wednesday share be extend clear flat base december component qorvo spiked analyst upgrade stock follow fiscal third quarter report wednesday close supplier chip apple iphone be trading just buy point cup base almost so far week facebook trade higher re-cover hour dip late thursday social medium giant report better forecast result fourth quarter raise concern effect change news feed share be still buy range buy point ebay nokia vault more investor respond quarterly performance information technology service firm nic egov post session most perilous early decline paypal fall open ebay announce earning report late wednesday curtail use paypal switch digital payment provider ayden loss send share back buy point flat base have clear early january stop short cut stock week move average alibaba group holding baba give almost mixed fiscal third quarter report china base commerce leader also announce have retake share ant financial unit have spun loss erased stock gain buy point flat base have break jan economic news ahead friday payroll report show layoff announce employer surge month month january accord job cut report challenger gray christmas layoff run almost lower january report say retailer lead january payroll reduction layer worker almost fewer cut layoff announce january last year first time unemployment claim be roughly even week end jan labor department say compare claim prior week projection uptick new application labor department preliminary estimate fourth quarter productivity show dip far monster surge third quarter well consensus estimate increase unit labor cost pop vs decline third quarter estimate increase add inflation fear raise fed wednesday dollar reversed recent gain vs yen buoy wary view inflation convey wednesday policy announcement federal reserve stock japan respond send tokyo nikkei muscular rebound end day decline have follow currency comment treasury secretary steven mnuchin davos switzerland last week china market continue lower shanghai composite hong kong hang seng index take loss europe market turn lower afternoon trade cac paris give early gain drop frankfurt dax dive ftse london post decline other important early market news thursday big picture stock edge nasdaq january large cap keep lead paypal share plunge ebay contract exit adyen move dealgood news apple earning tech leader go wild ride
142,VRTX,imagine editing gene cure debilitating disease small biotech company combine annual sale less crispr therapeutic crsp intellium therapeutic ntla edita medicine edit say soon be reality biotech stock go public bet big simple premise alter specific gene create curative medicine estimate disease be cure change target gene say former intellium chief executive nessan bermingham world health organization have higher estimate be know monogenic disease say actually north person have be talk personalize medicine year yet ve never have system allow do bermingham tell investor business daily step role dec first time ever actually have system do system be base personalize genome system be know crispr crispr intellium edita be putt chip cheaper faster gene editing method accord bermingham key advance personalize medicine analyst think crispr technology provide platform next generation giant biotech company crispr technology not be confused crispr therapeutic company build project sequence human genome first map cost be complete then cost map individual genome have drop precipitously come just hundred dollar next few year bermingham say large datum analytic also have part play sifting genome ibd take biotech company account large share recent ipo stock yet investing have profit sale be risky learn identify best ipos trade potential big gain first human genome be map investigator be absolutely horrify find just gene human body code protein bermingham say be estimate essentially protein coding gene serve word genetic language investigator also find region dna be initially thought have purpose be controversially call junk dna do not code protein turn sequence do have key purpose regulate expression gene together better understand human genome have allow biotech company utilize crispr acronym technology know cluster regularly interspaced short palindromic repeat be caveat however january paper publish biorxiv say be evidence human immune system fight major form genome editing used enzyme call cas thus render science ineffective paper however have yet be peer review process develop various university essentially used specialize strand dna act molecular scissors scissors be capable editing other dna specific point allow biotech company edit add remove faulty gene responsible disease be vary type scissors crispr intellium edita be used cas crispr technology ark invest analyst manisha samy tell ibd estimate cas reach human genome develop new scissors expand reach more gene disease say gene editing isn new add older technique call talen zinc finger nuclease have be time notably biotech company bluebird bio blue be used variation talen sangamo therapeutic sgmo be used method zinc finger nuclease liken crispr technology word processor think crispr gene editing be analogous dna word processor function find delete say january report addition scientist be work rudimentary paste function allow crispr insert appropriate dna code repair mutation older technology used biotech company be more old fashion typewriter require actual cut paste say crispr technology be also cheaper easier use talen zinc finger say jmp security analyst mike king so powerful crispr be so easy use tell ibd high school student be do experiment biology lab knock gene zinc finger take lot talent time have fiddle lot system create crispr be quite robust january biorxiv online archive distribution service unpublished report life science field publish paper cast doubt durability crispr gene therapy time suggest body build immunity analyst biotech company be not worry however say be nonissue time science catch many company work crispr be do so used cas enzyme short crispr associate protein cas be derive bacterium cause infection human high rate meaning immune system have develop immunity crispr gene editing used enzyme work patient depend crispr therapeutic say follow email ibd important note lead investigator writer biorxiv paper be matthew porteus scientific founder advisory board member crispr therapeutic gene editing be do ex vivo outside body cas enzyme be degraded therefore essentially go time cell be reintroduce patient crispr tell ibd vivo application gene editing be do body crispr therapeutic say used several approach ensure transient expression cas enzyme do not expect pre exist immunity cas cause issue firm say ark samy also note other enzyme be use edita be also used cpf enzyme enzyme be derive other bacterium overcome immunity challenge involve cas intellium tell ibd follow email clinical testing delivery system treatment rodent human primate have yet falter further intellium note used advanced form cas none donor have pre exist immunity study datum be still early edita have do own work immune response crispr genome editing present paper future jmp king say jan note client management have indicated find immune response be much lower report other paper immune response be not uncommon samy say scientist have work decade evade immune recognition be numerous workaround be implement reduce potential side effect cas have prove number other therapeutic modality biotech company crispr therapeutic be ahead competition regulatory standpoint dec firm submit first application clinical trial testing gene therapy know ctx blood disorder know beta thalassemia company be work vertex pharmaceutical vrtx beta thalassemia well sickle cell disease therapy be part crispr ex vivo program gene editing be do cell outside body be reintroduce patient crispr be also look vivo therapy liver muscle lung accord crispr news release trial be set begin europe adult patient be expect be first human trial gene editing treatment base crispr technology crispr also plan file application begin testing ctx treat sickle cell disease intellium also have vivo ex vivo program gene editing also be work sickle cell disease furthest partnership regeneron pharmaceutical regn therapy treat know transthyretin amyloidosis condition characterize buildup abnormal protein deposit body alnylam pharmaceutical alny ionis pharmaceutical ion also be work separately treat disease used different method call rna interference antisense technology respectively meanwhile edita be work inject treatment inherited eye disease know leber congenital amaurosis be characterize severe loss vision birth be also used gene editing sickle cell disease beta thalassemia intellium edita also be expect start human trial analyst say intellium have not say begin testing regulator be get more comfortable idea gene editing crispr therapeutic president sam kulkarni tell ibd benefit gene editing potential trouble be meant be permanent fix biotech company be work ensure hit bull eye time ve show make edit do precise fashion used target industry call molecular zip code say eliminate edit happen outside place want happen manufacture high quality fashion understand pharmacology kulkarni intellium bermingham be succeed john leonard former abbvie abbv executive say room big player group sizing market be challenge ark samy say matter slice number be big lot depend disease company target set pricing crispr be able address monogenic disease diagnosed year market globally say address disease person already live diagnosis be market product be not go cure everything say re see volatility main crispr company doesn really make sense room more come crispr kulkarni say unlikely market remain just publicly trade biotech company crispr technology long run technology be just remarkable once lifetime be little bit stretch maybe not say definitely once generation type advance field last time kind excitement happened biotech field be antibody be apply therapeutic modality basis technology company genentech now own roche rhhby be create add here have basis crispr platform create next big biotech giant related top biotech company innovation earn recognition new awardswhy bluebird downgrade send rival best stock buy watch nowmeet best broker overall investor need
143,VRTX,halozyme therapeutic halo see ibd smartselect composite rating rise thursday day new score indicate company be now outperform stock term most important fundamental technical stock pick criterium history show top market performer tend have higher score launch major climb halozyme therapeutic be currently form consolidation buy point look stock break volume least average see ibd help make more money stocksone weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company post ep growth have now post accelerate ep increase consecutive quarters top line growth increase prior quarter company have now post accelerate growth last quarters halozyme therapeutic earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv enanta pharmaceutical enta be top highly rate stock group related company be now outperform stock
144,VRTX,alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx be likely beat fourth quarter earning estimate analyst predict biotech guidance be cautious windfall tax reform fourth quarter earning report season kick next week dow johnson johnson jnj novartis nvs weigh tuesday wednesday pharma side celgene celg biogen biib be deck early thursday abbvie abbv trail friday leerink analyst geoffrey porge expect cautious prediction begin note example celgene pre announcement earlier month uncertainty payer dynamic competition drug access be likely play forecast factor imminent return more challenge political environment suggest management team be more typically cautious guidance first provide financial community earning call say note client fourth quarter porge call vertex cystic fibrosis drug orkambi kalydeco gilead hepatitis hiv drug regeneron pharmaceutical regn eylea dupixent latter eye disease eczema treatment respectively surprise upside ibd take biotechs suffer third quarter high profile drug miss expectation smaller player take headline beating view head industry snapshot more happened prior quarter history be expect repeat see older drug amgen amgn include psoriasis arthritis med enbrel risk disappointing investor biogen multiple sclerosis drug avonex plegridy abbvie cancer med imbruvica also disappoint say needham analyst alan carr see investor focuse merger fourth quarter call week rumor emerge celgene be consider takeover juno therapeutic juno biogen be consider putt bid acorda therapeutic acor continue believe pharma have bias risk asset be market case still regulatory review write note client first half expect food drug administration approve vertex cystic fibrosis regimen kalydeco tezacaftor well hiv combination gilead abbvie neurocrine bioscience nbix also get drug treat severe menstrual pain alnylam pharmaceutical alny be also likely grab approval patisiran drug treat condition abnormal protein deposit body cause systemic problem achaogen akao tetraphase pharmaceutical ttph be also near approval antibiotic related celgene rumore acquisition juno actually make sensedow merck do face release cancer trial hospital plan put pressure generic drug maker
145,VRTX,aldr have relative strength rs rating upgrade thursday ibd unique rs rating identify market leadership show stock price action last week compare other stock major index decade market research show market biggest winner often have rs rating north begin biggest climb see ibd help make more money stocksalder be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week line earning growth fall most recent quarter revenue gain moved higher look next report feb company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
146,VRTX,important metric look stock be higher relative strength rating radius health rdus clear benchmark friday jump friday unique rating identify technical performance used worst best score indicate stock price action trail week match other publicly trade company history reveal market biggest winner typically have rs rating north begin biggest price move look winning stock try simple routineradius health break earlier have fall back prior entry double bottom case stock break then fall more entry price consider fail happen best new base form also keep mind most recent consolidation be later stage base involve more risk radius health report earning growth most recent report revenue gain come keep eye company next round number feb radius health earn rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
147,VRTX,flexion therapeutic flxn have relative strength rs rating upgrade thursday welcome improvement still higher score prefer see ibd proprietary rs rating measure market leadership show stock price movement last week compare other stock database history show stock go make biggest gain typically have higher rs rating begin largest climb see flexion therapeutic continue show renew price strength clear threshold look best stock buy watch start hereflexion therapeutic be not currently show potential buy point see stock go build sound pattern kick new climb company post earning growth most recent report sale growth come look next report mar flexion therapeutic hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
148,VRTX,thursday halozyme therapeutic halo get upgrade relative strength rs rating ibd unique rating identify market leadership worst best score rating show stock price performance last week compare other stock database history reveal top perform stock typically have higher rs rating launch biggest climb look winning stock try simple routinehalozyme therapeutic be build consolidation buy point see break volume least average term top bottom line number halozyme therapeutic have post quarters increase earning growth revenue gain have also moved higher same period company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
149,VRTX,friday acceleron pharma xlrn receive upgrade relative strength rs rating ibd proprietary rs rating identify market leadership show stock price movement last week compare other stock database decade market research reveal market biggest winner typically have rs rating north launch biggest climb look winning stock try simple pharma be still buy range move past buy point cup handle proper buy range be initial entry once stock hit benchmark best set buy opportunity earning share growth decrease last quarter top line rise company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
150,VRTX,relative strength rs rating voyager therapeutic vygr enter new percentile thursday rise ibd unique rating track market leadership worst best score score show stock price movement last week stack other stock database decade market research reveal best perform stock often have better rs rating early stage move see ibd help make more money stock be not ideal buy zone right now see be able form break proper consolidation earning growth fall last quarter revenue rise voyager therapeutic earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
151,VRTX,thursday acceleron pharma xlrn earn upgrade relative strength rs rating exclusive rating investor business daily track market leadership worst best score score show stock price performance trail week hold other stock database history show top perform stock often have rs rating north begin biggest price move see ibd help make more money stocksacceleron pharma be work cup handle buy point see stock break heavy trade ep growth decline prior quarter revenue grow prior report company hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
152,VRTX,regenxbio rgnx see welcome improvement relative strength rs rating thursday rise ibd unique rating measure price performance worst best score grade show stock price movement last week hold other stock database decade market research show best stock often have rs rating north early stage move look winning stock try simple be build cup handle entry see stock clear price volume least average earning grow last quarter prior report revenue also increase company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
153,VRTX,aerie pharmaceutical aeri have relative strength rs rating upgrade wednesday proprietary rating track market leadership show stock price action last week compare other stock database year market history show market biggest winner often have rs rating north begin biggest run look winning stock try simple routineaerie pharmaceutical be not currently potential buy area see stock go form promising consolidation kick new price move company report earning growth most recent report revenue rise company hold rank peer medical biom biotech industry group sucampo pharmaceutical scmp vertex pharmaceutical vrtx emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
154,VRTX,abbvie abbv follow footstep gilead science gild celgene celg analyst suggest monday abbvie guide unexpectedly low tax rate expect narrative stock come month develop buy story similar gilead celgene more recently leerink analyst geoffrey porge write note client acquisition narrative follow abbvie fourth quarter earning friday biopharma giant top quarterly expectation beat guidance prediction also guide tax rate tax rate term also follow announcement last week celgene acquire juno therapeutic juno sanofi sny acquire biogen biib spinoff bioverativ bivv today sanofi also say buy ablynx ablx abbvie do seek acquisition likely be neuroscience early stage immuno oncology solid tumor medicine porge say abbvie seek deal build complement early stage alzheimer disease pipeline ahead key readout so far abbvie be play card close vest firm doesn seem incline make large disruptive transaction porge say credit suisse analyst vamil divan note firm be constantly look asset believe already have strong pipeline further do not have burn platform need acquire asset say isn compelling need company be deal many other thing probably be not best time do merger acquisition ibd take celgene abbvie have already report fourth quarter earning slew biopharmas be still slate issue report head ibd industry theme closer look analyst expect biotech drug group put abbvie slightly different boat gilead celgene gilead acquire kite pharma slow hepatitis drug sale last week celgene say buy juno year begin lose exclusivity cancer drug revlimid divan comment follow conversation abbvie management post fourth quarter earning analyst suggest lower expect tax rate mean abbvie have extra cash hand engage merger acquisition abbvie say look earlier stage single asset build pipeline find anything timeframe even neuroscience readout not necessarily feel need divan say note client divan boost price target abbvie keep neutral rating porge also up price target downgrade abbvie market perform rating outperform current valuation prefer celgene abbvie larger cap name coverage say growth name such vertex pharmaceutical vrtx alexion pharmaceutical alxn regeneron pharmaceutical regn continue offer more upside view abbvie close bell stock market today abbvie dip fraction related celgene reverse fourth quarter otezla sale sanofi ablynx deal spur biopharma buy spree biotech merger spigot turn juno bioverativ
155,VRTX,future index fall modestly monday morning treasury yield continue climb dollar strengthen somewhat start busiest week earning season alibaba baba google parent alphabet googl mastercard vertex pharmaceutical vrtx paypal pypl servicenow now align technology algn be company quarterly financial tap boast best possible composite rating composite rating combine several ibd proprietary rating earning other key factor time stock winner often have composite rating better start big run future sank vs fair value year treasury yield top highest level nearly year german year yield turn positive first time nasdaq future lose future dow industrial dip nasdaq composite dow industrial hit high friday alibaba report early thursday chinese commerce giant earning be expect rise share revenue surge mark strongest top line growth quarters alibaba close friday become slightly extend buy point shallow cup base alibaba struggle entry initially stock have be difficult trade recent month stock have be generally hasn make headway vs broader market late august relative strength line track stock performance vs index have be flat lag do show strength last week alibaba fall premarket trading monday alibaba be key shareholder chinese social medium giant weibo wb weekend suspend several portal week punishment content violate social stability vulgar standard weibo majority owner sina sina lose meanwhile chinese web portal sohu com sohu tumble early report weaker expect result alphabet release result thursday night google parent be likely report earning share vs year earlier revenue grow alphabet decisively clear buy point oct follow earning report share didn make much progress testing entry day move average early december share be now well extend prior base close friday rs line have largely moved sideway mastercard report ep gain thursday morning revenue rise rival visa release fiscal result thursday night visa have composite rating be see report revenue gain ep cent mastercard visa be well extend possible buy point rs line be rise fractionally just outpace sprint index vertex pharmaceutical report wednesday expect ep gain cent revenue swell biotech clear buy point friday month consolidation close volume be normal paypal earning be due late wednesday paypal ep increase cent revenue rise stock close friday slightly extend buy point paypal limp entry several weak effort generally lackluster volume servicenow report wednesday night earning climb cent share revenue servicenow have rise single session so far year stock be well extend possible buy point align technology report tuesday maker invisalign brace be expect report earning cent share vs year earlier revenue swell align technology close friday slightly extend cup base buy point align initially clear entry jan volume be only normal be interested ibd tech stock be buy rangewhat apple stock chart be tell ahead earning guidancethese top stock be buy point leader just break outfacebook apple amazon grab earning spotlight investing action plan
156,VRTX,concert pharmaceutical cnce see welcome improvement relative strength rs rating thursday rise ibd unique rs rating measure technical performance used worst best score identify stock price action trail week match rest market decade market research reveal market biggest winner typically have rs rating launch largest climb look best stock buy watch start hereconcert pharmaceutical have rise more past entry second stage cup handle meaning now proper buy zone look stock create new chance get week tight pullback day week line top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase concert pharmaceutical earn rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
157,VRTX,important metric look stock be higher relative strength rating innoviva inva now clear threshold jump thursday ibd proprietary rating identify market leadership worst best score grade show stock price movement last week hold other stock database decade market research reveal market biggest winner typically have better rs rating begin biggest climb see ibd help make more money stocksinnoviva be still buy range move past entry cup handle proper buy range extend initial entry once stock move range best set buy opportunity innoviva post ep growth latest quarterly report sale rise keep eye company next round number feb company hold rank peer medical biom biotech industry group bioverativ bivv therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
158,VRTX,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
159,VRTX,nasdaq composite find comfort tuesday strong earning report netflix fuel broad rally fang stock overall nasdaq outperformed afternoon trading price action be quieter dow jone industrial average dow be fractionally lower eke small gain volume nyse nasdaq be tracking very close monday level stock market today traveler trv be big winner dow strong earning clear flat base entry monday ahead result dow component johnson johnson jnj underperform earning slumping nearly consumer product firm be buy point still hold day move average netflix nflx be big gainer report bullish earning sale late monday head earning netflix be extend entry other fang name facebook fb leaderboard name amazon com amzn rise more alphabet googl add china name alibaba baba enjoy nice bounce day move average rise heavy volume work later stage base buy pointamong breakout enterprise software name workday wday clear cup handle buy point see day chart early december workday hit intraday low undercut low prior base serve reset base count workday weekly chart show alternate entry biotech space vertex pharmaceutical vrtx rise top month consolidation show conventional entry share jump nearly vertex own composite rating thank part big earning sale growth recent quarters meanwhile president trump decision impose new duty much foreign make solar equipment fuel big early gain first solar fslr share reversed lower rise nearly intraday share be stock be poise second test week move average late october year treasury yield slip basis point ahead busy week economic datum have december exist home sale datum due wednesday new home sale datum thursday meanwhile first read gross domestic product be due friday economist expect growth new york mercantile exchange crude oil future add just barrel result unite airline ual be due close work big cup handle base buy point ahead result share be related unite airline weigh option boee eye new midsize jet sfirst solar tesla winner solar tariff decision hit chinathese be top stock millennial investor be hold say robinhood
160,VRTX,welcome move amag pharmaceutical amag see relative strength rating improve wednesday ibd unique rating identify price performance worst best score score show stock price performance trail week hold other stock database year market history show market biggest winner typically have better rs rating begin largest climb see amag pharmaceutical continue rebound clear threshold see ibd help make more money stocksamag pharmaceutical be work cup handle buy point see stock break volume least average company post earning growth most recent report sale growth come amag pharmaceutical hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx alk be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
161,VRTX,welcome move momenta pharmaceutical mnta see relative strength rating improve thursday unique rating identify technical performance used worst best score identify stock price performance trail week compare rest market decade market research reveal best stock typically have rs rating north early stage move see momenta pharmaceutical continue rebound clear threshold look best stock buy watch start heremomenta pharmaceutical break earlier have fall back prior entry cup handle stock re watch break past buy point then decline more original entry price consider fail base best stock form new base also keep mind latest consolidation be later stage base involve more risk momenta pharmaceutical see earning sale growth rise last quarter earning share increase revenue rise momenta pharmaceutical earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx bioverativ bivv enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
162,VRTX,la jolla pharmaceutical ljpc have relative strength rs rating upgrade tuesday ibd unique rs rating identify market leadership used worst best score indicate stock price action trail week match other stock decade market research show market biggest winner tend have rs rating north early stage move see ibd help make more money stocksla jolla pharmaceutical be not currently potential buy area see stock go form base launch new move company report ep growth most recent report revenue rise keep eye company next round number feb la jolla pharmaceutical hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx enanta pharmaceutical enta be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
163,VRTX,welcome move aldr see relative strength rating improve wednesday exclusive rating investor business daily track price action worst best score grade show stock price performance trail week compare other stock database year market history show top perform stock typically have rs rating least early stage move see continue rebound clear threshold look best stock buy watch start herealder be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week line ep growth drop company most recent report top line rise look next report feb hold rank peer medical biom biotech industry group bioverativ bivv vertex pharmaceutical vrtx alk be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
164,VRTX,wednesday exelixis exel hit important technical milestone see relative strength rs rating jump percentile improvement day exclusive rating investor business daily track share price action worst best score grade show stock price behavior last week stack other stock database decade market research reveal stock go make biggest gain typically have better rs rating early stage move look winning stock try simple routineexelixis be work consolidation entry see stock clear price volume least average earning growth rise last quarter revenue gain fall company hold rank peer medical biom biotech industry group sucampo pharmaceutical scmp vertex pharmaceutical vrtx emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
165,VRTX,portola pharmaceutical ptla see positive improvement relative strength rs rating wednesday upgrade ibd proprietary rating measure price performance worst best score grade show stock price performance trail week stack other stock database year market history reveal best stock typically have rs rating least early stage move see ibd help make more money stocksportola pharmaceutical be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth increase last quarter sale fall company hold rank peer medical biom biotech industry group sucampo pharmaceutical scmp vertex pharmaceutical vrtx emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
166,VRTX,galapago glpg stock pop monday vertex pharmaceutical vrtx detriment figured piece triple combination puzzle treat cystic fibrosis analyst say galapago still have long road truly challenge vertex treat cystic fibrosis accord leerink analyst geoffrey porge vertex already have potential triple pill combo midstage testing galapago just have potential piece triple late sunday galapago say drug know glpg be safe tolerable group patient cystic fibrosis drug also help reduce chloride patient sweat test cystic fibrosis increase patient ability forcefully expel air lung function result be inferior vertex result tezacaftor ivacaftor fail phase trial porge say sweat chloride glpg be inferior vertex tezacaftor alone phase trial same patient population be vast amount work front galapago potential partner abbvie abbv challenge vertex category say result do not yet compel cystic fibrosis market ibd take vertex start hepatitis effort be dampen gilead science massive hepatitis franchise so moved cystic fibrosis see transition firm crisis visit new america porge currently forecast galapago have chance success cystic fibrosis maintain outperform rating price target vertex vertex be plan use drug tezacaftor ivacaftor backbone triple close bell stock market today galapago lift end trading day vertex dip finish related roche cancer trial be kick tooth dow stock merckvertex pop analyst question rival have viable drug biotech firm top third quarter view only pop
167,VRTX,putt together watch list look stock higher rs rating heron therapeutic hrtx be stock just reach mark now earn score ibd proprietary rating identify market leadership worst best score rating show stock price behavior trail week hold other stock database history reveal top perform stock typically have rs rating early stage move look winning stock try simple routineheron therapeutic break earlier have fall back prior entry cup handle stock re tracking climb buy point then decline more original entry price consider fail base best stock form new base also understand latest pattern be later stage base such basis be more prone failure take look top bottom line number company have post rise ep growth last report revenue growth have not follow same trajectory come last quarter company hold rank peer medical biom biotech industry group sucampo pharmaceutical scmp vertex pharmaceutical vrtx emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
168,VRTX,acorda therapeutic acor see welcome improvement relative strength rs rating friday increase unique rating measure technical performance show stock price movement last week measure other stock database history reveal stock go make biggest gain often have rs rating north early stage move see acorda therapeutic continue show renew price strength hit benchmark look winning stock try simple routineacorda therapeutic be build consolidation entry see break heavy trading earning growth picked last quarter sale fall look next report feb company earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
169,VRTX,avexis avxs see welcome improvement relative strength rs rating friday increase exclusive rating investor business daily measure price movement worst best score rating show stock price movement last week stack other stock database decade market research show stock go make biggest gain tend have rs rating early stage move look best stock buy watch start hereavexis break earlier have fall back prior entry cup handle stock re tracking clear buy point then retreat more original entry price consider fail base stock set new chart pattern buy point also keep mind latest consolidation be later stage base such basis be more prone failure company show earning growth most recent report revenue increase company earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
170,VRTX,aldr see positive improvement relative strength rs rating friday rise exclusive rating investor business daily identify share price performance worst best score grade show stock price performance trail week stack other stock database year market history show market biggest winner tend have rs rating north launch biggest price move see continue rebound hit benchmark look winning stock try simple routinealder have rise more past entry first stage cup handle meaning now proper buy zone look stock create new chance get week tight pullback day week move average company bottom line growth decline company most recent performance report revenue grow prior report company earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
171,VRTX,relative strength rs rating biogen biib moved new percentile thursday get lift unique rating measure market leadership used worst best score show stock price performance trail week compare rest market decade market research show market biggest winner often have higher rs rating early stage move see biogen continue show renew price strength clear threshold see ibd help make more money stocksbiogen be still buy range climb buy point cup handle once stock move higher original entry consider extend buy range earning growth rise last quarter revenue gain fall look next report jan biogen hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
172,VRTX,tuesday voyager therapeutic vygr hit important technical milestone see relative strength rs rating jump percentile improvement day ibd unique rating track price action worst best score score show stock price movement trail week hold other stock database year market history reveal best perform stock tend have better rs rating early stage move see ibd help make more money stocksvoyager therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week line ep growth decrease last quarter sale rise voyager therapeutic hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
173,VRTX,acceleron pharma xlrn have relative strength rs rating upgrade tuesday welcome improvement still shy better score look exclusive rating investor business daily track market leadership worst best score grade show stock price movement last week hold other stock database history show market biggest winner often have rs rating north early stage move see acceleron pharma continue show renew price strength hit benchmark see ibd help make more money stocksacceleron pharma be build cup handle buy point see clear price volume least higher normal earning growth drop company latest report sale rise acceleron pharma hold rank peer medical biom biotech industry group sucampo pharmaceutical scmp vertex pharmaceutical vrtx therapeutic cort be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
174,VRTX,vertex pharmaceutical vrtx galapago glpg stock diverged friday analyst suggest galapago have interesting molecular formula not have viable cystic fibrosis drug hand xby close bell stock market today vertex pop finish galapago fall close biotechs make presentation friday north american cystic fibrosis conference indianapoli galapago have well research molecule have intriguing activity variety laboratory system molecular model cystic fibrosis so far be difficult know molecule actually make viable drug leerink analyst geoffrey porge say note client biotechs be work triple pill combination treat genetic lung condition analyst mostly estimate galapago be several year vertex already have potential triple pill combination midstage testing catch galapago appear be compress attempt skip many traditional aspect clinical testing have raise question investor porge say give lack progress combination don foresee sort rapid development timeline galapago combination be propose plan europe say ibd take point vertex look be go go bust work pivot cystic fibrosis hepatitis drug tank visit new america more vertex transition next presentation galapago indicated plan introduce molecule single drug add study first then advance novel triple combination trial very rapidly porge say goal be seemingly avoid traditional phase trial food drug administration hasn endorse strategy mean current soon start trial galapago combination be conduct only europe say still galapago be aim advance combination phase testing abbvie abbv acquire right galapago cystic fibrosis combination program term deal abbvie have fund execute phase trial abbvie likely prefer more traditional complete path expensive phase testing say abbvie have decide opt deal abbvie discontinue delay decision go forward be view negatively galapago positively vertex say such decision doesn seem imminent be fortunate galapago make challenge time galapago abbvie opt doesn advance combination porge have outperform rating price target vertex stock related biotech firm top third quarter view only popsionis rebound beating alnylam drug application exelixis juno stock rocket crush view
175,VRTX,trump administration chance push tax reform legislation be improve pressure so call fang stock facebook fb amazon com amzn netflix nflx google parent alphabet googl other momentum stock high hedge fund ownership say jpmorgan manager overweight growth momentum take defensive approach tax reform appear prudent say jpmorgan report publish thursday passage tax reform provide mid single digit upside also estimate equity allocation most investor type be historical high potentially leave less willing increase allocation equity further thus passage tax reform be likely result style implication equity value vs growth jpmorgan recommend protective strategy high growth momentum stock high hedge fund ownership include facebook salesforce com crm apply material amat wynn resort wynn qorvo qrvo marriott international mar vertex pharmaceutical vrtx autodesk adsk also list be micron mu align technology algn netflix jd com jd activision blizzard atvi red hat rht lam research lrcx mercadolibre meli paypal holding pypl adobe system adbe ibd take read ibd big picture column day stay top market direction key indicator let know be aggressive move sideline stock rise early thursday investor eye pending tax reform vote senate technology sector sell wednesday fang stock trade higher lead netflix goldman sachs lead dow continue rally bank financial stock passage tax reform increase speculation thereof cause continue rotation growth momentum say jpmorgan analysis suggest strong active manager performance be be drive record high stock dispersion high exposure growth momentum skewing stock return favore few select stock fang related be trump bump sector gear rally reason jpmorgan citigroup other financial be seize market leadershipin ai technology race chip be ace hole vs china
176,VRTX,wednesday sage therapeutic sage reach important technical milestone relative strength rs rating jump percentile improvement increase day ibd proprietary rs rating measure market leadership show stock price movement last week compare other stock database history reveal best stock typically have higher rs rating begin new price run look winning stock try simple routinewhile not currently ideal time jump see stock manage form base break sage therapeutic post ep growth latest quarterly report revenue increase sage therapeutic hold rank peer medical biom biotech industry group therapeutic cort hutchison china meditech hcm vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
177,VRTX,wednesday zynerba pharmaceutical zyne get upgrade relative strength rs rating ibd proprietary rs rating track technical performance used worst best score show stock price action last week match other publicly trade company year market history reveal best stock often have better rs rating begin biggest climb look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock be able offer clear proper buy point company post earning growth most recent report sale growth come zynerba pharmaceutical hold rank peer medical biom biotech industry group therapeutic cort hutchison china meditech hcm vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
178,VRTX,franchise be safe large cap biotechs be feel pressure food drug administration speed approval rival brand generic medicine analyst say monday theme be continuation leerink analyst geoffrey porge say note client record number drug approval large cap sector fall favor investor name more punish concentrated product portfolio loom brand generic competitor say head management confidence be low revenue trajectory high profile product face slowdown courtesy payer competitive pressure porge doesn see uncertainty lift possibly not ever competitive pressure slug like celgene celg gilead science gild celgene be feel pain inflammation unit mount competition eli lilly lly novartis nvs gilead see rival hepatitis drug sale abbvie abbv early next year porge expect guidance lion share large cap biotechs be conservative most stock move guidance come alexion pharmaceutical alxn gilead predict alexion be work drug dub alxn treat pair rare blood disease also undergo restructure meanwhile gilead hepatitis franchise again come microscope even attempt pivot further hiv drug bictegravir believe be share value gilead stock hepatitis stock price move hepatitis revenue guidance meaningfully differ consensus estimate porge say ibd take small cap biotechs perform well third quarter large cap suffer mount competitive concern see translate stock price visit industry snapshot note abbvie plan hepatitis product be likely hurt gilead stock abbvie recently launch mavyret treat genotype hepatitis abbvie likely provide guidance fourth quarter call ahead gilead porge expect sale outlook celgene alexion vertex pharmaceutical vrtx gilead amgen amgn abbvie miss analyst estimate biogen biib provide outlook encompass analyst view say later year large cap universe face political pressure porge predict midyear congressional midterm election be underway campaign be likely renew focus pharmaceutical company pricing policy say continue favor stock company be structural demand growth story product protected commercial scientific clinical legal barrier entry top pick be vertex alexion leerink analyst michael schmidt peg clovis oncology clvs puma biotechnology pbyi top pick small midsize biotechs focuse treat cancer group stock have outperformed broader biotech market thus far schmidt write note client dynamic be set continue favorable regulatory environment large cap expand portfolio acquisition incyte incy seattle generic sgen exelixis exel clovis agio pharmaceutical agio puma array biopharma arry be set launch key product count group set unveil pivotal trial result pending regulatory decision total firm emerge technology remain interest car therapy train patient immune cell fight cancer precision oncology have strong success immuno oncology combination cancer vaccine certain antibody have only be modest think next generation antibody drug conjugate be re emerge area interest represent clinically validate category significant room upside schmidt say antibody drug conjugate be antibody link cell kill agent antibody bound specific mark surface cancer cell immunogen imgn mersana therapeutic mrsn seattle be work area latter furthest say related big pharma biotech company be gird pricing knife fight teva restructure plan case be here do generic drug maker face pricing issue other pharmas don
179,VRTX,atara biotherapeutic atra have relative strength rs rating upgrade friday ibd proprietary rs rating track market leadership show stock price movement last week compare other stock database history show market biggest winner tend have rs rating north early stage move look winning stock try simple routineatara biotherapeutic be work cup handle buy point see stock break volume least higher normal take look top bottom line number company have post rise ep growth last quarters sale growth have be different story come most recent quarterly report company hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
180,VRTX,build watch list look stock higher rs rating agio pharmaceutical agio just clear benchmark upgrade ibd proprietary rating track price performance worst best score score show stock price movement trail week compare other stock database year market history show best perform stock typically have rs rating north launch biggest climb look winning stock try simple routineagio pharmaceutical be build cup handle entry see stock break volume least higher normal earning growth rise company latest report revenue fall agio pharmaceutical hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
181,VRTX,regenxbio rgnx have relative strength rs rating upgrade thursday ibd unique rating measure price movement worst best score score show stock price performance last week hold other stock database decade market research show best stock often have better rs rating early stage move see ibd help make more money stock be not proper buy range right now see go form break proper base top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase regenxbio earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
182,VRTX,thursday heron therapeutic hrtx earn upgrade relative strength rs rating ibd proprietary rating identify share price movement worst best score grade show stock price performance trail week stack other stock database decade market research show stock go make biggest gain tend have rs rating north launch biggest run look best stock buy watch start hereheron therapeutic have climb more past entry first stage cup handle meaning now proper buy range look stock create new chance pick share week tight pullback day week line term top bottom line number heron therapeutic have post rise ep growth last report sale gain have be less impressive come latest report heron therapeutic earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
183,VRTX,aldr see positive improvement relative strength rs rating thursday upgrade proprietary rating measure market leadership used worst best score indicate stock price performance trail week match other publicly trade company history show best stock tend have rs rating begin biggest price move look winning stock try simple routinealder be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week line earning share growth decline company most recently report quarter sale grow prior report company hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
184,VRTX,thursday omero omer receive positive adjustment relative strength rs rating exclusive rating investor business daily identify share price action worst best score rating show stock price behavior trail week compare other stock database decade market research show best stock typically have rs rating north early stage move look winning stock try simple routineomero have rise more past entry second stage consolidation meaning now proper buy zone look stock create new chance pick share week tight pullback day week move average top bottom line growth moved higher last quarter earning be compare prior report revenue increase omero hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
185,VRTX,thursday halozyme therapeutic halo clear important performance benchmark see relative strength rs rating jump percentile improvement day exclusive rating investor business daily track price performance worst best score grade show stock price behavior last week stack other stock database year market history show stock go make biggest gain often have rs rating early stage move see ibd help make more money stockshalozyme therapeutic have climb more past entry first stage cup handle meaning now proper buy zone look stock create new chance pick share week tight pullback day week move average regard top bottom line number company have post rise ep growth last report sale growth have also rise same time frame company hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
186,VRTX,relative strength rs rating biogen biib enter higher percentile thursday get lift exclusive rating investor business daily measure price performance worst best score grade show stock price behavior last week compare other stock database history reveal market biggest winner tend have higher rs rating early stage move see biogen continue show renew price strength clear threshold look winning stock try simple routinebiogen break earlier have fall back prior entry cup handle case stock break then fall more entry price consider fail happen best new pattern take shape also keep mind most recent consolidation be later stage base such basis be more prone failure earning growth rise last quarter sale fall next quarterly number be expect jan biogen earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
187,VRTX,wednesday array biopharma arry receive positive adjustment relative strength rs rating unique rating track market leadership show stock price action last week measure other stock database decade market research reveal stock go make biggest gain often have higher rs rating begin largest run see ibd help make more money stocksarray biopharma have moved more past entry third stage cup handle meaning now proper buy zone look stock create new buy opportunity week tight pullback day week move average array biopharma report negative growth top bottom line last quarter company be expect release next quarterly number feb array biopharma earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
188,VRTX,supernus pharmaceutical supn have relative strength rs rating upgrade wednesday exclusive rating investor business daily track market leadership worst best score grade show stock price behavior last week hold other stock database decade market research reveal best stock tend have rs rating least early stage move look best stock buy watch start heresupernus pharmaceutical be work consolidation entry see stock break volume least average company post earning growth last quarter sale growth come supernus pharmaceutical earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
189,VRTX,wednesday portola pharmaceutical ptla reach important technical milestone relative strength rs rating climb percentile improvement rise day unique rating identify market leadership used worst best score show stock price action trail week match rest market history reveal stock go make biggest gain typically have rs rating north early stage move look best stock buy watch start hereportola pharmaceutical be now consider extend buy range clear buy point first stage flat base see stock form new pattern follow buy opportunity week tight pullback day week move average earning growth increase last quarter revenue gain fall portola pharmaceutical earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
190,VRTX,future index nasdaq dow industrial rise slightly tuesday morning major average close session lows monday top rate medical biom biotech group fall again several lead biotech stock test key level biogen biib amgen amgn gilead science gild celgene celg vertex pharmaceutical vrtx alexion pharmaceutical alxn be tap earning week future rise vs fair value dow future climb nasdaq future edge fraction nasdaq composite lead monday retreat lose index fall dow industrial medical biom biotech group fall ninth straight decline hit month high oct even so still rate industry ibd track biogen report better expect earning tuesday morning amgen vertex follow wednesday celgene alexion gilead science report thursday addition biogen slew big earning report tuesday include mcdonald mcd unite technology utx lockheed martin lmt general motor gm open biogen earning rise nearly share sale climb analyst have expect ep revenue biogen be leader multiple sclerosis drug have new hit spinraza only spinal muscular atrophy drug market investor be also bullish prospect aducanumab have indicated early testing reduce cognitive decline early alzheimer patient biogen share rise market open tuesday monday stock fall monday stock market trading third straight decline close just buy zone entry initially clear end august ibd take buy hold stock be risky head earning report here earning option strategy help cash post earning stock gain minimize risk weak quarter amgen vertex gilead science fall day move average monday amgen close old buy point first time amgen vertex gilead be new flat basis vertex bust july promising datum new cystic fibrosis drug gilead science be best know hiv aids hepatitis drug last week win fda approval car drug treat aggressive form hodgkin lymphoma drug yescarta come gilead recent acquisition kite pharma gilead earning be expect fall hepatitis drug sale tumble amgen ep be see vertex earning be expect go vertical surge cent celgene share rise monday tumble friday celgene scrap late stage trial crohn disease treatment wall street forecast ep gain alexion retreat monday undercut low short flat base alexion drop day move average friday alexion earning be expect rise popular way avoid stock specific risk biotech be etfs ishare nasdaq biotech ibb fall drop day move average buy point clear end august related stock buy zone earning due investing action big picture nasdaq add rd distribution day sessionsbiogen biomarker mark way alzheimer parkinson abandon crohn drug other take spot do gilead now have new multibillion dollar franchise top biotech company innovation earn recognition new award
191,VRTX,left sometimes look stock buy feel show party hour late only edible left serve plate be lonely item nobody else want xin stock market term be sort situation most good stock be too extend buy
192,VRTX,earning season caterpillar cat have second best earning growth big cap company have already report xearning grow share third quarter only vertex pharmaceutical vrtx top performance vertex grow quarterly earning however many investor pass vertex point
193,VRTX,relative strength rs rating pharmaceutical adms climb new percentile thursday increase proprietary rating measure market leadership show stock price action last week compare other stock database decade market research show stock go make biggest gain tend have better rs rating launch biggest run see ibd help make more pharmaceutical be not ideal entry right now see go form break proper chart pattern pharmaceutical report negative growth sale earning last quarter pharmaceutical be expect release next quarterly number nov pharmaceutical hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
194,VRTX,biotechs amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx top third quarter estimate late wednesday boost guidance not meet good fortune hour trading xin late trading stock market today amgen sank close sarepta defy deficit close rise close bell vertex conclude trading day fall hour amgen wrapped third quarter adjust income share sale earning rise revenue dip metric top consensus analyst poll zack investment research adjust profit share sale sale cancer drug blincyto have yearly sale gain revenue prolium treatment increase bone mass follow distantly grow sale enbrel amgen biggest drug dip ibd take biotech drug stock be trouble president donald trump enact executive order tug drug price action washington base expert say happen day head ibd industry theme more effort recover impact hurricane marium puerto rico be also underway amgen say news release amgen doesn expect impact product supply manufacturing facility puerto rico firm also boost low end sale guidance bracketing analyst view year now expect bring adjust profit share earlier view top consensus sarepta crushed third quarter expectation adjust loss cent sale vs year earlier period report adjust loss cent share revenue consensus have modeled cent adjust loss share sale firm have approve drug call exondys treatment duchenne muscular dystrophy patient specific genetic mutation be proud exondys be track be most successful ultrarare disease launch history be prouder still exondys performance advancement pipeline third quarter further mission improve life child duchenne muscular dystrophy chief executive dougla ingram say statement third quarter run sarepta boost guidance now see sale smash consensus view sarepta didn give adjust loss expectation analyst model adjust loss share year board third quarter beat vertex stock topple late wednesday say cystic fibrosis study fail case failure wasn surprise consider study close week have be report result be positive rbc analyst brian abraham say other failure be bit more surprising say still quarterly result be positive say vertex deliver strong beat raise sale cystic fibrosis drug kalydeco orkambi kalydeco print sale top view orkambi revenue beat consensus expectation scientific rationale add corrector kalydeco sensitive population be not quite clear earlier datum have look promising say however note success study not have expand market substantially patient be already receive kalydeco total sale grow top consensus adjust income cent increase year year beat analyst average view cent cystic fibrosis drug sale rise vs year earlier period vertex now see total cystic fibrosis sale come earlier expectation orkambi be expect account kalydeco related glaxosmithkline scoop pfizer counter unit edward topple third quarter miss soft guidancebiogen dife top view lilly novartis beat
195,VRTX,tuesday aimmune therapeutic aimt clear noteworthy performance benchmark relative strength rs rating climb percentile improvement day ibd unique rating identify share price movement worst best score rating show stock price behavior last week hold other stock database decade market research show market biggest winner tend have rs rating north early stage move see ibd help make more money stocksaimmune therapeutic have climb more past entry first stage cup handle meaning now proper buy zone look stock create new buy opportunity week tight pullback day week line company post earning growth last quarter sale rise company be expect report latest performance number nov company hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
196,VRTX,earning have kick high gear more busy week loom result polaris industry pii be due tuesday open worth look call option trade technical health improve fundamental buy point stock have be trading tightly just
197,VRTX,top rate biotech stock vertex pharmaceutical vrtx be try set breakthrough move get new food drug administration fda approval cystic fibrosis drug kalydeco aug vertex announce fda approve kalydeco use person cystic fibrosis have certain residual function mutation base approval
198,VRTX,big cap stock facebook fb be remain hot growth stock thing have happen uncool factor have be hold arm length facebook need find way be innovative least continue be useful xit hard argue facebook ad growth advertising increase
199,VRTX,friday neurocrine bioscience nbix hit noteworthy performance benchmark see relative strength rs rating jump percentile improvement day ibd unique rating identify share price performance worst best score score show stock price performance trail week hold other stock database year market history reveal best perform stock typically have higher rs rating begin new climb see ibd help make more money bioscience have climb more past entry first stage cup handle meaning now proper buy zone look stock offer new buy opportunity week tight pullback day week line neurocrine bioscience show earning growth last quarter sale growth come company earn rank peer medical biom biotech industry group celgene celg therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
200,VRTX,friday supernus pharmaceutical supn get upgrade relative strength rs rating unique rating measure technical performance used worst best score indicate stock price action last week match other stock year market history reveal market biggest winner typically have higher rs rating early stage move see ibd help make more not currently ideal time jump see stock manage form base break earning growth fall last quarter revenue rise company hold rank peer medical biom biotech industry group celgene celg therapeutic cort vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
201,VRTX,jeffrey leiden office shelve be plaster accoutrement expect chief executive biotech award letter accommodation inevitable family photo emerge theme gratitude leiden vertex pharmaceutical vrtx currently aim treat cystic fibrosis patient globe cystic fibrosis be progressive genetic lung condition survive adulthood generally don live past age accord most estimate xin vertex set change success see medicine soon be market have generate piece mail plaster leiden shelve re letter thank graduate newlywed get letter email week patient family thank do leiden tell investor business daily know patient most be kid teenager watch grow be part family not company vertex wasn always cystic fibrosis play earlier day be focuse treat hepatitis launch drug know incivek then gilead science gild launch drug sovaldi launch be most successful history also nearly put vertex business incivek become blockbuster drug shortly launch vertex pull market demand withered leiden describe time crisis company be middle crisis say have go be hepatitis company dollar drug literally year essentially revenue be very few company frankly survive kind crisis simply so hard pivot new area drug year division company san diego have be quietly work cystic fibrosis arena indication fit leiden strategy investing scientific innovation create medicine serious disease large unmet medical need specialty area vertex specialty focus allow keep sale marketing force slim turn allow reinvest nearly dollar revenue back research development sell cystic fibrosis drug sale force fewer leiden say fast forward vertex have drug market kalydeco orkambi second quarter sale kalydeco first approve cystic fibrosis drug grow year year orkambi rocket year date vertex stock have more double rise share begin form cup handle buy point late july meanwhile broader biotech industry group have rise be rank eighth group track just week share vertex dip close friday vertex be rarity biotechs way pipeline be almost solely cystic fibrosis drug pipeline not already license bigger pharmaceutical be cystic fibrosis leiden acknowledge risk portfolio standpoint product simply don make sense vertex say vertex have farm drug flu cancer dow johnson johnson jnj merck kgaa enormous sale contingent take sell drug indication take away reinvest science reinvest science have allow vertex do something else unique medicine other firm target symptom cystic fibrosis vertex be work correct genetic underlie cause disease eventually prevent infant diagnosed ever fully develop underlie science focus genetic mutation be divide bucket leiden say kalydeco treat patient orkambi combination kalydeco drug know lumacaftor treat eventually vertex plan treat patient get third bucket patient require prong treatment strategy already backbone triple be be consider approval europe combination kalydeco drug call tezacaftor look likely be approve february top kalydeco tezacaftor vertex be add next generation corrector drug fix other abnormality gene treat patient vertex have strong phase datum next generation corrector combination kalydeco tezacaftor fourth ready read soon eventual goal be decide possible triple pill combination provide most efficient treatment few side effect vertex plan use gene editing treat last cystic fibrosis patient traditional small molecule medicine win work leiden win comment expect triple pill get approval see pivotal trial begin next year most analyst take mean food drug administration approve triple pill vertex vertex goal triple be prevent infant less year age develop cystic fibrosis know today adult already have lung damage kalydeco have be show improve lung function week time slow rate decline lung function ibd take vertex be several leader near buy zone head ibd list stock buy zone other term opportunity include entertainment stock financial service play rather decline year decline year lung function leiden say not sound significant sort compound interest take lifetime make enormous difference survival quality life quality life improvement be huge leiden say used go hospital time year now time year say used be transplant list now re not transplant list used be able walk block now walk mile not just longevity quality life galapago glpg abbvie abbv have team follow vertex step leiden jmp security analyst liisa bayko be doubtful duo catch get fda approval triple pill combo show strong datum component first bayko estimate galapago be several year even do make market triple pill have have outstanding efficiency persuade vertex patient switch new medicine vertex have do good job continually improve med tell ibd keep move bar higher make challenge person want go drug be just good vertex want do just get vertex drug be more bearish jeffery analyst michael yee see galapago eventually get cystic fibrosis market still note vertex have create strong setup make barrier enter market high deliver strong medicine other question vertex do cystic fibrosis well run dry leiden acknowledge cystic fibrosis journey be near end say vertex have plan shift other rare disease sickle cell genetic lung liver condition deadly nerve disorder alpha antitrypsin deficiency lung liver condition look lot cystic fibrosis leiden say have technology know go bear skeptical vertex cystic fibrosis pipeline group analyst investor say well really great want do ll see re able skeptical say reason weird be ve already do ve proven do ve proven model don think question anymore think ve demonstrated work related biotech catch rally add celgene break biotech giant close buy pointstop biotech stock buy zone fda drug approval
202,VRTX,alexion pharmaceutical alxn cut workforce reinvest research biotech say tuesday just month hire new chief executive away baxalta xby close trading stock market today alexion be alexion have trend past month be year biotech expect deliver pretax saving year result cost cut measure plan reinvest year build pipeline business development add new complement indication approve drug streamline operation create leaner organization greater financial flexibility be highly focuse deliver patient grow rare disease business leverage leadership complement pursue discipline business development expand pipeline chief executive ludwig hantson say statement ibd take alexion recently stage happen head new high stock list closer look potential well competitor alexion have have tough year overall share plummet early year low exec announce departure just month ludwig come alexion baxalta baxalta be acquire shire pharmaceutical shpg last year july alexion confirm investigation department health human service leerink analyst recently list alexion top pick celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx related biotech catch rally add biotechs outperformed pharma brother june quarteralexion pharma stock dife report federal scrutiny
203,VRTX,here investing action plan tuesday need know investor come day xapple finally unveil latest smartphone meanwhile splunk splk vertex pharmaceutical vrtx mgm resort international mgm ollie bargain outlet olli stock be highly rate apple have composite rating cr mean stock outperform
204,VRTX,nasdaq composite climb open friday add dow jone industrial average slip wall street continue debate likelihood meaningful tax reform small cap expect be biggest beneficiary tax reform russell soar wednesday time close high marked close high thursday rise small cap zogenix zgnx soar company report positive late stage result experimental epilepsy drug accord report reuter fellow biotech vertex pharmaceutical vrtx picked early trading davidson btig research initiate coverage buy rating price target new issue roku roku continue soar rise solid debut thursday stock price wednesday night open thursday close elsewhere share tesla tsla be higher chief executive elon musk also lead spacex outlined plan mar include landing cargo ship planet manned mission accord publish report ibd take stock tend make biggest move early stage business look new always be look closely stock selection process check area ibd university tesla recently try clear buy point volume never come stock be short live tesla be now day move average meanwhile homebuilder kb home kbh jump open report healthy earning late thursday fourth straight quarter sale growth kb home have be consolidate july pullback kb home chart now show entry nvidia nvda add nearly open hold day move average back buy range buy point year treasury yield ease basis point early friday benchmark wti crude oil future be mostly unchanged barrel related kb home share notch gain late earning sale top viewstax plan put insurer buy zone investing action planfree access ibd premium content
205,VRTX,accelerate quarterly earning be crucial trait lead stock build winning run be slim trading methodology stand current quarterly earning stock list ibd stock spotlight list friday show triple digit earning growth most recent quarter biggest jump come vertex pharmaceutical vrtx post
206,VRTX,vertex pharmaceutical vrtx stock pull back friday analyst upgrade share likelihood vertex succeed competitor galapago glpg treat cystic fibrosis needham analyst alan carr upgrade vertex stock buy rating price target top biotech market cap work complete triple pill combination treat genetic mutation tie cystic fibrosis lung disease cf landscape continue favor vertex give substantial lead market few competitor carr write research report expect vertex triple pill combination cystic fibrosis launch late vertex stock fall stock market today biotechs take breather rapid day run carr expect vertex identify least safe effective triple pill cystic fibrosis company be currently testing candidate combination drug know ivacaftor tezacaftor ibd take biotechs be run week generalist investor return space subside worry trump work bring drug price number company see double digit high single digit gain rundown visit ibd industry theme other program be underway galapago abbvie abbv proqr prqr proteostasis therapeutic patient recruitment cystic fibrosis be challenge carr say give vertex lead competitor be likely progress slowly say earlier week galapago say hold trial own triple pill treat cystic fibrosis fourth quarter put galapago more year vertex janney analyst say wednesday related galapago stock fire delay key vertex rivale drugwhy biotech rally still tack upsidebiotechs hit pause day rally regeneron bluebird topple
207,VRTX,nasdaq composite look head weekly gain dominate other key index late afternoon trade friday apple aapl trigger pair sell signal last week sank week move average accelerate turnover be show oomph weekly gain more iphone giant stand less point away regain key support level stock be now past early january early stage cup handle base meanwhile vertex pharmaceutical vrtx be show type price volume action typically see true market leader ibd take succeed growth stock critical know sign major market top latest investor corner show tracking distribution day have allow investor move stock cash top bull run ahead black monday crash oct year boston base specialist cystic fibrosis treatment cool light trading be likely halt day streak yet stock clear deep cup handle large cap member ibd biomedical biotech industry group have rise more less month time tech rich market cap weight nasdaq be less minute left friday session wall street easily overpowering gain practically break even session dow jone industrial average prior week nasdaq fall combine note big picture column current outlook return uptrend resume monday hit time new high ibd industry group big winner have be solar biotech generic drug educational software datum storage desktop software weekly gain more contrast fast slide crude oil future currently week make bear market level correction week high oil drill field service oil machinery well apparel retail western bank stock have pace downside week more last friday dow industrial commodity drive name continue drag blue chip index recent week bank have fail regain positive momentum stock dow jone industrial average be point more include home depot hd goldman sachs gs home depot fall more heavy trading mega cap diy home improvement retailer pierce rise day move average second time less month brick mortar chain be fall sympathy bed bath bbby plummet more whale turnover report dismal fiscal first quarter result ep revenue flat stock issue key sell signal late december gap hard take day move average fail recover bed bath be now more year date vertex however be more jan reason be stock have show classic element bottom base pattern pattern be especially bullish represent opportunity get potential new leader break early stage base bottom base former leader go deep dive usually fall high often more bottom base apple aapl form drag long time frustrate disgruntle holder eventually ditch share vertex case stock dive more low see good first stage basis vertex plow back week week move average start year watch upside resistance turn help generate follow entry success investment new molecule biotechnology vertex have completely turn profit picture lose money then earn cent share last year street see profit vaulting year share next vertex grow revenue analyst expect revenue climb year see ibd stock checkup vertex now sport terrific composite rating scale reflect recent strong increase earning sale stock rise relative price strength vertex biomedical biotech group now rank excellent industry group term month relative price performance related spot major stock market top here be simple ibd far current leader fall check measurepremier growth screen ibd big cap be bottom base do help make money investor corner do distribution day pile black monday
208,VRTX,tuesday sarepta therapeutic srpt earn upgrade relative strength rs rating ibd unique rs rating track market leadership used worst best score identify stock price action last week match rest market history show market biggest winner often have rs rating north begin new run look best stock buy watch start heresarepta therapeutic have moved more past entry first stage cup handle meaning now proper buy zone look stock offer new chance get week tight pullback day week move average earning growth rise last quarter sale fall company earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
209,VRTX,intra cellular therapy itci have relative strength rs rating upgrade tuesday ibd unique rating measure share price movement worst best score rating show stock price behavior last week compare other stock database decade market research show stock go make biggest gain typically have rs rating north begin new climb see ibd help make more money stocksintra cellular therapy be not currently potential buy area see stock go form sound pattern kick new price move earning growth picked last quarter sale fall company be expect report latest number nov company earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
210,VRTX,biogen biib see positive improvement relative strength rs rating tuesday upgrade proprietary rating identify technical performance used worst best score show stock price performance trail week stack other stock database history reveal best perform stock often have better rs rating early stage move see biogen continue show renew price strength clear threshold look winning stock try simple routinebiogen be not currently show potential entry point see stock go form base kick new price move earning growth increase company latest report revenue fall biogen hold rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
211,VRTX,pharmaceutical adms see positive improvement relative strength rs rating tuesday rise exclusive rating investor business daily measure market leadership worst best score score show stock price movement trail week hold other stock database decade market research reveal stock go make biggest gain typically have rs rating least launch largest price move look best stock buy watch start hereadamas pharmaceutical be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week line company post negative growth top bottom line last quarter company be expect report next quarterly number nov pharmaceutical earn rank peer medical biom biotech industry group therapeutic cort ligand pharmaceutical lgnd vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
212,VRTX,stock be mixed celgene celg dive hurt biotechs investor await amazon amzn alphabet googl earning due close spdr dow jone industrial average dium spdr spy rise respectively powershare qqq trust qqq slip home construction financial semiconductor lead upside sector fund stock market today ishare home construction itb advanced spdr homebuilder xhb add biotech oil real estate play underperform spdr biotech xbi ishare nasdaq biotechnology ibb sank respectively moved further day move average line biotechs celgene gap sank month low sale miss view amgen amgn pare loss alexion pharmaceutical alxn vertex pharmaceutical vrtx fall more apiece respective quarterly report most gold etfs fall underlie commodity price oil fund be mostly higher west texas intermediate crude price reversed upward want invest same stock billionaire investor warren buffett so watch fund soon trigger buy point ishare russell value iwd be get close buy point month flat base pull back broader market wednesday be still less entry etf advanced mid february start current base fund track market cap weight index bearing same name turn year old russell value index be compose large midcap stock be consider undervalue market vs comparable equity iwd target cheaper stock index base price book project growth historical sale growth accord morningstar direct financial represent biggest sector weighting oct asset health care be next nearly follow energy just apiece industrial consumer staple information technology iwd top position include berkshire hathaway brkb jpmorgan chase jpm exxon mobil xom johnson johnson jnj top name account nearly portfolio fund year date return oct lag gain average annual return longer haul have also underperform benchmark index year return be roughly line period ibd take look improve chance successful investing watch video learn follow simple routine increase odd iwd annualize dividend yield be ahead average payout half fund top stock be dividend aristocrat company have raise annual payout least past consecutive year top be also hold buffett berkshire hathaway june iwd carry expense ratio wednesday pick vanguard small cap vb schwab small cap scha remain buy range respective entry related dow sell boee ge weigh chance buy small cap earning fuel dow new record high fang play buy zonedow hold gain wal mart rise nvidia lead hot chip sector
213,VRTX,major market index trade mixed early morning trade thursday european central bank decision hold interest rate unchanged taper bond buy program start january dow jone industrial average set morning pace surge moved tech heavy nasdaq decline dow jone industrial component dowdupont dwdp set pace rise nearly company announce preliminary result top estimate stock be now flat base entry meanwhile iphone maker apple aapl advanced higher battle regain day line stock have etch handle cup base move risk optimal entry fang stock amazon com amzn alphabet googl report earning result close analyst expect commerce giant earn cent share year year decline revenue be expect grow share be battle support day line build right side potential base meanwhile alphabet be flat base entry share inched higher thursday also close today internet giant baidu bidu also announce result consensus estimate show china base firm profit grow share jump revenue share be well extend cup base entry share slip company report earning biotech stock be pressure stock market today slew disappointing result amgen amgn trim heavy loss mere decline former lead biotech celgene celg follow plunge miss sale meanwhile alexion pharmaceutical alxn vertex pharmaceutical vrtx be alexion report mixed result sale come bit light vertex top street earning sale target alexion give day line last week vertex fall level monday drugmaker bristol myer squibb bmy adjust income come short compare analyst forecast share drop nearly stock be build right side giant cup handle base potential buy point ibd earning result weigh many lead issue china base education provider tal education tal crash rival new oriental education edu fall sympathy stock plunge day line heavy volume upside pra health science prah reclaim flat base entry rise almost solid earning result related dow jone industrial average dow stock news top chinese school operator miss earning view stock divesfang stock news quote facebook amazon netflix googlethese tech giant ecb dominate thursday investing action planbiotech pharma industry stock news
214,VRTX,nasdaq composite index close week record high heaviest week earning season amazon amzn alphabet googl mmm caterpillar cat be big winner celgene celg boee ba baidu bidu be notable loser nasdaq composite have be week rally friday hit time high rise week amazon amzn alphabet googl microsoft msft surge friday earning apple aapl facebook fb hit buy point ahead earning next week index also rise new high friday week dow climb week hit record level earlier week celgene celg merck mrk several other biotech drug stock sell earning guidance week so do boee ba several defense giant treasury yield rise multimonth high solid economic datum european central bank voting taper bond buy president trump loom decision be next federal reserve chief amazon amzn share soar commerce leader report third quarter adjust earning share cent vs view cent revenue rise include whole food market acquisition amazon complete aug amazon web service revenue soar account well operate profit amazon soar hit record high related amazon blow past earning view beat sale share soargoogle parent alphabet googl vault time high internet giant profit smash estimate google say gaap earning be share year revenue jump top consensus estimate google traffic acquisition cost pay partner website carry ad rise alphabet say grow tac have be overhang google stock share rise friday record high back buy point related google shoot time high beating earning viewsboee ba take charge kc refueling tanker bring total cost overrun taxe taxe charge aerospace giant raise full year cash flow outlook full year core ep prior view ep midpoint be still analyst view boee ep fall top forecast revenue rise estimate boee share fall week related boee shake air force tanker cost outlook imply weak blue chip caterpillar cat mmm throttle earning estimate hike guidance make clear global economy have shift higher gear caterpillar earn share year cent ahead estimate revenue leap construction equipment firm earning guidance share be cent ahead prior estimate see broad growth industrial health care electronic energy segment beating ep cent say expect full year ep earlier outlook week caterpillar rise raise outlook strong earning dow stock gap highcaterpillar soar blowout earning raise martin lmt raise full year outlook earning revenue cut guidance sale aeronautic unit defense giant miss estimate northrop grumman noc also raise ep outlook report result wall street estimate global hawk maker announce wouldn submit bid navy unmanned tanker competition be see major player raytheon rtn report mixed result also raise full year ep outlook however raise guidance be still analyst consensus general dynamic gd quarterly result beat view lockheed raytheon general dynamic share fall northrop rally related lockheed grow leap bound sale slow northrop win bid navy drone contract result beat viewsraytheon report mixed result raise ep outlookbiogen biib slide tuesday beating top bottom line expectation sale spinraza lag view amgen amgn sarepta therapeutic srpt vertex pharmaceutical vrtx deliver board beat third quarter report late wednesday up sale guidance amgen sank sale top drug enbrel fall year year vertex say late stage cystic fibrosis trial fail celgene celg crash thursday revenue miss otezla sale lag consensus lead biotech cut sale guidance alexion pharmaceutical alxn fall weak sale gilead science gild top sale adjust earning view late thursday hepatitis drug sale decline third narrowly miss estimate big pharma giant merck mrk bristol myer squibb bmy novartis nvs eli lilly lly glaxosmithkline gsk fall follow earning report biotech firm top third quarter view only popscelgene result call alarm alexion bristol mixedgilead top sale profit view narrow miss hepatitis drugssoftware giant microsoft msft race past wall street target september quarter point sale view december quarter send stock record high territory friday day microsoft earn cent share year year sale fiscal first quarter analyst expect cent microsoft credit growth cloud compute business related microsoft top september quarter sale earning targetsinvestor cheer intel intc stm teradyne ter september quarter earning report jeered advanced micro device amd ultra clean holding uctt intel top wall street target third quarter sale earning guide analyst higher current quarter rival amd deliver better expect third quarter result disappoint guidance flat gross profit margin current quarter biggest loser be ultra clean plummet thursday mixed third quarter result related intel beat third quarter goal guide highergeneral motor gm ep fall revenue shrank broad slowdown car sale plan reduction fleet sale retreat certain european african asian market result crushed forecast ep revenue gm also guide full year earning consensus gm share have be rally investor see automaker combine strong profit now be lead pack autonomous drive electric car ford earning surge cent revenue rise automotive revenue top estimate ep cent revenue management narrow profit outlook remain consensus fiat chrysler fcau report mixed result china base school operator tal education tal fall short earning estimate penny report flat ep cent revenue climb enrollment more double outlook be line forecast fellow heavyweight new oriental education edu turn mixed result better expect guidance tal education plunge new oriental related china leader be flash long term sell signalsexxon mobil xom report ep rise cent revenue nearly expectation credit higher oil price production refinery margin fellow dow energy stock chevron cvx fall short earning send share friday recent buy point exxon rise friday crude future hit month high mcdonald mcd same store sale beat estimate help drink line signature craft sandwich see thinner margin invest training technology whopper deal burger king likely help comp owner restaurant brand qsr share reversed lower record high friday cost cut promotional switch boneless wing help buffalo wild wing bwld fly nearly thursday even sport bar chain contend elevated price traditional chicken wing question ceo transition chipotle grill cmg share crash concern sale recovery higher menu price next month plan slow new store addition next year visa fiscal fourth quarter result beat top bottom line help solid payment cross border volume strong show visa europe payment volume growth be strong country russia india australia come worry state retail mizuho analyst note mobile tmus sprint call earning call avoid discussion raise speculation merger announcement come november regulatory hurdle mobile add postpaid phone subscriber september quarter sprint add lose report flat profit revenue drop say expect purchase time warner twx close year end analyst say sell be related equity dilution expect twx deal be issue stock finance half deal side analyst say carrier include verizon vz have be restrain promotion soon be release high end apple aapl iphone improve margin december quarter cable tv firm comcast cmcsa charter chtr report higher video subscriber loss lower customer addition comcast have lower guidance early september send stock ahead earning charter stock fall disclose similar trend company aim hike price service video subscriber switch internet tv charter add customer vs estimate charter acquire time warner cable last year comcast add customer vs year earlier baidu bidu crushed third quarter earning estimate chinese search engine giant give weak guidance share plunge friday cisco system csco acquire broadsoft bsft maker communication software telecom company include debt share cisco pass buy ringcentral rng rival software firm fortinet ftnt sank friday maker computer security software forecast december quarter revenue expectation september quarter result beat view grubhub grub report third quarter earning beat estimate provide fourth quarter guidance also top view share surge week breaking buy point td ameritrade amtd top earning view gain revenue growth accelerate fourth straight quarter share online brokerage rise record high servicenow now report earning revenue top expectation billing growth disappoint share enterprise software provider fall earning release close week slightly higher earning call management indicated be strong start aid part few more deal closing normal be push december quarter whirlpool whr crash weak earning news sear longer sell appliance twitter twtr share soar week high better expect adjust earning rise monthly user forecast possible gaap profit
215,VRTX,market confirm uptrend gain steam monday tech heavy nasdaq composite jump monday market surge send lead stock much higher market leader be approach buy point stock market today previous base fail nvidia nvda be back striking distance new buy point
216,VRTX,catch rally biotech sector tack stock celgene celg alexion pharmaceutical alxn regeneron pharmaceutical regn lead charge analyst say week xyear date ishare nasdaq biotechnology etf ibb be same time spdr biotech etf xbi be be currently buy zone strong performance biotech multiple be only just historical time trough leerink analyst geoffrey porge say recovery be underway large cap biotech stock be april beat market handily second quarter still biotechs continue trading significant discount pharma medtech brother porge say note client premium biotechs have enjoy pharma medtech respectively have erode reversed porge be banking return sentiment biotech sector compare revenue multiple group be be still additional upside sentiment sector return prior level say ibd take industry observer say september be make break month biotech sector base number upcoming investor health care conference well expectation nearly dozen trial readout excel be face pitfall head ibd industry theme closer look recovery be already underway late august gilead science gild say pay acquire cancer play kite pharma kite day later rival novartis win approval key treatment set stage key drug kite be approve november announcement ibd company biotech industry group have climb porge call catch rally significant extend be rally investor have be hope look follow surprisingly tepid july group strong second quarter operate result porge say consensus expectation third quarter be pick porge say revenue view be modest call average growth earning share forecast be trend first time year porge be more bullish consensus top pick be outperform rate alexion celgene regeneron vertex pharmaceutical vrtx january even slow grow large cap have deliver outperformance standout include regeneron vertex celgene have more pipeline optionality have not appreciate much lately alexion say be also recommend regeneron vertex current valuation see less upside name celgene alexion related alnylam topple celgene astrazeneca rise drug setbackstop biotech stock buy zone fda drug abbvie chip away regeneron potential blockbuster
217,VRTX,stock market award ph be give prudence humility disaster survival not piggishness hubris denial disaster survival be most important item investor have live bear market have idea contagious panic be fortunately marketwide disaster be rare individual mistake be more common art investing be survive mistake learn first mistake new investor make be think stock market be buy stock brilliant reason market eventually come brilliant idea so believe stock market isn money put stock market be pocket lint compare big fund power shape market so experience investor ask set preliminary question research stock further recent look big cap find stock be day line have quality fund support electronic art ea be trading well day move average number fund hold share increase almost past quarters overall stake fall quality fund stock fidelity magellan fmagx buy share most recently report quarter fidelity contrafund fcntx increase stake paypal pypl be day line fund participation exposure be quarters quality fund buy share include rate fund rowe price growth stock fund prgfx fidelity otc portfolio focpx contrafund vertex pharmaceutical vrtx be day line form base buy point fund overall stake decline past quarters number fund increase quality fund buy share include contrafund rowe price growth pass minimum test aren enough qualify stock buy test be good way cull stock deserve closer look go friday session big cap outperformed past month be careful past month be vs decline big cap related gm stock breaking chip stock probably never hear be back
218,VRTX,celgene celg break friday join biogen biib bluebird bio blue enter buy zone thursday biotechs broadly gap major merger cancer space xin afternoon trading stock market today celgene rise clear entry flat base bluebird continue rise soar top buy point cup thursday bluebird be now extend biogen climb look vertex pharmaceutical vrtx join list biotech breakout near entry flat base begin form late july share lift close amgen amgn advanced potentially close buy point biotech stock have broadly rally week pop nearly announcement gilead science gild acquire kite pharma kite aftermath rival bluebird juno therapeutic juno have enjoy increase ibd take novartis nvs beat kite finish line know car drug therapy teach immune system identify fight cancer approval open new sector cancer treatment head ibd industry theme deeper dive implication novartis new treatment rally be less definitive friday juno rise gilead inched biogen rise remain buy zone top entry yearlong consolidation major exchange trade fund spdr biotech etf xbi ishare nasdaq biotechnology index ibb climb breaking thursday respective ibd biotech industry group rise related biotechs just moved buy zone be giant next biogen alzheimer drug show promise break gilead kite deal boost biotech etf clear buy novartis cancer approval validate gilead kite dealanalyst mixed gilead kite key rival stand benefit
219,VRTX,nasdaq be back record high bring number lead growth stock new high market uptrend continue more more lead stock move break past proper entry market leader be breaking stock market today third be striking distance
220,VRTX,nasdaq composite end modest gain monday help outperformance biotech stock solid show apple aapl china base stock generally underperform recent strength nasdaq manage decent close rise end just day move average gain less dow jone
221,VRTX,nasdaq composite wednesday deflect yet pound crude oil future related company stock market move moderately higher dow jone industrial average harbore light loss late wall street regular session nasdaq composite new york time be stretch year date lead fractionally wednesday dow jone industrial show distribution day past session volume wednesday be run higher nyse vs same time tuesday lower nasdaq ibd big picture column track heavy institutional selling form distribution day witness nasdaq tuesday higher volume monday sudden rash big decline heavier volume prior session be enough bull market nasdaq be nearly jan towering advance dow jone industrial average be also lag gain so far year buy biotech software sector continue unabated aftermath solid quarterly result like adobe system adbe extend january red hat rht also extend early entry long choppy first stage base biotech group jump ibd industry group term month relative price performance celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx pump more higher heavy turnover show kind action see iphone giant apple aapl big run mid early part celgene have market value regeneron be vertex vs iphone ipad macbook maker stock break tend already be close week time high already be trading day move average show tremendous increase share volume show strong finish session price definitely case biomedical name mentioned be highly profitable developer novel therapy address difficult disease chronic condition celgene run higher power past cup base buy point volume be currently triple usual level stock day average volume be share cup be see part long saucer base go way back july peak notice weekly chart celgene have break month saucer pattern july do hairpin curve lower undercut low base such action be healthy shakeout uncommitted investor reset base count back street see first quarter profit summit firm rise share celgene have post ep increase prior quarters celgene sport outstanding composite rating ep rating ibd stock checkup watch see relative price strength score improve term regeneron composite rating ep rating be extend first stage bottom base entry share have soar more so far week however notice weekly chart stock run upside resistance price level vertex composite ep surge fast turnover be move further past recent handle long base give solid entry cent intraday high handle stock slope lower intraday lows correct more back apple megacap tech be show still have wherewithal recover sharp sell prior week trigger key sell signal read stock market today column learn more exact sell rule apple gain volume be light stock be limit drop day move average apple relative price strength rating remain strong now much better lowly see start year however keep mind rs rating cover month worth price action vs rest market extra weight be give most recent month worth action be plenty reason long term holder thick profit cushion keep hold apple be still well long term day move average earning picture be improve fy profit see fy profit revenue growth apple service unit be currently solid double digit pace likelihood major iphone replacement cycle begin fourth quarter current calendar year be very high ibd take way track emerge industry sector rotation market be watch change ibd right now still chock full electronic internet computer networking related stock medical biotechs stage larger presence go here day watch new leader unfold present wonderful new opportunity investing profit ibd tech leader nvidia nvda coherent cohr apply optoelectronic aaoi have re-cover nicely price spill prior week remain solid uptrend related investor corner bottom base make money astute tradersinvestor corner ii apple form bottom base be market head correction soon check big simple way detect key stock market best brightest large cap land today big cap
222,VRTX,biotech galapago glpg have shot make dent cystic fibrosis market lag vertex pharmaceutical vrtx analyst say wednesday galapago push key trial analyst head galapago research development event tuesday expect firm outline timeline trial examine pill series treat cystic fibrosis janney analyst debjit chattopadhyay say note client instead galapago be hold trial fourth quarter pending regulatory guidance chattopadhyay say closest rival vertex plan roll triple combo datum third quarter putt galapago more year positive side cf portfolio have multiple shot goal program do get green light galapago be plan execute multiple triple combination mimic competitor vertex say midmorning trading stock market today galapago stock fall close share vertex jump firm be take triple pill approach treat cystic fibrosis disease lung digestive system triplet combination be expect be able treat genetic mutation tie cystic fibrosis ibd take vertex stock be biotechs be watchlist now head ibd industry theme closer look vertex strongest peer galapago be work narrow potential contender final triplet delay begin trial likely mean galapago partner abbvie abbv finalize selection chattopadhyay say credit suisse analyst vamil divan anticipate delay give relatively aggressive timeline company have layer previously galapago first focus market expand triplet other country say note client accord cystic fibrosis market galapago drug need show improvement drug placebo be clinically meaningful trial see galapago grab open prove drug be equivalent vertex also see potential place new player market give increase flexibility give patient physician term enrolling patient new clinical trial prescribe medicine once be available commercially divan say related amgen gilead biogen win lead biotech boom so vertex rocket month high cystic fibrosis drug resultsgalapago cystic fibrosis drug trial vertex mega franchise rbc
223,VRTX,xstock moved mildly lower friday nasdaq dow industrial dip slip slip tech heavy nasdaq composite be pace weekly gain come consecutive week relatively heavy loss dow jone industrial average show fractional loss week edge early friday defend slim gain week dow industrial upside advancer be scarce jpmorgan jpm coca cola ko procter gamble pg cling small gain downside unitedhealth group unh caterpillar cat fall home depot hd nike nke decline eqt eqt align technology algn pace upside advancer rise respectively downside sysco corp sys drop signet jeweler sig decline harley davidson hog fall analyst action restoration hardware rh vertex vrtx receive upgrade cause retailer vertex reversed lower early gain meanwhile piper jaffray hike price target electronic art ea jpmorgan initiate coverage servicenow now overweight rating share ea servicenow fall earning front bloodbath brick mortar store continue stock market today bed bath bbby fiscal result late thursday retailer miss top bottom line estimate result plunge stock price meanwhile finish line finl revenue come street estimate early friday share still advanced nearly lead retailer ollie bargain outlet olli burlington store burl haven be spare sector carnage last month have see ollie fall back week line be attempt muster support burlington plunge day line thursday early friday ollie decline burlington fall ibd grubhub grub jump macom tech solution mtsi rise momo momo advanced downside regeneron pharmaceutical regn fall mercadolibre meli decline video game maker activision blizzard atvi trade related earning calendar analyst estimate stock watcharista network ea get pt hike logmein rate buy lumentum holddow jone industrial average dow stock news analysisfinish line sale miss amazon nike threat rattle sectorretail commerce news stock watch
224,VRTX,apple aapl continue prove rally bottom base october last year january not be yet biotechs select chip stock help sustain rebound stock wednesday nasdaq composite rally more et outperform gain dow jone industrial average small cap be do even better smallcap gain turnover be run mildly lower vs same time tuesday main exchange note latest big picture column ibd downgrade outlook market uptrend pressure due sell nasdaq higher volume tuesday know distribution flurry big distribution day be enough halt bull market advance even turn bear market lower turnover less hour remain stock market today volume have be average past trading session nasdaq banking stock meanwhile resume advance follow comment federal reserve chief janet yellen appear indicate hike short term interest rate be card rest year yield year treasury benchmark bond edge highest wti crude oil future add more barrel silver future rise gold edge fractionally higher nearly troy ounce comex apple nearly be still hold large portion gain jan excellent cup handle base furnished buy point cent handle high apple then gain much space just month further rebound iphone giant produce new buy point share be hop back day move average currently watch see stock retake line street see apple sale rebound current fiscal year end september follow rare slide fy profit be expect climb share apple hold annualize dividend yield ibd take apple be get boost top line recent quarters due strong demand service observer question apple need make acquisition fuel continue revenue gain area business fulfill goal double business read ibd latest tech team coverage increasingly vital part apple business model see ibd stock checkup apple relative price strength rating continue be positive meaning now beating publicly trade company term month relative price performance meanwhile biotech industry group be show not intend backtrack leadership position stock market today large industry group biggest name celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx be behave well be trading respective day move average sign strength celgene more be wipe away loss prior session break cup base buy point last week chase zone go celgene sport highest possible composite rating earning share rating accumulation distribution mean past week stock have show evidence heavy share accumulation mutual fund bank insurer pension regeneron vertex be extend now provide follow buy point future watch mild pullback day week move average make sure ibd current outlook be show confirm uptrend uptrend pressure signify odd make money be higher vertex more be now extend more past recent past entry long deep first stage base similar bottom base pattern base vertex crumble create massive shakeout chip sector broadcom avgo nvidia nvda be also show leadership quality gain former be also find continue support day line recent flat base nvidia composite ep be extend have yet challenge holder test day move average have be climb sharply more week street see fiscal second quarter earning jump cent share be very impressive light fact nvidia score increase adjust ep year quarter accord research william neil co related buy sell latest investor cornerwhen do current market outlook go uptrend pressure see big top growth stock be perform ibd invest new ipos avoid initial trap
225,VRTX,even nasdaq reversal monday trading many lead stock have significantly rebound past week sector rotation have continue rout technology stock biotechs homebuilder see increase institutional interest biotech stock once again rotate back favor celgene celg be lead stock head charge big
226,VRTX,xbiotech stock regeneron regn amgen amgn biogen biib spin bioverativ bivv have be boom week celgene celg have also joined party now trading upper end buy zone follow wednesday important metric look stock be higher relative strength rating celgene now clear threshold jump thursday ibd proprietary rating identify market leadership worst best score rating show stock price behavior trail week compare other stock database year market history reveal top perform stock often have rs rating least begin biggest price move celgene break wednesday first stage flat base end thursday session just upper end buy range once stock be more initial entry price consider extend earning growth decrease last quarter revenue gain moved higher company earn rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx be also group highest rate stock related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
227,VRTX,bluebird bio blue clovis oncology clvs kite pharma kite climb higher fellow biotech stock incyte incy be try regain foot launch new run tuesday developer small molecule drug treat cancer see relative strength rs rating jump new percentile tuesday increase ibd unique rs rating track market leadership used worst best score indicate stock price performance last week match other stock year market history reveal market biggest winner tend have rs rating least launch biggest price move stock be try complete consolidation potential buy point see break heavy trade tuesday stock be move back day line volume be trend average ep growth have fall last quarters revenue rise company hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx celgene celg be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
228,VRTX,vertex pharmaceutical vrtx investor key more datum cystic fibrosis drug late thursday biotech market cap be set report first quarter earning analyst broadly expect vertex report triple digit growth adjust profit double digit sale growth follow pair trial last month show drug pill cystic fibrosis improve lung function share rocket month high day vertex say combination tezacaftor ivacaftor significantly improve lung function cystic fibrosis patient age specific genetic mutation wall street now be likely look more detail drug regimen more perspective vertex expect have pill regimen also call triplet ready cystic fibrosis ibd take vertex pharmaceutical stock have ibd composite rating best possible meaning outperform stock term key growth metric head ibd datum story closer look stock consensus analyst widely model vertex report cent adjust earning share vs year earlier period sale grow year year basis guidance second quarter analyst view vertex guide revenue adjust earning cent share respective year street forecast adjust earning share sale stock action vertex stock sank less close stock market today share be now year have trade day move average late january related vertex rocket month high cystic fibrosis drug result
229,VRTX,regeneron pharmaceutical regn vertex pharmaceutical vrtx alexion pharmaceutical alxn look likely catch next wave biotech analyst say friday suggest year sector be slate boom win be value stock gilead science gild amgen amgn biogen biib drive boom leerink analyst geoffrey porge tell client note large cap drag performance index exchange trade fund growth stock already seem be capture sustain new investor interest say advice investor remain identify scrutinize evidence competitive advantage look management maximize profitability exist business first foremost ibd company biom biotech industry group be first month finishing boom year stock tack growth group close stock market today such be pattern biotech market porge say typical correction run quarters follow year sideway performance today much excitement mid have dissipate leave share long term median relative multiple consensus expectation biotech sale profit have decline respectively last year sign be get better porge say first quarter result yielded mixture positive negative result vs consensus prompt additional negative revision so far quarter estimate have be remarkably stable ibd take regeneron stock outperformed broad market plunge thursday top saucer buy point head ibd new high list look other strong performer political pressure be also begin subside say president trump have promise introduce competitive system cut escalate drug price meanwhile industry have seemingly begin self regulate drug pricing be exception biogen ionis pharmaceutical ion spinraza spinal muscular atrophy drug debut year treatment first year porge see price tag regeneron sanofi sny eczema drug dupixent price roche rhhby multiple sclerosis drug ocrevus more reasonable furthermore manufacturer establish brand be take more modest price increase fewer be adopt voluntary price increase limit remain too high be step right direction porge say approval many time earlier expect have accelerate year food drug administration hit year low so far year drug have grab fda approval match total last year label also appear broader meaning drug have greater use porge see number drug launch come next month outdo consensus view key be gene therapy rare disease treatment end stage cancer therapy severe disease create process harness rna molecule inhibit certain gene process finally validate capital be invest remarkable technology boom year have seeming head disappointment many point bust last month porge say related biogen takeover prospect soured mere comeback kid regeneron survive amgen cholesterol squeeze
230,VRTX,wednesday vertex pharma vrtx get upgrade ibd smartselect composite rating upgrade mean stock be now outpace other stock term key performance metric technical strength vertex pharma be not currently proper buy zone see stock go form new base offer new buy opportunity stock rocket higher mar result cystic fibrosis drug weak spot be company ep rating track quarterly annual earning growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company report earning gain vertex have now post triple digital ep gain last quarters just barely miss rise top line growth increase prior report mark quarter rise revenue increase vertex pharma earn rank peer medical biom biotech industry group supernus pharmaceutical supn be top rank stock group related company be now outperform stock vertex rocket month high cystic fibrosis drug result
231,VRTX,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
232,VRTX,nobody win time rowe price growth stock fund prgfx come pretty close joseph fath fourth year manager fund have outperformed large cap growth rival track morningstar inc so far year past year respectively fund be go thursday far outrun gain fath have do resort trick play course aware last november election offer ongoing opportunity company benefit rise interest rate lighter regulatory load heighten spending infrastructure write shareholder january investment approach remain largely same past believe discipline fundamental analysis enable identify high quality company durable growth prospect be poise stand broader market say continue favor company have more control destiny be position benefit powerful secular trend be used innovation disrupt less efficient business model create new one see strategy be expressed fund top holding top holding april be alphabet googl so far year amazon amzn be ibd leaderboard stock be apple aapl leaderboard stock be facebook fb be ibd list stock strong relative price strength fundamental be mastercard be fath have place shareholder money just sector end last month fund weighting information technology stock be weighting consumer discretionary be smaller holding also illustrate fath appetite innovator drive secular trend mgm resort mgm be hold tight recent consolidation break april day report first quarter earning share jump newcomer mgm portfolio borgata national harbor casino resort kick result gaming stock get boost news macau gaming revenue rise march then gain april mgm have property macau be slate open new resort cotai section macau later year addition firm have be tame debt debt equity ratio be dec vs ibd take mgm resort rank ibd leisure gaming equipment industry group see fundamental technical datum stack rival ibd stock checkup servicenow now trading be buy zone stretch cup pattern buy point company develop cloud base software automation ep grow past quarters stock have composite rating ibd composite rating start run combine ibd performance rating stock poise move higher often have comp rating higher servicenow also have smr rating ibd mean be top stock term sale growth profit margin return equity ratio base ibd proprietary formula salesforce com crm be stock upswing break double bottom base have buy point now extend past buy point trading demand cloud base application be drive growth company provide customer relationship management software service sporting comp rating smr rating ep rise past quarters more recent buy mutual fund be mercadolibre meli run online marketplace provide electronic payment service latin america widely describe poise growth way amazon be earlier stage life cycle stock be so far year be now extend mercadolibre be ibd member share gap commerce giant report ep revenue growth firm core marketplace perform well mercadopago electronic payment service jump pogo stick total payment volume sprang nearly mercadoenvio shipping service unit see nearly boost item ship stock have smr rating ibd vertex pharmaceutical vrtx trading be extend handle buy point share be year share gap march news strong clinical datum phase trial company cystic fibrosis drug earning share rise past quarters related vroom vroom top fund bet lead stock ferrari
233,VRTX,market end dull thud run loss nasdaq dow jone industrial average be nasdaq seventh straight monthly advance end manage gain dow industrial eke only thinnest fractional advance datum play key role wednesday action dow industrial nasdaq open higher then reverse sharply release chicago purchasing manager index et correct version pmi show much stronger report first release chicago pmi show read hard prior month tally consensus view correct version show read highest mark year well forecast overnight datum china show better expect manufacturing growth steel equipment mining stock normally react positively such news come pressure early session addition claim libya production have re-cover long term ceiling barrel help send crude price almost barrel leave month stock fall then gradually regain ground release federal reserve beige book show continue modest growth increase sign optimism be flagging report be closely watch last beige book report ahead fed meeting interest rate june majority investor expect increase rate pfizer pfe lead dow industrial announce food drug administration european medicine agency have accept submission expand approve use sutent include treatment recurrent renal cell carcinoma patient follow kidney surgery pfizer share be work first weekly advance late april pressure come michael kor kor tenet healthcare thc southwestern energy swn goldman sachs gs goldman jpmorgan jpm drive downside dow stock goldman tumble jpmorgan follow revelation jpmorgan cfo marianne lake speaking investor conference firm trading revenue be year year loss be more subdue nasdaq reilly automotive orly baidu bidu hardest hit apiece top nasdaq vertex pharmaceutical vrtx rise take new high analog device adi thrash higher open then backtrack close higher big trade norwood mass company report big fiscal earning deliver revenue earning guidance analyst expectation share end buy range buy point flat base ibd stock control ctrl roar higher big trade needham upgrade connect home software developer buy price target stock be extend april rebound week move average drugmaker perrigo prgo lead strong first quarter report stock remain deep month consolidation related tech leader high earning loom investing action plan here look semtech broadcom earning
234,VRTX,vertex pharmaceutical vrtx be big winner friday wake slew biotechs drugmaker issue first quarter report thursday stock market today vertex rise climb much best level january meanwhile ibd company biom biotech industry group edge higher celgene celg bristol myer squibb bmy rise respectively abbvie abbv stock drop buy point temporarily achieve thursday share fall friday astrazeneca azn stock fall vertex investor be now key triple pill treatment cystic fibrosis leerink analyst geoffrey porge say report friday see chance vertex successfully bring triple pill regimen market ibd take navigate biotech trading world be tricky relatively unknown name esperion therapeutic espr launch nearly mere month head ibd technology page primer industry player look good vertex decide phase strategy triple regimen latter half biotech be currently evaluate next generation drug be used combination tezacaftor ivacaftor cystic fibrosis drug porge raise price target keep outperform rating vertex stock note investor likely prod vertex stock raise guide cystic fibrosis drug kalydeco separate report porge boost price target celgene stock keep market perform rating miss sale psoriasis psoriatic arthritis drug otezla lead overall sale miss porge note catalyst celgene future celgene portfolio be undoubtedly broader peer management appear be focuse create long term shareholder value focus later stage clinical program write note celgene have key trial multiple myeloma hodgkin lymphoma brain tumor crohn disease have generally be cautious view several late stage candidate celgene pipeline however now expect several key inflection point late stage candidate celgene pipeline next couple year say abbvie buck rocky earning season trend meeting consensus view first quarter sale grow revenue humira porge say report adjust income beat cent result other biopharma name drug immuno oncology market have be volatile notable miss mainly attribute overall market weakness say abbvie result suggest part trend also come share loss give solid performance humira abbvie biggest moneymaker porge be more constructive abbvie outlook year year abbvie see sale top porge boost price target abbvie stock keep market perform rating related acorda topple year low street lag sale lossesalexion beat first quarter sale profit top cent
235,VRTX,share biotech leader supernus pharmaceutical supn briefly break tuesday struggle remain key level support ibd company biom biotech industry group broadly fall stock market today supernus stock lift much top buy point ascend base begin february share settle back buy point close bell end regular session meanwhile biotech stock collectively lose agio therapeutic agio audente therapeutic bold galapago glpg stock be biggest loser drop respective supernus be rank second biotech industry group composite rating meaning outperform stock term key growth metric trail celgene celg be tie bioverativ biiv therapeutic cort vertex pharmaceutical vrtx cytokinetic cytk group ibd take want more information highly rate stock head ibd stock checkup smartest pick biotech stock drop day move average april group be still rank group track last week still big boost just week related biotech unveil breakthrough treatment movebiotech bolt higher drug result
236,VRTX,major market index finished mixed wednesday nasdaq outperformed thank big gain amazon amzn vertex pharmaceutical vrtx amazon rejoin leaderboard wednesday share gain new high average volume top buy range handle buy point initially clear mid february stock
237,VRTX,vertex pharma vrtx see ibd smartselect composite rating jump thursday day revise score mean stock currently top other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb vertex hold spot peer medical biom biotech industry group celgene corp celg therapeutic cort cytokinetic cytk supernus pharmaceutical supn vertex soar wednesday positive result cystic fibrosis drug be add gain thursday now outside proper buy range so see stock go form new chart pattern stock have ep rating meaning recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company report ep growth top line growth come prior quarter related vertex rocket month high cystic fibrosis drug resultswhich company be now outperform stock
238,VRTX,xfuture dow jone industrial average index nasdaq russell signale little change wednesday open bell solid gain tuesday vertex pharmaceutial vrtx dave buster play be likely move sharply opposite direction late tuesday news future dow jone industrial average index russell be fraction higher vs fair value early wednesday nasdaq future be tuesday dow jone industrial average index russell climb nasdaq composite big financial such bank america bac citigroup jpmorgan chase jpm goldman sachs gs fall day move average last week bond yield fall investor worry prospect tax cut other part president trump agenda tuesday citigroup dow industrial component jpmorgan chase moved key support level bank america goldman sachs dow stock cusp meanwhile vertex pharmaceutical late tuesday report experimental cystic fibrosis drug improve lung function vertex say file approval fda european equivalent third quarter vertex share shot hour trading be month high dave buster report better expect earning late tuesday sport bar arcade operator give cautious sale guidance dave buster stock fall more late trading dave buster have close tuesday slightly extend buy point japan nikkei be flat wednesday intraday trading most other asian market be modestly higher related good day bull index score solid gain darden break outdow jpmorgan retake key support tesla focus investing action plandave buster guide light beat ollie top guide high
239,VRTX,vertex pharmaceutical vrtx sank more late wednesday biotech top second quarter expectation reiterate sale guidance xin hour trading stock market today vertex share dip close share have climb year strong datum triple pill treat underlie genetic mutation tie cystic fibrosis quarter vertex total sale cystic fibrosis drug grow vs year earlier quarter sale drug orkambi comprise nearly third total kalydeco bring balance second quarter end june total sale grow top consensus analyst poll zack investment research adjust profit rise year year cent share beat cent ibd take biotech stock be now rank third group track ibd miss send higher be merger acquisition say industry observer visit ibd industry theme look potential buyer seller vertex keep guidance cystic fibrosis drug sale orkambi bring kalydeco accounting biotech expect spend more research development cost year continue development triple pill earlier month vertex catapult day strong datum trial related vertex hit record high result cystic fibrosis techs hammer new high nasdaq ralliesvertex catapult strong trial cystic fibrosis
240,VRTX,biotech stock have show somewhat predictable pattern ibd first identify biotech stock industry group innovative power new medicine biotech stock naturally have period steep climb also have sharp sell off monthly chart be easiest place see pattern most recent sell start june
241,VRTX,september be make break month number biotechs include alnylam pharmaceutical alny axovant science axon versartis vsar be expect present phase datum upcoming week xbiotech stock be poise run say loncar investment chief executive brad loncar year date ve rise hit month high share have rise follow gilead science gild announcement acquire kite pharma kite come incredibly newsworthy september feature least major medical conference least big investor conference nearly dozen phase trial expect read loncar tell investor business daily be most newsworthy month biotech history say so amazing september be be ton phase trial be schedule read company be go succeed fail trial readout count be make break company loncar say loncar count key trial readout september principal note be alnylam be expect unveil result trial drug dub patisiran rare disease cause buildup abnormal material call amyloid body success be major catalyst technology know rna interference antisense essentially turn malfunctioning gene leerink analyst paul matteis write note client tuesday ibd take novartis ibd relative strength rating be boost friday best possible grade show stock price moved past week other stock database head ibd datum story see novartis stack rival ionis pharmaceutical ion be also work phase drug know inotersen treat disease call ttr amyloidosis matteis call upside depend magnitude success safety downside drug prove effective mixed safety see downside alnylam drug fail completely trial accord loncar most person be convince go succeed cite note see range failure success putt alnylam stock price share close tuesday company window say be bellwether biotech company everyone be count succeed probably trial fail stock crash alnylam loncar note axovant be expect announce result drug dub intepirdine mild moderate alzheimer disease recently biogen biib stock break strong phase datum alzheimer trial axovant be work different theory treat alzheimer intepirdine be know serotonin receptor antagonist have potential cognition memory learn enhance side effect be originally develop glaxosmithkline gsk sell axovant so far nothing have work alzheimer so always excitement trepidation trial readout disease loncar say last december eli lilly lly topple drug solanezumab fail phase trial alzheimer axovant do succeed see stock go day say axovant close tuesday extreme kind euphoria alzheimer create also note trial versartis zogenix zgnx growth hormone deficiency form epilepsy know dravet syndrome respectively win just be september chock full catalyst leerink analyst write note client tuesday solid year return biopharma stock be still number catalyst back half year large cap leerink geoffrey porge note abbvie abbv have datum trial inflammatory cancer drug alexion pharmaceutical alxn be expect grab approval drug soliris treat disease immune system attack healthy cell amgen amgn update label ldl cholesterol lower drug repatha include add benefit cardiovascular outcome meanwhile regeneron pharmaceutical regn sanofi sny be appeal court decision vs amgen rival drug praluent celgene celg have readout ulcerative colitis form hodgkin lymphoma fibrogen fgen be expect have datum fibrosis anemia drug analyst expect vertex pharmaceutical vrtx provide update datum cystic fibrosis trial gilead kite car drug likely be approve treat aggressive form hodgkin lymphoma november follow approval novartis nvs kymriah car drug treat form acute lymphoblastic leukemia patient age expect car remain most closely follow emerge area biotech second half leerink analyst michael schmidt write note launch kymriah read drug bluebird bio blue juno therapeutic juno adaptimmune therapeutic adap related biogen alzheimer drug show promise break partnership bit dust gilead kite break biotech giant close buy novartis cancer approval validate gilead kite dealgilead kite deal boost biotech etf clear buy point
242,VRTX,boston area team enter winner circle star take break work super bowl champ tom brady new england patriot last year fidelity investment hope same be true growth discovery fund fdsvx jason weiner take month leave absence next year leave new co manager call signal xasher anolic become co manager july give more month grow more familiar fund marquee manager weiner start leave jan travel family pursue educational opportunity anolic age be pair industry top name go thursday fund weiner have helmed be year outperform large cap growth rival track morningstar inc averaged gain be past year fund top peer weiner have be helm february try massage fund best growth opportunity market be offer overlay valuation sensitivity say weiner be year old unit growth buy minimize valuation achieve fund do better not hard see portfolio be cook moment vertex pharmaceutical vrtx be hold share price have more double year amazon com amzn be netflix nflx have climb ibd take vertex pharmaceutical amazon netflix be leaderboard ibd premium service spotlight play play top stock amazon netflix be also buy point ibd reader optimal price buy stock be poise start big run gain scant day weiner ibd leaderboard stock be be vertex amazon netflix
243,VRTX,gilead science gild end do nothing oncology right takeover deal doesn present chief executive john milligan reportedly tell analyst wednesday third largest biotech market cap gilead have struggle decline sale hepatitis drug several quarters first quarter gilead hint be look buy oncology player gilead remain mum potential merger recent second quarter appear gilead be look acquisition leerink analyst geoffrey porge write note client meeting biotech management wednesday firm be struggle identify such opportunity ceo john milligan explain didn think make much sense buy something small today hope grow something large porge say instead milligan be look company substantial datum value scale analyst have suggest gilead look acquire company tesaro tsro incyte incy clovis oncology clvs kite pharma kite cancer vertex pharmaceutical vrtx cystic fibrosis recently unite therapeutic uthr spiked potential gilead take ibd take biotech industry be await merger acquisition spike higher say industry observer do gilead fit visit ibd industry theme closer look gilead also note still interested fibrosis program buy firm nonalcoholic steatohepatitis nash program phenex pharmaceutical nimbus therapeutic nash be liver disease meantime gilead be call decline hepatitis unit beating view second quarter porge see revenue hepatitis drug fall then dip annually decline be likely accelerate better competitive hepatitis regimen come market write outlook company hiv business remain positive be not sufficient offset dynamic hepatitis business competitive regimen abbvie abbv mavyret gain approval earlier month treat genotype hepatitis gilead acknowledge abbvie biggest advantage be treatment genotype rivale gilead epclusa sovaldi chief operate officer kevin young say contract cycle be now full swing doesn mean payer defer abbvie mavyret gilead drug mavyret be be price discount gilead harvoni epclusa porge say note last week hiv unit gilead remain bullish chance fend glaxosmithkline gsk be work drug combination recently concern have emerge regard safety glaxo double drug hiv question infection ability adapt treatment gilead stock close stock market today related gilead be make acquisition not thinkhow abbvie gauntlet squeeze gilead drug hepatitis cgilead hepatitis franchise topple again share beat
244,VRTX,biotechs lead alexion pharmaceutical alxn gilead science gild vertex pharmaceutical vrtx outperformed pharmaceutical brother june quarter analyst say earning season near close xleerink analyst geoffrey porge estimate large cap biotechs sale top wall street expectation average most impressive beat come alexion gilead vertex biogen biib alexion sale top consensus gilead hepatitis unit fall again quarter total revenue top vertex report sale beating biogen top sale comparison pharma company result be more tepid eli lilly lly merck mrk deliver significant revenue surprise otherwise fairly tepid result consist modest beat line result modest miss porge say note client last week dow component merck lilly top consensus respectively bristol myer squibb bmy glaxosmithkline gsk roche rhhby deliver modest beat novartis nvs astrazeneca azn nordisk nvo be line sanofi sny pfizer pfe johnson johnson jnj miss earning side performance be even more robust biotech porge say large cap biotechs beat average relative consensus bigger pharmas deliver earning top consensus average revenue growth vs year earlier quarter be biotechs drug firm average porge say board company report improve patient access drug well positive demand inventory currency effect ibd take biotech fever look chilly late july sector overcome challenge outlined ibd industry theme report
245,VRTX,quarter rare disease player biotech side do particularly well brad loncar chief executive loncar investment tell investor business daily biogen vertex sarepta therapeutic srpt positively surprised market spinraza treatment spinal muscular atrophy biogen ionis pharmaceutical ion nearly triple consensus model drug bring obliterate view analyst say sarepta absolutely crushed analyst expectation rise month high july key drug exondys treat duchenne muscular dystrophy bring more analyst have expect sarepta also cut loss expectation half think category drug investor have be expect payer pushback loncar say so far hasn show be ever group company be go boom more rare disease company sentiment have soured biotech sector hit month high late july loncar cite political uncertainty note lion share biotechs drugmaker revenue earn product beat expectation raise guidance fact re not trading indicate investor have already reset expectation year so maybe just hasn be quite impressive context say have big run come earning season play factor well uncertainty tax reform be keep most major player look make big deal porge say trump administration have yet offer further detail plan cut corporate tax rate make corporate inversion less desirable gilead have be gun buy something wake slow hepatitis sale didn comment second quarter call dow pfizer say putt deal pause await more tax situation washington loncar note pfizer call be really crystalize theme broader medtech sector have previously say big deal biotech really send stock higher look unlikely term mega deal be pause happen happen say pretty disappointing shouldn really affect call bolt deal mega deal seem be hold thing related gilead hepatitis franchise topple again share be beatwill pfizer cancer drug help grow merger biotech just blow past buy point sale beatastrazeneca beat stock dife drug failure more reportvertex sing late crush sale profit expectation
246,VRTX,ironwood pharma irwd have relative strength rs rating upgrade monday ibd unique rs rating track market leadership show stock price movement last week measure other stock major index history reveal top perform stock typically have rs rating least early stage move ironwood pharma be not currently potential buy area see stock go build promising consolidation ignite new run ironwood pharma report negative growth top bottom line last quarter company be expect release next quarterly number aug company earn rank peer medical biom biotech industry group celgene celg supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
247,VRTX,biotech investor likely be key launch biogen biib spinraza regeneron regn dupixent first quarter result roll analyst say wednesday sector preview ibd company biotech industry group be rank group track just week first quarter be choppy inventory seasonality challenge leerink analyst geoffrey porge say wednesday analysis suggest be not go be particularly impressive quarter large cap name coverage universe neither be go be disaster slow result suggest write note client give flux shipping day inventory level investor be likely pay most attention key launch already underway anticipate biogen spinal muscular atrophy drug ionis pharmaceutical ion be likely be scrutinize recent payer pushback meanwhile investor be look commentary roche rhhby multiple sclerosis drug ocrevus hurt biogen ms franchise celgene celg be also work ms drug ozanimod expectation be still high regeneron sanofi sny dupixent eczema injection launch end first quarter initial feedback company physician month be critical assess launch sale trend especially anecdote accessibility patient price announcement write ibd take gilead science be suffering slow hepatitis drug franchise buy decline head ibd industry theme better look gilead have sight acquire amgen amgn regeneron be also likely get question reimbursement change medicine lower bad ldl cholesterol amgen show recent study lower ldl cholesterol reduce risk heart attack stroke street be hope push payer reimburse drug upcoming filing investor look amgen commentary migraine drug erenumab romosozumab drug treat osteoporosis postmenopausal woman alexion pharmaceutical alxn be work soliris neuromuscular disease vertex pharmaceutical vrtx be testing tezacaftor cystic fibrosis gilead science gild be likely comment hiv drug bictegravir gilead be push hiv drug potential replacement decline sale hepatitis drug company hepatitis unit rake north year fall related gilead hiv franchise plan be dash trumpcare gilead be pay price actually cure diseasebiotech etfs defy trump tweet rally send higher
248,VRTX,eli lilly lly abbvie abbv top credit suisse evaluation pharmaceutical company head leave more challenged pfizer pfe astrazeneca azn nordisk nvo dust pharmavalue list do little ibd company medical ethical drug industry group fall fraction stock market today fifth consecutive day group be more year touch month low monday be trading day move average ibd take biotech pharmaceutical stock have be trample last month earning report come climb wall worry credit suisse rank big pharma stock factor enterprise value net present value pricing replacement power sale growth overall eli lilly top list europe base sanofi sny novartis nvs trail closely abbvie rank highest fundamental investor likely assume long life span humira credit suisse analyst write research report humira be brand name adalimumab abbvie drug treat arthritis plaque psoriasis ankylose spondylitis crohn disease ulcerative colitis abbvie stock slip small fraction monday lilly stock fall nearly meanwhile pfizer be weak board astrazeneca have high ev npv enterprise value net present value nordisk be expose pricing pressure astrazeneca investor be potentially factor oncology pipeline credit suisse say recent result other demonstrate significant risk teva pharmaceutical teva score well ev npv valuation most sale power drive generic division gilead science gild incyte incy vertex pharmaceutical vrtx be trading discount vertex only need minimal further pipeline success justify current valuation report say biotechs vertex top credit suisse list amgen amgn flail bottom pharmaceutical ibd company medical biom biotech industry group have be month group fall fraction monday ethical drug group also fall fifth straight trading day fall seventh day past trading day bottom overall astrazeneca score well term pricing power shift oncology product nordisk be eye diabetes rebate storm credit suisse say pricing power credit suisse analyst note be important help company resist discount pressure formulary manager government regard allergan agn be clear winner only shire shpg rivale dry eye market alexion pharmaceutical alxn focus rare disease be most exceptional biotech analyst say biomarin bmrn incyte vertex also get high mark be unique bristol myer squibb bmy eli lilly beat cohort productivity ability drive current pipeline follow dramatic seesaw bristol myer squibb merck mrk bristol myer lung cancer drug opdivo fail meet key endpoint eli lilly score well launch trulicity diabetes taltz psoriasis
249,VRTX,investor toast third quarter strongest year september alone be exciting bottle bubbly go flat third quarter rise lift diversify stock mutual fund average broad market advanced barely breaking even september nose upward modest stock fund edge ahead mere last month raise stock fund gain year date stock market start stop motion third quarter have prompt many fund manager plan ahead sticking name drive strong trend such shift cloud compute company seem capable grind growth matter blah growth be broader economy click here see list ibd mutual fund quarterly leader first half year see more defensive lead rally say lew piantedosi manager eaton vance fund total asset reversed cyclical tech industrial do better click here see list mutual fund month leadersworld equity fund advanced outperform diversify stock fund last month world equity fund rise china regional fund gain lead world equity market september rac return cyclical sector stay hot then stock tie transportation industrial good commodity continue third quarter gain piantedosi hold norfolk southern nsc gain third quarter focuse growth opportunity class eifgx july tax manage growth eitmx hold union pacific unp rolled gain most cyclical lose head steam piantedosi prefer long view focus big picture growth trend be sustainable shift macro noise say facebook fb amazon amzn alphabet googl be sustainable grower benefit great secular tailwind say name have do well especially amazon still runway ibd take ibd brian deagon analyze tailwind drive amazon buy sell column julie mak point lead mutual fund have be selling alphabet amazon tech sector be acquisition seem be pick say click here see list mutual fund category say investor brace volatility election democratic white house senate house republican hand mean continue gridlock say still impression be support tax reform be grow party be huge positive say health care wary many drugmaker due political call price regulation still like celgene celg vertex vrtx biogen biib biotechs feel little safer biotech drugmaker say be do wonderful thing cure big disease combine positive reward risk re beaten trading valuation attractive valuation retail like few name area watch head holiday especially more apparel oriented stock piantedosi say be short term theme macy have go markdown have discount last year overstock say mild winter dampen consumer demand warm clothe competition be stiff amazon company have do great job manage inventory go holiday year piantedosi say expectation be low ve be monetize real estate selling close unneeded location continue home improvement giant lowe low home depot hd housing be still strong say interest rate be still low consumer be stock price have come little fear housing slowdown jeff rottinghaus rowe price manager growth income prgix large cap core trulx say stock price general seem fairly price like name health care price have be push call becton dickinson bdx medtronic mdt unitedhealth group unh quiet none be political pressure drug pricing becton develop medical supply medtronic develop implantable cardiac device other product unitedhealth be industry biggest manage care provider yet rottinghaus be shopping biotechs price be so beaten be underweight tech sector like company benefit secular trend cloud compute growth include alphabet microsoft msft also like sustainable secular growth visa facebook rottinghaus also like nextera energy nee have dividend yield largest renewable energy generator say dividend yield be roughly wouldn own low double digit earning growth expect growth oriented sector lead stock fund third quarter charge science technology fund zoom ahead quarter top september gain health biotechnology fund be also strong manufacturing gain quarter small cap growth fund gain average lead diversify stock fund category left year september gain be related stock fund manager seek scarce profit durable growth stocksmarket tread water august investor shift growth stock
250,VRTX,biotech gilead gild be most likely scoop incyte incy next month accord survey industry watcher evercore isi investment bank ahead presidential election pit donald trump hillary clinton survey say most see gilead purchase incyte identify incyte biopharma most likely be acquire next year nearly respectively see biogen biib biomarin pharmaceutical bmrn target gilead acadium pharmaceutical acad celgene celg kite pharma kite be least likely be target only industry expert identify likely takeover candidate departure needham analysis last week identify potential suitor acadium incyte takeover likely come heavy price june gilead have cash equivalent market security hand market cap gilead be biotech trail only amgen widely view big biotechs most need be active front incyte have market capitulation smaller coalition say gilead buy vertex vrtx bristol myer squibb bmy outside lion share expert expect biotechs outperform broader market next month respondent say biopharmas merely be line trade election say expert ibd company medical biom biotech industry group be year loss be early year overall market tumble group be more late june now rank group track just week close stock market today group be more buck day downtrend ibd take latest industry snapshot explore biotech promising new drug stock be lead biotech sector drug pricing initiative rout stock year rbc analyst say thursday acknowledge drugmaker amgen amgn gilead celgene biogen regeneron regn vertex easily find loophole skirt new regulation still fewer person poll evercore expect government take meaningful action drug pricing nearly largest chunk say government win ever push reduction drug price other prediction stem specific company only expect eli lilly lly alzheimer drug solanezumab hit cognition function endpoint more broadly say hit cognition miss function more half say celgene phase testing ged oral mongersen treatment crohn fail reach overwhelming efficacy see phase testing phase patient take milligram be clinical remission day small say celgene see better result phase testing only expect study fail entirely result show endoscopic improvement respondent say celgene stock pop third expect share remain stagnant related gilead paralyzed likely hep share lossamgen biogen gilead spike va pricing skirt california pharmaceutical fall combo therapy eylea alone
251,VRTX,california ballot initiative require state medicaid arm buy drug comparable price department veteran affair pay backfire thus preserve sale nation biggest drugmaker rbc analyst michael yee say thursday proposition california drug price relief act cdpra sound good theory yee write research report assume drugmaker don simply eliminate steep discount already provide va say happened year congress pass law require drugmaker grant medicaid similar discount give manufacturer larger customer write law ultimately prompt manufacturer raise price paid larger customer include va likely be fate cdpra write californian appear overwhelmingly support initiative early month university southern california los angele time survey find respondent approve cdpra san francisco firm poll july find support drugmaker amgen amgn gilead gild celgene celg biogen biib regeneron regn vertex vrtx cdpra offer merely headline risk yee write assume large price cut medicaid sale earning decrease only company product be expose medicaid state enact such measure mean earning share risk large cap player yee write year california be alone initiative ohio proposition didn make ballot however va price discount then probably become nonexistent lower va price lead reduce medicaid price write note medicaid already get discount date cdpra opposition have only spend donation yee expect spending ramp significantly ahead nov ballot rbc research show proposition be win side have most funding cdpra supporter have raise only supporter include former presidential candidate bernie sander say cdpra save californian taxpayer year va pay less other government agency prescription drug opponent argue cdpra invalidate exist contract state drugmaker force increase state drug price reduce funding medi cal initiative also increase state expense employee spend time resource match state price va pay ibd take ibd company medical biom biotech industry group rank group track have climb just week stock have heated wall street expectation major big pharma action however stock market today group close hurt intra cellular therapy stock plunge
252,VRTX,vertex pharmaceutical vrtx share fall tuesday say late monday have stop cystic fibrosis drug trial due futility phase trial be testing combination vertex ivacaftor sell individually kalydeco combination pipeline drug call vx treat cf patient copy del mutation copy mutation result minimal cftr protein function know het min patient independent monitoring board conduct interim analysis determine wasn enough improvement patient lung function be worth continue nonetheless vertex say combo work extra help result suggest triple combination regimen provide group person cf best chance obtain meaningful benefit look forward begin first study next generation corrector together vx ivacaftor group patient later year pending datum ongoing phase study healthy volunteer vertex chief medical officer jeffrey chodakewitz say statement ibd take orkambi launch last year turn vertex profitable last quarters previous year loss have drag longer term measure such ep rating year sale growth rate still analyst be forecasting strong earning growth least so rating likely improve indeed most analyst have be see triple combo rather double successor vertex currently market drug orkambi so weren too disappoint failure duo effect failure vertex expect entry additional cf population likely be small expectation be low vertex be continue plan investigate next generation triplet therapy het min patient population launch potentially early write evercore isi analyst mark schoenebaum email success fail trial have open population largest remain untreated cf subpopulation cf patient patient treatment year be expect company have be clear long term goal rest triple combination leerink analyst geoffrey porge note lack safety issue trial be important future combo orkambi currently treat majority potentially addressable patient vx be associate discontinuation due side effect have lower persistence patient therapy have reduce peak revenue potential orkambi porge write research note cleaner safety profile especially term shortness breath vx still increase revenue show superior efficacy orkambi open new patient subpopulation vertex stock close stock market today vertex stock hit month high last tuesday share be not highly rate ibd relative price strength rating just
253,VRTX,typically slow stretch late august biotech news be bound pick company prepare fall season conference investor day most stock move event likely be update key clinical trial several expect september celgene celg be due release long await midstage trial result ged mongersen drug crohn disease license drug initially spark excitement wall street strong week remission rate beat even lead inject tumor necrosis factor drug such abbvie abbv humira johnson johnson jnj remicade amgen amgn enbrel next datum set cover full year evaluate patient endoscopy rather just symptom investor confidence be somewhat shake celgene refuse provide interim analysis trial interpreted lack confidence number leerink analyst geoffrey porge write close inspection earlier datum also raise red flag trial be consistent earlier phase ii result original investment be make endoscopic remission rate be range be well see even best biological immunomodulator porge write july research note fact assessment earlier result lack crp reactive protein response be biomarker crohn disease inflammatory activity suggest result be materially lower tnfs remission rate more likely be range note ged be oral rather inject still find market niche not be mega blockbuster initially hope ibd take medical biotech group have be roll lately rise ibd industry group ranking last week see other industry be hot follow industry theme column kite pharma kite be expect release headline datum zuma phase trial car cell therapy kte diffuse large cell lymphoma car cell chimeric antigen receptor cell be genetically engineer attack cancerous cell trial result be crucial kite hope use file fda approval treatment make first car therapy hit market next year rbc capital market analyst michael yee estimate friday study yield overall response rate percent tumor shrank perhaps complete response rate tumor disappearance base earlier datum initiation report tuesday btig analyst dane leone write much depend datum stack result competitor juno therapeutic juno novartis nvs be yet unknown novartis present pivotal datum set ash potential first datum cd specific antibody write leone refer american society hematology conference december juno be also expect present clinical update ongoing cd trial vertex pharmaceutical vrtx provide report triplet pill cystic fibrosis consist already market drug ivacaftor kalydeco combine experimental drug vx additional drug vx vx trial ivacaftor vx alone recently fail do present clean safety profile analyst have be expect triplet be next generation treatment case also month fda be due render verdict expand label vertex already market cf drug orkambi child age related be epipen price fda fault hold new generic novartis close cell therapy unit car stock tumblebiotech stock seesaw hope meet new pricing fear
254,VRTX,acorda therapeutic acor have relative strength rs rating upgrade friday ibd unique rs rating identify market leadership show stock price action last week measure other stock database year market history show stock go make biggest gain tend have better rs rating early stage move stock be not proper entry right now see be able form break proper base earning grow last quarter prior report revenue also increase company hold rank peer medical biom biotech industry group celgene celg supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
255,VRTX,jpmorgan large cap growth fund seegx be barrele fast lane manager giri devulapally fuel lot financial technology stock include morgan stanley ms mastercard apply material amat ibd friday rally broad market midday key fund holding be rise too chip gear maker apply material be internet television network netflix nflx be regeneron pharmaceutical regn maker eylea macular degeneration eye treatment be consumer electronic colossus apple aapl be credit card provider visa be fund be year go friday top large cap growth fund peer track morningstar inc averaged be mutual fund gain past month top peer well have fund achieve such eye pop gain start fund investment approach fund literature boil target company large market sustainable competitive advantage strong price momentum large cap growth fund seek harness return potential america fastest grow company fund be rare naming strong price momentum trait seek stock indicate acknowledgement technical analysis play important role stock selection financial tech be jpmorgan large cap growth largest sector overweight june vs benchmark russell growth index devulapally recently tell shareholder financial still have positive view company exposure capital market interest rate information technology overweight add continue be drive variety industry such payment semiconductor video game software mobility outlook have lead devulapally fund such holding money center bank morgan stanley stock be so far year brokerage charle schwab schw year benefit float customer cash float be profit cash time customer authorize disbursement cash actually leave account rise interest rate lift profit float tech stock grouping credit payment processor mastercard be year chip gear maker apply material be ibd take apply material be member ibd list stock strong relative price strength fundamental video game publisher electronic art ea member ibd be year earning share grow past quarters nice rally prior quarters ep fall software space digital medium marketing software firm adobe system adbe vault past wall street estimate fiscal second quarter june report accelerate sale earning growth period also guide analyst higher ep grow past stanzas digital medium segment provide total corporate revenue online payment processor paypal pypl ibd stock be year other holding vertex pharmaceutical vrtx have ibd composite rating share price have soar year strong datum triple pill treat underlie genetic mutation tie cystic fibrosis have be key driver stock biotech company expect spend more research development cost year continue development triple pill graphic chipmaker nvidia nvda yet member ibd benefit shift more use graphic process unit away regular cpu computer chip faster process speed application such gaming artificial intelligence self drive car ep grow triple digit pace past quarters nvidia be stock ibd electronic semiconductor fabless industry group earn spot part post jump sale last quarter annual pretax margin compare other technical fundamental strength rival ibd easy use stock checkup tool else do fund have go large cap stock mutual fund have outperformed other diversify stock fund category past month well past year reflect fund commitment large cap stock own dow jone industrial stock visa microsoft msft apple home depot hd visa be also fund payment stock be year software titan microsoft be year iphone maker apple year be devulapally mobility stock home improvement retailer home depot fall nearly tuesday company report result beat wall street expectation ibd report analyst see potential slowdown stronger full year outlook pull back thursday friday share be year related reynold american bolster jpmorgan large cap growth make boss add
256,VRTX,biotech stock topple midday thursday line broader index include pitfall large player vertex pharmaceutical vrtx unite therapeutic uthr spark therapeutic once long term view look weak uncertain xon stock market today vertex dove unite therapeutic fall spark dip broadly ibd company biotech industry group lose reflect major index trend follow beat amgen amgn biogen biib gilead science gild vertex celgene celg alexion pharmaceutical alxn week vertex increase guidance vertex keep full year view see slowdown third quarter leerink analyst geoffrey porge trim third quarter view vertex cut sale forecast keep outperform rating vertex price target stock get haircut second quarter sale cystic fibrosis drug orkambi kalydeco beat expectation porge note be due inventory stocking ahead anticipate summer slowdown vertex be also work triple pill cystic fibrosis outside cystic fibrosis franchise vertex say earning conference call look make small technology base early stage acquisition likely avoid large stage large investment many investor fear porge say report unite therapeutic second quarter sale be highest company have ever see resumption growth be not guarantee leerink analyst joseph schwartz say note client unite be work drug treat rare blood disease know pulmonary arterial hypertension pah schwartz increase third fourth quarter sale model strong second quarter report ibd take biotechs be now rank fourth group track ibd merger acquisition send higher vertex consider takeover target acquirer circle get deep dive ibd industry theme due lack curative therapy pah provide suite pah medicine keep patient transition unite product say however be reluctant assume rebound product sale quarter materialize resumption growth trajectory other unite product also thursday alexion celgene top expectation alexion rise celgene still dip investor be likely look celgene raise top line guidance instead celgene lift adjust profit forecast year share main surprise result be lack increase top line guidance normally have expect time year leerink porge say second quarter be only time celgene have not increase revenue guidance second quarter elsewhere biotech analyst be more bullish gilead see hepatitis drug sale fall collective slower revenue harvoni sovaldi beat analyst view predict fall porge say raise price target magnitude beat point stabilize hepatitis drug sale say windfall be short live however abbvie abbv next generation doublet be set enter market week be likely represent first real competition gilead hepatitis dominant market position related astrazeneca beat stock dife drug failure more reportthis biotech nearly triple street expectation key druggilead hepatitis franchise topple again share beat
257,VRTX,vertex pharmaceutical vrtx stock rocket nearly fourth late tuesday biotech report positive phase result triple pill treatment cystic fibrosis rivale fellow biotech galapago glpg hour trading stock market today vertex have catapult rise regular session meanwhile share galapago give back earn regular session be share have climb close regular session triple pill regimen aim correct underlie genetic mutation associate lung condition know cystic fibrosis vertex be hope ultimately treat patient north america europe australia condition accord vertex news release be first datum demonstrate potential treat underlie cause cystic fibrosis patient have severe difficult treat type disease datum phase trial show improvement patient ability forcefully expel air course second combination used drug know vx vx respectively air expel improve percentage point baseline average ibd take vertex be expect be lead biotech rally second quarter earning season head ibd technology page more biotech rally still see upside phase trial patient specific set mutation ability forcefully expel air improve percentage point baseline average treat triple pill include drug know vx overall trial test different triple combination used vertex next generation corrector regimen be generally well tolerate study majority adverse event be mild moderate vertex say related gilead acquire biotech vertex be still better analystgilead vertex join don hold breath analysteven upgrade couldn save vertex biotech deluge
258,VRTX,nasdaq add ninth day rally wednesday longest month round technology stock soar new high xnetherland base asml hold asml gap more heavy volume boost strong second quarter result share climb maker lithography system used map
259,VRTX,vertex pharmaceutical vrtx stock blast record high wednesday phase trial datum triple pill regimen have cystic fibrosis patient breathe easy accord analyst xby close bell stock market today vertex have catapult earlier run more heavy volume share hit time high help biotech stock gap collective stock launch follow vertex announcement late tuesday better expect result trial testing drug know vx vx vx combine other cystic fibrosis drug patient treat combination be better able forcefully expel air average vertex be likely advance triple pill regimen phase trial credit suisse analyst alethia young suggest vertex gain accelerate approval triple pill phase trial act confirmatory study term accelerate approval think question come size safety database next generation corrector be novel mechanism action write note client vertex be look possible combination triple pill regimen aim treat underlie genetic mutation associate cystic fibrosis lung condition analyst broadly expect shorter trial population patient specific mutation be limit treatment option vertex be now year ahead prior estimate year ahead potential competition say janney analyst debjit chattopadhyay fellow biotech galapago glpg be also work triple pill regimen cystic fibrosis ibd take vertex big move land biotech ibd leaderboard wednesday company now hold ibd composite rating meaning outrank other stock market clearly be outstanding question compound advance pivotal program be high class problem have base efficacy tolerability profile thus far write note client chattopadhyay call triple pill combination add company sale see vertex cystic fibrosis franchise approach peak sale expand compound annual growth rate leerink analyst geoffrey porge boost price target vertex stock see vertex likely succeed type cystic fibrosis patient specific genetic mutation previously porge forecast vertex launch triple pill vs earlier view model sale grow longer term overall sale cystic fibrosis drug be expect reach vertex have be cautious price triple pill porge say expect regimen cost be lower price vertex orkambi pill cystic fibrosis treatment give outcry concern exist price vertex combination larger addressable market product believe be most prudent forecast company revenue growth base increase patient adoption treatment persistence rather forecasting product price upgrade say credit suisse young janney chattopadhyay see vertex potential takeover candidate wake strong cystic fibrosis trial datum tuesday chattopadhyay call vertex most logical large cap merger target young see share total price fair value buy vertex vertex have market cap gilead science gild have be suggest potential acquirer related vertex catapult strong trial cystic fibrosis druggilead acquire biotech vertex be still better analysteven upgrade couldn save vertex biotech deluge
260,VRTX,be salad day biotech sector number industry leader be hit new high group whole be top game term stock performance xstock inflow hit last week have be number clinical trial success new industry friendly food drug administration regime be place result investor business daily company biotech industry group have claw way group track ibd sixth just last week share look likely close month high stock market today slew earning next week just everything be go right biotech lately have be go right brad loncar chief executive loncar investment tell ibd friday onslaught biotech earning next week really give investor fodder say thing miss say loncar merger acquisition last piece fit puzzle then biotech sector really be cook gas say gilead science gild be likely linchpin loncar call gilead poster child large biotech need do deal gilead multibillion dollar hepatitis drug franchise topple first time now gilead say interested deal cancer space analyst have key vertex pharmaceutical vrtx smart acquisition loncar see gilead more likely buy early cancer asset something develop commercialize rather putt money work buy develop revenue stream vertex be already hugely successful biotech own right say earlier year vertex deliver best news year space point have exceptional result phase trial look triple pill treat cystic fibrosis stock gap nearly wednesday ibd take rare disease cancer play have be front center biotech sector late cut edge firm keep rally go head industry snapshot deeper dive multibillion dollar stock loncar say company vertex go something everybody stock market notice gilead be set report second quarter earning wednesday be sandwich slew strong contender biotech space include celgene celg amgen amgn biogen biib alexion pharmaceutical alxn biotech celgene be slate report second quarter earning open thursday stock have ibd composite rating lead peer be sit high last see july leerink analyst geoffrey porge say celgene alexion be bellwether group time same way dow johnson johnson jnj be often see proxy pharmaceutical group call celgene beat raise alexion rise top low view alexion be slate thursday tuesday amgen overtake month high jump record high second quarter earning report prove strong share break cup handle july buy point still remain buy zone trio help catapult sector analyst say meanwhile pharma side investor key astrazeneca azn early thursday recent week rumor have emerge chief executive pascal soriot jump ship teva pharmaceutical teva loncar note timing rumor be bad astrazeneca astrazeneca be set day now report result immuno oncology combination trial lung cancer lung cancer treatment be huge commercial opportunity astrazeneca be take player merck mrk bristol myer squibb bmy regardless rumor controversy do think not overstatement say pascal soriot job be line trial be make break astrazeneca say study be most important thing astrazeneca last year biotech stock be year still room run cfra research analyst jeffrey loo tell investor business daily valuation hit historic lows presidential election be still overall health care sector relative historical valuation biotech sector be still attractively price say late june sector get massive push president donald trump release draft proposal drug pricing initiative didn include much really tug drug price loo say didn credit entire gain proposal certainly help loo say clinical trial term fda approval strong launch trend have also help prod sector year include cystic fibrosis news vertex gene therapy novartis nvs duchenne muscular dystrophy drug sarepta therapeutic srpt latter development loncar say sarepta second quarter sale beat exondys bode well broader sector sarepta also raise guidance year most analyst have call conservative everybody be watch sign drug launch be go payor be push back thing say fact launch exondys be go well be good sign not just sarepta biotech company related biotechs find strength number treat multiple sclerosistoo late catch biotech rally trump fear subside biotech rally get second wind small cap near break outwhy biotech rally still tack upside
261,VRTX,nasdaq hammer ninth straight advance wednesday rise seize new high record longest streak february xat head nasdaq vertex pharmaceutical vrtx soar discovery communication disca leap railroad csx csx bring rear decline follow latest earning report scramble ahead dow jone industrial average manage gain nose dive ibm ibm report result late tuesday dupont dd boee ba cisco system csco unitedhealth unh make difference gain more tech issue grab headline name vertex asml hold asml rocket new high oil related industry take top gain industry group session oil price jump nearly follow positive supply datum energy information administration oil related stock lead transocean rig murphy oil mur notch top gain stock other industry post top gain day include fiber optic solar energy stock mail order retailer group also notch top gain liberty interactive qvc qvca rise apparently response report cable content operator discovery communication scripp network interactive sni be talk regard possible combination news drive discovery share highest level early scripps vault take gain stock earning drive broad portion day action morgan stanley ms gain heavy trade retake handle buy point follow strong second quarter report transport have tough day railroad csx airline unite continental ual take heavy loss earning report leader ibd leaderboard issue vertex soar narrowing early gain leaderboard name trade desk ttd post nearly advance heavy trade stock find support day move average third ibd advanced ttm technology ttm ichor holding ichr nova measure nvmi lead pack ttm remain buy range buy point flat base ichor be back week line climb right side possible week base pattern nova be also back day line form base buy point related dow giant buy range ahead earning investing action planthese stock be buy zone ahead earning tonightchip gear maker asml jump record high beatthese tech firm be corporate america biggest cash hoarder
262,VRTX,major market index moved higher morning trade wednesday tech heavy nasdaq extend winning streak day set record high rise dow jone industrial average have more muted advance less respectively xamong dow industrial dupont dd unitedhealth group unh pace advancer rise dupont remain buy range double bottom entry unitedhealth touch new high gain flat base entry approach downside ibm ibm report earning late tuesday prompt fall share share reach new low almost high other company report earning investment bank morgan stanley ms jump stock market today way back cup handle entry company report stronger expect result early wednesday meantime railroad operator csx csx drop trade day line company top target late tuesday suggest shareholder return not be plentiful analyst action paypal pypl be downgrade hold buy suntrust robinson humphrey share fall early share slip back buy range flat base buy point meanwhile chipotle grill cmg receive duel analyst opinion follow report tuesday customer be sicken restaurant virginia bmo capital market well fargo security downgrade stock market perform telsey advisory group upgrade outperform share trade follow tuesday decline stock be approach nov lows record high lead stock vertex pharmaceutical vrtx soar company report positive phase result cystic fibrosis treatment share be now cup base entry ibd chip stock lam research lrcx apply material amat trade higher respectively stock be approach buy point lam research entry be cup shape base apply material have form flat base entry be later stage basis downside medidata solution mdso decline tuesday brutal reversal new high share be approach day line related morgan stanley flirt buy earning solid trading revenuevertex catapult strong trial cystic fibrosis drugchipotle ibm divide analyst paypal downgrade transunion price hikeddow jone industrial average dow stock news analysis
263,VRTX,do invest successfully fidelity investment do help game know large cap stock fidelity approximately stock stock bond mutual fund make biggest second quarter add sell todd rosenbluth global market intelligence director mutual fund research pore newly release sec holding disclosure second largest mutual fund manager compare past filing boston base behemoth have long term asset june snapshot trade give insight stock fidelity manager thought be worth get be willing trim information technology remain fund giant largest sector collective asset june be case even many fidelity manager sell share tech titan microsoft msft apple aapl second quarter fidelity trim microsoft share count compare stake peel apple back microsoft stock fall have rally june word yet fidelity resume buy apple share sank have rally then contrast fidelity beef share home entertainment software stock activision blizzard atvi feburary atvi complete purchase king digital report first second quarter result ahead capital iq consensus rosenbluth report client thursday afternoon share be close end stock end june higher begin quarter be flat then health care sector fidelity be net buyer seller fidelity like prognosis biotech firm vertex pharmaceutical vrtx enough graft additional exist share count turn be good call july vertex get fda approval new cystic fibrosis drug rosenbluth note now share be end go other director fidelity slice johnson johnson jnj stake unitedhealth group unh hold be end other sector fidelity add stake cell tower owner american tower amt cable provider charter communication chtr carmaker tesla motor tsla fidelity add position american tower be be june charter be stock be see solid earning estimate revision activity analyst say zack equity research still charter telecom service integrate industry group be rank week tesla be fractionally close stock fidelity trim be amazon amzn cut visa shave fidelity largest stock mutual fund continue hold many largest megacap stock even fund family group trim rosenbluth say blue chip growth fbgrx have top holding apple visa other top stock include tesla complex add blue chip growth be year go thursday vs large cap growth peer track morningstar inc dividend growth fdgfx hold trim target apple johnson johnson microsoft dividend growth be year separate datum morningstar inc highlight stock fund have add recently fidelity contrafund fcntx manage have interesting add contrafund be largest stock mutual fund available have add gold canadian base gold producer run mine globally midday friday share be so far year earning share grow past quarters note share be trading just have never reach contrafund hold dozen mining stock have boost stake recently half itau unibanco itub be name contrafund have raise stake brazilian bank hold company adrs be so far year ep have decline quarters row analyst see expect gain current quarter increase company have so so composite rating ibd composite rating start run combine ibd performance rating include ep relative price strength rating stock poise move higher often have high comp rating look stock rating be higher mean ve outperformed other stock term composite rating ibd take alan elliot explain high comp rating be not always buy signal itau also have ibd smr rating smr rating be best contrafund open stake apply material amat latest disclosure ep go decline quarters growth most recent frame ep gain be report thursday top wall street expectation apply revenue be slightly analyst consensus maker chipmake equipment post revenue period fall short street forecast analyst survey zack expect current quarter end october apply material expect share earning range cent cent stock gap huge volume friday semiconductor equipment maker share be so far year
264,VRTX,find winning stock poise pre sprint mode be not push button business savvy investor don rely indicator tool say buy now trust former president ronald reagan say verify even top grade stock meet requirement sound investment method deploy hard earn cash have make sense accord know industry leadership chart analysis state market so broad base measure such ibd composite rating provide solid start point keep mind be start point only introduce jan composite rating have be flagging top stock more decade be immense time saver don assume stock bearing high composite rank be ready purchase composite rating digest bundle ibd smartselect rating include ep rating relative price strength rating smr rating accumulation distribution grade single best worst scale ibd take fastest way see stock rating be go ibd stock checkup access research tab investor com rating also crunch datum far stock be week high closer high else be equal higher grade factor get add weight stock rating investor try determine stock high composite rating be leader always start basic technical metric stock price average daily trading volume biomedical biotech industry group example alexion pharmaceutical alxn sciclone pharmaceutical scln hold best possible composite rating back june be better quality stock show strong fundamental interesting chart pattern also trade healthy average daily volume share day alexion trade sciclone have yet hit share ibd minimum lead stock let view pair therapeutic anik vertex pharmaceutical vrtx hold composite again rating have guide stock compelling fundamental pricewise be also loosely target range vertex look stronger trade kicker here be average daily trading volume trade scant share day time vertex see more share change hand trading session be sign large institution work be vital element great run true market leader editor note column be originally publish june edition ibd study prime stock list investor com be sure view weekly chart spot potential buy point basis form
265,VRTX,drugmaker medivation mdvn stock be jump monday lift other big biotechs pfizer pfe announce acquire company cash pfizer medivation deal be formally announce weekend leak long campaign big french pharma sanofi sny take maker prostate cancer drug xtandi sanofi didn completely rule make bid statement monday make sound pfizer share cash be too rich blood recognize potential strategic benefit combination medivation be first foremost discipline acquirer remain commit act best interest sanofi shareholder medivation stock rise stock market today share pfizer stock fall fraction monday ibd take last week ibd medical biom biotech industry group have rise industry group month ibd look drive biotech stock rally jeffery analyst note reignite speculation sanofi turn attention rare disease specialist biomarin pharmaceutical bmrn june biomarin stock rise anonymously source report blog betaville biomarin be sanofi fallback option monday biomarin stock pop meanwhile incyte incy maker blood cancer drug jakafi perpetual object buyout speculation various partner rise research note sizing several biotech buyout target bmo capital market analyst do kim write incyte go base valuation time peak sale wouldn bring much upside current market cap kim add believe company potentially command higher multiple give limit number late stage clinical commercial biotechs other name likely target include rare disease player alexion pharmaceutical alxn vertex pharmaceutical vrtx rise respectively monday related
266,VRTX,leerink offer mostly bullish preview come earning season big biotechs wednesday offer hope lag sector analyst geoffrey porge raise estimate alexion pharmaceutical alxn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn write prescription datum im health im indicate flat slightly trend celgene standing year year volume growth drive new psoriasis drug otezla top drugmaker evidently shrug recent political criticism raise price number product wac wholesale acquisition cost price celgene otezla increase april follow raise january increase last june represent year year cumulative increase celgene also raise price abraxane april year year cumulative increase porge write other price increase include amgen kyproli yoy biogen tecfidera avonex plegridy medivation mdvn xtandi leerink nonetheless lower estimate medivation base lower xtandi sale well lower royalty sale outside also modestly lower forecast amgen amgn vertex pharmaceutical vrtx add be still consensus company celgene stock climb stock market today stock also have be help anonymously source report be company sign disclosure agreement medivation ahead possible buyout regeneron stock climb alexion advanced biogen rise gilead vertex stock rise announce licensing deal moderna therapeutic develop cystic fibrosis treatment used moderna messenger rna technology vertex agree cash investment upfront milestone payment drug succeed
267,VRTX,stock market be mixed just few minute left friday session biotechs outperformed nasdaq name biomarin bmrn biogen biib vertex vrtx lead way nasdaq ease dow jone industrial average turn rise less solid showing general electric ge boee ba caterpillar cat volume nyse nasdaq be tracking close thursday level biotech telecom paper food stock outperformed retail stock online travel firm lag latter hurt news overnight terror attack nice france priceline pcln expedia expe tripadvisor trip fall be session high economic news june retail sale come better expect meanwhile day wholesale price come little hotter expect consumer price rise june consensus estimate core price rise line expectation core consumer inflation climb match february peak hasn be higher september manufacturing front new york fed empire state manufacturing index softened july june read economist expect read stock market today herbalife hlf be well session high still rise ftc conclude company be not pyramid scheme persh square bill ackman have be long time critic company billionaire investor carl icahn have defend elsewhere chipotle grill cmg drop ahead july earning report morgan stanley downgrade share lower price target morgan stanley say be year chipotle fully recover fallout food bear illness chipotle report result july ibd take sign institutional selling be apparent chipotle late last year recognize be able sell stock get hurt learn more recognize sell signal stock visit ibd university ibd yirendai yrd be far best percentage gainer news be hard yirendai come morgan stanley bring china base lend platform public december
268,VRTX,biotech stock analyst ponder potential impact brexit friday morning find most big biotechs have low exposure run other headach exposure european union general range regeneron pharmaceutical regn celgene celg accord jeffery celgene nevertheless tell evercore isi less revenue come gilead science gild eu exposure be exposure be accord evercore calculation vertex pharmaceutical vrtx eu exposure be britain rbc capital market note expect grow vertex latest cystic fibrosis drug orkambi be suppose get reimbursement next year rbc analyst michael yee say research note not clear reimbursement negotiation be impact way however edison investment analyst maxim jacob opined research note measurement exposure be look wrong kind risk risk be global bear market kill biotech funding needham analyst alan carr write britain separation eu also bring regulatory complication road european medicine agency ema conduct centralize drug review process europe be base london carr write research note article withdrawal clause be invoked ema need move need establish new separate regulatory organization do not expect meaningful impact company drug now review ema brexit lead less efficient more expensive potentially lengthier regulatory process company seek approval eu biotechs be hammer rest market stock market today celgene fall regeneron be lowest level october gilead faltered year low vertex shed ibd biotech industry group plunge
269,VRTX,stock upshifted start bell wednesday nasdaq front early trade press new high look add ninth day recent rally take gain dow jone industrial average battl ing decline ibm ibm cling very narrow gain xibm fall weigh dow early action transition big tech brand deliver mixed second quarter result late tuesday management say restructure plan be track high level investment share buyback first half ibm share have be trading sideway february high unite health unh jump strongest early move dow industrial manage care provider report second quarter earning revenue expectation withdrawal independent affordable care act market reduce revenue gain hoist share new high stock july peak vertex pharmaceutical vrtx lead nasdaq soar report late tuesday positive phase result triple pill treatment genetic condition cause cystic fibrosis stock be december low scripps network interactive sni rocket discovery communication disca leap news report late tuesday company be talk regard possible combination number be provide cable content provider carry market value more discovery scripp morgan stanley ms bolt more report second quarter revenue earning target heavy volume gain retook cup handle buy point stock remain buy range follow unite airline ual drop second quarter result report tuesday close loss send share support week move average very heavy trade sell signal railroad csx csx slip report look strong second quarter performance late tuesday earning rise revenue climb higher expect drive coal related gain accord management company reaffirm second quarter earning guidance remain just consensus view china yirendai yrd jump powerful trade online lend operation clear buy point heavy trade monday end tuesday extend entry first solar fslr spiked upgrade buy hold axiom capital share be now april low solar stock have outpaced other industry wide margin last week period homebuilder stock trade generally higher commerce department report stronger expect rebound housing start june rise annualize rate start be start june consensus estimate build permit also jump rate more tally easily clear consensus view pace start energy information administration report weekly crude oil inventory datum et related vertex catapult strong trial cystic fibrosis drugibm sale wo continue yet quarterqualcomm asml kick chip earning investing action big picture several tech group fuel nasdaq run new high
270,VRTX,stock future index nasdaq dow industrial be mixed wednesday morning vertex pharmaceutical vrtx soar dow component ibm ibm stumble xdure regular session nasdaq composite rise eighth straight session hit record high netflix nflx soar record high blowout subscriber growth guidance offset weak earning netflix also be help fellow fang stock amazon amzn facebook fb google parent alphabet googl amazon facebook also hit time best index rise less dow industrial retreat index future rise fractionally vs fair value dow future be slightly lower nasdaq future climb vertex pharmaceutical late tuesday report strong phase result triple pill treatment cystic fibrosis vertex have make cystic fibrosis long time focus be first treatment underlie genetic condition vertex share sky-rocket premarket trading tuesday vertex close tuesday stock market trading ibd take way play biotechs be etfs ishare nasdaq biotech ibb be buy range almost month etf commonly know ibb ticker be rally late vertex news here be list several notable biotech etfs ibm late tuesday report better expect second quarter earning revenue fall expect be big blue st straight quarter fall revenue vs year earlier analyst have call ibm transition faster growth higher margin software service tedious painful ibm share fall premarket action trade threaten open wednesday month low asian trading japan nikkei rise hong kong hang seng climb shanghai composite advanced european trade intraday ftse germany dax be little change france cac rise look wednesday trading american express axp chip gear maker asml hold asml morgan stanley ms steel dynamic stld be notable earning tap dutch base asml report better expect earning give strong guidance related vertex catapult strong trial cystic fibrosis drugibm sale wo continue yet quarterqualcomm asml kick chip earning investing action big picture several tech group fuel nasdaq run new high
271,VRTX,gilead science gild fill hole portfolio acquire incyte incy analyst suggest friday offer caveat vertex pharmaceutical vrtx still be less risky bet gilead make play now incyte tune premium stock price biotech largely be bet commercial success incyte immuno oncology drug epacadostat meanwhile deal slump hepatitis drug sale unit much value acquisition depend achieve substantial sale more epacadostat highly competitive somewhat unpredictable world immuno oncology leerink analyst geoffrey porge write note client porge imagine gilead afford pay share acquire incyte earlier year gilead acknowledge be open deal particularly oncology analyst have suggest incyte tesaro tsro clovis oncology clvs kite pharma kite potential target incyte help fill gap gilead portfolio porge say flagship product jakafi be approve number blood disorder region incyte be also work immuno oncology drug trial dow merck mrk bristol myer squibb bmy ibd take cancer therapy be winning investor approval kite pharma sit top run streak check industry snapshot closer look company prove be strong bet premium incyte stock price deal generate accretion year say transaction create rate return gilead shareholder next year projection be dependent strong sale epacadostat used premium model gilead earning be dilutive internal rate return north vertex incyte deal be similar size vertex represent lower risk less strategic option gilead give limit still substantial application vertex product technology say incyte other hand offer high risk high reward epacadostat broader development portfolio write stock market today gilead fall cent incyte be vertex be cent related be gilead fortune change acquisition gilead vertex join don hold breath analystwhy biotech rally still tack upside
272,VRTX,index nasdaq composite dow jone industrial average hit record high week techs fuel selling start thursday afternoon federal reserve signale not worry stock price facebook fb dow boee ba verizon vz mcdonald other company be hailed strong earning alphabet googl amazon com amzn other have less ideal result tobacco stock such altrium mo crash friday fda say reduce nicotine level cigarette sub addictive level nasdaq composite index fall week week retreat thursday morning record high flood earning report dow industrial rise fuel boee verizon facebook leap earning amazon alphabet fall result oil price soar treasury yield rise dollar continue trend lower treasury yield rise week dollar continue trend lower boee ba swung profit take charge year quarter revenue decline miss view boee raise full year ep outlook analyst view aerospace giant say have talk customer new midmarket plane see demand aircraft northrop grumman noc general dynamic gd raytheon rtn also raise full year earning outlook report earning result estimate northrop say aerospace system sale climb higher manned aircraft demand include work advanced hawkeye aircraft raytheon see higher air defense missile smart bomb sale general dynamic revenue get support strong gulfstream defense product demand boee share soar week raytheon rise northrop be lower general dynamic tumble related boee put midrange demand plane stock hit sell signfacebook jump week hit record high earning revenue growth blow past expectation facebook exceed view various metric include user growth monthly active user twitter twtr earning beat view monthly active user be flat vs first quarter twitter share plunge snapchat operator snap fall hit record lows related facebook earning surge fang duo monopolize digital adsamazon earn cent share vs year earlier way view due heavy spending commerce giant operate income wasn great revenue be growth accelerate second straight quarter amazon web service revenue swell amazon share retreat friday close recent buy point undercut intraday related be winter come amazon shareholder big investment google parent alphabet stock retreat internet search giant earning fall short heighten expectation report higher expect traffic acquisition cost pay partner website google recognize nondeductible european union fine worry eu regulator crack more google say second quarter earning be share year revenue rise exclude time charge google say earn share related food drug administration announce fda aim require nicotine level cigarette sub addictive level roil tobacco stock friday altrium mo sell marlboro cigarette lose british american tobacco bti recently buy rest reynold american fall philip morris international pm sell marlboro cigarette overseas initially tumble close related fda act vs cigarette tobacco giant be hold federal reserve keep wall street prefer script wednesday leave key interest rate unchanged putt announcement begin unwinding balance sheet fed patience come economy be perform pretty well real gdp grow pace second quarter inflation wage gain have be more muted expect combination have be good stock market partly prospect low interest rate have weigh dollar be boon earning multinational second half year decision fed september announce shift reinvestment policy gradual pullback current stance reinvest principal mature mortgage treasury bond portfolio also send signal policymaker aren overly concern financial market be too exuberant next interest rate hike be expect december real uncertainty hinging inflation outlook be fed policy look flurry chip industry player post beat raise june quarter result include chipmaker advanced micro device amd cypress semiconductor cy intel intc texas instrument txn well chip gear supplier lam research lrcx teradyne ter amd earn adjust cent share sale analyst expect break even sale current quarter amd forecast sale rise vs wall street target cypress earn cent share ex item sale vs estimate cent cypress expect earn cent ex item sale vs view cent intel earn cent share ex item sale top view cent intel forecast adjust earning cent share sale analyst be look cent ti earn share ex item sale june quarter vs analyst expectation cent current quarter ti expect earn share sale vs wall street target lam earn adjust share sale june quarter analyst be expect september quarter lam expect earn share sale wall street be modele teradyne earn cent share ex item sale top expectation cent teradyne expect earn cent share ex item sale analyst have be expect cent paypal pypl earning rise year revenue rise slightly top consensus estimate digital payment processor member ibd raise full year outlook analyst view share rise record high pare gain crude future spiked barrel sign supply be fall revive shale boom be peter nigeria say ll eventually join rest opec curb production saudi arabia agree cut oil export crude inventory tumble barrel domestic production dip energy company trim capital spending plan month sub oil halliburton hal warn see exploration production company tap brake rig count plateau exxon mobil xom chevron cvx earning miss general motor gm report adjust profit grow beating view revenue drop view gm reaffirm full year ep guidance cut second half production swell inventory fall industry sale ford motor top view raise guidance largely lower tax rate gm fall further buy point ford fall back multiyear lows fiat chrysler fcau hold buy point adjust ep swell sale fall short maseratus luxury brand do well biogen biib obliterate sale expectation spinal muscular atrophy drug spinraza amgen amgn fall late tuesday boost ep ex item guide lag view gilead science gild report hepatitis drug franchise decline be partially offset growth hiv hepatitis drug sale vertex pharmaceutical vrtx say total cystic fibrosis sale gap celgene celg alexion alxn also beat view latter bust ep expectation cent astrazeneca azn crash thursday report mystic lung cancer trial immuno therapy combination fail drugmaker also announce deal merck mrk gain access latter blockbuster keytruda merck rise thursday bristol myer squibb bmy have have several setback drug opdivo slide concern mystic failure bode ill similar opdivo combo study wall street soured casino player mgm resort international mgm wynn resort wynn melco resort entertainment mlco sector overall put mixed result guidance concern mass market gaming macau weigh wynn result nonetheless beat estimate mgm offer weak revenue available room outlook also cite higher anticipate disruption monte carlo be be revamp park mgm challenge comparison la vegas strip la vegas sand lvs top result melco focuse boyd gaming byd penn national gaming penn be mixed share verizon communication vz soar telecom report better expect wireless result stiff competition narrow loss high spending postpaid phone subscriber verizon add more forecast say strategy packaging video wireless service be jell verizon say consumer be willing pay premium unlimited datum service high perform network comcast cmcsa report second quarter profit revenue top estimate nbcuniversal film entertainment business deliver strong box office result video subscriber loss be higher expect citigroup speculate comcast acquire verizon charter communication chtr miss earning sale share soar speculation be acquire well mcdonald mcd earning same store sale top estimate help cheap drink offering premium menu item chipotle cmg be testing queso face concern sale recovery have stumble follow food bear illness scare begin sale impact report customer fall ill july remain unclear domino pizza dpz crash part disappointing international comp lower margin ep help tax rate already high stock valuation starbucks sbux tumble fiscal same store sale revenue miss ep match view coffee chain say close teavana retail store several industrial dow giant rolled past estimate tuesday thank part improve global growth caterpillar cat surge week high company see ep revenue unite technology utx see earning climb share revenue rise share tumble lowest level raise full year ep revenue guidance dupont dd also beat top bottom line dow peer mmm be outlier overall miss share tank proofpoint pfpt report profit revenue top expectation forecast current quarter sale earning just consensus estimate sunnyvale calif base proofpoint specialize email datum loss protection corporate network cloud compute infrastructure proofpoint rise modestly friday morning fortinet ftnt post mixed result beat ep revenue billing growth disappoint outlook provider computer security software have yet improve recent ransomware attack fortinet share tumble tal education tal top earning sale estimate share profit cent revenue come ahead forecast cent current quarter china base education company see revenue view yahoo finance estimate meanwhile peer new oriental education edu also pull ahead forecast cent ep addition bump total student enrollment midpoint revenue guidance pull just ahead current view tal new oriental share rise respectively latter fail thursday mastercard report better expect second quarter earning revenue share reversed modestly lower record high remain buy range baidu bidu earning rise well view revenue climb line share chinese search giant rise friday electronic art ea report better expect quarterly earning video game publisher give cautious revenue guidance ea share rise friday briefly fall recent buy point
273,VRTX,dow jone industrial average be driver seat again second straight session wednesday help strong move share boee ba maker commercial military aircraft soar company top earning estimate raise full year earning cash flow guidance xboee be well extend proper buy point head earning fact rally have be so strong trigger ibd sell rule say generally take profit stock gain hit rule be stock rally past buy point usually time start pull back price build new base hour remain session dow be nasdaq composite add small cap lag solid performance wednesday fall volume be lower nyse slightly higher nasdaq day fomc end today decision keep interest rate steady be unanimous fed say process selling bond shrink bloated balance sheet begin relatively soon perhaps early september meeting stock market today technical breakout advanced micro device amd texas instrument txn look good fade amd gap buy point rise stock be session low early strength ditto texas instrument share break early buy point stock be recently trading advanced micro have look turnaround story company report fourth straight quarter double digit sale growth nvidia be daunting competitor amd amd graphic card gaming continue see strong demand company be make inroad nascent field artificial intelligence ibd china base education stock see most interest tal education tal jump nearly ahead earning report thursday close new oriental education edu gain follow nicely wednesday upside reversal new oriental be still buy range cup handle buy point september west texas intermediate crude oil future rise almost datum show domestic crude supply fall barrel latest week more expect fourth straight weekly drawdown watch earning report close solid performer fortinet ftnt facebook fb servicenow now vertex pharmaceutical vrtx other related fed leave balance sheet unchanged act relatively soon here be key area focus facebook report earning
274,VRTX,future index nasdaq dow jone industrial average edge higher early wednesday ahead new wave big earning federal reserve latest policy announcement strong result late tuesday texas instrument txn be good news apple aapl iphone ecosystem ahead apple own earning meanwhile facebook fb paypal pypl be ibd stock earning due wednesday facebook provide further evidence be beating back snapchat operator snap snap dow industrial rise tuesday regular session lead earning caterpillar cat mcdonald mcd well strength financial nasdaq composite weigh google parent alphabet googl close just break even do hit new time high index rise fresh record meanwhile cboe volatility index vix hit yet record intraday low tuesday vix lows be sign investor complacency often associate least short term market top still dow future rise vs fair value nasdaq future equity generally advanced globe crude oil price continue climb big gain tuesday fed be not expect make policy change wednesday afternoon policymaker surprise announce plan let central bank balance sheet start decline most analyst see shift happen september meeting president trump tell wall street journal apple build plant trump have make similar statement apple have comment tuesday operation ease political pressure likely be more expensive possible foxconn key assembler iphone set plant america ibd take buy hold stock be risky head earning report here earning option strategy help cash post earning stock gain minimize risk weak quarter option strategy be highlighted ibd weekly earning preview column meanwhile texas instrument report better expect earning late tuesday give bullish guidance texas instrument be big automotive chip many other segment well mobile device apple iphone ti follow beat raise last week skywork solution swks apple iphone chipmaker ibd member report better expect wireless subscriber figure churn hit record low good sign apple iphone sale be spring lull ahead iphone later year relatively strong iphone demand be key give likelihood next generation iphone be delay apple share edge higher premarket trading apple close tuesday stock market trading apple be approach flat base buy point facebook paypal lam research lrcx edward lifescience ew be ibd stock report earning wednesday also facebook paypal lam research boast best possible composite rating mean outperform other stock base proprietary fundamental technical rating big stock winner often have composite rating least start big price run facebook be third fang facebook amazon com amzn netflix nflx google parent alphabet stock report result follow alphabet late monday netflix last week amazon be set close fang earning thursday facebook presumably provide new figure grow popularity instagram story other offering clone snapchat feature here stat already snap march ipo facebook market capitalization have increase snap market value have retreat just so facebook have add equivalent nearly snapchat snap brief history public firm facebook dip tuesday stock market trading hit fresh record high monday facebook be extend possible entry snap fall hit new record low paypal dip just chase zone flat base buy point clear earlier month mobile payment firm expand reach deal month apple jpmorgan chase jpm chip equipment maker lam research be cup base just possible buy point edward lifescience have fall back buy point big cup handle base undercut day line tuesday vertex pharmaceutical vrtx horton dhi servicenow now fortinet ftnt be many other top rate stock set report earning wednesday related texas instrument amd beat target guide higherat adjust profit beat pay tv video subscriber fallwill facebook earning support strong stock growth big picture nasdaq lag alphabet loss industrial financial growth stock netflix nvidia earning
275,VRTX,pair nasdaq tracking fund be respective buy point tech heavy index climb new high monday powershare qqq trust qqq be buy range rise past entry last week etf rally prior flat base december start pattern just clear pull back rebound day move average mid april set buy opportunity fund have attract march launch be weight technology july consumer cyclical contribute health care top holding apple aapl microsoft msft amazon com amzn facebook fb alphabet googl account nearly asset apple regain day line last week have rally more year iphone maker report fiscal result aug close expect launch upcoming iphone year qqq gain year july respective year period accord morningstar inc have return ytd same timeframe etf carry expense ratio first trust nasdaq equal weight index fund qqew name suggest be equal weight play nasdaq track nasdaq equal weight index be rebalance quarter index be reconstitute december be update year reflect replacement nasdaq index fund top holding be biotechs vertex pharmaceutical vrtx gilead science gild regeneron pharmaceutical regn alexion pharmaceutical alxn netflix nflx be other stock fund have also outpaced ytd return year year accord morningstar qqew launch april be trading just buy point flat base expense ratio be friday etf pick pull back slightly remain respective buy point first trust europe alphadex fep be just flat base entry europe small cap dividend dfe be shy flat base buy point bank homebuilder retail be winning sector early tuesday utility tech health care lag spdr retail xrt rebound regain day line component stock barne noble bks gap soar speculation put sale key index fund spdr dow jone industrial average dium gain spdr spy add powershare qqq trust qqq be fractionally lower remain flat base buy point spdr oil gas exploration production xop leap retake day line hit resistance late january share be still week high vaneck vector oil service oih ishare energy iye energy select sector spdr xle gain more show similar action xop unite state oil uso rise west texas intermediate crude price surge barrel gold play be mixed gold future slip ounce vaneck vector gold miner gdx advanced vaneck vector junior gold miner gdxj dip ishare gold trust iau spdr gold share gld be respectively related retail slip sector gain top fund buy point top growth play buy range gold lead sectorsapple iphone launch timing initial supply subject debate
276,VRTX,treasury department annual financial review medicare find growth rate win trigger cost cut panel week send drug stock higher wednesday ahead report tuesday speculation have break growth be high enough trigger independent payment advisory board ipab come way cut spending brooking institution have schedule event thursday discuss issue last year report project hospital insurance trust fund be deplete just year now brooking say report also predict more immediate controversial event independent payment advisory board ipab famously nickname death panel be require submit proposal reduce medicare spending reduction take place report medicare board trustee actually moved depletion date year earlier say still wasn enough growth cost trigger ipab seem turn major medical group biotech stock have head south tuesday afternoon mid morning announcement ibd medical biotech group rise ethical drug group be even ipab have be trigger analyst doubt impact have be big give restriction sort cut panel make late tuesday rbc capital market michael yee run number note dual eligible add medicaid patient thus grow yee write research note take amgen amgn biogen biib celgene celg gilead science gild regeneron pharmaceutical regn vertex pharmaceutical vrtx medicaid exposure grow get larger medicaid rebate calculation show change revenue more so happened celgene stock fall heavy trading tuesday rise more intraday close stock market today regeneron stock climb intraday set rise drop tuesday amgen biogen share rise fractionally sank nearly tuesday timing hedge fund manager leonard yaffe wasn convince ipab business be actual reason stock move biotechs have be trend downward early june rebound biopharma stock today be much more offset concern mentioned yesterday well likelihood fund redemption stock have become very attractive prospect several company be bright yaffe write email
277,VRTX,drug pricing be wall street mind again friday well fargo tap mylan myl next target activist rbc consider impact potential new law limit price california well fargo analyst david maris write valeant pharmaceutical vrx turing pharmaceutical be haul front congress scrutinize press policy drastically hike price recently acquire drug be keep eye other company universe have be do lot price increase last month mylan have raise price more product more product maris write research note late thursday mylan have take exceptionally large price increase include increase ursodiol generic medication used treat gallstone increase metoclopramide generic medication commonly used treat reflux disease gerd gastroparesis increase dicyclomine medication used treat irritable bowel syndrome maris add last month mylan add price tag biggest product contribute revenue most recent quarter believe give regulatory environment pricing action bring greater regulatory scrutiny headline risk additionally wonder aggressive price increase be be used make ep target offset disappointing sale other area mylan respond follow statement mylan have always be know have industry broadest most globally diversify business model portfolio have successfully manage balancing numerous variable include natural price reduction have always be inherent generic industry flaw analysis focuse small number product more product mylan sell globally approx product sell north america be simply self serve mislead investor be especially true give generic product represent extremely small percentage mylan approx north american generic business mylan business model be not today have ever be premised price hike mylan stock fall stock market today fall low valeant retreat friday week rbc capital market biotech analyst michael yee be also ponder drug pricing friday calculate potential impact california drug price relief act cdpra stock universe include amgen amgn gilead science gild celgene celg biogen biib vertex pharmaceutical vrtx cdpra go popular vote california proposition system november require state health care payer medical buy drug similar price veteran administration usually obtain large discount believe cdpra create slippery slope measure encourage other state follow suit ohio have also propose be get signature yee write think such attempt reduce drug cost merely prompt drug maker just raise va drug price thus help less person not result real saving benefit nonetheless yee estimate similar law pass state shave annual ep cover company discussion large cap biotech company suggest firm be aware wouldn be surprised proposal pass so note investor very least be inform potential headline model pricing risk write drug stock be friday rest market amgen fall gilead biogen celgene vertex pharma dip
278,VRTX,most stock mutual fund extend rally begin march strategist be figure way deal expect stock market headwind summer month average diversify stock fund rise vs setback january february follow rally march inch april leave higher year date comparison advanced go forward most investor speak ibd expect market volatility summer re ready click here see list mutual fund month leaderslew piantedosi manager eaton vance mutual fund total asset have guardedly optimistic glass half full outlook believe core portfolio secular grower say include name amazon amzn facebook fb alphabet googl such name like be nxp semiconductor nxpi provide semiconductor content automobile industrial space say piantedosi be manager focuse growth elcix focuse growth opportunity eifgx tax manage growth eitgx tax manage multus cap growth eacpx huge secular shift area automation other new technology be drive demand new semiconductor content add car new feature include crash avoidance music rear view camera driver assist sensor other safety system overall trend electrical vehicle industrial product comparable shift robotic other form automation say area nxp be lead provider say click here see list mutual fund category more cautious investor glass half empty view be james lead manager payden equity income fund pyvlx brace volatility say re enter summer do not take lot bad news move market so equity income investor drink own kool aid say investor be serve well focuse company continue provide income low volatility manner theme park operator flag entertainment be sort stock like right now come bankruptcy start decade say re improve revenue stream management have improve quality park introduce new ride ve increase membership rate mean person go more often spend more money ve introduce go front line pass person gobble change have help ve improve recur revenue model say so re steady cash generate company able maintain grow dividend yield market notch modest gain investor be embolden stock market news turn be less scary have fear month outset say earning season be negative not bad person have expect say prospect brexit exit european union fade slightly add price oil rise just barrel april just addition many investor grow more comfortable prospect interest rate hike soon june july small cap growth fund lead tack science technology fund pace sector jump investor be optimistic gravitate growthier area market piantedosi say tech world equity fund fared far lose japanese fund do best abroad gain taxable bond fund lose treasury fund edge tax exempt fund gain capped streak month row market gain fear dominate start year keep fading piantedosi say add consumer have be strong housing be robust europe be look better term investor focus day day event such brexit decision federal reserve meeting november election monthly jobless report monthly purchasing manager index pmi indicator health manufacturing sector noise remember fed raise rate see sign strengthen economy help corporate earning say karyn cavanaugh senior market strategist voya investment management member multiasset strategy solution group end day stock buy boil buy corporate earning cavanaugh expect uptick corporate earning still fail occur don expect consumer spending stay strong warn cavanaugh be also manager voya global perspective iwpvx say market winning streak be likely end valuation be high earning growth be weak note piantedosi expect disruptive innovator continue grab market share so like amazon instead brick mortar department store macy dd kohl kss report lower quarterly earning share suffer stock price decline amazon report ep gain april accelerate prior frame share gain like facebook google similar reason huge shift continue advertising spending traditional medium online social medium say ditto health care political talk potential drug price regulation bullish long term big cap biotechs gilead science gild celgene celg vertex pharmaceutical vrtx know pricing issue shake say plenty growth company continue innovate piantedosi be not confine bet high flyer diversify portfolio don want be pedal metal time say name consumer staple not cheap provide stability predictability yield philip morris international pm be favorite say be focuse overseas smoking headwind be less have lot pricing power currency headwind be diminish likely turn tailwind dividend yield be pinnacle food pf be like nice steady eddie food company decent growth characteristic food group doesn show great characteristic say pinnacle dividend yield be
279,VRTX,stock higher flat start wednesday enough lift nasdaq narrowly back day move average nasdaq rise add dow industrial tack gain stock market today volume be quiet nyse lower nasdaq relative action same time tuesday pfizer pfe run head dow more breaking takeover allergan agn nixing pfizer allergan inversion reportedly cost pfizer breakup fee avoid run afoul treasury department launch inversion regulation monday allergan stock also rise more uninverted drug medical play lead nasdaq celgene celg illmina ilmn vertex pharmaceutical vrtx jump more ibd stock acuity brand ayi padded early gain press higher big fiscal sale earning gain put share past cup handle buy point baker hughe bhi spiked halliburton hal pop justice department file antitrust lawsuit challenge plan acquisition baker hughe halliburton suit claim merger eliminate competition specific product service related oil gas field production
280,VRTX,be midcap techs go be market champion next month many prediction end worthless yet tuesday action name cadence system cdns atlassian team ionis pharmaceutical ion appear indicate fund manager still find attractive value midsize company bullish fundamental xall qualify midcap firm
281,VRTX,nasdaq composite index hit new high techs continue reassert market leadership netflix nflx amazon com amzn facebook fb microsoft msft hit record high netflix soar subscriber gain amazon sell kenmore appliance sear shld send latter sharply higher hit several retailer include dow home depot hd dow jone industrial average also be hit general electric bank blue chip visa american express axp continue good news payment stock nasdaq composite rise hit record high week rise straight session thursday netflix other fang stock such facebook amazon contribute index climb also hit fresh high week dow industrial fall weigh goldman sachs gs general electric ge home depot internet television network netflix add net new subscriber june quarter vs wall street consensus estimate also guide higher current quarter forecast net new subscriber top consensus view bull point strong subscriber growth bear voiced caution ballooning video content obligation include original tv series stranger thing glow netflix end subscriber worldwide include foreign market netflix international stream subscriber top first time netflix sky-rocket record high week sear sell alexa enabled kenmore appliance amazon send share soar thursday give most gain friday whirlpool whr major seller appliance home depot lowe low best buy bby be hit home improvement chain home depot lowe have be see amazon proof least amazon resistant best buy have bounce back recent year amazon initial onslaught be hurt earlier month news amazon be create geek squad rival amazon appear be get more government attention size scope grow ftc probe antitrust rumbling software giant microsoft earn cent exclude item june fiscal fourth quarter year year well view cent revenue rise forecast microsoft credit demand cloud compute service azure office well acquisition linkedin dow component give cautious guidance current quarter share dip friday remain buy range related microsoft crush earning estimate stock dip outlookgeneral electric fall friday say full year ep be trend low end target cite oil gas weakness ge report smaller earning revenue decline analyst cite weakness headline figure fellow industrial conglomerate honeywell international hon also beat top bottom line guide full year estimate slightly higher honeywell share rise friday retake buy point related general electric stock dife earning outlookamerican express beat top bottom line provision loss jump due loan portfolio growth rise rate lend off visa earning also top strong cross border travel help stronger dollar global payment volume drive result accord mizuho analyst thomas company also hike full year revenue growth outlook view visa american express dow component rise respectively still buy range td ameritrade amtd stock break long consolidation july online broker beat top bottom line even industry trading fee stock etfs have plunge year charle schwab schw day match view share fall buy point have clear late june trade etfc share gap make new week high friday company score overall beat thursday share be now buy range chip gear maker asml asml wireless communication chipmaker qualcomm qcom be first major semiconductor industry player report june quarter earning year asml rise record high post better expect sale earning second quarter qualcomm disappoint current quarter profit outlook come short view even beat estimate fiscal apple aapl chip supplier skywork swks report better expect fiscal sale earning guide higher current period drug giant novartis nvs johnson johnson jnj report better expect earning tuesday dow component report adjust income share top view cent sale be light novartis share exclude various item sale top analyst view drug stock rise week be still buy range friday close goldman sachs fix income trade revenue plunge second straight quarter trading heavy bank say misread market weaker trading net interest income also hurt bank america bac fed rate hike have help bank say expect net interest income rise morgan stanley ms report trading revenue fall less so rival jpmorgan jpm citigroup have also signale caution slow loan growth longer term bond yield indicate flagging confidence chance long term economic gain morgan stanley clear buy point goldman undercut day day move average check point software chkp report better expect second quarter earning thursday give weak guidance current check point tumble day fall day move average check point wednesday briefly top buy point close trigger so do other cybersecurity stock day stock proofpoint pfpt retreat modestly check point warning unite airline ual tuesday offer disappointing third quarter unit revenue forecast airline competition pick head further summer send share plunge delta air line dal american airline aal have remain bullish key metric fall significantly well unite say take least several month plan expand service different part rollout cheaper basic economy fare pay health insurer earning share rise top forecast revenue grow roughly line be smallest gain quarters unitedhealth unh have exit obamacare exchange big player medicare medicaid coverage optum service unit see revenue rise unitedhealth now see adjust full year profit share analyst have expect result unitedhealth rise republican health care struggle also influence share insurer hospital related unitedhealth raise full year target earning jump top rail company top quarterly forecast csx csx say crude oil train shipment have fall hint return shareholder be more cautious union pacific unp predict nearly flat volume coal shipment stabilize still see second half volume improve first half kansa city southern ksu benefit auto production energy market reform mexico csx fall week union pacific lose kansa city southern edge vertex pharmaceutical vrtx stock rocket time high wednesday strong phase datum trial cystic fibrosis treatment triple drug combo aim treat genetic disease underlie cause intuitive surgical isrg easily top analyst second quarter view thursday adjust income share sale share maker robot surgical system fall friday afternoon chipotle grill cmg share tumble year low report fast casual chain temporarily close restaurant virginia follow report diner have get sick once trendy fast casual burrito eatery have be try mend reputation sale food bear illness scare begin harley davidson hog cut motorcycle shipment outlook unit dealer year drop prior guidance flat modest decline iconic motorcycle brand report ep decline be better estimate sale slide retail sale new motorcycle tumble weak industry condition share fall
282,VRTX,give apple aapl stock outperformance year not too surprising iphone maker be top many equity growth fund holding xapple be top hold spdr growth spyg july accord morningstar inc nearly asset microsoft msft be next follow amazon com amzn facebook fb alphabet googl apple share be wednesday track ninth straight advance technology account biggest sector weighting health care be distant second consumer cyclical industrial weigh respectively fund turn september have gather asset expense ratio be spyg track growth index contain stock display strong growth trait base sale growth earning change price ratio momentum etf have outperformed broader market year date return vs gain also lead benchmark index smaller margin past year share be buy range climb past flat base entry tuesday rise late april prior flat base start most recent pattern powershare dwa momentum portfolio pdp own apple top hold july other top name include american tower amt priceline group pcln technology industrial consumer cyclical be biggest sector respectively fund track dorsey technical leader index include nasdaq list company fund index get rebalance reconstitute quarterly basis pdp outpaced ytd gain have lag benchmark index longer period year old etf clear flat base entry last week be buy point carry expense ratio check tuesday pick vanguard growth vug break past buy point flat base ishare russell mid cap growth iwp clear flat base buy point wednesday be buy range index fund early wednesday powershare qqq trust qqq rise spdr spy spdr dow jone industrial average dium emerge market outperformed ishare msci emerge market eem pop most sector be higher lead biotech oil homebuilder ishare nasdaq biotechnology ibb gap more be slightly extend flat base buy point component stock vertex pharmaceutical vrtx soar more report positive trial result late tuesday ishare home construction itb spdr homebuilder xhb lift respectively boost higher expect housing start build permit june oil play gain crude price datum show sharp drop inventory last week vaneck vector oil service oih spdr oil gas exploration production xop surge apiece unite state oil uso powershare db oil dbo rise nearly gold fund be mostly lower related tech heavy fund beating market be buy outsize dividend check hot emerge market playsu crude output jump highest year inventory fallsvertex catapult strong trial cystic fibrosis drug
283,VRTX,apply optoelectronic aaoi lumentum lite momo momo netflix nflx nvidia nvda veeva system veev vertex pharmaceutical vrtx be highflier possibly other go be one child friend talk year now superstock course know judge wednesday market action appear
284,VRTX,gilead science gild be better acquire vertex pharmaceutical vrtx oncology asset tesaro tsro incyte incy analyst suggest friday lament gilead cautious approach merger biotech market cap have show interest make oncology centric buy struggle decline hepatitis drug sale hepatitis franchise bring north year fall first time leerink analyst geoffrey porge say gilead turn away obvious cancer biotech buy tesaro incyte clovis oncology clvs kite pharma kite instead set sight vertex say likely gilead ignore advice view acquisition grow largely risk revenue stream such vertex much more positively comparable investment set investment intensely competitive technologically uncertain field oncology say vertex offer gilead rare disease portfolio robust pipeline vertex be now work triple pill combination treat cystic fibrosis lung disease year ahead nearest rival galapago glpg abbvie abbv regimen look likely launch gilead have cash meaning company wouldn have stretch too much make acquisition porge say vertex have market cap gilead market cap porge expect gilead pay share vertex stock still make acquisition accretive year realistic synergy together vertex gilead feasibly expand growth time slow grow major pharmas ibd take big biotechs gilead struggle recent biotech rally instead analyst say keep eye biotechs highlighted industry snapshot vertex tow gilead reverse revenue trajectory project decline compound annual growth rate transaction similarly improve expect fractional decline earning estimate growth rate year more likely gilead make series small transaction relatively early stage asset porge say note client win be enough diversify gilead hepatitis roller coaster even help nascent hiv drug bictegravir have be apparent gilead need major acquisition possibly even then be inexplicable company have be so faint hearted exercise cash flow advantage now say company still appear be respond opportunity present rather initiate create opportunity ahead availability even gilead go obvious oncology asset investor question company be pay premium today potential company be apparent last year price be current level porge have market perform rating price target gilead stock valuation say be time low otherwise justify recommendation substantial termination uncertainty make hard see stock recover multiple foreseeable future close bell stock market today gilead stock dip fraction vertex pop much settle be incyte stock fall tesaro stock lose related biotech rally still tack upsideare sanofi gilead bidding war small cap upgrade couldn save vertex biotech deluge
285,VRTX,seller be control get go thursday never loosen grip nasdaq slump lose dow jone industrial average fall volume nasdaq come slightly higher wednesday level nyse volume be very close wednesday level nasdaq also lose weigh weak performance vertex vrtx alexion alxn ebay ebay ebay slump nearly channeladvisor say ebay same store sale march fall growth february new york mercantile exchange west texas intermediate crude oil delivery give cent barrel gold meanwhile rise ounce spdr gold share gld track price gold rally pace try buy pointon nyse decline stock outnumber advancer nasdaq decliner top advancer also stock market today global payment gpn add more strong volume work solid cup shape base buy point single digit decelerate sale growth recent quarters be yellow flag growth investor earning news radar retailer ollie bargain outlet olli gap rise report solid earning late wednesday recently clear cup handle base buy point ibd china base tal education xrs be handful name close higher share rise tal stock be seek support week move average first time base mid february also ibd facebook fb reversed lower lose only carve cup handle base buy point earning be due april close
286,VRTX,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
287,VRTX,major average turn higher afternoon trading tuesday recover nicely news terror attack belgium nasdaq rise add dow jone industrial average gain volume exchange be tracking slightly lower monday level health care space drugmaker biotech stock outperformed second straight session biotechs amgen amgn alexion pharmaceutical alxn vertex pharmaceutical vrtx score gain more stock market today ibd airline group slump early moved nicely lows be recently leader group ryanair ryaay gap day average rally lows share fall work cup handle base buy point ibd phillip partner psxp trex trex stamp com stmp be top percentage gainer gain more also ibd concrete uscr follow monday cup handle base share rise nearly elsewhere small cap granite construction gva outperformed rise high end buy range buy point semiconductor space small cap inphi iphi extend gain recent double bottom base share rise group peer mellanox mlnx also outperformed gain close watch earning dow component nike nke red hat rht
288,VRTX,stock market pare gain ahead close tuesday still end well early loss spark terror attack belgium nasdaq lead gain dow jone industrial average give dip volume run slightly lower major exchange vs monday preliminary figure show attack fuel flight safe haven area market such gold april gold future rise settle ounce biotechs other drugmaker rally second day today stock market action biotech space alexion pharmaceutical alxn vertex pharmaceutical vrtx rise more amgen amgn add therapeutic anik gain more near top buy range cup base entry clear feb stock be week high generic drug maker akorn akrx gap vault higher report preliminary full year guidance estimate share re-cover day move average first time month travel stock get hit aftermath brussel terror attack dairy apparel stock also lag priceline pcln gap fall more early trade pare loss share online travel site slip double bottom buy point rival expedia expe ease less volume be flat former well average latter indicate institutional investor weren likely selling iii apparel giii gap sank more breach day move average massive trade apparel maker report result miss view do fiscal earning guidance close nike nke be report fiscal earning top view revenue miss athletic shoe maker record future order growth least analyst forecast gain nike share climb regular session ibd concrete uscr rise new close high follow monday cup handle base mark fifth straight advance stock be top buy range entry ibd investing rule include never buy stock more extend past proper entry concrete case maximum allowable entry be economic datum tap wednesday include new home sale february weekly mortgage application petroleum status report
289,VRTX,stock end narrowly mixed tuesday session lows recover slide spark terror attack belgium nasdaq lead gain dow jone industrial average give dip volume run slightly lower major exchange vs monday preliminary figure show attack fuel flight safe haven area market such gold april gold future rise settle ounce biotechs other drugmaker rally second day today stock market action biotech space alexion pharmaceutical alxn vertex pharmaceutical vrtx rise more amgen amgn add therapeutic anik gain more near top buy range cup base entry clear feb stock be week high generic drug maker akorn akrx gap vault higher report preliminary full year guidance estimate share re-cover day move average first time month travel stock get hit aftermath brussel terror attack dairy apparel stock also lag priceline pcln gap fall more early trade pare loss share online travel site slip double bottom buy point rival expedia expe ease volume be lighter stock indicate institutional investor weren likely selling iii apparel giii gap sank more breach day move average massive trade apparel maker report result miss view do fiscal earning guidance ibd concrete uscr rise new close high follow monday cup handle base mark fifth straight advance stock be top buy range entry image provide shutterstock
290,VRTX,big biotech vertex pharmaceutical vrtx slide trading friday fda reject expansion label best selling drug vertex have apply approval cystic fibrosis drug kalydeco know generically ivacaftor cf patient age have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene
291,VRTX,biotech pharma stock sell sharply thursday busy earning week even overall market rise ibd medical biom biotech industry group hit month low stock market today be early afternoon separately ethical drug group be number company group report earning thursday
292,VRTX,regeneron pharmaceutical regn gilead science gild be most likely beat wall street view june quarter sale profit analyst say monday xleerink analyst geoffrey porge say star align widespread beat biopharma result large cap also see abbvie abbv celgene celg biogen biib gilead most likely top revenue expectation quarter quarter sale abbvie alexion pharmaceutical alxn biogen vertex pharmaceutical vrtx be likely be slow say abbvie biogen be face competition pricing pressure alexion vertex be still high growth company temporary slow revenue growth trajectory pending new indication formulation product write note client health tracker im see abbvie leukemia drug imbruvica testosterone gel androgel likely come materially north consensus humira landing street view other major project be expect miss im datum suggest biogen multiple sclerosis drug tysabri tecfidera beat porge estimate respectively tecfidera however be expect miss street ms drug plegridy avonex be forecast be light come grow competition ms field like roche rhhby novartis nvs sanofi sny roche drug ocrevus be approve earlier year treat relapse remit well primary progressive ms first industry ibd take biotech stock be rank group track sentiment tick ahead second quarter earning season make sure bookmark ibd biotech stock watch pharma industry news latest sector major drug celgene be expect top consensus chemotherapy revlimid likely come consensus porge write pomalyst drug treat blood cancer be expect be higher consensus gilead be likely be biggest second quarter surprise im datum gilead sale top be largely dependent reliability recent hepatitis datum have be unreliable past hepatitis drug sale topple high cure rate accounting highly variable sale hepatitis drug gilead total sale miss porge forecast analyst consensus target same time gilead genvoya hiv drug beat consensus porge write note client amgen amgn be most likely match slightly underperform consensus porge say rheumatoid arthritis drug enbrel be expect be line consensus view top porge view much im datum bone health drug prolium bone marrow stimulating aranesp be project beat help offset expect sale miss bone health drug xgeva other bone marrow stimulant drug porge say however change price dynamic many amgen product make im adjustment factor less reliable porge write call amgen hike price july bump price cancer drug kyproli april adjust profit share side gilead have chance beat consensus view porge say regeneron vertex also top expectation respectively biogen miss earning view due time research development expense not fully recognize analyst estimate porge say abbvie too be likely miss adjust earning share say afternoon trading stock market today ibd medical biom biotech group be fractionally related surprise spike beleaguered biotech stock gilead acquire biotech vertex be still better analystwhy biotech be poise run topple june
293,VRTX,call etf cool stuff ishare exponential technology xt pool most innovative company stock market big datum analytic medicine computer network environmental system robotic printing be field represent portfolio stock exponential technology displace older technology create new market have potential effect significant economic impact prospectus say research team morningstar create index tap company deem be creator groundbreaking technology user such technology portfolio be health care information technology component be equally weight portfolio portfolio consist mainly product maker include provider innovative service such netflix nflx amazon com amzn latin american counterpart mercadolibre meli other holding note innovation doesn guarantee consistent stock gain tesla motor tsla pioneer electric car be have great worry battery shortage china order send stock reel month irobot irbt inventor roomba self operate vacuum cleaner battlefield robot break support day move average etf be tech heavy good year technology stock have help fund outperform general market be more december march inception nearly share etf be find support day move average create buy area second pullback line dec past buy point share find support day line april give etf boost ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related novartis face key fda panel cancer drug kite be alnylam have edge smaller biotech rare disease
294,VRTX,key hepatitis drug gilead science gild top wall street expectation investor be tune company second quarter report july more hint potential activity analyst say friday gilead hepatitis sale slip month follow biotech say be open deal especially oncology analyst have be quick offer incyte incy tesaro tsro kite pharma kite clovis oncology clvs potential acquisition target other have say vertex pharmaceutical vrtx be smart buy help fend larger dip hepatitis franchise credit suisse analyst alethia young expect gilead harvoni key hepatitis drug beat analyst second quarter model period model gilead pull sale just north consensus adjust income share top broader forecast nickel expect beat harvoni sale still be year year young also expect gilead genvoya hiv medication top wall street view sale model period see total prescription grow quarter quarter vs consensus expectation just growth however don expect share react strongly beat think investor be look gilead do deal write note client ibd take big biotechs be likely struggle year investor focus turn smaller cancer rare disease focuse biotechs analyst say head industry snapshot closer look company be pique analyst interest biogen biib also be limelight investor look strategic update plan growth heighten competition multiple sclerosis arena drugmaker roche rhhby march gain approval drug ocrevus treat form multiple sclerosis young see biogen key ms drug tecfidera tysabri pull line sale long term number be street quarter young forecast line total sale see adjust profit miss view share consensus view biogen be schedule report result give strategic update july strategic update look biogen give insight collaboration eisai well newly seat chief executive michel vounatsos long term vision company investor also likely want update alzheimer drug aducanumab think investor be hope hear company give interim readout aducanumab phase trial next year say think make want own other want datum incyte beat top line strong jakafi sale investor focus likely be immuno oncology drug epacadostat strategic partnership dow merck mrk bristol myer squibb bmy incyte be set report earning aug more broadly young expect line quarter large cap biotechs see amgen amgn alexion pharmaceutical alxn vertex biomarin pharmaceutical bmrn report metric line consensus view related gilead acquire biotech vertex be still better analystare gilead fortune change acquisition biotech rally still tack upside
295,VRTX,boost explosive earning growth recent quarters recent gain fellow biotech stock celgene celg exelixis exel regeneron regn innoviva inva see sharp improvement relative strength rs rating monday rise ibd unique rs rating measure market leadership used worst best score indicate stock price action last week match other stock decade market research show stock go make biggest gain often have rs rating north launch biggest climb see innoviva continue rebound clear threshold innoviva be try complete cup handle buy point monday rise light trade close entry see stock break volume least average company show ep growth latest quarterly report putt average gain last quarters sale growth have slow triple digit growth recent quarters still strong company earn rank peer medical biom biotech industry group celgene supernus pharmaceutical supn vertex pharmaceutical vrtx be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
296,VRTX,celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx lead biotech sector more upside follow second quarter analyst say thursday share trek fifth straight day xat close bell stock market today ibd company biotech industry group be trading month high leerink analyst geoffrey porge credit lack drug pricing headwind day uptrend current rally reflect lift perceive fear pricing regulation favorable tone fda do not yet reflect more positive operate result not mention industry consolidation still expect write note client porge expect industry tack upside follow likely be strong second quarter earning season biotech stock have add june thursday leader include number small cap trading riser porge prefer call growth stock celgene regeneron vertex alexion pharmaceutical alxn mid regeneron stock have add follow gain celgene vertex stock gilead science gild perform worst only gain be still higher overall market say major biotech index have add last month broader market have only tack growth ibd take analyst begin predict biotech rally last month be sign benefit most head industry snapshot closer look analyst have say reason sector surge be fear be subside prospect president donald trump take action curb pricing analyst now say trump rhetoric tamp pricing appear be lip service wall street expectation amgen amgn gilead regeneron second quarter earning have dip last month revenue view have be largely flat decline amgen gilead large cap biotechs have beat second quarter view gain upside porge say last year large cap have beat second quarter expectation time amgen celgene gilead beating view time guidance increase be more likely second quarter first say expect biotech sector rally much compare long term relative multiple vs medtech pharma sector related small biotech pique interest gilead other biotechs surge generalist return subside trump biotechs be lead sector month high today
297,VRTX,gilead science gild fortune be likely change summer expect approval key hepatitis drug regimen biotech unveil phase datum hiv trial analyst say friday xyear date gilead stock be friday close share decline much year low june have re-cover somewhat biotech rally see sector rise collectively month high late june gilead stock be marginally friday needham analyst alan carr list gilead biotechs potential upside specific event upside be sorely need gilead be struggle decline hepatitis franchise european market mature follow decline gilead have identify hiv drug know bictegravir next big hit july gilead be expect unveil phase datum bictegravir international aids society conference paris carr say note client august food drug administration be expect approve gilead combination sofosbuvir velpatasvir voxilaprevir chronic hepatitis patient have fail specific prior treatment regimen be week treatment other analyst have suggest gilead make acquisition bolster pipeline company have indicated explore merger oncology fuel rumor be look tesaro tsro incyte incy ibd take strong biotechs exelixis stock have rocket high year not see decade head new america see catalyst send stock fly more be corner outside gilead carr see catalyst number player alnylam pharmaceutical alny intercept pharmaceutical icpt neurocrine bioscience nbix vertex pharmaceutical vrtx alnylam be expect have phase datum drug patisiran september patisiran be be investigate potential treatment rare disease cause abnormal buildup material call amyloid tissue deposit damage organ approve patisiran rival drug ionis pharmaceutical ion ionis be currently work trial drug inotersen population patient study help provide proof mechanism patisiran inotersen carr say later third quarter intercept be likely announce phase result drug ocaliva treatment disease cause inflammation scar tissue bile duct ultimately result liver damage ocaliva be already approve treat similar liver disease expect positive outcome await clarity registration requirement carr say second quarter ocaliva sale estimate be vs consensus neurocrine second quarter earning first time include sale drug ingrezza approve treatment involuntary movement associate long term use certain medication carr model sale period also second quarter carr estimate vertex bring sale kalydeco orkambi respectively kalydeco orkambi be cystic fibrosis drug patient specific genetic mutation related gilead vertex join don hold breath analystwhy biotech rally still tack small biotech pique interest gilead other
298,VRTX,tuesday avexis avxs earn upgrade relative strength rs rating unique rating track technical performance used worst best score show stock price action last week match other stock database history reveal stock go make biggest gain often have rs rating least begin new climb see ibd help make more money stocksavexis break earlier have fall back prior entry cup handle stock re watch clear buy point then decline more original entry price consider fail base best stock form new consolidation also understand most recent consolidation be later stage base such basis be more prone failure avexis post ep growth last quarter revenue gain come company earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
299,VRTX,important metric look stock be higher relative strength rating ptc therapeutic ptct clear benchmark tuesday jump tuesday proprietary rating measure market leadership show stock price movement last week measure other stock database history show best perform stock tend have rs rating north early stage move see ibd help make more money stocksptc therapeutic be build consolidation buy point see stock break volume least average sale growth fall last quarter earning share grow previous report company hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
300,VRTX,supernus pharmaceutical supn see welcome improvement relative strength rs rating monday rise ibd unique rs rating measure market leadership used worst best score show stock price performance last week stack other stock database decade market research show stock go make biggest gain often have rs rating north early stage move see supernus pharmaceutical continue show renew price strength clear threshold look best stock buy watch start heresupernus pharmaceutical be build consolidation buy point see break volume least average company post ep growth latest quarterly report sale gain come company earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
301,VRTX,monday crispr therapeutic crsp hit important technical milestone relative strength rs rating climb percentile improvement increase day exclusive rating investor business daily identify market leadership worst best score rating show stock price movement last week compare other stock database decade market research reveal best stock often have rs rating north launch largest climb look winning stock try simple routinecrispr therapeutic be now consider extend buy range clear buy point first stage consolidation see stock form new pattern follow buy opportunity week tight pullback day week line crispr therapeutic post ep growth last quarter sale increase company hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
302,VRTX,beleaguered biotech investor likely have get relief trial datum drug approval help stoke ember formerly red hot group take analyst say be relief horizon don expect anything earth shatter say next quarter half be likely feature significant disclosure number company coverage be unlikely be period strongly stock move event leerink analyst geoffrey porge write recent note client porge view follow third quarter large cap struggle historic moneymaker catch double whammy increase competition pricing concern meanwhile smaller cap crushed expectation result ibd company biotech industry group rank first just month be now list group ibd track share touch month high october have lose nearly however flow event be set accelerate early first quarter offer more opportunity meaningful value inflection company stock leerink analyst write recent note frustration depress biotech stock group have post impressive number new approval year jmp security analyst mike king say accord food drug administration original application drug biologic have be approve year need product approval tell investor business daily even most jaded observer sector have say sector whole have produce very satisfactory result come major trial readout don see change regard tack drug approval successful datum readout be key company celgene celg gilead science gild pair large biotech leader face grow field competitor moneymaker revlimid hepatitis drug respectively celgene be set have readout type hodgkin lymphoma have car development partner bluebird bio blue juno therapeutic juno car drug treat cancer used patient own re engineer immune cell be important celgene have long enjoy revenue gain chemotherapy revlimid analyst have be expect generic competition dr reddy laboratory rdy recently dr reddy miss key deadline file generic still less ideal celgene rely so heavily stream revenue fbb partner analyst mike bailey say celgene have be prepare replace patent challenged revlimid sale crohn disease drug firm say october win initiate phase trial drug bull case celgene previously be have new drug limit risk revlimid tell ibd take away risk management piece focus be drug be go go generic point similarly gilead have hiv combination used drug bictegravir set gain potential approval february accelerate hiv sale start second quarter porge say same time ark invest analyst manisha samy say gilead likely get further car gilead also announce thursday acquisition cell design lab privately hold car player october gilead acquire kite pharma nearly follow fda approval kite drug dub yescarta treat large cell lymphoma adult due individualized nature car drug aren likely rake same sale gilead now falter hepatitis drug year line be huge revenue maker tell ibd ibd take big cap struggle third quarter isn surprising consider patent cliff next year be set hit annual sale blockbuster drug say analyst head industry snapshot more biotechs fared period yescarta win replace gilead hepatitis franchise peak grow steadily bailey say guess be hepatitis be go shrink really quickly say point expect car replace hepatitis sale way peak be once ever term gilead do never be big next several month leerink porge look abbvie abbv regeneron pharmaceutical regn disclose pivotal trial regulatory event vertex pharmaceutical vrtx report more value confirm event abbvie have datum inflammatory treatment know upadacitinib say result add more detail evolve landscape be know jak inhibitor treat psoriasis rheumatoid arthritis ulcerative colitis number condition regeneron be deck file result drug dupixent asthma drug be already approve treat eczema firm also report datum eye drug eylea immuno oncology drug cemiplimab type skin cancer also look vertex provide phase datum triple pill combination treat cystic fibrosis total vertex be testing potential regimen bring phase trial firm be also likely gain approval drug combination february big pharma world leerink analyst seamus fernandez say be few significant stock move catalyst left first half be busy dow merck mrk bristol myer squibb bmy astrazeneca azn have immuno oncology combo result lung cancer bristol merck incyte incy be set deliver result regimen melanoma bristol also offer interim datum trial immuno oncology drug opdivo yervoy first treatment lung cancer outside major immuno oncology catalyst thankfully be limit say high bar bristol interim datum require nothing short stopping study early extreme effectiveness unlikely so expectation be probably low say nonetheless early stop be major validation bristol strategy likely drive stock view say continuation study likely increase concern bristol strategy ultimate success study final analysis possibly push stock parp inhibitor yet class cancer drug be set have trial result well astrazeneca have result drug lynparza first maintenance treatment ovarian cancer think parp space be quite large jmp king say hard tell real world doctor see drug better so start produce satisfactory sale figure related biotechs sell drove be investor seek merger biotech just near year high strong cancer regimenthis cancer biotech be fall bayer deal
303,VRTX,biogen biib see welcome improvement relative strength rs rating wednesday upgrade ibd unique rs rating identify technical performance used worst best score show stock price action last week stack other stock database year market history show best perform stock often have better rs rating early stage move see biogen continue show renew price strength hit benchmark look best stock buy watch start herebiogen be work cup handle buy point see stock clear price heavy trading earning growth rise company most recent report top line fall look next report jan biogen earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
304,VRTX,big biotech biogen biib beat analyst earning estimate early wednesday send batter stock early trading biogen earning exclude time item rise year earlier quarter share beating consensus cent accord thomson reuter revenue climb wall street average estimate
305,VRTX,stock stumble start gate mixed trade monday economic datum oil price overseas pressure weigh early action dow industrial dip nasdaq backed volume be mixed stock market today nyse lower nasdaq relative action
306,VRTX,san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday
307,VRTX,news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction
308,VRTX,celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate
309,VRTX,celgene be schedule report final earning jan
310,VRTX,celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue
311,VRTX,nonetheless celgene add cent ep guidance have already raise last summer
312,VRTX,celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business
313,VRTX,scott head inflammation immunology business add role chair global management committee
314,VRTX,regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line
315,VRTX,speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch
316,VRTX,analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early
317,VRTX,believe investor debate change result alle do go forward yee say research note
318,VRTX,celgene stock slide monday
319,VRTX,illumina team bill gate
320,VRTX,illumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample
321,VRTX,monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference
322,VRTX,also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year
323,VRTX,flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however
324,VRTX,flatley also say expect revenue grow year line consensus ep guidance share be street estimate
325,VRTX,vertex key drug beat
326,VRTX,vertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore
327,VRTX,new cf drug orkambi launch summer sell hair consensus
328,VRTX,year company forecast kalydeco sale operate expense didn forecast orkambi sale
329,VRTX,kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year
330,VRTX,say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year san francisco big biotechs celgene vertex pharmaceutical disappoint investor guidance gene sequence giant illumina preview variety futuristic product major investor conference monday news annual jpmorgan healthcare conference san francisco send celgene celg vertex vrtx stock fall monday illumina ilmn share rise fraction celgene say ep totale share year earlier quarter miss cent consensus analyst poll thomson reuter product sale cover not quite revenue be line wall street revenue estimate celgene be schedule report final earning jan celgene guide ep expect final number low side analyst projection product sale be guide analyst forecast revenue nonetheless celgene add cent ep guidance have already raise last summer celgene also say march bob hugin lead company year become executive chairman hand ceo job mark alle currently president coo alle turn hand position jacqualyn fouse now president celgene hematology oncology franchise make majority business scott head inflammation immunology business add role chair global management committee regard celgene say include cent charge due milestone payment oncomed omed stem positive datum demcizumab cancer drug celgene have license evercore isi analyst mark schoenebaum write research note be unclear consensus forecast have factor write other number be basically line speaking conference hugin say celgene have absorb cent hit close acquisition receptos bring potential blockbuster immunology drug ozanimod be highly optimistic celgene bud immunology franchise general psoriasis drug otezla launch bring hugin call most successful launch therapeutic history therapeutic area term progress first full year launch analyst be divide management change schoenebaum write change have generally be expect rbc capital market analyst michael yee write ceo transition seem early believe investor debate change result alle do go forward yee say research note celgene stock slide monday illumina team bill gatesillumina stock meanwhile seesaw monday close fraction battery announcement company sunday say be launch new business call grail several partner include microsof msft co founder bill gate bezos expedition family foundation amazon com amzn founder jeff bezos aim company be develop new genetic test early stage cancer be derive simple blood sample monday announce miniseq system simplest cheapest gene sequencer have yet produce miniseq expect launch quarter be price sample cost process ceo jay flatley say conference also monday illumina unveil new partnership bio rad bio develop next generation sequence solution analyze single cell single cell analysis be useful understand cell variation cancer other disease flatley say normally be analyze only small batch illumina bio rad aim high throughput solution combine technology expect launch late year early next year flatley also preview handheld sequence device illumina be work call firefly base cmo technology company acquire couple year be way road however flatley also say expect revenue grow year line consensus ep guidance share be street estimate vertex key drug beatsvertex stock fall preliminary result guidance sunday disappoint investor vertex say flagship cystic fibrosis cf drug kalydeco sell beating consensus accord evercore new cf drug orkambi launch summer sell hair consensus year company forecast kalydeco sale operate expense didn forecast orkambi sale kalydeco guidance appear be street view analyst schoenebaum write email say company guidance have be conservative past year say vertex be wait additional information launch give orkambi guidance analyst expect orkambi sell year
331,VRTX,etf investor get taste snap back market action be hope tuesday choppy trading session major index steady modestly sharp drop kick stock reversed lower intraday oil briefly dip barrel first time december however etfs tracking dow finished higher well session lows health care help lead advance sector utility real estate post loss powershare qqq qqq tech biotech heavy exchange trade fund pop stock market today etf be dec high stock holding celgene celg jump illumina ilmn vertex pharmaceutical vrtx give regeneron regn investor seem have digest monday biotech related news big biotechs celgene vertex have offer mixed outlook major investor conference cause disappointment illumina meanwhile announce new unit call grail focuse detect cancer early simple blood sample apple aapl hold qqq portfolio weighting gain tuesday iphone maker stock briefly re-cover level first time day buoy analyst upgrade well rumor cheaper base model iphone apple electric car stock be week high diving deeply day move average december spdr biotech xbi surge massive volume however equal weight etf hold stock be july high xbi monday undercut late september lows be spur presidential candidate hillary clinton comment price gouge drug industry recent slump analyst rbc capital market be report reaffirm confidence growth prospect biotech sector tuesday note ishare nasdaq biotechnology ibb advanced cap weight etf also breach late september low monday be week high hold stock biggest stake celgene biogen biib amgen amgn gilead gild regeneron regn xbi smaller cap skew help give performance boost rise vs gain ibb gold dollargold price fall third straight session tuesday gold price be moderately lower tuesday more profit take chart consolidation follow recent gain see price hit month high late last week jim senior technical analyst write commodity monitor kitco news less anxious world market scene day firmer dollar index be also help pressure safe haven gold market etf bullish dollar extend gain retake day line monday greenback rise vs other major world currency bellwether etfs here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs follow aparna narayanan twitter ibd_anarayanan
332,VRTX,gilead science gild stock price finished flat friday follow analyst downgrade activision blizzard atvi get higher price target mcdonald mcd pfizer pfe google googl also see analyst action morgan stanley downgrade gilead equal weight give price target share world biggest biotech finished penny higher
333,VRTX,biotech group be perch high ibd industry group ranking good reason several high quality name continue show exceptional relative price strength biotechs be basically be divide group make institutional quality name top fundamental high caliber fund sponsorship other be more speculative name many great potential
334,VRTX,major stock index close mixed wednesday fed raise key lend rate quarter point also agree detail start shrink balance sheet year nasdaq lose fall pare loss final hour dow jone industrial average climb russell small cap index give back volume nyse be higher tuesday level nasdaq volume be lower early figure show economic datum release open didn do anything strengthen argument more rate hike consumer price be tame fall vs consensus estimate flat exclude food energy price rise vs expectation gain meanwhile retail sale unexpectedly fall worst drop january dollar weaken news year treasury yield tumble basis point fed dot plot be mostly unchanged march meeting committee member expect more quarter point hike end year stock market today homebuilder health care even retail group outperformed celgene celg rebound day move average rise stock work new base vertex vrtx gain nearly continue show support action week move average pultegroup phm be pace fourth straight gain cup handle base still buy range benchmark crude oil july delivery slump nearly barrel oil be weak news gasoline inventory rise barrel last week accord energy information administration crude inventory fall barrel starbucks sbux look poise eighth straight decline wedbush downgrade share neutral outperform maintain price target share fall close day move average first time march related stunning economic report give fed pausebank stock test buy point support weak datum fed odd
335,VRTX,major market index open higher gain quickly fade final trading session second quarter tech heavy nasdaq composite be just fractionally higher meanwhile dow jone industrial average be respectively xamong dow industrial nike nke be big winner early trade surge nearly inking deal amazon com amzn sell shoe clothe accessory directly amazon com apparel company also report fiscal earning late thursday exceed street top bottom line forecast analyst action lead biotech celgene celg be downgrade neutral buy btig research share fall fellow leader industry include regeneron pharmaceutical regn vertex pharmaceutical vrtx regeneron fall vertex rise nearly stock be extend proper buy point company report earning micron technology mu fall beating earning sale target late thursday memory chip maker be look test day line trade buy range flat base entry have be rather choppy move lead chip stock look regain recently lose momentum stock market today apply material amat broadcom avgo be fractionally higher rise early friday stock have fall day line recent trading session be attempt reclaim action ibd be mixed thursday bloodbath coherent cohr jump list lead share pierce day line june trigger sell signal grubhub grub rise early turn flat food delivery service trigger sell rule june fail flat base entry related micron technology beat earning sale target stock risesnike deal amazon send dow stock soaringdow jone industrial average dow stock news analysis
336,VRTX,heel purchase true north therapeutic biogen biib spinoff bioverativ bivv be work way potential new developer therapy treat hemophilia other blood disorder go public february have be climb steadily higher clearly outperform year big buzz initial public offer snapchat parent snap snap monday bioverativ have relative strength rs rating upgrade monday exclusive rating investor business daily identify price action worst best score rating show stock price movement last week compare other stock database year market history show market biggest winner typically have rs rating north begin biggest price move bioverativ be work flat base entry see stock break heavy trade earning growth moved last quarter sale fall bioverativ hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx biospecific technology bstc be top highly rate stock group related biogen spinoff bioverativ square roche buybiotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
337,VRTX,big cap have lose luster even have gain biotech stock such celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx xso far year big cap still lead advantage have fluctuated recent session low percentage point
338,VRTX,top biotech stock amgen amgn celgene celg regeneron regn bluebird bio blue have rally week biogen biib spinoff ipo bioverativ bivv have jump new buy zone developer treatment hemophilia other disorder see positive improvement relative strength rs rating tuesday increase exclusive rating investor business daily identify market leadership worst best score score show stock price performance last week hold other stock database decade market research reveal stock go make biggest gain typically have higher rs rating begin new run bioverativ be still buy range breaking past buy point cup handle wednesday stock be fractionally day still entry once stock move more initial buy point consider buy range revenue growth fall last quarter ep grow prior report company hold rank peer medical biom biotech industry group supernus pharmaceutical supn vertex pharmaceutical vrtx celgene be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
339,VRTX,stock clock broadly mixed finish wednesday weak oil price drag biotechs rally name include red hat rht winnebago wgo turn day biggest gain nasdaq climb dow jone industrial average drift lower end preliminary datum show volume be also mixed lower nasdaq higher nyse end trade tuesday biotechs be big story nasdaq accounting top gain nasdaq stock incyte incy biomarin bmrn vertex pharmaceutical vrtx gain more also top nasdaq surge news report company be discuss be take private deal bmc software news be unconfirmed bloomberg quote unnamed source say talk be early stage gain left share new high clear left side high month consolidation oil related stock turn worst performance day oil price slough putt west texas intermediate crude friday oil hammer away fifth straight weekly decline caterpillar cat take worst loss dow industrial weak trade nike nke rise take dow top slot boost news plan sell product directly amazon com amzn part amazon rise weak trade investor continue monitor rebound support week move average nike amazon news appear pressure foot locker fl shed heavy trade do pare back initial dive earning report also play strong role wednesday action fedex fdx climb deliver better expect result late tuesday rv maker winnebago bolt higher more time average trade forest city iowa outfit report weaker forecast fiscal earning revenue easily top estimate company report strong performance newly acquire grand design division share be well right side month old consolidation low open source software developer red hat surge solid fiscal first quarter report snap share fresh high massive trade related bank buy point ahead stress test investing action plan apple iphone sale expect september quarter
340,VRTX,wednesday la jolla pharmaceutical ljpc reach important technical milestone see relative strength rs rating jump percentile improvement day ibd unique rating track share price action worst best score score show stock price behavior trail week stack other stock database history show top perform stock typically have better rs rating early stage move look best stock buy watch start herela jolla pharmaceutical be work consolidation entry see break heavy volume la jolla pharmaceutical show earning growth latest quarterly report sale growth come la jolla pharmaceutical earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
341,VRTX,putt together watch list focus stock higher rs rating ptc therapeutic ptct be stock just reach mark now earn score unique rating track technical performance used worst best score show stock price action last week match other publicly trade company year market history show market biggest winner tend have rs rating early stage move look winning stock try simple routineptc therapeutic be work consolidation buy point see clear price heavy volume earning growth rise company latest report sale fall ptc therapeutic earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
342,VRTX,friday flexion therapeutic flxn earn upgrade relative strength rs rating exclusive rating investor business daily measure price movement worst best score score show stock price performance last week hold other stock database year market history show stock go make biggest gain tend have better rs rating early stage move see flexion therapeutic continue rebound hit benchmark look best stock buy watch start hereflexion therapeutic be build cup handle buy point see stock clear price heavy trade keep mind later stage consolidation entail more risk company report earning growth latest quarterly report revenue gain come company hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
343,VRTX,supernus pharmaceutical supn have relative strength rs rating upgrade friday proprietary rating track technical performance used worst best score identify stock price performance trail week match rest market history reveal top perform stock tend have rs rating north early stage move look best stock buy watch start heresupernus pharmaceutical be try complete consolidation buy point see break heavy trading supernus pharmaceutical show ep growth last quarter sale increase company earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx ligand pharmaceutical lgnd be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
344,VRTX,welcome move innoviva inva see relative strength rating improve wednesday unique rating measure market leadership show stock price movement last week compare other stock database decade market research show top perform stock typically have higher rs rating launch biggest price move see innoviva continue show renew price strength hit benchmark look winning stock try simple routineinnoviva be build cup handle entry see break volume least average company report ep growth last quarter sale increase innoviva earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
345,VRTX,relative strength rs rating pacira pharmaceutical pcrx moved higher percentile wednesday get lift proprietary rating track technical performance show stock price action last week measure other stock database decade market research reveal market biggest winner often have rs rating north early stage move see pacira pharmaceutical continue show renew price strength hit benchmark look winning stock try simple routinewhile now be not ideal time invest see stock be able establish enter buy range heavy volume term fundamental health pacira pharmaceutical have post quarters increase earning growth revenue growth have be different story come most recent report company hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
346,VRTX,morgan stanley analyst matthew harrison downgrade gilead science gild upgrading alexion pharmaceutical alxn vertex pharmaceutical vrtx base see term catalyst current volatile market harrison maintain price target gilead lower rating equal weight overweight base relative attractiveness other stock harrison write research note true gilead have cash make substantial acquisition doesn think really big immediate future management offer few comment recent conference suggest management be focuse multiple deal clinical stage asset await derisk datum similar bristol myer bmy string pearl strategy harrison write believe be smart strategy gilead generate average long term return also do not see strategy offer single deal re rate gilead investor have suggest same time harrison write long term outlook hepatitis market be unclear next year eu rollout be more advanced merck mrk have unveil more datum own pipeline gilead stock be midday trading stock market today pick big cap harrison like position vertex move expect be first profitable quarter year thank recent launch cystic fibrosis drug orkambi see strong orkambi launch base physician feedback suggest revenue much consensus harrison write biotechs transition profitability have historically outperformed peer time month follow transition harrison upgrade vertex stock overweight equal weight set price target vertex stock be midday friday touch nearly year low tuesday harrison also upgrade alexion stock overweight equal weight price target writing recent sell drug stock have create attractive entry point orphan drug stock alexion have only decline vs other large cap biotech peer alexion have be underperformer year date most large cap biotechs harrison note thus give robust set new product launch potential pipeline upside consensus now more aware competitive landscape soliris see potential alexion outperform weakness generate concern government pricing alexion stock be midday trading friday still leave share more time high touch july stock market tumble prove especially tough biotechs follow amy reeve twitter ibd_areeve facebook
347,VRTX,european union medical advisory committee endorse several key drug lead stock friday make eu approval likely potential blockbuster committee medicinal product human use know french abbreviation chmp adopt positive opinion gilead science gild genvoya manage hiv infection genvoya be drug combo pill identical gilead popular treatment stribild place ingredient viread gilead have put new drug tenofovir alafenamide taf taf be know wall street son viread similar compound alter so lower dose be used turn reduce side effect crucially gilead also win hit viread patent expiry be due start stribild sale pass last year be expect top next year be key revenue driver even company big gilead chmp also endorse blood cancer drug amgen amgn kyproli amgen get acquire onyx pharmaceutical be first approve multiple myeloma hasn yet hit market european union be first approve lone treatment amgen have be push combo kyproli celgene celg revlimid dexamethasone base successful new trial patient ve receive least prior therapy fda approve combo july kyproli isn big revenue driver big biotech now analyst expect annual sale hit chmp also backed newer drug blincyto certain type acute lymphoblastic leukemia blincyto be bispecific cell engager bite antibody combine bit different antibody engage body cell attack cancer cell analyst expectation aren huge blinctyo amgen recently cut licensing deal use xencor xncr longer last bite technology develop newer better drug vertex pharmaceutical vrtx orkambi cystic fibrosis also get chmp thumb friday orkambi gain fair bit medium attention win approval july cystic fibrosis be devastate disease few treatment give vertex considerable pricing power consensus call annual sale pass model already reflect orkambi launch europe early cf patient older write maxim group analyst jason kolbert research note however anticipate slower launch trajectory due need obtain reimbursement country country basis speaking orphan disease horizon pharma hznp ravicti also get chmp endorsement treatment ultra rare urea cycle disorder ucds ravicti be drug horizon acquire hyperion therapeutic year piper jaffray analyst david amsellem highlighted potential growth driver march deal be announce ravicti be approve fda february now have sale annualizing amsellem write accord hyperion prevalence ucd be hyperion have estimate only ucd patient be actually diagnosed only be treatment ravicti cost year amsellem point not steep orphan drug horizon price higher do not estimate european pricing however endorsement stock be stock market today drug stock continue recent bumpy ride afternoon trading friday gilead amgen share be vertex horizon stock be follow amy reeve twitter ibd_areeve facebook
348,VRTX,piper jaffray place bet biotech speculation game friday say gilead science gild acquire incyte incy bristol myer squibb bmy probably wouldn be interested vertex pharmaceutical vrtx report review biopharma sector analyst joshua schimmer write best fit gilead be derisked later stage asset
349,VRTX,rare disease specialist raptor pharmaceutical rptp be friday announce buyout late thursday bring field cystic fibrosis raptor pharmaceutical inked deal privately hold tripex pharmaceutical acquire quinsair inhaled drug help manage chronic pulmonary infection be common cf patient drug have be approve european
350,VRTX,fda thursday afternoon approve vertex pharmaceutical vrtx potential blockbuster cystic fibrosis drug orkambi company price year high side investor expectation
351,VRTX,agency give nod orkambi combination ivacaftor vertex market separately kalydeco lumacaftor booster make drug effective treat much larger population ivacaftor alone
352,VRTX,fda approve product patient condition be cause copy del mutation homozygous account half cf patient
353,VRTX,however improvement orkambi yielded clinical trial be smaller kalydeco lead widespread expectation vertex price orkambi lower kalydeco year mark buyside investor survey conduct evercore isi monday find mean expect price be median be so eventual price be bit high side
354,VRTX,company chief financial officer ian however hint discount rate orkambi be higher kalydeco discount kalydeco cost average year
355,VRTX,conference call analyst note estimate homozygous del patient be medicaid higher percentage group take kalydeco suggest population be poorer
356,VRTX,vertex have assistance program place call vertex gps help ensure patient be able afford pricey medicine chief commercial officer stuart arbuckle say most kalydeco patient pay less month pocket vertex plan continue strategy orkambi
357,VRTX,arbuckle say lift orkambi likely be slower be kalydeco
358,VRTX,uptake kalydeco be fast product ve personally be involved get eligible patient month arbuckle say orkambi expect get very very strong demand physician patient just sheer volume patient lead believe time peak be go be longer
359,VRTX,arbuckle note cf center averaged only patient eligible kalydeco have apiece hope orkambi
360,VRTX,trading vertex stock be halter just noon et news break stock rise nearly morning trading resume trading et vertex stock be stock touch record high april
361,VRTX,follow amy reeve twitter ibd_areeve fda thursday afternoon approve vertex pharmaceutical vrtx potential blockbuster cystic fibrosis drug orkambi company price year high side investor expectation agency give nod orkambi combination ivacaftor vertex market separately kalydeco lumacaftor booster make drug effective treat much larger population ivacaftor alone fda approve product patient condition be cause copy del mutation homozygous account half cf patient however improvement orkambi yielded clinical trial be smaller kalydeco lead widespread expectation vertex price orkambi lower kalydeco year mark buyside investor survey conduct evercore isi monday find mean expect price be median be so eventual price be bit high side company chief financial officer ian however hint discount rate orkambi be higher kalydeco discount kalydeco cost average year conference call analyst note estimate homozygous del patient be medicaid higher percentage group take kalydeco suggest population be poorer vertex have assistance program place call vertex gps help ensure patient be able afford pricey medicine chief commercial officer stuart arbuckle say most kalydeco patient pay less month pocket vertex plan continue strategy orkambi arbuckle say lift orkambi likely be slower be kalydeco uptake kalydeco be fast product ve personally be involved get eligible patient month arbuckle say orkambi expect get very very strong demand physician patient just sheer volume patient lead believe time peak be go be longer arbuckle note cf center averaged only patient eligible kalydeco have apiece hope orkambi trading vertex stock be halter just noon et news break stock rise nearly morning trading resume trading et vertex stock be stock touch record high april follow amy reeve twitter ibd_areeve
362,VRTX,drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition
363,VRTX,johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing
364,VRTX,happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market
365,VRTX,yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development
366,VRTX,gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development
367,VRTX,not new hep
368,VRTX,be also hcv game drug olysio be different class drug not directly competitive sovaldi
369,VRTX,be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own
370,VRTX,clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity
371,VRTX,yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close
372,VRTX,still maxim group analyst achillion bull jason kolbert do not sound very worry
373,VRTX,alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race
374,VRTX,high price sovaldi
375,VRTX,investor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day
376,VRTX,gilead charge day treatment typically run week
377,VRTX,monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme
378,VRTX,budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately
379,VRTX,however july france joined other country coordinate strategy drive sovaldi price
380,VRTX,gilead stock slip tuesday close drama continue big biotech gilead science tuesday johnson johnson moved viral disease turf front acquisition johnson johnson jnj disclose buy privately hold alio biopharma cash press release tout alio drug candidate respiratory syncytial virus rsv major cause lung infection have current treatment drug al be midstage clinical testing happen gilead gild also have rsv drug gs phase clinical trial be overshadowed gilead bigger drug rbc capital market analyst michael yee believe have blockbuster potential astrazeneca azn synagis used prevent rsv infection high risk infant draw more year just niche market yee point research note tuesday alio be potential competitor gilead way have nucleotide drug hepatitis virus hcv early stage development gilead megablockbuster sovaldi be first nucleotide drug hcv hit market back december year merck mrk shell buy idenix pharmaceutical also have nuke development not new hep cj be also hcv game drug olysio be different class drug not directly competitive sovaldi be often prescribe together have help buoy olysio sale launch last november first half year alone sell give success combo not surprising want nuke own clearly think long term call option upside here be alio nuke show log reduction hcv virus have good safety profile yee write course be not layup know development nuke be extremely difficult bar continue progression be very high reminder vertex vrtx be partner prior alio nuke drop development due narrow therapeutic window weak efficacy have sign liver toxicity yee also write be interesting see development read achillion pharmaceutical achn stock boast ibd relative strength rating base largely expectation be next nuke developer be buy investor seem be read negatively achillion stock fall tuesday close still maxim group analyst achillion bull jason kolbert do not sound very worry alio nuke be old news kolbert tell ibd think achn be be bit nonsense nuke show good datum be race high price sovaldiinvestor analyst be interested future competition sovaldi not just effect market share also sovaldi price have question day gilead charge day treatment typically run week monday government france address issue social security budget bill propose new taxe seller hepatitis drug revenue make france social security have spend more euro drug government call progressive contribution scheme budget still have be approve lawmaker sign european country be continue drive hard bargain gilead roll sovaldi eu approve sovaldi sale january country have own payment system drugmaker have negotiate separately however july france joined other country coordinate strategy drive sovaldi price gilead stock slip tuesday close
381,VRTX,stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high
382,VRTX,nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure
383,VRTX,european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting
384,VRTX,retailer medical apparel stock lead upside datum storage energy steel stock underperform
385,VRTX,nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average
386,VRTX,alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range
387,VRTX,downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report stock rise friday european central bank hint new stimulus measure boost inflation major average end intraday high nasdaq rise dow jone industrial average gain be volume be mixed stock market today rise nyse fall nasdaq compare thursday accord preliminary figure european central bank head mario draghi suggest ecb introduce new stimulus measure dec meeting retailer medical apparel stock lead upside datum storage energy steel stock underperform nike nke lead dow ibd jump heavy volume announce stock split share buyback dividend increase late thursday stock be well extend past buy point have find support day move average alaska air alk be also best perform ibd stock regional airline climb nearly line oil plunge barrel near buy point flat base hawaiian holding also rise nearly carrier be just time high well buy range downside mentor graphic ment plunge week low mentor developer software used test electronic system issue disappointing quarterly earning report
388,VRTX,vertex pharmaceutical vrtx cystic fibrosis drug sale pop first quarter help drive sale beat profit top wall street expectation penny hour trading vertex stock lift close less share be year outperform ibd company medical biom biotech industry group be just january first quarter end march vertex report sale vs year earlier period be help collaborative payment merck kgaa quarter be paid taxe german authority vertex file expect refund sale easily beat analyst expectation collaborative payment merck kgaa have lag model adjust earning cent share grow beat penny vertex bread butter segment cystic fibrosis see sale grow first quarter orkambi kalydeco cf drug bring sale respectively grow ibd take vertex have ibd composite rating best possible meaning outperform stock term key growth metric head ibd stock checkup list top rate biotechs vertex see continue uptake orkambi child age complete application same group patient regulator europe ceo jeffrey leiden say statement quarter vertex also unveil strong datum phase study combine tezacaftor ivacaftor treat cystic fibrosis combination show statistically significant improvement lung function patient disorder company be also look potential drug be combine tezacaftor ivacaftor create triple pill cystic fibrosis patient vertex expect have datum second half have datum early remain focuse advance key cf program include triple combination regimen support goal provide treatment person cf leiden say related abbvie hover buy point earning sale topcelgene dip lag psoriasis sale earning topbristol myer stock pop street crush revenue profit
389,VRTX,vertex pharmaceutical vrtx stock rocket month high wednesday biotech announce drug pill cystic fibrosis improve lung function pair late stage study close bell stock market today vertex stock have jump earlier rise much share last hit level january ibd company biom biotech industry group spiked vertex say combination tezacaftor ivacaftor latter sell brand name kalydeco significantly improve lung function cystic fibrosis patient age specific genetic mutation week evolve study combo pill doublet show percentage point improvement baseline patient ability forcefully expel breath second vs placebo week study patient doublet show percentage point improvement average week compare placebo ivacaftor alone ivacaftor monotherapy show percentage point improvement vertex plan file application fda regulator europe third quarter study doublet be well tolerate most common side effect include cough ineffective pulmonary exacerbation only patient doublet discontinue use due adverse event differ orkambi associate tighten muscle lung result cough wheeze shortness breath vertex orkambi be doublet comprise lumacaftor ivacaftor wall street have broadly expect tezacaftor ivacaftor show improvement lung function janney analyst debjit chattopadhyay say call low respiratory event rate compellingly positive only patient have adverse respiratory event ibd take medical aesthetic drugmaker be lead way anyone challenge player head industry snapshot more safety profile mitigate commercial concern surround orkambi suggest potential upside fiscal estimate write note client have neutral rating vertex stock say challenge loom triplet jmp analyst liisa bayko say tezacaftor ivacaftor combination provide stronger backbone triple combo reiterate market perform rating raise price target vertex stock triplet combine tezacaftor ivacaftor drug know vx credit suisse analyst alethia young boost expectation ivacaftor model peak sale ivacaftor young have outperform rating vertex stock boost price target ub analyst carter also raise expectation ivacaftor vertex tezacaftor ivacaftor doublet compare favorably orkambi point write research report raise price target vertex stock buy rating related biotech stock catalyze plunge key sector vertex sale guidance cystic fibrosis drug orkambi missesamgen biogen celgene eye trump pro biotech world
390,VRTX,just ace baseball pitcher mix throw top mutual fund manager vary investment manager columbia large cap growth fund be mingle semiconductor stock biotech stock online travel agency chinese fast food chain good effect be benefit investor retirement account other portfolio fund be work way back multiyear top notch outperformance year go wednesday fund gain top large cap growth rival track morningstar inc advance improvement show past month fund outpaced just direct rival nonetheless decent rise so year date relative performance be turn back accomplish past year beat direct rival key piece credit go fund stake technology stock be portfolio largest sector feb weighting nearly double second largest sector then consumer discretionary have tech weighting fund semiconductor stock include lam research lrcx so far year micron technology mu year broadcom avgo ibd take broadcom be rank ibd electronic semiconductor fabless industry group composite rating be highest possible earning share growth have accelerate quarters row see additional easy understand fundamental technical datum stack rival ibd stock checkup biotech bet include vertex pharmaceutical vrtx celgene celg fund consumer discretionary play be online travel agency priceline pcln expedia expe be respectively year china base restaurant chain yum china yumc be security consumer discretionary space year ve also try make play multicategory straddler alibaba baba amazon amzn lam have benefit trend be grow complexity semiconductor manufacturing equipment say peter deininger manager fund second be consolidation semiconductor equipment space have cut inventory volatility smooth industry cycle mean higher margin higher return lam deininger say addition lam be leader etching deposition segment semiconductor equipment field help increase market share rate excess other player deininger say combine have put company good situation anticipate have leg go micron make memory datum storage device industry have go enough consolidation pricing be stable rise micron key dram product deininger say lead rise margin add industrywide earning share price do so well last year segment be top explain recent pullback space affected micron other stock deininger be not ready retreat yet continue be very balanced supply pricing remain firm lead time product be modestly extend say combine lack significant new capacity argue share price strength hold time go forward fund manager tchintcia barro like vertex exist treatment cystic fibrosis well development vertex gap march news favorable result late stage trial new treatment combination therapy vertex plan add drug create drug cocktail treat thousand more cystic fibrosis patient barro say several month competitor galapago create fear investor vertex have portfolio treatment barro say datum show galapago be year vertex fund manager have mixed feeling consumer discretionary space hand end last year have shift underweight overweight sector vs russell growth index ve sell position brand apparel manufacturer vf vfc yogawear chain store lululemon athletica lulu pharmacy operator cvs health cvs online company have put lot pressure traditional retail area manager john wilson say other hand fund still like online travel agency priceline expedia manager yum china pure play china restaurant stock yum china gap april day release first quarter financial result earning share grow slip sale sale nose consensus estimate company open new store quarter include little sheep east dawn outlet guidance fiscal company say open least new store operate profit grow double digit pace yum brand yum fund also hold say have complete spinoff yum china nov begin trading day share new company be related top columbia fund load stock leadersyou need much retirement saving age income
391,VRTX,do get handle biotech market unknown stock esperion therapeutic espr nearly january outperform like industry top name amgen amgn sure esperion have have breakthrough cholesterol medication amgen recently have own moment cholesterol drug prove decrease bad ldl cholesterol also cut risk heart attack stroke still amgen isn get respect smaller biotech player be get comparatively paltry year don get discourage analyst say just amgen isn get lot love doesn mean other biotech stock be slouch really question navigate be complex sector leerink analyst geoffrey porge say biotechs have do well election stock be subject whim political debate drug pricing health care re worry donald trump health care reform re worry fda reform now re worry drug pricing regulation say just doesn seem accumulate worry be go go away hurry overall group look strong now rank group track week be rank ibd take drugmaker allergan be sweeping medical aesthetic market hologic want play head industry snapshot breakdown battle porge mizuho analyst salim sy call stock picker market biotechs be bound do well number catalyst still ahead other be more likely struggle macroeconomic politic be still pressure investor need be cognitive drug pricing sy tell ibd folk thought be presidential platform topic keep come now postelection ibd company biom biotech industry group be year major exchange trade fund ishare nasdaq biotechnology index ibb spdr biotech xbi be respectively top biotechs include amgen gilead science gild celgene celg biogen biib regeneron pharmaceutical regn have be news none stock price amgen have gain most gilead lag january sy have buy rating amgen celgene gilead stock neutral rating biogen stock smaller player potential takeout candidate incyte incy tesaro tsro have see big gain wall street tesaro be likely remain stand alone company grab fda approval ovarian cancer drug zejula stock rise much mid february be now only year incyte other hand have tack january rumor biotech gilead be look acquire incyte open gilead oncology world hepatitis franchise struggle high cure rate once again re start year best perform stock be be cheapest more takeout candidate porge tell ibd so make prediction have definitely be somewhat challenge earlier month nektar therapeutic nktr stock hit year high strong datum pain pill be alternative potentially addictive oxycodone nektar stock catapult single day share extend cup handle formation late march have give back gain stock remain year other big stock earner include kite pharma kite bluebird bio blue be work drug class call car cell therapy drug engineer patient immune cell treat cancer kite stock be whopping lead rise bluebird stock esperion rocket amgen heart study so too do medicine company mdco share be january porge list medicine co stock watch note spectacular return have right stock right set event then still generate incredibly attractive return excitement biotech porge say be company be approach critical readout ongoing development program investor think reasonable chance critical trial critical milestone turn positively mizuho sy suggest look individual stock equity rather hope broad biotech resurgence see good number catalyst market note drug pricing debate be likely still weigh market president trump have key drug pricing debate limit detail say have plan competitive base system bring price drug trump pick run fda scott gottlieb have say drug pricing need be more transparent struggle unfold porge layer rule pick biotech stock likely have better return want be growth company early life cycle treat very serious illness say follow rule be generally go end portfolio go perform better average better index better benchmark rule porge say epizyme epzm vertex pharmaceutical vrtx alexion pharmaceutical alxn be interesting epizyme stock be january have top buy point cup handle formation early february vertex stock have gain year alexion stock be actually year date stock fit bill used porge rule rare disease company be work drug treat disorder central nervous system blood disease genetic disorder worst thing do biotech investing be sell just stock be porge say don hesitate buy stock same reason axiom investing biotech be always never want say not go buy stock be industry routinely see tenfold increase value cycle emergence product say so often see stock investor say only go market cap market cap scheme thing be pretty small say have real drug re go be company related esperion medicine co recover amgen induced edward best stock own gilead be pay price actually cure disease
392,VRTX,major index mainly tread water late tuesday relatively quiet session dow jone industrial average however be show bullish action maintain strength day move average dow jone industrial enjoy strong gain like industrial giant caterpillar cat unite technology utx edge day narrow range trading contrast monday stock blue chip index fall intraday low bounce higher challenge support key day move average dow show earlier test strength intermediate term support line march cat try fail tuesday climb back day move average lead stock tend travel day line preparation potential good news cat shareholder be stock be trading less week high unite tech meanwhile have make limit upside progress stock rally past cup handle entry point late november early december nasdaq composite be practically flat however lose stock be outpace winning issue nearly margin nasdaq nyse winner loser be roughly evenly match russell lose volume be run mildly lower vs same time monday main exchange medical sector remain laggard here be stock consider watchlist pra health prah be rank ibd stock edge lower be show gain bust stubborn resistance raleigh clinical trial firm have grow earning share vs year level past quarters due part tough year year comparison wall street see earning just cent share pra hold good composite rating scale ibd stock checkup celgene celg have be trading quietly lately top perform biotech be still nominally feb past cup handle entry celgene be trading firmly day move average have be rise more week relative price strength rating be not superb meaningful improvement low week rs rating mean large cap biotech specialize treatment cancer immunological disorder be now outperform stock ibd database past month other notable leader ibd biotech group be incyte incy small cap epilepsy adhd specialist supernus pharmaceutical supn be sharply year so far fourth member biotech group be vertex pharmaceutical vrtx rise heavy trading day zoom massive trading positive clinical trial datum regard pill treatment cystic fibrosis colo base heska hska thinly trade expert veterinary product continue soar clear buy point huge volume nov keep mind heska trade just share day elsewhere stock market today interactivecorp iac roar day line rise more heavy volume search engine operator have find nice support day month stock clear buy point long bottom base pattern october last year feb interactivecorp stage profit turnaround fourth quarter earning rise share crush consensus analyst estimate nearly drop sale halter quarter streak shrink profit now wall street have revise full year ep estimate higher earning see share earning related stock market today be time take profit lead techs income investor dividend leader finish big ibd leader be thrive even testing week move average
393,VRTX,most stock big cap be too extend buy stock have pop screen be potentially advantageous position alphabet googl break october stock gap move oct meant open price be alternative buy point stock leap
394,VRTX,consider name put watch list look stock higher rs rating array biopharma arry just meet criterium new score ibd unique rs rating measure market leadership show stock price movement last week compare other stock major index year market history reveal market biggest winner often have rs rating north early stage move see ibd help make more money stocksarray biopharma be work cup handle entry see clear price volume least average later stage pattern investor be aware be less likely lead significant gain company post negative growth sale earning last quarter array biopharma earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
395,VRTX,voyager therapeutic vygr have relative strength rs rating upgrade tuesday ibd unique rating track price action worst best score score show stock price behavior last week compare other stock database history reveal best stock often have higher rs rating launch biggest run look best stock buy watch start herewhile now be not ideal time jump see stock be able establish enter buy zone heavy volume earning growth decline most recent report revenue moved higher company earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
396,VRTX,relative strength rs rating ptc therapeutic ptct enter new percentile tuesday rise proprietary rating track technical performance used worst best score show stock price action last week match rest market year market history show top perform stock typically have higher rs rating launch biggest price move see ibd help make more money stocksptc therapeutic be build consolidation buy point see break heavy trade earning growth rise last quarter revenue gain fall ptc therapeutic earn rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
397,VRTX,exelixis exel have relative strength rs rating upgrade tuesday exclusive rating investor business daily track market leadership worst best score grade show stock price movement last week stack other stock database history reveal stock go make biggest gain tend have rs rating north begin new run look best stock buy watch start hereexelixis be build cup handle entry see stock break volume least higher normal earning growth moved company most recent report revenue fall exelixis hold rank peer medical biom biotech industry group therapeutic cort vertex pharmaceutical vrtx sucampo pharmaceutical scmp be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
398,VRTX,past year state have legalize marijuana medical used lead past few year rush startup pop well weed cater new market june new york become latest state medical marijuana many observer mention gw pharmaceutical gwph pot
399,VRTX,tuesday announcement celgene celg agree acquire receptos rcpt pleased investor stock investor gilead science gild be rumore be interested receptos mean wait edge seat literally only question get gilead be be go buy say evercore isi analyst mark schoenebaum monday video record client stock have moved broker meeting month say re ready do deal crucial question gilead future sign be blockbuster hepatitis franchise be already hit ceiling record launch month however launch do give gilead enormous pile cash buy next major drug line have set wall street collective imagination overdrive target be here be most prominent suggestion have come last few month incyte incy be suggest tuesday nomura analyst ian somaiya note mainly celgene receptos deal incyte drug jakafi treat rare form bone marrow cancer well blood disease call polycythemia vera gilead recently enter blood cancer market zydelig launch just shy year chronic lymphocytic leukemia kind lymphoma somaiya note incyte also have promising pipeline include drug solid tumor incyte month revenue totale mostly jakafi company have have inconsistent quarters bottom line analyst expect record first annual profit next year however grow rapidly stock have reflect bullish expectation relative strength rating accumulation distribution grade incyte stock hit new high early stock market today retreat back yesterday close vertex pharmaceutical vrtx bernstein analyst geoffrey porge cause minor commotion endorse combination back april vertex own hepatitis blockbuster be stomp existence gilead be position dominant player cystic fibrosis only company proven have disease alter treatment devastate condition porge point gilead already sell product market call cayston so have foot door gilead need promise high probability incremental revenue reassure investor future outlook porge write time fact year be many predict vertex cf drug be go do eventually however other analyst doubt such deal happen ground vertex be expensive market cap be hover porge suggest price be gilead prefer buy development stage asset then launch vertex stock have be flat base porge floated idea achillion pharmaceutical achn buy achillion be go opposite direction term size achillion be startup market cap be just however have be subject speculation give have promising hepatitis drug candidate own potentially help gilead extend franchise come next generation treatment november achillion candidate yielded excellent week result clinical trial combine gilead sovaldi fbr capital analyst andrew beren argue buy achillion get gilead expect trend hcv intervention shorten treatment duration currently available week week course then twitter storm speculation erupt achillion abruptly pull investor conference suggest be announce something big turn be achillion have actually sign licensing deal johnson johnson jnj diminish chance gilead buyout bristol myer squibb bmy biotech buy big pharma well actually gilead be bigger bristol now do almost sale last year vs bristol bristol hottest new drug be biologic cancer drug opdivo be thestreet com adam feuerstein be think propose idea back january not sure exactly company gilead buy acquisition focus be oncology be just pharmasset be hepatitis business potential be certainly vast give opdivo alone be expect pass annual sale however price be even more staggering vertex bristol market value have continue go feuerstein prediction now stock hit new year high wednesday close more follow amy reeve twitter ibd_areeve
400,VRTX,stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute
401,VRTX,dow jone industrial nasdaq climb grab gain
402,VRTX,volume be quietly mixed nasdaq lower nyse relative trade same time tuesday
403,VRTX,stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase
404,VRTX,dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list
405,VRTX,norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more
406,VRTX,conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year
407,VRTX,base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly
408,VRTX,array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum
409,VRTX,china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result
410,VRTX,leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average
411,VRTX,citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base stock pull together nice gain early wednesday investor ignore weak housing datum ahead afternoon release fed minute dow jone industrial nasdaq climb grab gain volume be quietly mixed nasdaq lower nyse relative trade same time tuesday stock market today get reasonably healthy start commerce department datum show october housing start slump month low market be tune et release minute federal open market committee oct meeting seek sign timing interest rate increase dow stock be mostly positive apple aapl pound gain top group be add goldman sachs conviction buy list norfolk southern nsc lead nearly canadian pacific railway cp offer buy rail peer cash stock deal value more conagra cag rally more omaha neb base package food giant announce strip frozen potato business separate lamb weston name begin next year base oil driller ensco esv be close gain nearly energy stock make strong show early action oil price rise modestly array retail stock post mixed early move follow quarterly report energy information administration report weekly inventory datum china base vipshop vip spiked jack box jack climb staple spls slip target tgt give premarket gain slump report third quarter result leader healthcare staffing agency amn healthcare rumble start trade san diego base operation say late tuesday agree buy privately hold cash amn say deal be immediately accretive adjust ep stock have be scrawl erratic pattern attempt regain support week move average citrix system ctxs shed early action developer enterprise software solution announce late tuesday lay worker spin goto unit separate business company say move result pretax charge create saving year loss send share week move average heavy trade buy point cup handle base
412,VRTX,ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch
413,VRTX,still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month
414,VRTX,roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write
415,VRTX,roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug
416,VRTX,think uncertainty create wait game limit upside potential stock year roden write
417,VRTX,roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month
418,VRTX,none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more
419,VRTX,regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june
420,VRTX,positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug
421,VRTX,conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep
422,VRTX,roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year
423,VRTX,vertex gilead stock be fraction early trading thursday
424,VRTX,follow amy reeve twitter ibd_areeve ub downgrade regeneron regn amgen amgn adjust price target several other biotech stock thursday ground sector be slow patch still think biotech continue outperform broader market health care spdr xlv be get more selective price target rating consider fewer term catalyst power drive material upward revision key driver stock past year couple fact ultra bullish thesis midcaps have be reward extent have play analyst matthew roden write second quarter earning preview hence now struggle find term conviction idea remain confident big bull case number name look month roden downgrade regeneron sell neutral valuation ground model price target remain same regeneron stock have be trading past month make valuation far highest large cap biotech write roden downgrade amgen stock neutral buy lower price target remove sale estimate immunology drug brodalumab model revelation suicide risk cause amgen withdraw development partnership astrazeneca azn write point impossible model impact new biosimilar competition amgen flagship neutropenia drug think uncertainty create wait game limit upside potential stock year roden write roden also maintain rating lower price target number other biotechs include puma biotechnology pbyi price vs previous wake disappointing datum breast cancer drug last month none seem hurt stock much morning market be rally couple bad day early trading stock market today share regeneron be just fraction amgen stock be fraction puma stock be more regeneron be latest ibd ranking top perform stock trading early thursday be buy point touch regeneron stock touch record high june positive side roden raise price target vertex pharmaceutical vrtx wake approval pricing orkambi vertex potential blockbuster cystic fibrosis drug conservative patient number be outside consensus come consensus revenue figure view command higher net present value write also believe previously underestimated gross margin together higher revenue drife greater earning power prior forecast ep roden also raise price target gilead science gild note number be still go gilead be talk ll do buyout deal year vertex gilead stock be fraction early trading thursday follow amy reeve twitter ibd_areeve
425,VRTX,gilead science have be winning streak recent year competition price pressure push biotech pace setter go acquisition continue momentum gilead gild revenue climb percent year earlier period company share earning more double foster city calif base gilead annual sale total more past year market value have rise more fivefold reach impressive stock earn best possible ibd composite rating mean stock have outperformed other stock combination factor include earning share relative strength rating gilead have flourished focuse treat hiv hepatitis patient hepatitis drug sovaldi harvoni have chalk more half company product sale backlash have be build sovaldi gilead have price drug pill week life treatment time get major move very hard person completely forget say michael holland head new york money management firm holland co management have task show person biotech boom isn ready end yet gilead continue be major player industry have show world have strong long last growth strategy just case kind bad news surface again consumerism be grow health care gilead surely feel pressure price charge say paul carroll partner devil advocate group consult firm ceo pressure take time build attempt deny use medicine base cost bring person woodwork shout death panel gilead need be prepare doomsday scenario imagine life be world longer charge pill not everyone agree rhetoric surround sovaldi gilead be very strong position strategically say dan mendelson ceo health business advisor avalere health strong position globally hep be big public health issue time dr barnett mennen physician long experience pharmaceutical industry have say sovaldi have change game many patient ve offer cure much be worth someone be suffering gilead be other price put pressure gilead company share plunge percent last dec reach month low fda approve rival abbvie abbv hepatitis product same time abbvie forge agreement express script esrx offer drug lower price become only hepatitis product big pharmacy benefit entity sanction industry observer say gilead handle pressure be look few acquisition target way lock continue solid growth brian skorney analyst baird milwaukee tell ibd jacob plieth senior editorial analyst epvantage also expect gilead pursue acquisition hard know else proceed have competitor come recent earning conference call gilead coo president john milligan say typically acquire company have impact phase drug trial accelerate product approval process integrator indication approval process tend think still re look thing feel catalyze development product have greater utility overall acquisition targetsin early gilead acquire danish drugmaker epitherapeutic other company gilead buy skorney be eyee such potential takeover target south boston mass base vertex pharmaceutical vrtx global biotech entity have draw praise work cystic fibrosis vertex fit nicely gilead skorney say point vertex have put stamp treat cystic fibrosis much gilead have focuse hepatitis also vertex have more dozen continue program target other life threaten disease acquisition be nothing new gilead company announce acquisition pharmasset give further range treat hepatitis sufferer acquisition turn be huge success not acquisition succeed remain dicey be long history bad acquisition pharmaceutical world note carroll devil advocate nevertheless epvantage plieth say gilead be very strong position right now have be most amazing biotech stock look back past year
426,VRTX,advisory panel food drug administration vote favor approve vertex pharmaceutical vrtx cystic fibrosis drug orkambi tuesday afternoon fda have july decide approval usually follow recommendation panel so much buzz surround event trading vertex stock be halter day tuesday panel debate issue orkambi be combination vertex drug kalydeco have already proven hit treat patient rare mutation lumacaftor product potentially expand use more common del mutation analyst predict multibillion dollar sale eventually panel be generally expect vote yes fda briefing document release friday raise serious issue datum benefit treatment be statistically significant small patient pool involved be also not large create real possibility panel want vertex gather more datum next question approval say analyst be vertex be go price combo pricing kalydeco year be controversial not completely line drug small patient pool rare yet serious disease payer be normally willing shell issue raise panel discussion however come back haunt vertex say evercore isi analyst mark schoenebaum especially single payer europe believe risk regulatory approval be still low not bear mind question raise document make reimbursement discussion outside more difficult schoenebaum write email friday vertex have be unprofitable last year orkambi launch be expect right ship bring profit share next year accord analyst estimate stock have steep ibd relative strength rating market cap north follow amy reeve twitter ibd_areeve
427,VRTX,stock be narrowly mixed early wednesday trading earning continue drive stock brexit start overseas nasdaq composite lead thank gain biotechs internet retailer nasdaq composite hold gain be flat dow jone industrial average dip small cap russell be volume be tracking slightly higher nyse nasdaq stock market today vs same time tuesday biotechs retailer lead steel utility lag wal mart wmt merck mrk be top gainer dow home depot hd traveler co trv be more internet retailer show strength amazon amzn alibaba group baba rise stock be buy range respective entry vertex pharmaceutical vrtx soar more month high gapping past buy point bottom base massive trade biotech late tuesday say clinical trial drug combo tezacaftor kalydeco treat cystic fibrosis show positive result plan seek marketing approval fda european medicine agency dave buster play fall heavy turnover drop stock back buy range flat base entry close tuesday restaurant arcade chain report result top view top bottom line midpoint full year revenue outlook be slightly street consensus estimate ollie bargain outlet olli pop nearly fast turnover share remain buy range flat base entry deep discount retailer late tuesday report better expect share earning sale extend double digit gain straight quarter full year ep outlook midpoint revenue guidance range be higher consensus lululemon athletica lulu gain ahead earning report close analyst expect yoga wear maker earn share sale mark respective year year increase related dave buster guide light beat ollie top guide highdow jpmorgan retake key support tesla focus investing action planvertex stock rocket strong cystic fibrosis datum
428,VRTX,dow industrial stumble finish wednesday major index post mixed close nasdaq lead stride lift index gain so far week manage gain dow jone industrial average backed trading volume be weak wednesday session complicate bleed overseas officially set motion year deadline negotiate exit european union legislator also weigh approve bill late tuesday permit much broader use consumer datum internet service provider rise oil price analyst upgrade downgrade season slow trickle earning report also have say today stock market action department store rank dead last ibd industry group score tuesday best gain industry dd surge jcpenney jcp jump jwn ring gain home furnishing retailer post second largest gain industry rh rh formerly restoration hardware be big winner here mark gain high end furnishing retailer report fourth quarter revenue earning decline slightly better pre announce guidance management first quarter revenue guidance be well consensus projection william sonoma wsm catch updraft post gain heavy trade enough retake support stock day move average chevron cvx lead dow industrial aid pop oil price unitedhealth unh notch dow weakest move top dog wednesday be vertex pharmaceutical vrtx boston base biotech vault higher report positive result clinical trial experimental cystic fibrosis treatment pill combine tezacaftor ivacaftor gain send share buy range double bottom base buy point amazon com amzn lead fang group big tech name rise firm trade barclay initiate coverage amazon facebook fb alphabet googl overweight rating facebook rise alphabet jump amazon move lift ibd leaderboard stock past buy point week tight pattern ibd stock china base weibo wb swat advance barclay also launch coverage microblogging site price target share end buy range prior buy point related other nato face threat investing action plancrude near weak inventory gain gasoline supply drop
429,VRTX,dow jone industrial average index nasdaq composite rebound week investor moved past concern health care bill failure derail tax cut other part president trump agenda dave buster play darden restaurant dri red hat rise strong earning lululemon athletica lulu plunge weak ep guidance chinese internet giant tencent tcehy acquire tesla tsla stake help china car market worst weekly loss major average rebound somewhat lead retailer fang stock facebook fb amazon amzn netflix nflx google parent alphabet googl apple aapl apple amazon netflix hit retook buy point beaten retailer be big winner lead chain such dave buster prosper earning nasdaq composite climb week nearly hit fresh time high index rise dow jone industrial average nasdaq jump be dow related stock aren wait trump make america greatdave buster play fourth quarter earning jump cent share beating analyst view cent revenue rise also view same store sale only rise fall short estimate arcade sport bar see full year revenue midpoint view dave buster share fall wednesday mixed message rally time high thursday closeout retailer earn cent share vs year earlier revenue hit third straight quarter analyst have expect fourth quarter ep cent sale ollie bargain outlet olli also guide current year estimate higher ollie stock rise just buy range spiking record week related lululemon athletica lulu report better expect revenue earning fall short yoga apparel maker retailer also give full year guidance view see same store sale fall mid single digit cite slow start year lululemon share haven make headway past year plunge thursday lowest level end related rh rh run restoration hardware upscale furnishing chain report earning revenue be modestly view also give bullish guidance rh stock shot wednesday hit month high give batter retail sector lift oil future rise barrel week variety factor suggest supply be not hand crude stockpile only rise barrel latest week accord energy information administration vs barrel expect gasoline stockpile fall barrel oil price also get support libya national oil corp declare force majeure tuesday protester block field send output month low opec member make more noise extend production curb past midyear crude production do rise barrel day highest february oilfield service firm baker hughe bhi expect oil gas industry condition remain challenge longer period big datum initiative merger partner general electric ge help create more efficiency producer conocophillip cop agree sell nonoperated interest oil sand partnership most western canada deep basin gas asset double repurchase program reduce debt big weekly gain crude oil be nearly so far related china internet giant tencent holding tcehy acquire stake tesla tsla purchasing stock open market investment be part tencent pursuit self drive car electric vehicle china rival alibaba baba baidu bidu have be aggressively chasing tesla get strong partner help overcome hurdle penetrating chinese market tesla share rise work cup base buy point tesla earlier month announce plan raise more electric vehicle maker work expand manufacturing operation upcoming model related red hat rht report fiscal revenue rise top view line ep red hat forecast full year fiscal earning expectation provider open source linux software now have more customer run openstack cloud compute software standard red hat share advanced week hit record high related general motor gm share ascend push david einhorn greenlight capital create class stock lift automaker value propose class pay dividend other entitle holder earning buyback post dividend payment say wall street journal source gm reject idea call unprecedented untested gm share rise week meanwhile more datum suggest auto industry wo include rise inventory subprime lend problem follow earlier report fall used car price related darden restaurant dri parent olive garden longhorn steakhouse other eatery announce buy cheddar scratch kitchen cash meanwhile darden report better expect result same store sale growth restaurant yard house year company raise profit outlook narrow comp forecast share rise week hit record high delta air line dal agree form joint venture korean air share sale cost schedule american airline aal agree invest china southern airline znh move follow international air transport association expectation eastward shift travel demand iata october say asia pacific region likely be source more half new passenger next year network carrier also face low cost rival home europe related paychex payx report fiscal third quarter earning share beat wall street expectation sale miss provider payroll human resource service keep full year forecast share tumble week drop day day line vertex pharmaceutical vrtx stock lead ibd biotech group wednesday spiking day drug pill cystic fibrosis improve lung function pair late stage trial regeneron pharmaceutical regn sanofi sny stock tumble tuesday grab fda approval eczema drug dupixent analyst split annual price tesaro tsro stock too fall monday announce fda approval ovarian cancer drug zejula approval lessen tesaro likelihood be acquire term related
430,VRTX,stock open tight loss quickly improve mixed trade wednesday dow industrial nasdaq fought protect narrow gain week dow jone industrial average open nasdaq open lower then quickly reversed very slight gain merck mrk pop take early lead dow industrial boee ba upshifted boost berenberg initiate coverage stock buy rating price target fang stock be positive ground amazon com amzn lead pack barclay launch coverage stock overweight rating price target google parent alphabet googl climb barclay initiate coverage stock overweight rating price target facebook fb also receive overweight rating price target gain alphabet weak open action verizon vz run counter expectation follow approval house representative late tuesday end privacy provision enact federal trade commission provision require internet service provider obtain permission consumer order share employ certain specific internet use datum rule be see benefit company such google alphabet facebook remain free use such datum reversal rule approve senate week give company verizon comcast cmcsa freedom use sell third party specific customer internet use datum provide new profit marketing source comcast share trade flat open vertex pharmaceutical vrtx blast higher top biotech drugmaker announce late tuesday clinical trial show positive result combination drug tezacaftor kalydeco treatment cystic fibrosis company plan submit drug marketing approval food drug administration european medicine agency vertex chart be read bottom base cup handle buy point rh rh formerly restoration hardware soar early trading fine home furnishing retailer report earning revenue decline be not bad forecast close fiscal year share have climb recent week bottom network ffiv slip deutsche bank downgrade stock sell hold loss send share test week move average ollie bargain outlet olli gain report fourth quarter earning analyst target raise full year earning guidance consensus view huge volume gain left share still buy range flat base buy point dave buster play slump report fourth quarter performance late tuesday be stronger expect slip put share back buy range buy point trade edge higher europe london ftse reverse early loss rise fraction prime minister theresa tuesday night sign unite kingdom official letter resignation european union officer reportedly turn letter eu official today trigger article set year deadline exit negotiation frankfurt dax trade cac paris add oil price be positive west texas intermediate hold barrel ahead energy information administration weekly inventory report due et national association realtor deliver pending home sale datum february et stock market today also get speech federal reserve bank president charle evan chicago federal reserve bank speak et boston fed eric rosengren take dais et john william san francisco fed be et earning report expect close include hb fuller ful lululemon athletica lulu metal processor worthington industry wor other related jp morgan retake day tesla focus investing action planwhich sector fund be top market beater
431,VRTX,therapeutic cort see positive improvement relative strength rs rating friday upgrade exclusive rating investor business daily track share price movement worst best score score show stock price behavior trail week hold other stock database year market history reveal stock go make biggest gain often have rs rating north early stage move look winning stock try simple routinecorcept therapeutic be try complete consolidation buy point see stock clear price volume least higher normal keep mind later stage consolidation entail more risk earning growth drop most recent quarter sale moved higher therapeutic earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx be rank stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
432,VRTX,welcome move array biopharma arry see relative strength rating rise friday exclusive rating investor business daily track share price performance worst best score rating show stock price performance trail week hold other stock database history show stock go make biggest gain typically have better rs rating launch largest climb see array biopharma continue rebound clear threshold look winning stock try simple routinearray biopharma be build cup handle buy point see stock break volume least average keep mind later stage consolidation be riskier earlier stage pattern array biopharma report negative growth top bottom line last quarter company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
433,VRTX,friday innoviva inva earn upgrade relative strength rs rating exclusive rating investor business daily identify market leadership worst best score rating show stock price movement trail week compare other stock database year market history reveal best stock tend have higher rs rating launch largest run see innoviva continue show renew price strength hit benchmark look winning stock try simple routineinnoviva be try complete cup handle buy point see stock break heavy trading innoviva show earning growth most recent report sale rise company earn rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newsstock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
434,VRTX,friday edita medicine edit earn positive adjustment relative strength rs rating proprietary rating measure market leadership show stock price movement last week compare other stock database history reveal market biggest winner typically have higher rs rating launch largest price move look winning stock try simple routinewhile edita medicine be not proper entry right now see go form break proper consolidation company bottom line growth drop last quarter revenue grow previous report edita medicine hold rank peer medical biom biotech industry group vertex pharmaceutical vrtx sucampo pharmaceutical scmp emergent biosolution ebs be top highly rate stock group related biotech pharmaceutical industry stock newswhich stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
435,VRTX,stock open lower monday upgrade dupont buffer dow jone industrial average loss small cap take hit dow fall lose nasdaq slide russell be broad swath stock industry be motion stock market today volatile premarket session dow industrial dupont dd rise slightly stock receive upgrade jeffery buy hold upgrade also lift dupont price target dow chemical dow also receive jeffery upgrade price hike buy hold share also rise fraction dow dupont agree merger december snap snap trek higher open then reversed lower trade nearly high profile initial offer rise first day trade last week fresh ipos expect week include apparel retailer jill trading jill tech service company presidio ticker psdo early jump natural gas price help boost gas producer range resource rrc pop nearly southwestern energy swn climb more drugmaker spiked early action tg therapeutic tgtx nearly double price announce positive trial result tg drug target high risk chronic lymphocytic leukemia stock reach highest level more year concert pharmaceutical cnce soar news vertex pharmaceutical vrtx buy concert ctp cystic fibrosis treatment deal worth much concert be climb month correction vertex share be little change ibd stock charle schwab schw trade nearly lower schwab have be key player fee price war break brokerage month schwab be consolidate week support extend november flooring afi tumble open lancaster pa base company report mixed fourth quarter performance announce company restructure economic calendar open week quiet note commerce department release january factory order datum et minneapoli federal reserve bank president neel kashkari speaking et oil rise early action leave west texas intermediate trading barrel gold edge ounce dollar be mixed vs yen year treasury yield rise basis point europe market trade lower afternoon trade ftse london frankfurt dax cac paris china market gain monday hong kong hang seng index add shanghai composite swung japan tokyo nikkei shed related job oil chief ipos ulta momo investing action plan
436,VRTX,biotechs have lot ride drug datum ibd company medical biom biotech industry group plunge rocky election year relief hillary clinton lose white house spiked group nearly week follow election gain have dissipate donald trump pledge tackle rise drug price group have face challenge day move average april meanwhile large cap amgen amgn vertex pharmaceutical vrtx be trading pipeline valuation accord rbc analyst michael yee tug sentiment month low require strong drug datum remain potential coil spring catalyst company go play many large pharmas continue be hunt yee write dec research report see ariad pharmaceutical aria incyte incy tesaro tsro biomarin bmrn possible acquisition target outside yee say lack material catalyst get sector move ibd take top biotechs end triple digit gain outplay broader industry be biotech pick list check ibd industry theme deeper dive nearly dozen biotech company year be slate post key drug trial datum just key arena drug treat spinal muscular atrophy drug treat cystic fibrosis parp inhibitor treat several type cancer therapy treat lymphoma success turn sentiment positive second failure weigh many drug stock spinal muscular atrophy result wasting away muscle lead early death see least new datum sector also host yee recent research report call overall drug industry only new real launch year biogen biib ionis pharmaceutical ion team develop spinraza brand name nusinersen drug target single rna treat symptom sma ionis ceo stanley crooke tell ibd recent biogen exercise worldwide right spinraza august food drug administration approve spinraza late december first sma treatment get fda approval crooke say expect biogen bring drug market early year describe sma diabolical disease chemically denervate body be fatal infant progress toddler rob ability walk eat breathe own affect motor nerve cell spinal cord accord cure sma spinraza launch midcap cytokinetic cytk be expect release result phase trial ck describe novel skeletal muscle troponin activator help treat sma patient other suffering similar degeneration ck differ spinraza aim slow rate calcium release regulatory troponin complex fast skeletal muscle fiber phase trial examine sma patient look patient chronic lung disease trial result latter further future cytokinetic be lightly trade small cap have ibd relative strength rating best possible stock buy zone late december hit entry point cup handle formation have slip thursday close trigger sell rule anytime stock fall least buy point share rise handful cystic fibrosis trial be expect wrap vertex triple pill have spark most analyst chatter yee credit suisse analyst vamil divan say phase datum vx vx be likely be available latter half trial result sooner vx vx vx be be investigate prong treatment cystic fibrosis genetic disease cause mucus collect block airway damage digestive system vx be phase testing result patient population expect first half year yee estimate vx vx vx add long term sale vertex see fairly good chance triple work second half drive company growth note investor remain wary vertex stock fall be year fall thursday vertex be far alone cystic fibrosis game many other publicly trade biotechs be expect release clinical trial datum mid cap biotech pct therapeutic pctc appear furthest phase datum translarna due quarter pct trial examine cf patient nonsense mutation accord cystic fibrosis news translarna potentially make cellular protein machinery run so call stop sign cf cause cftr gene replace amino acid similar enough allow protein do work clovis oncology clvs pull ahead tesaro late december fda grant accelerate approval parp inhibitor rupacarib day later fda give tesaro parp inhibitor niraparib priority review be duke rival lynparza parp inhibitor approve astrazeneca azn be deadlock race treat ovarian breast cancer clovis be track unveil phase datum rupacarib sell brand name rubraca patient brca mutation latter half brca mutation be often associate breast cancer tesaro niraparib be deck phase breast cancer phase ovarian cancer datum second half niraparib have prescription drug free user pdufa date june accord biopharma catalyst fda tracker niraparib rupacarib olaparib chemical name astrazeneca lynparza class drug call parp inhibitor several form cancer be dependent parps type enzyme inhibit enzyme company clovis tesaro astrazeneca hope treat several cancer abbvie abbv pfizer pfe acquisition medivation also be work parp inhibitor abbvie veliparib miss several endpoint include progression free survival pfs phase trial recurrent metastatic breast cancer brca mutation unveil early december phase testing be underway veliparib be also be investigate treatment small cell lung cancer nsclc pfizer acquire medivation september medivation talazoparib be development treat breast cancer germ line brca mutation neither abbvie pfizer parp inhibitor be expect have datum ariad kite pharma kite seattle genetic sgen look poise lead lymphoma battle many publicly trade biotechs be expect present datum year vary drug next month kite kte likely come away solid month durability datum diffuse large cell lymphoma dlbcl say rbc yee lead roll biologic license agreement bla pdufa date year end kte belong class drug call car cell therapy drug patient immune system fight specific cancer kite drug be be investigate treatment refractory hodgkin lymphoma relapse refractory mantle cell lymphoma ariad pharma other hand already have pdufa date april brigatinib treatment anaplastic lymphoma kinase positive alk metastatic small cell lung cancer nsclc resistant crizotinib pfizer chemotherapy pdufa date be april first line datum win be available competitor roche rhhby have similar datum rival drug due same time frame ariad complete new drug application nda brigatinib october also seattle genetic be angle fourth indication approve adcetris adcetris be be examine treatment cutaneous cell lymphoma ctcl also unveil result yearlong phase trial adcetris chemotherapy front line hodgkin lymphoma seattle genetic be try establish redefine front line therapy hodgkin lymphoma nearly year same therapy ceo clay siegall tell ibd recent interview related investor siphon biogen ionis gain spinal disease drug okionis pharma eye sustainable profitability fda approvalamgen plan robust alzheimer migraine oncology ceo myer win seek accelerate opdivo lung cancer
437,VRTX,biotech gilead science gild likely guide decline sale hamstrung limit hepatitis visibility rbc analyst michael yee say wednesday note expectation be better amgen amgn biogen biib earning season get underway yee expect gilead guide product sale bracketing consensus view be midpoint guidance vs early guidance appreciate visibility be tough hep right now buy side consensus be also fairly low gilead give know uncertainty yee write research report predict decline more hep sale gilead make sovaldi harvoni combat hep prescription hep drug fall quarter quarter accord market tracker im europe remain wild card volume patient fall markedly yee write be ongoing concern give bolus continue wear eu launch have occur major region past year so write note client merck be now launch number region possible lower pricing ibd take small biotech ipos outlast giant amgen biogen top stock gain company start year trade average daily volume share be pick check ibd industry theme yee expect gilead report sale tick broader consensus view consensus analyst poll thomson reuter expect gilead report earning share ex item yee see gilead be set report earning issue guidance hour feb big biotechs amgen biogen be set well earning share guidance be current investor uncertainty nervousness yee say amgen be schedule report late feb be widely modeled sale ep item then amgen report datum cardiovascular outcome trial cvot pcsk inhibitor repatha yee write cvot datum be see cvot benefit higher end stock trading write street want own name hit earning give good guidance cvot datum be risk biogen analyst poll thomson reuter view sale ep item yee see biogen be set report early jan biogen story be clearer settle patent dispute tecfidera forward pharma fwp company also likely discuss spinoff hemophilia unit bioverativ spinoff cut sale ep item cent vertex pharmaceutical vrtx celgene celg be slate report earning late jan early jan respectively preannounce financial result annual jpmorgan healthcare conference san francisco cystic fibrosis drug sale grow vertex say cf drug orkambi kalydeco pull celgene preannounce net sale company also guide sale midpoint outlook full year company see ep item grow midpoint related investor siphon biogen ionis gain spinal disease drug okcelgene ceo drug pricing debate hinge incentive innovation
438,VRTX,vertex pharmaceutical vrtx fall early monday reverse sharply later session company forecast sale cystic fibrosis drug orkambi lag wall street expectation sunday vertex say expect full year sale drug analyst have be forecasting evercore isi analyst john scottus say email client sunday scottus say vertex number be likely closer expectation buy side analyst mutual fund pension fund hedge fund other vertex release forecast ahead presentation monday annual jpmorgan jpm healthcare conference be biggest event year biotech other drug company conference san francisco start monday end thursday most major company be present other company executive make presentation monday include amgen amgn biogen biib celgene celg ibd take rare not single drugmaker be ibd list top perform stock be case time uncertainty industry face possibly change health care law perhaps ibd have report legislation drug price check ibd learn stock have be perform better other vertex stock fall much early trading stock market today end day regain day move average first time november vertex stock have rough share fall more quarterly result disappoint have mixed result drug trial company sale outlook orkambi launch also miss wall street forecast case sale orkambi be blockbuster combination ivacaftor treatment cystic fibrosis vertex market separately kalydeco lumacaftor booster make drug effective treat much larger population ivacaftor alone annual treatment orkambi kalydeco cost vertex guidance sale kalydeco also miss wall street expect scottus say related trump pledge bring drug priceswhich biotechs outperformed tough
439,VRTX,datum biotech amgen amgn ldl bust drug boost regeneron regn disappoint too high expectation amgen investor credit suisse analyst alethia young say tuesday young upgrade regeneron stock outperform rating up price target cite april launch dupixent eczema drug sanofi sny pcsk datum top rival amgen due also also be catalyst regeneron own pcsk drug write research report amgen investor however have set expectation too high repatha amgen pcsk inhibitor follow successful datum study september say coronary intravascular imaging trial repatha meet primary secondary endpoint coronary artery disease still see upside repatha outcome datum write research note think risk reward be unfavorable expectation be pretty high success glagov study ibd take trump break republican pressure drug price look more more likely biotechs survive political pressure young downgrade amgen stock neutral rating cut price target see amgen base business rheumatoid arthritis drug enbrel become weaker trim total product sale view enbrel sale come flat contract negotiation next year enbrel sale be drive volume rather net selling price company say earning conference call analyst company up guidance time celgene celg vertex pharmaceutical vrtx top young biotech watchlist be cautious general however give comment president elect donald trump go escalate drug price week follow election biotech drug stock have nearly round trip first rise then fall ibd company medical biom biotech industry group hit week high nov trump election be then still share remain close nov rise stock market today amgen stock fall tuesday regeneron stock slip don expect drug pricing chatter moderate especially consider comment already make president elect young write think company best execution have best stock performance related amgen biogen celgene eye trump pro biotech worldbiotech climb third straight day leader be buyable
440,VRTX,amgen amgn biogen biib celgene celg gilead science gild look follow donald trump election set fewer regulatory hurdle likely biotech resurgence rbc analyst michael yee say monday biotech stock have surge trump election largely notion be less likely pressure drug price hillary clinton likely push business friendly legislation include tax incentive repatriate cash election uncertainty yee expect big biotechs make good plan capital remain inexpensive organic growth slow trump appear poise embrace innovation administration yee write research report monday ibd take biotechs aren alone experience trump effect defensive stock be furious upswing follow election get defensive stock now get ibd industry theme answer end trump meet patrick soon weekend soon be biotech exec former ceo abraxis bioscience celgene acquire tell come trump meeting soon yee note regardless investor be start key pro biz environment election share ibd company medical biom biotech industry group spdr biotech etf xbi be nearly ishare nasdaq biotech etf ibb be more bar big policy surprise trump be increase feel pro business include pro biotech gop yee write so see unlikely major legislation derail innovation increase be merely begin yee write note good thing happen believe stock go much higher alzheimer datum late early eli lilly lly be catalyst biotechs also likely update guidance january potentially push stock higher biotech celgene be most risk postelection world term catalyst fear big disappointment yee write celgene have multiple sclerosis datum due first half likely win raise guidance january celgene stock dip dilutive deal note view pullback buy opportunity long term tail question be sufficient pipeline long term investor want see term earning variance be less important tail question write meanwhile amgen biogen likely be uncertainty remain share biomarin pharmaceutical bmrn vertex pharmaceutical vrtx yee write biogen stock bound strong alzheimer result eli lilly amgen stock be still suffering fallout commentary enbrel pricing stock market today celgene stock lift share amgen biogen gilead be fraction vertex stock be biomarin share related small cap biotech take gilead celgene biogen alzheimer
441,VRTX,health care fund be top perform sector past year wasn full speed ahead health care fund build much lead consumer staple technology fund mid here play investment make june average health care stock mutual fund have mushroomed
442,VRTX,american have unofficially make memorial day kickoff summer go be hot drug industry now labor day company be look fda decision launch blockbuster drug make big impact bottom line first be drug valeant pharmaceutical industry vrx
443,VRTX,stock fall tuesday end well morning lows market be sharply morning european stock bond drop worry greece nasdaq drop dow jone industrial average be stock market today
444,VRTX,market action godaddy gddy be initially then report earning stock pop buy point ipo base regular session couldn finish
445,VRTX,mckesson mck be initially hour then miss revenue beat earning guide fiscal year line estimate announce stock buyback
446,VRTX,vertex pharmaceutical vrtx be halter clear begin trading close company announce fda panel have recommend approval cystic fibrosis drug orkambi stock rise sharply hour stock fall tuesday end well morning lows market be sharply morning european stock bond drop worry greece nasdaq drop dow jone industrial average be stock market today market action godaddy gddy be initially then report earning stock pop buy point ipo base regular session couldn finish mckesson mck be initially hour then miss revenue beat earning guide fiscal year line estimate announce stock buyback vertex pharmaceutical vrtx be halter clear begin trading close company announce fda panel have recommend approval cystic fibrosis drug orkambi stock rise sharply hour
447,VRTX,biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate
448,VRTX,gilead doesn give ep guidance add full year product sale target now
449,VRTX,essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast
450,VRTX,evercore isi analyst mark schoenebaum say guidance raise be especially significant
451,VRTX,company tend be conservative so raise revenue guidance early year speak volume write email client
452,VRTX,conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach
453,VRTX,bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash
454,VRTX,cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product
455,VRTX,gilead stock rise hour trading share have close
456,VRTX,abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week
457,VRTX,earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent
458,VRTX,sale dip beat estimate exclude currency headwind divestment sale rise
459,VRTX,teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september
460,VRTX,teva stock slide
461,VRTX,celgene sale miss
462,VRTX,celgene celg report mixed quarter ep rise penny view sale grow miss consensus more
463,VRTX,big biotech affirm full year guidance product sale ep last year make share revenue
464,VRTX,sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus
465,VRTX,celgene stock dive close
466,VRTX,danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus
467,VRTX,nordisk hike profit growth guidance add percentage point low end sale growth guidance
468,VRTX,president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen
469,VRTX,stock rise biotech gilead science handily beat first quarter expectation raise revenue guidance thursday cap busy day big cap drugmaker earning gilead gild report earning time item share year earlier quarter beating analyst consensus cent accord thomson reuter revenue jump more wall street estimate gilead doesn give ep guidance add full year product sale target now essentially entire revenue beat come hepatitis drug harvoni first full quarter market harvoni notch well analyst estimate predecessor sovaldi however miss expectation gilead hiv franchise once mainstay now minority revenue also come forecast evercore isi analyst mark schoenebaum say guidance raise be especially significant company tend be conservative so raise revenue guidance early year speak volume write email client conference call analyst commercial operation chief paul carter say hcv patient base seem be somewhere north gilead have predict last year add be first franchise have picked significant number patient europe reach bernstein analyst geoffrey porge last week say gilead buy fellow big cap biotech vertex pharmaceutical vrtx delicately bring be do cash cfo robin washington say gilead do keep eye opportunity say prefer phase earlier stage asset seem cut vertex already have commercial product gilead stock rise hour trading share have close abbvie abbv have rival hepatitis treatment viekira pak be steady late beat ep estimate last week earlier thursday israeli generic drug giant teva pharmaceutical industry teva report adjust ep beating view cent sale dip beat estimate exclude currency headwind divestment sale rise teva raise ep guidance year cent imply profit upside be not go be sustain biggest threat horizon be launch generic version best seller copaxone date be uncertain likely take place september teva stock slide celgene sale misscelgene celg report mixed quarter ep rise penny view sale grow miss consensus more big biotech affirm full year guidance product sale ep last year make share revenue sale flagship blood cancer drug revlimid beat esti mate foreign revlimid sale other individually report drug sale miss consensus celgene stock dive close danish diabetes specialist nordisk nvo report earning kroner cent share beating consensus revenue rise kroner kroner consensus nordisk hike profit growth guidance add percentage point low end sale growth guidance president kaare schultz say be leave follow management reorganization eliminate other job chief operate officer schultz have aspire be ceo board decide keep lar sorensen stock rise
470,VRTX,stock open tightly mixed wednesday investor patiently wait afternoon release fed minute
471,VRTX,nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high
472,VRTX,stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon
473,VRTX,move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi
474,VRTX,airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble
475,VRTX,telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection
476,VRTX,american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high
477,VRTX,hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point
478,VRTX,lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high
479,VRTX,ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece stock open tightly mixed wednesday investor patiently wait afternoon release fed minute nasdaq slip edge fraction lower dow jone industrial average hold positive territory just tuesday intraday high stock market today get quiet start trade fraction lower nasdaq nyse compare volume same time tuesday trading be likely remain quiet ahead release minute federal open market committee april meeting due afternoon move be generally subdue early action dow pfizer pfe lead mcdonald mcd lag move less nasdaq biggest mover be vertex pharmaceutical vrtx drop more better gain analog device adi airline be take hard hit early southwest airline luv diving american airline aal delta air line dal tumble telecom service provider dycom industry dy roar ahead start trade palm beach garden fla company fiscal sale earning be far expectation management boost earning revenue guidance well consensus projection american eagle aeo soar report healthy sale earning beat put stock back week move average week pullback april high hormel food hrl climb follow fiscal second quarter result earning outpaced analyst expectation revenue growth come bit short management say lower pork cost be impact avian influenza challenge turkey business hormel be base buy point lowe low slump revenue earning stop short consensus expectation management full year earning guidance be also just forecast stock have be struggle regain support week move average trading march high ibd stock open generally lower bottom list alaska air alk broadsoft bsft drop regeneron regn noah noah horizon pharma hznp post best gain nearly apiece
480,VRTX,stock drift higher quiet trade wednesday ride broad mix factor
481,VRTX,nasdaq jump russia vimpelcom vip vertex pharmaceutical vrtx hold high ground nasdaq climb dow jone industrial average grab gain
482,VRTX,volume be tracking tuesday level nasdaq lower nyse
483,VRTX,early influence stock market today be mixed healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect buoy europe market tough couple day stock feel pressure april retail sale number come expectation datum show gain overall sale gain sale auto gas half economist consensus forecast
484,VRTX,april import export price be also expectation commerce department report export sale vs view gain export price have gain march import price slip equal march decrease outlook gain price datum be positive hope federal reserve stave interest rate increase
485,VRTX,merger acquisition news lead early dramatic move pipeline operator william partner wpz soar open acquire partner william co wmb leap filtration specialist pall pll pop give gain week news be acquire test equipment maker dhr share rise
486,VRTX,earning also have say early action
487,VRTX,mckesson mck break heavy volume clear buy point flat base company report quarterly result tuesday close beating view earning match consensus estimate revenue
488,VRTX,zebra technology zbra spiked result trounce consensus expectation earning rise vs estimate gain revenue soar well view management guidance be line analyst estimate heavy volume gain put share past buy point flat base
489,VRTX,international game technology igt be trimming loss release first earning report merger global lottery firm gtech shift headquarters la vegas london igt have be attempt climb month consolidation
490,VRTX,ibd list newlink genetic nlnk gain take back small piece tuesday dive
491,VRTX,china base noah noah rise early trade hover just tuesday high
492,VRTX,loss ibd stock be narrow vasco datum security vdsi spirit aerosystem spr valeant pharmaceutical vrx post biggest loss bit more
493,VRTX,busy hour earning calendar include report cisco system csco jack box jack middleby midd ctrip com international ctrp shake shack shak stock drift higher quiet trade wednesday ride broad mix factor nasdaq jump russia vimpelcom vip vertex pharmaceutical vrtx hold high ground nasdaq climb dow jone industrial average grab gain volume be tracking tuesday level nasdaq lower nyse early influence stock market today be mixed healthy eurozone gdp growth number suggest european central bank quantitative ease program be have positive effect buoy europe market tough couple day stock feel pressure april retail sale number come expectation datum show gain overall sale gain sale auto gas half economist consensus forecast april import export price be also expectation commerce department report export sale vs view gain export price have gain march import price slip equal march decrease outlook gain price datum be positive hope federal reserve stave interest rate increase merger acquisition news lead early dramatic move pipeline operator william partner wpz soar open acquire partner william co wmb leap filtration specialist pall pll pop give gain week news be acquire test equipment maker dhr share rise earning also have say early action mckesson mck break heavy volume clear buy point flat base company report quarterly result tuesday close beating view earning match consensus estimate revenue zebra technology zbra spiked result trounce consensus expectation earning rise vs estimate gain revenue soar well view management guidance be line analyst estimate heavy volume gain put share past buy point flat base international game technology igt be trimming loss release first earning report merger global lottery firm gtech shift headquarters la vegas london igt have be attempt climb month consolidation ibd list newlink genetic nlnk gain take back small piece tuesday dive china base noah noah rise early trade hover just tuesday high loss ibd stock be narrow vasco datum security vdsi spirit aerosystem spr valeant pharmaceutical vrx post biggest loss bit more busy hour earning calendar include report cisco system csco jack box jack middleby midd ctrip com international ctrp shake shack shak
494,VRTX,antenna developer airgain airg soar monday second straight trading day follow third quarter earning result late thursday beat estimate airgain stock spiked hit record high stock market today friday airgain climb san diego base company recently make initial public offer much fanfare raise offer share be stock end first day trading aug close thursday airgain report earning share item cent smash consensus estimate cent loss revenue rise year earlier quarter vs estimate airgain be lead provider embed antenna technology include wi fi used enable high performance wireless networking range home enterprise industrial device ibd take ipos be wellspring innovation be huge stock winner reverse quickly click link more ipo news analysis other ipo news coverage be initiate crispr therapeutic crsp lead gene editing company come public oct piper jaffray initiate coverage overweight rating price target barclay initiate coverage overweight rating price target guggenheim give buy rating price target crispr have collaboration agreement vertex pharmaceutical vrtx bayer bayry crispr say focuse development gene base medicine serious disease used proprietary gene editing platform crispr stock rise crispr price ipo
495,VRTX,vertex pharmaceutical vrtx miss wall street view late tuesday share rise time wednesday potential upside vertex send cystic fibrosis drug phase testing close bell stock market today however vertex stock have rise more earlier end trading flat ibd company medical biom biotech industry group also be fraction head possibly fourth straight day vertex stock time rise confidence vx vx next generation corrector cystic fibrosis rather metric narrowly miss street expectation vertex also plan send additional cf med phase testing year end early next year be important fundamental step get closer new mega franchise increase consensus peak sale add new revenue growth go cf market be not currently address rbc analyst michael yee write research report yee keep outperform rating vertex stock ibd take activity clinical trial have biotechs edge big rebound keep tab industry snapshot other red hot sector vertex report sale grow year earlier quarter cent earning share ex item swing cent loss analyst poll factset have modeled cent cf med orkambi kalydeco bring sale respectively grow vs year earlier quarter orkambi narrowly beat consensus kalydeco miss view yee write vx vx be expect start phase testing year end safety remain major concern evercore analyst john scottus write report vx be teratogenic able halt pregnancy vx cause nausea vomit phase testing pregnant patient be exclude vx female be require be hormonal birth control vx be test week vx week base differ therapeutic window vertex say credit suisse analyst alethia young boost price target wednesday vertex stock see upside phase testing vx support efficacy have outperform rating vertex stock related pfizer medivation deal reignite biotech buyout stock slip drug trial failure not surprise
496,VRTX,president elect donald trump be likely take affordable care act meaning biotech drug stock aren clear follow hillary clinton defeat analyst say wednesday year political pressure industry clinton be see more likely wage bureaucratic battle excessive drug price trump republican ally have repeatedly blast aca know obamacare president elect promising repeal replace get something great legislation have tragically predictably result runaway cost website don work greater rationing care higher premium less competition fewer choice trump say obamacare have raise economic uncertainty single person reside country trump propose system base free market principle hasn delve specific tuesday republican also retain majority house senate make trump path repeal aca easier such repeal hurt drug stock be unknown add uncertainty industry weigh ibd take biogen be head experimental spinal muscular atrophy drug partnership ionis close be biogen stock check industry theme skinny hospital stock tank wednesday trump biotech drug stock ride clinton wave rise likelihood trump win go excessive drug price republican congress probably win touch medicare reform ibd company biom biotech industry group jump midday trading stock market today company ethical drug climb company generic drug group surge tuesday close group have be respectively year lift likely be short live rbc analyst michael yee say advise investor buy brexit dip broader market likely assume risk environment sell short term trump uncertainty emotion say biotechs bounce don see anything fundamentally be negative biotech yee write research report recommend celgene celg biogen biib vertex pharmaceutical vrtx biomarin bmrn prothena prta stock biomarin vertex lead way midday wednesday vertex soar biomarin surge celgene stock skip gain prothena catapult biogen climb tuesday election result best case scenario biotechs yee say president congress less likely meddle drug pricing proposition california fail prop have limit state agency spending prescription department veteran affair pay sen bernie sander lose clinton primary be major proponent prop republican senate sander name be likely lose power yee see unlikely ll be tap chair health labor education pension help committee related drug stock rally relief clinton didn white houseclean energy stock plunge trump winapple microsoft eye trump overseas cash tax plan
497,VRTX,vertex pharmaceutical vrtx remain ahead galapago glpg develop triple drug treat cystic fibrosis rbc analyst michael yee say thursday galapago unveil positive phase datum first cf pill galapago glpg lower fev line datum vertex kalydeco fev be ratio used diagnosis obstructive restrictive lung disease glpg kalydeco class drug call potentiator develop triple be easy feat yee write research report galapago abbvie abbv backup potentiator moved phase testing earlier year corrector glpg be currently phase testing be only cf drug order have triple pill company have have drug look good combination together patient have minimal drug drug interaction safety issue dose once yee write galapago third piece triple pill hasn yet start phase testing yee write phase test involved only patient have previously be treat kalydeco little early say glpg have be derisked yee say so drug not be combination back half view write estimate vertex be year ahead already derisk drug vx vx contention become third begin phase testing year end yee keep outperform rating vertex stock see mega franchise cf have potential upside vertex stock fall close stock market today hit lowest more year galapago fall ibd take biotech sector isn look so hot now ibd company medical biom biotech industry group sank group track week company aerospace defense industry group be better bet keep eye industry theme potential winner relatedeli lilly abbvie top ranking pfizer astrazeneca flailingtesaro bolt ovarian cancer drug vs astrazeneca abbviepharma leader abbvie earning growth excel dividend screen
498,VRTX,share big cap biotech vertex pharmaceutical fall monday result latest cystic fibrosis drug disappoint investor vertex vrtx report datum mid stage study combine drug candidate vx al ready market ivacaftor brand kalydeco patient cystic fibrosis cause homozygous del mutation vertex other product already treat population firm hope vx be expand harder treat heterozygous del mutation population
499,VRTX,consistent prior phase study evaluate week treatment vx combination ivacaftor study show rapid improvement lung function week treatment patient complete treatment lung function return baseline vertex press release summarize
500,VRTX,rbc capital market analyst michael yee disagree be really consistent
501,VRTX,week datum be solid line prior result week datum be relatively disappointing vs expectation efficacy decline month have never be see write note monday
502,VRTX,week datum be average week vertex tell analyst number actually didn smoothly tail week bounce course treatment evercore isi analyst mark schoenebaum point webinar be likely product study be small be just person be take drug combo so larger phase study be need clear thing
503,VRTX,still say base odd vx succeed heterozygous patient have go
504,VRTX,vertex share fall fall buy point clear last week stock hit record friday
505,VRTX,yee estimate vertex still rake year just homozygous case most other analyst be also project big growth vertex next year onward cf drug roll currently lose money result former blockbuster incivek be push market gilead science gild new hepatitis drug sovaldi harvoni
506,VRTX,side note gilead fall monday biotech warn doctor friday patient take cardiac drug amiodarone sovaldi harvoni be danger heart attack
507,VRTX,however analyst yee write amiodarone be old drug used only arrhythmia case so not have significant impact drug sale share big cap biotech vertex pharmaceutical fall monday result latest cystic fibrosis drug disappoint investor vertex vrtx report datum mid stage study combine drug candidate vx al ready market ivacaftor brand kalydeco patient cystic fibrosis cause homozygous del mutation vertex other product already treat population firm hope vx be expand harder treat heterozygous del mutation population consistent prior phase study evaluate week treatment vx combination ivacaftor study show rapid improvement lung function week treatment patient complete treatment lung function return baseline vertex press release summarize rbc capital market analyst michael yee disagree be really consistent week datum be solid line prior result week datum be relatively disappointing vs expectation efficacy decline month have never be see write note monday week datum be average week vertex tell analyst number actually didn smoothly tail week bounce course treatment evercore isi analyst mark schoenebaum point webinar be likely product study be small be just person be take drug combo so larger phase study be need clear thing still say base odd vx succeed heterozygous patient have go vertex share fall fall buy point clear last week stock hit record friday yee estimate vertex still rake year just homozygous case most other analyst be also project big growth vertex next year onward cf drug roll currently lose money result former blockbuster incivek be push market gilead science gild new hepatitis drug sovaldi harvoni side note gilead fall monday biotech warn doctor friday patient take cardiac drug amiodarone sovaldi harvoni be danger heart attack however analyst yee write amiodarone be old drug used only arrhythmia case so not have significant impact drug sale
508,VRTX,busy morning earning slew financial report be close include apple aapl supplier nxp semiconductor nxpi chinese search giant baidu bidu cystic fibrosis drugmaker vertex pharmaceutical vrtx nxp semiconductor make chip be used apple iphone help power new apple pay service nxp serve other mobile customer
509,VRTX,monday drift quiet start stock post narrow early loss weak volume
510,VRTX,nasdaq slip fall dow jone industrial average hold decline volume open nasdaq lower nyse
511,VRTX,investor receive few clear early signal stock market today sole piece economic news federal reserve labor market condition index come positive read better april negative show well consensus estimate increase
512,VRTX,overseas china report sunday import drop sharply export decline slow report be widely see show weak domestic demand investment china market speculate meant more central bank stimulus measure ahead
513,VRTX,oil price slip more monday last week pullback benchmark west texas intermediate crude lose europe brent crude fall
514,VRTX,energy stock remain largely resilient drill contractor post market best early gain
515,VRTX,tesla motor tsla lead automaker higher jump report robert baird say stock have more room run raise price target gain lift share just buy point cup handle base
516,VRTX,casino owner be pressure la vegas sand lvs wynn resort wynn drop apiece stock have surge last week la vegas sand ceo chairman sheldon adelson reportedly say company be ponder takeover wynn resort adelson say wynn operated la vegas sand biggest market takeover be only remote thought stock have be decline march
517,VRTX,leader cyberark software cybr ambarella amba jump head ibd list healthy early gain monday drift quiet start stock post narrow early loss weak volume nasdaq slip fall dow jone industrial average hold decline volume open nasdaq lower nyse investor receive few clear early signal stock market today sole piece economic news federal reserve labor market condition index come positive read better april negative show well consensus estimate increase overseas china report sunday import drop sharply export decline slow report be widely see show weak domestic demand investment china market speculate meant more central bank stimulus measure ahead oil price slip more monday last week pullback benchmark west texas intermediate crude lose europe brent crude fall energy stock remain largely resilient drill contractor post market best early gain tesla motor tsla lead automaker higher jump report robert baird say stock have more room run raise price target gain lift share just buy point cup handle base casino owner be pressure la vegas sand lvs wynn resort wynn drop apiece stock have surge last week la vegas sand ceo chairman sheldon adelson reportedly say company be ponder takeover wynn resort adelson say wynn operated la vegas sand biggest market takeover be only remote thought stock have be decline march leader cyberark software cybr ambarella amba jump head ibd list healthy early gain
518,VRTX,biotech stock continue slide thursday prompt analyst weigh cause prognosis sector piper jaffray joshua schimmer note same thing happened year spark price debate gilead science gild hepatitis drug sovaldi also valuation concern long runup obviously turn be stellar year biotech believe industry fundamental remain strong write research note still be good year industry once pass latest round selling schimmer write profitable big cap such celgene celg biogen biib alexion pharmaceutical alxn be attractively value relative peer other hand say money lose big cap such vertex pharmaceutical vrtx biomarin pharmaceutical bmrn be more difficult value rbc capital market analyst michael yee report write reasonable make sense correction profit take have be possible give significant outperformance first month yee note be exaggerate move smaller biotechs last week such car stock juno therapeutic juno jump kite pharma kite rise turn revive long run concern biotech bubble kite stock be midday trading stock market today juno stock be fall more wednesday yee add however real bear market be drive poor fundamental say aren evident yet biotech re watch pillar risk biosimilar flux pricing rebate ip risk seem be risk individual company not whole sector write thursday mark fifth straight trading day decline ibd company medical biom biotech group have slump nearly span now still rank group track ibd follow amy reeve twitter ibd_areeve related biotechs track worst week year
519,VRTX,earning report start roll next month likely biggest mover biotech pharma stock be release clinical trial datum here be such report expect month street expect probably most anticipate be biogen idec biib presentation phase result alzheimer disease drug
520,VRTX,stock fall mildly monday seller pounce final hour lead stock get ding otherwise quiet session snap week lose streak last week slip hold modest gain much session benchmark index be less feb record high nasdaq waver
521,VRTX,stock remain mixed monday afternoon broader index continue be little change blue chip show life dow jone industrial average rise help gain pfizer pfe apple aapl exxon mobil xom meanwhile edge nasdaq slip volume be run sharply lower nasdaq nyse friday expiration fuel heavy pace sonic sonc ramp new high clear buy point rare ascend base company run drive thru fast food restaurant report fiscal earning tuesday close expect post cent share year red robin gourmet burger rrgb bounce back early weakness rise new high share restaurant operator have be tear come low october rise more stock have yet form proper base february red robin report rise fiscal sale mark biggest gain year well second straight period acceleration technology avgo cool new high trimming gain more half earlier stock market today citigroup raise price target stock be still well extend buy point week tight pattern rebound week move average downside vertex pharmaceutical vrtx be session low still disappointing trial study share be nearly monday low
522,VRTX,big cap biotech alexion pharmaceutical alxn beat estimate report lower expect guidance thursday announce change leadership vertex pharmaceutical vrtx celgene celg also moved new earning report
523,VRTX,alexion sale rise year earlier quarter more ahead analyst consensus profit exclude time item gain share beating estimate penny
524,VRTX,full year sale rise profit share
525,VRTX,year alexion expect sale miss consensus guide ep street have expect
526,VRTX,so many other company earning season alexion cite big foreign exchange hit sale cent ep
527,VRTX,company also announce ceo leonard bell retire april be replace chief operate officer david hallal bell continue chairman
528,VRTX,conference call analyst thursday bell emphasize be plan leadership transition now company have reach size operate quality happy
529,VRTX,join alexion year david role have expand entire organization last several year have increasingly share responsibility bell say now be right time david lead alexion
530,VRTX,hallal part allay worry guidance say pretax operate margin year be similar last year constant currency sale growth be also underline lower tax rate previously guide just
531,VRTX,news seem mollify investor et call share be stock market today time call finished alexion stock be afternoon trading alexion share rise try retake day move average
532,VRTX,other drug news vertex pharmaceutical plunge report mixed close wednesday get couple downgrade company bestselling hepatitis drug be crushed competition last year lose cent share cent more expect other hand revenue prior year beat consensus
533,VRTX,maxim group analyst jason kolbert downgrade vertex hold buy largely have rebuild model not earning report point risk associate vertex cystic fibrosis program be main focus now hep be derive price target be right stock close wednesday
534,VRTX,needham analyst alan carr also downgrade hold valuation concern stock be trading time high thursday drop
535,VRTX,meanwhile celgene report result line have preannounce month sale turn be slightly higher vs affirm previous guidance late morning celgene stock be intraday
536,VRTX,fellow big cap biotech biogen idec biib be due report close thursday analyst estimate biogen earning jump share sale rise
537,VRTX,biogen stock fall intraday
538,VRTX,follow amy reeve twitter ibd_areeve big cap biotech alexion pharmaceutical alxn beat estimate report lower expect guidance thursday announce change leadership vertex pharmaceutical vrtx celgene celg also moved new earning report alexion sale rise year earlier quarter more ahead analyst consensus profit exclude time item gain share beating estimate penny full year sale rise profit share year alexion expect sale miss consensus guide ep street have expect so many other company earning season alexion cite big foreign exchange hit sale cent ep company also announce ceo leonard bell retire april be replace chief operate officer david hallal bell continue chairman conference call analyst thursday bell emphasize be plan leadership transition now company have reach size operate quality happy join alexion year david role have expand entire organization last several year have increasingly share responsibility bell say now be right time david lead alexion hallal part allay worry guidance say pretax operate margin year be similar last year constant currency sale growth be also underline lower tax rate previously guide just news seem mollify investor et call share be stock market today time call finished alexion stock be afternoon trading alexion share rise try retake day move average other drug news vertex pharmaceutical plunge report mixed close wednesday get couple downgrade company bestselling hepatitis drug be crushed competition last year lose cent share cent more expect other hand revenue prior year beat consensus maxim group analyst jason kolbert downgrade vertex hold buy largely have rebuild model not earning report point risk associate vertex cystic fibrosis program be main focus now hep be derive price target be right stock close wednesday needham analyst alan carr also downgrade hold valuation concern stock be trading time high thursday drop meanwhile celgene report result line have preannounce month sale turn be slightly higher vs affirm previous guidance late morning celgene stock be intraday fellow big cap biotech biogen idec biib be due report close thursday analyst estimate biogen earning jump share sale rise biogen stock fall intraday follow amy reeve twitter ibd_areeve
539,VRTX,stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action
540,VRTX,dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday
541,VRTX,stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation
542,VRTX,more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support
543,VRTX,close el pollo dd jwn symantec symc be long list company expect post quarterly result stock quietly step solid gain early trade thursday company report dip unemployment claim focal point early action dow jone industrial average rise nasdaq climb apiece volume be soft nasdaq lower nyse compare trade same time wednesday stock market today earning beat forecast management say sale accelerate march april stock have be work regain week move average shallow week consolidation more ibd stock moved higher start trade gain be moderate many evaporate quickly newlink genetic nlnk drop almost slip week line support close el pollo dd jwn symantec symc be long list company expect post quarterly result
544,VRTX,biotech industry be set hit ground run january alone bring passel potentially stock move event biggest player second full week month bring annual jpmorgan healthcare conference san francisco many company release product financial news first thing morning
545,VRTX,new england patriot quarterback tom brady be just barely favore beat top rate defense seattle seahawks super bowl xlix sunday stock battle best stock washington massachusett seattle be birthplace starbucks sbux launch international coffee addiction mcdonald mcd other fast food
546,VRTX,vertex pharmaceutical sail most crucial test year existence cystic fibrosis cf treatment hit goal late stage study disclosure tuesday vertex stock soar year high close
547,VRTX,vertex vrtx pooled result phase clinical trial look patient homozygous pair gene del genetic mutation most common cause cystic fibrosis patient take combination lumacaftor ivacaftor week show statistically significant improvement lung function well significant reduction rate pulmonary exacerbation improvement body mass
548,VRTX,pivotal result validate strategy used combination corrector lumacaftor potentiator ivacaftor treat underlie cause cf vertex ceo jeffrey leiden tell analyst tuesday
549,VRTX,company plan file approval europe analyst say probably launch mid
550,VRTX,wall street hesitate
551,VRTX,size stock move reflect uncertain wall street be treatment work well significant news be vertex vertex enjoy be time biggest drug launch history hepatitis treatment incivek year later sale fall sharply competition come online especially gilead science gild sovaldi have already surpass incivek launch record be approve december
552,VRTX,ivacaftor drug latest study be approve sale kalydeco be approve only patient mutation represent only cf sufferer accord cystic fibrosis foundation
553,VRTX,thank partly controversially aggressive pricing year vertex still have be able pull hundred million annual revenue patient base just few be able treat so patient del mutation homozygous heterozygous turn ivacaftor blockbuster
554,VRTX,nonetheless prior trial result didn inspire full confidence just last week bernstein analyst geoffrey porge warn high risk failure base talk scientist cf conference
555,VRTX,tuesday isi group analyst mark schoenebaum write result be not home run due modest rate lung function improvement mean improvement be lack better alternative mean peak annual sale hit
556,VRTX,franchise
557,VRTX,rbc capital market analyst michael yee point vertex be also testing third drug vx have whole library other corrector work wider range genetic type estimate peak annual sale whole cf franchise
558,VRTX,big picture investor remember be be major improvement sick cf patient typically kid doc feedback be drug be fda approve patient get access write
559,VRTX,yee raise price target maintain outperform rating
560,VRTX,question still air be combo price vertex get away pricing kalydeco so high patient pool be so tiny efficacy be so good analyst generally expect combo price much lower yee estimate write street be mostly think
561,VRTX,way vertex likely have only disease alter cf treatment market quite say morningstar analyst stefan quenneville also believe result have longer term moat implication company position dominant player cystic fibrosis write research note tuesday vertex pharmaceutical sail most crucial test year existence cystic fibrosis cf treatment hit goal late stage study disclosure tuesday vertex stock soar year high close vertex vrtx pooled result phase clinical trial look patient homozygous pair gene del genetic mutation most common cause cystic fibrosis patient take combination lumacaftor ivacaftor week show statistically significant improvement lung function well significant reduction rate pulmonary exacerbation improvement body mass pivotal result validate strategy used combination corrector lumacaftor potentiator ivacaftor treat underlie cause cf vertex ceo jeffrey leiden tell analyst tuesday company plan file approval europe analyst say probably launch mid wall street size stock move reflect uncertain wall street be treatment work well significant news be vertex vertex enjoy be time biggest drug launch history hepatitis treatment incivek year later sale fall sharply competition come online especially gilead science gild sovaldi have already surpass incivek launch record be approve december ivacaftor drug latest study be approve sale kalydeco be approve only patient mutation represent only cf sufferer accord cystic fibrosis foundation thank partly controversially aggressive pricing year vertex still have be able pull hundred million annual revenue patient base just few be able treat so patient del mutation homozygous heterozygous turn ivacaftor blockbuster nonetheless prior trial result didn inspire full confidence just last week bernstein analyst geoffrey porge warn high risk failure base talk scientist cf conference tuesday isi group analyst mark schoenebaum write result be not home run due modest rate lung function improvement mean improvement be lack better alternative mean peak annual sale hit franchise rbc capital market analyst michael yee point vertex be also testing third drug vx have whole library other corrector work wider range genetic type estimate peak annual sale whole cf franchise big picture investor remember be be major improvement sick cf patient typically kid doc feedback be drug be fda approve patient get access write yee raise price target maintain outperform rating question still air be combo price vertex get away pricing kalydeco so high patient pool be so tiny efficacy be so good analyst generally expect combo price much lower yee estimate write street be mostly think way vertex likely have only disease alter cf treatment market quite say morningstar analyst stefan quenneville also believe result have longer term moat implication company position dominant player cystic fibrosis write research note tuesday
562,VRTX,stock be track mildly lower start tuesday ahead batch housing datum housing market index fhfa case shiller be due et new home sale be et
563,VRTX,nasdaq future ease less point vs fair value future lose point dow future slump point
564,VRTX,stock be mostly flat monday lead stock again show strength buffalo wild wing bwld break cup base monday
565,VRTX,number issue be active premarket trading stock market today
566,VRTX,vertex pharmaceutical vrtx sky-rocket follow successful trial cystic fibrosis treatment combination kalydeco lumacaftor meet goal phase trial vertex plan file regulatory approval number country fourth quarter
567,VRTX,sonic sonc climb preopen trade reaction late monday upbeat fiscal result drive chain earning sale climb latest quarter be view stock be cup base buy point
568,VRTX,better expect quarterly result late monday also boost micron technology mu tuesday premarket share be less enthusiastic
569,VRTX,conference board consumer confidence survey richmond fed factory report be et fed official also be speaking tuesday earlier philadelphia federal reserve bank president charle plosser say central bank have start raise interest rate sooner expect due broad strength economy new york fed chief william dudley be speaking et meanwhile san francisco fed president speak close stock be track mildly lower start tuesday ahead batch housing datum housing market index fhfa case shiller be due et new home sale be et nasdaq future ease less point vs fair value future lose point dow future slump point stock be mostly flat monday lead stock again show strength buffalo wild wing bwld break cup base monday number issue be active premarket trading stock market today vertex pharmaceutical vrtx sky-rocket follow successful trial cystic fibrosis treatment combination kalydeco lumacaftor meet goal phase trial vertex plan file regulatory approval number country fourth quarter sonic sonc climb preopen trade reaction late monday upbeat fiscal result drive chain earning sale climb latest quarter be view stock be cup base buy point better expect quarterly result late monday also boost micron technology mu tuesday premarket share be less enthusiastic conference board consumer confidence survey richmond fed factory report be et fed official also be speaking tuesday earlier philadelphia federal reserve bank president charle plosser say central bank have start raise interest rate sooner expect due broad strength economy new york fed chief william dudley be speaking et meanwhile san francisco fed president speak close
570,VRTX,stock hold solid gain midday thursday ease session high nasdaq trim gain pare gain dow jone industrial average add turnover be run higher major exchange stock market today
571,VRTX,lead stock wn wn gap bolt nearly best level february blow past buy point cup base open indian outsource firm post fiscal earning view raise guidance
572,VRTX,inphi iphi rally hit time high stock clear buy point consolidation volume be heavy chip designer report earning oct analyst poll thomson reuter see profit double cent share mark eighth straight quarter double digit growth
573,VRTX,downside netflix nflx gap day line dump follow late wednesday disappointing result news soft subscriber growth
574,VRTX,valeant pharmaceutical vrx be session low still news receive federal subpoena drug pricing policy share canadian drugmaker be much intraday
575,VRTX,follow vincent mao twitter ibd_vmao stock hold solid gain midday thursday ease session high nasdaq trim gain pare gain dow jone industrial average add turnover be run higher major exchange stock market today lead stock wn wn gap bolt nearly best level february blow past buy point cup base open indian outsource firm post fiscal earning view raise guidance inphi iphi rally hit time high stock clear buy point consolidation volume be heavy chip designer report earning oct analyst poll thomson reuter see profit double cent share mark eighth straight quarter double digit growth downside netflix nflx gap day line dump follow late wednesday disappointing result news soft subscriber growth valeant pharmaceutical vrx be session low still news receive federal subpoena drug pricing policy share canadian drugmaker be much intraday follow vincent mao twitter ibd_vmao
576,VRTX,even re not biotech pharma investor ve probably catch earful news lately virus call hepatitis last december record breaking launch gilead science gild wonder drug sovaldi controversy price tag merck mrk recent buyout formerly neglected biotech idenix pharmaceutical idix
577,VRTX,stock start week quietly positive mood monday grab quick early gain weak read august home sale dow jone industrial average nasdaq push add
578,VRTX,stock market today rolled predictably soft trade volume nasdaq lower nyse vs option expiration inflate action friday tuesday wednesday also see softer trade yom kippur holiday begin sundown tuesday
579,VRTX,economic news exist home sale drop sharply august national association realtor say annualize pace economist consensus have expect mild slowdown july pace statement group say higher price be shut potential buyer
580,VRTX,atlanta federal reserve trim inflation estimate come year business inflation expectation index dip september vs result august
581,VRTX,stock lululemon athletica lulu cyberark software cybr jump apiece analyst upgrade
582,VRTX,chipmaker atmel atml fire advance announce sunday germany base dialog semiconductor buy atmel cash stock deal value company expect deal close wedbush topeka fbr capital downgrade atmel follow news
583,VRTX,nasdaq stock tesla motor tsla adobe system adbe add almost
584,VRTX,lennar len top gain just miami base homebuilder report stronger expect fiscal sale earning big volume gain put bit daylight stock day move average lennar be attempt build base beside base fail attempt
585,VRTX,injured list neogen neog be pare loss open dive maker diagnostic test kit food pharmaceutical animal vaccine report weak fiscal first quarter result loss damage base build effort follow fail attempt late july
586,VRTX,lead stock generally open good standing effectively ibd list advance get go
587,VRTX,cal maine calm climb more jackson miss base egg producer be just buy point double bottom base
588,VRTX,global payment gpn also jump more stock be week support buy point flat base stock start week quietly positive mood monday grab quick early gain weak read august home sale dow jone industrial average nasdaq push add stock market today rolled predictably soft trade volume nasdaq lower nyse vs option expiration inflate action friday tuesday wednesday also see softer trade yom kippur holiday begin sundown tuesday economic news exist home sale drop sharply august national association realtor say annualize pace economist consensus have expect mild slowdown july pace statement group say higher price be shut potential buyer atlanta federal reserve trim inflation estimate come year business inflation expectation index dip september vs result august stock lululemon athletica lulu cyberark software cybr jump apiece analyst upgrade chipmaker atmel atml fire advance announce sunday germany base dialog semiconductor buy atmel cash stock deal value company expect deal close wedbush topeka fbr capital downgrade atmel follow news nasdaq stock tesla motor tsla adobe system adbe add almost lennar len top gain just miami base homebuilder report stronger expect fiscal sale earning big volume gain put bit daylight stock day move average lennar be attempt build base beside base fail attempt injured list neogen neog be pare loss open dive maker diagnostic test kit food pharmaceutical animal vaccine report weak fiscal first quarter result loss damage base build effort follow fail attempt late july lead stock generally open good standing effectively ibd list advance get go cal maine calm climb more jackson miss base egg producer be just buy point double bottom base global payment gpn also jump more stock be week support buy point flat base
589,VRTX,major average finished seesaw trading session monday minor gain
590,VRTX,software solar stock help lift nasdaq gain stock market today dow industrial edge less volume run higher nyse slightly lower nasdaq accord preliminary datum
591,VRTX,tesla motor tsla rally heavy trade highest level month report nissan motor nsany bmw be interested discuss supercharger electric car maker say thursday open patent
592,VRTX,ibd stock shire shpg surge record high clear flat base buy point more twice normal trade irish drugmaker say last week agree conduct clinical trial response fda request look potential use vyvanse treat attention deficit hyperactivity disorder year old child already approve treat kid age older
593,VRTX,land end le extend gain third straight session jump new high brisk volume catalog base apparel retailer thursday announce strong earning sale result first quarter go public be spun sear holding shld april
594,VRTX,downside vertex pharmaceutical vrtx gap slump slice day move average big turnover bernstein say report see high risk failure biotech late stage trial vx treat cystic fibrosis other biotechs heavy volume ligand pharmaceutical lgnd fall aldr
595,VRTX,zoe kitchen zoe rise early reversed lower dip busy trade last week fast casual mediterranean style restaurant operator give first quarterly report april debut lose cent share jump revenue
596,VRTX,follow nancy gondo twitter https twitter com email protected major average finished seesaw trading session monday minor gain software solar stock help lift nasdaq gain stock market today dow industrial edge less volume run higher nyse slightly lower nasdaq accord preliminary datum tesla motor tsla rally heavy trade highest level month report nissan motor nsany bmw be interested discuss supercharger electric car maker say thursday open patent ibd stock shire shpg surge record high clear flat base buy point more twice normal trade irish drugmaker say last week agree conduct clinical trial response fda request look potential use vyvanse treat attention deficit hyperactivity disorder year old child already approve treat kid age older land end le extend gain third straight session jump new high brisk volume catalog base apparel retailer thursday announce strong earning sale result first quarter go public be spun sear holding shld april downside vertex pharmaceutical vrtx gap slump slice day move average big turnover bernstein say report see high risk failure biotech late stage trial vx treat cystic fibrosis other biotechs heavy volume ligand pharmaceutical lgnd fall aldr zoe kitchen zoe rise early reversed lower dip busy trade last week fast casual mediterranean style restaurant operator give first quarterly report april debut lose cent share jump revenue follow nancy gondo twitter https twitter com email protected
597,VRTX,vertex pharmaceutical vrtx stock fall then rise morning trading thursday investor analyst assessed result phase iii test treatment cystic fibrosis call kalydeco study do not meet primary endpoint vertex say press release early thursday company also say pre specify subset analysis patient year
598,VRTX,strength biotech stock have be well document recent month innovation abound sector new company be sprout time biom realty trust bmr be real estate investment trust poise benefit continue innovation expansion sector headquarter san diego major life science market company have property other
599,VRTX,biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi
600,VRTX,letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford
601,VRTX,due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi
602,VRTX,meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april
603,VRTX,health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet
604,VRTX,biotech stock cheaper
605,VRTX,gilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing
606,VRTX,alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat
607,VRTX,biogen idec biib have costly multiple sclerosis treatment tecfidera lose
608,VRTX,ibd top rate medical biom biotech group fall
609,VRTX,abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction
610,VRTX,gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund
611,VRTX,sovaldi bargain
612,VRTX,analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market
613,VRTX,deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain
614,VRTX,liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low
615,VRTX,isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday
616,VRTX,dem seek public shaming
617,VRTX,schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year
618,VRTX,letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write
619,VRTX,such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi
620,VRTX,gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release
621,VRTX,have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early
622,VRTX,shouldn be completely unexpected kind issue come fore periodically say just part investing health care biotech stock sell hard friday wall street blame letter several house democrat ask gilead science justify price hepatitis blockbuster sovaldi letter date thursday be sign rep henry waxman frank pallone diana degete ranking member committee energy commerce call sovaldi breakthrough hcv treatment expressed concern treatment not cure patient afford due sovaldi price tag letter go say colorado pennsylvania medicaid program have already announce re funding sovaldi only sickest patient california be still figure reimbursement policy letter also note pharmacy benefit manager express script esrx be encourage doctor network delay prescribe sovaldi meanwhile hepatitis be disease find poor result lawmaker tell gilead provide explanation pricing april health insurer wellpoint wlp chime friday concern new hepatitis drug cost say executive ken goulet biotech stock cheapergilead gild fall nearly month close low biotechs selling expensive drug fall even harder perhaps fear larger change national mood drug pricing alexion pharmaceutical alxn sole drug soliris go upward year tumble vertex pharmaceutical vrtx also sell expensive hepatitis drug call incivek retreat biogen idec biib have costly multiple sclerosis treatment tecfidera lose ibd top rate medical biom biotech group fall abbvie abbv likely come rival possibly cheaper rival sovaldi later year initially rally friday close fraction gilead catch cold rest market catch pneumonia say tom vandeventer portfolio manager tocqueville opportunity fund sovaldi bargain analyst most part advise stay calm michael yee rbc capital market write email client friday pricing discussion generate headline concern view underscore drug be go be huge re cure patient improve society hcv be important public health issue hiv be validate significance market deutsche bank analyst robyn karnauskas write client note speak gilead official be already make case sovaldi be actually bargain liver transplant related hcv cost year med so person do not reject liver write gilead have co pay program place pocket cost be low isi group analyst mark schoenebaum point sovaldi compare favorably older hepatitis drug especially vertex incivek go year sovaldi cure rate be also much higher incivek so cost cure be even better say webinar friday dem seek public shaming schoenebaum also query terry haine longtime washington lawyer lobbyist once serve senior republican counsel same congre sional committee send letter haine respond government actually have little power address drug price view waxman et al hope accomplish be public shaming not waxman deliver tobacco industry year letter be bank shot get thing go goal get gilead significantly lower price sovaldi haine write such move be politically popular add discontent high price sovaldi new drug general have be swell payer general public time now aids healthcare foundation large nonprofit history criticize gilead hiv drug pricing recently turn fire sovaldi gilead latest display touch greed come heel company january pricing new hepatitis treatment sovaldi sofosbuvir pill more gilead most expensive aids drug stribild ahf say feb press release have play biotech stock have hit lull last few week bull run not see lead fear party be vandeventer say biotechs be high beta group be probably just correction point drug price have be political football early shouldn be completely unexpected kind issue come fore periodically say just part investing health care
623,VRTX,biotech stock be selling hard friday consensus wall street seem pin blame letter send several house democrat gilead science gild ask briefing price hepatitis blockbuster sovaldi letter sign rep henry waxman frank pallone diana degete date thursday expressed concern
624,VRTX,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
625,VRTX,volume nasdaq nyse be tracking tuesday level
626,VRTX,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
627,VRTX,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
628,VRTX,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
629,VRTX,solar stock be day best performer lead first solar fslr jump new high heavy volume
630,VRTX,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
631,VRTX,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
632,VRTX,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
633,VRTX,stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory
634,VRTX,dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss
635,VRTX,option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action
636,VRTX,broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be
637,VRTX,symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august
638,VRTX,lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base
639,VRTX,downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high stock get positive start friday slip mixed trade several drugmaker fall abruptly pull nasdaq negative territory dow jone industrial average be ahead nasdaq fall gilead science gild celgene celg vertex pharmaceutical vrtx other drugmaker post sharp loss option expiration force volume stock market today trade triple digit percentage nyse nasdaq compare thursday early action broadcaster medium general meg ahead announce buy peer lin medium lin cash stock deal value combination include nearly lin debt create tv broadcaster station serve market providence base lin medium be symantec symc tank start trade antivirus software maker announce late thursday have drop ceo steve bennett company say decision be result ongoing deliberative process not result event impropriety company name director michael brown interim ceo symantec share have be deepen correction august lead stock buffalo wild wing bwld pop powerful trade grab new high fast casual sport bar chain remain buy range buy point cup handle base downside alexion pharmaceutical alxn reversed early gain backed heavy trade drugmaker have be flattish consolidation feb high
640,VRTX,stock add early gain quiet trade market moved early et close
641,VRTX,nasdaq climb dow jone industrial average haul gain
642,VRTX,stock advanced stock market today volume hover well level same time wednesday
643,VRTX,homebuilder be give gain strong week horton dhi kb home kbh fall
644,VRTX,agricultural commodity leader daniel adm dump modest trade australia treasurer block company acquisition grain corp largest grain handler australia east coast daniel share have be consolidate just nov high
645,VRTX,drugmaker post morning best move vertex pharmaceutical vrtx pop weak trade move test resistance converge week move average stock have be correct july
646,VRTX,alexion pharmaceutical alxn tack higher weak trade be finishing fifth week flat base buy point
647,VRTX,stock open higher friday then backtrack mixed terrain drugmaker lead stock add drag early trade
648,VRTX,dow jone industrial average remain ahead be nasdaq slip celgene celg vertex pharmaceutical vrtx biogen idec biib weigh nasdaq medical sector continue bout weakness
649,VRTX,volume start mixed nyse lower nasdaq
650,VRTX,stock market today receive early boost february payroll report show new hire january well forecast many have be braced disappointing job number harsh weather tamper other economic reading month
651,VRTX,leader edge broadly moderately higher open ibd qihoo qihu ubiquiti network ubnt jazz pharmaceutical jazz rexnord rxn open ahead more
652,VRTX,korn ferry international kfy gap gain executive headhunter late thursday top analyst fiscal expectation pop earning revenue advance los angele base company report year year growth line business region strongest top line result company history
653,VRTX,stock break week base be buy point
654,VRTX,downside qiwi qiwi slip putt share week stock continue be link investor reaction crisis ukraine
655,VRTX,ambarella amba drop report earning revenue gain latest quarter view stock have be work base stock hold week move average stock open higher friday then backtrack mixed terrain drugmaker lead stock add drag early trade dow jone industrial average remain ahead be nasdaq slip celgene celg vertex pharmaceutical vrtx biogen idec biib weigh nasdaq medical sector continue bout weakness volume start mixed nyse lower nasdaq stock market today receive early boost february payroll report show new hire january well forecast many have be braced disappointing job number harsh weather tamper other economic reading month leader edge broadly moderately higher open ibd qihoo qihu ubiquiti network ubnt jazz pharmaceutical jazz rexnord rxn open ahead more korn ferry international kfy gap gain executive headhunter late thursday top analyst fiscal expectation pop earning revenue advance los angele base company report year year growth line business region strongest top line result company history stock break week base be buy point downside qiwi qiwi slip putt share week stock continue be link investor reaction crisis ukraine ambarella amba drop report earning revenue gain latest quarter view stock have be work base stock hold week move average
656,VRTX,vertex pharmaceutical vrtx receive key drug approval europe friday biotech prepared report second quarter earning monday
657,VRTX,european commission approve kalydeco treatment cystic fibrosis chronic disease impair lung company press release boast first cf treatment address underlie genetic cause disease instead just treat symptom be approve january
658,VRTX,success cf franchise have be cause investor heartburn last few month stock rocket more vertex release very strong interim datum ongoing clinical trial kalydeco combine new drug candidate few week later fall again company restate number have report more datum release june only cause further confusion dip stock share be midday friday be still more high
659,VRTX,nonetheless wall street be expect boom quarter new kalydeco sale add vertex other approve product hepatitis drug incivek analyst poll thomson reuter expect report profit cent share close monday reverse year loss cent sale be see explode more
660,VRTX,related amgen gilead pop quarterly earning beat vertex pharmaceutical vrtx receive key drug approval europe friday biotech prepared report second quarter earning monday european commission approve kalydeco treatment cystic fibrosis chronic disease impair lung company press release boast first cf treatment address underlie genetic cause disease instead just treat symptom be approve january success cf franchise have be cause investor heartburn last few month stock rocket more vertex release very strong interim datum ongoing clinical trial kalydeco combine new drug candidate few week later fall again company restate number have report more datum release june only cause further confusion dip stock share be midday friday be still more high nonetheless wall street be expect boom quarter new kalydeco sale add vertex other approve product hepatitis drug incivek analyst poll thomson reuter expect report profit cent share close monday reverse year loss cent sale be see explode more related amgen gilead pop quarterly earning beat
661,VRTX,share vertex pharmaceutical vrtx soar nearly monday morning biotech release good datum experimental cystic fibrosis drug vertex announce press release phase study patient take vx vertex already approve cf drug kalydeco find show improve lung function day treatment cf genetic disorder cause scarring
662,VRTX,janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning
663,VRTX,glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail
664,VRTX,whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note
665,VRTX,yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process
666,VRTX,market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be
667,VRTX,related offer steady stock janssen pharmaceutical subsidiary johnson johnson jnj have acquire hepatitis drug candidate glaxosmithkline gsk janssen biotech partner medivir announce tuesday morning glaxo have develop drug gsk partnership vertex pharmaceutical vrtx never launch phase trial janssen however plan test combination simeprevir drug medivir janssen develop be await regulatory approval be used combination standard therapy interferon ribavirin accord press release janssen hope glaxo drug take place interferon cocktail whole point be jnj try develop oral possibly once daily hcv combo compete simplest easiest regimen write rbc capital market analyst michael yee client note yee view current simplest easiest regimen be gilead science gild sofosbuvir ribavirin also be fda review write news shouldn interfere expect strong launch sofosbuvir next year take least other competitor finish testing approval process market seem agree be trading cent stock market tuesday morning gilead have be slip hit time high be related offer steady stock
668,VRTX,vertex pharmaceutical vrtx tumble more heavy trading early thursday company report positive trial result be nonetheless not quite investor be hope company report datum phase study cystic fibrosis patient take vertex kalydeco experimental drug candidate vx study find improvement lung function
669,VRTX,share vertex pharmaceutical vrtx be early trading tuesday fall much company restate trial result cause stock soar week study question be interim analysis phase trial cystic fibrosis drug kalydeco drug candidate vx previous report
670,VRTX,constellation brand inc stz free report share decline company report fiscal first quarter adjust earning share miss zack consensus estimate shareshare kb home kbh free report jump company report second quarter fiscal earning share surpass zack consensus estimate sharevertex pharmaceutical incorporate vrtx free report share surge company announce health canada have approve cystic fibrosis drug prsymdekoshare fiat chrysler automobile fcau free report rise news company become possible target takeover bid hyundai motor
671,VRTX,vertex pharmaceutical incorporate vrtx free report share rally more jun follow announcement lower expect top line result galapago nv glpg free report phase ii study cystic fibrosis cf candidate glpg galapago be evaluate candidate top vertex cf drug orkambi lumacaftor ivacaftor phase ii pelican study cf patient be homozygous class ii del mutation patient treat glpg be treat orkambi least week study continue receive study company be develop glpg triple combination regimen treat cf patient datum study show glpg combination orkambi improve ppfev measure lung function reduce sweat chloride mmol baseline versus placebo however investor have find datum disappointing lead decline galapago share price last friday vertex be also develop triple combo regimen candidate vx vx combination tezacaftor ivacaftor have improve ppfev respectively early mid stage study reduction sweat chloride patient be also materially higher glpg moreover candidate be phase iii stage development number stage show vertex be clear leader development process triple combo regimen cf patient study result be also significantly higher probably competition longer term so far year vertex share have gain decrease register industry galapago be also develop triple combination regimen own cf potentiator corrector glpg glpg glpg phase study interim datum expect third quarter cf study be be conduct partnership abbvie abbv free report however abbvie have opted not proceed development previously contemplated second triple combination therapy comprise glpg glpg glpg meanwhile vertex announce press release third cf drug be approve treatment patient age older copy del mutation cftr gene canada drug available brand name prsymdeko corbus pharmaceutical holding inc crbp free report base clinical stage pharmaceutical company be also develop cf candidate lenabasum mid stage study vertex pharmaceutical incorporate price vertex pharmaceutical incorporate price vertex pharmaceutical incorporate quotevertex currently carry zack rank hold see complete list today zack rank strong buy stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
672,VRTX,be second half year time analyze first half turn be pharma biotech stock term fda decision regulatory body approve novel drug first half be less year period figure however several fda decision line second half higher number drug be approve rest year key fda approval first half include amgen amgn free report novartis first cgrp antibody aimovig erenumab prevention migraine jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor biomarin pharmaceutical palynziq treat pku drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month july fda decision indivior schizophrenia injection rbp jul fda be expect give decision indivior plc invvy free report rbp have be develop treatment schizophrenia rbp be once monthly injectable risperidone give used atrigel delivery system indivior be zack rank hold stock see complete list today zack rank strong buy stock here progenic pharmaceutical azedra review progenic pharmaceutical pgnx free report new drug application nda look get pipeline candidate azedra approve treatment patient suffering malignant rare neuroendocrine tumor paraganglioma be review fda be expect give decision jul month delay previous fda action date march azedra be add progenic portfolio acquisition molecular insight pharmaceutical decision insys therapeutic pain candidate jul fda be also expect give decision insys therapeutic insy free report buprenorphine sublingual spray moderate severe acute pain be important remember fda advisory committee vote approval company have file new drug application nda september last year base positive datum pivotal study candidate fda accept nda review december assign pdufa date jul be quite possible unfavorable vote committee influence fda decision delay approval drug fda panel back new indication glaxo nucala end month fda panel be expect give opinion glaxo gsk free report label expansion filing eosinophilic asthma drug nucala mepolizumab new indication chronic obstructive pulmonary disease copd latest filing glaxo be look get nucala approve add maintenance treatment copd eosinophilic phenotype nucala be presently approve treat severe eosinophilic asthma eosinophilic granulomatosis polyangiitis egpa glaxo hadfiled supplemental biologic license application sbla label expansion nucala include use copd november last year fda take recommendation panel advisory committee account review application be not bound follow same today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
673,VRTX,sarepta therapeutic inc srpt free report be star performer tuesday trading session stock sky-rocket much new high close little lower rise read sector etfs crushed year bull run surge propel company market cap more make fifth most valuable drugmaker headquarter massachusett biogen biib free report vertex pharmaceutical vrtx free report alexion pharmaceutical alxn free report alnylam pharmaceutical alny free report massive gain mid cap biotech firm come encourage early trial result gene therapy duchenne muscular dystrophy dmd study be conduct patient reveal average reduction more creatine kinase enzyme find muscle cell leak bloodstream damage have occur muscle day indicate sarepta muscular dystrophy drug successfully treat produce robust level protein protect muscle cell dmd be rare genetic disease marked progressive muscle degeneration cause physical disability life threaten problem heart respiratory system disease mostly affect boy age typically kill patient age positive clinical trial also send share fellow dmd gene therapy developer solid bioscience sldb free report more yesterday see healthcare etfs here etf news lead surge biotech etfs especially virtus lifesci biotech product etf bbp free report ishare nasdaq biotechnology etf ibb free report andspdr biotech etf xbi free report trio have rise respectively fact bbp xbi touch new week high bbp etf follow lifesci biotechnology product index measure performance biotechnology company primary product offer product candidate have receive food drug administration approval hold stock sarepta therapeutic take fourth position basket share product have accumulate aum charge bps fee year have zack etf rank buy high risk outlook ibb fund provide exposure firm tracking nasdaq biotechnology index sarepta accounting asset ibb be most popular fund be biotech space aum expense ratio come ibb have zack etf rank hold high risk outlook read small cap biotech etfs be soar xbi aum xbi provide equal weight exposure stock tracking biotechnology select industry index sarepta be seventh firm fund portfolio make share xbi have expense ratio zack etf rank high risk outlook bottom linein fact etfs clearly outpaced other product biotech space last trading session alp medical breakthrough etf sbio free report virtus lifesci biotech clinical trial etf bbc free report add just day product have exposure sarepta therapeutic want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
674,VRTX,investor biotech sector be glue last week highly await annual meeting american society clinical oncology asco overshadowed usual regulatory other update space meeting hold chicago jun jun provide company platform showcase datum scientist physician investment community other focus be mainly asco datum company biogen biib free report vertex vrtx free report remain limelight pipeline update recap important story biogen eisai report encourage datum elenbecestat biogen partner eisai announce encourage result alzheimer candidate elenbecestat bace inhibitor phase ii study study study be multicenter randomize double blind placebo controlled parallel group month study patient mild cognitive impairment mci due alzheimer disease mild moderate dementia due alzheimer disease confirm amyloid pathology pet positron emission tomography screening patient be randomize treatment arm receive elenbecestat mg placebo daily more half patient elenbecestat mg mg arm be switch mg arm month more datum show elenbecestat be generally safe well tolerate result demonstrated statistically significant difference amyloid beta a level brain measure amyloid pet suggest delay clinical symptom decline exploratory endpoint eisai biogen be jointly develop elenbecestat march company be currently conduct global phase iii study mission ad early alzheimer disease biogen currently carry zack rank hold see complete list today zack rank strong buy stock here vertex crispr sickle cell disease candidate put hold vertex pharmaceutical incorporate crispr therapeutic announce fda have place clinical hold investigational new drug application ind ctx treatment sickle cell disease pending resolution certain question raise fda company have submit ind fda april support plan initiation phase ii trial unite state adult patient sickle cell disease ctx be experimental gene edit autologous hematopoietic stem cell therapy be also be evaluate patient suffering thalassemia sickle cell disease fda clinical hold company plan initiate phase ii trial ctx europe adult patient transfusion dependent thalassemia crispr vertex equally share research development cost profit worldwide ctx read more vertex crispr sickle disease candidate put hold fda sarepta get negative chmp opinion exondys sarepta therapeutic inc srpt free report announce committee medicinal product human use chmp european medicine agency ema have adopt negative opinion duchenne muscular dystrophy dmd candidate exondys eteplirsen negative opinion be expect follow oral explanation trend vote consequently sarepta request re examination opinion result assignment new rapporteur co rapporteur additionally sarepta request scientific advisory group sag dmd be call turn allow neuromuscular specialist provide expert guidance insight other thing validity external control used importance certain functional endpoint re examination be complete end finally look asco result celgene celg free report have multiple presentation oncology drug revlimid pomalyst other experimental therapy american society clinical oncology asco annual meeting chicago il result transcend study experimental cd direct car cell therapy candidate lisocabtagene maraleucel liso cel jcar patient relapse refractory aggressive cell hodgkin lymphoma nhl be encourage read more celgene present datum car therapy revlimid pomalyst regeneron regn free report partner sanofi also announce datum trial evaluate cemiplimab advanced cutaneous squamous cell carcinoma asco datum study show patient treat cemiplimab experience robust tumor effect cemiplimab treat patient show response rate median observed time response month datum cut date gilead gild free report kite also announce result ongoing phase study asco show clinical response be observed investigational cell receptor tcr cell therapy target human papillomavirus type hpv solid tumor cancer cause hpv meanwhile gilead have also collaborate hookipa biotech ag obtain exclusive right hookipa therat vaxwave arenavirus vector base immunization technology major chronic infectious disease indication hepatitis virus hbv human virus hiv gilead partner galapago nv also announce phase ii study equator pipeline candidate filgotinib achieve primary endpoint improvement sign symptom psoriatic arthritis week amgen amgn free report also announce result phase iii trial asco show kyproli administer once weekly mg dexamethasone achieve superior progression free survival pfs overall response rate orr compare twice weekly kyprolisat mg dexamethasone twice weekly kd patient relapse refractory multiple myeloma separately share amgen be fda approve biosimilar blockbuster drug neulasta biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gain past month celgene have lose alexion have gain see last biotech stock roundup here biotech stock roundup gild epclusa china approval bmrn palynziq fda nod next biotech stay tune regulatory update pipeline development news today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
675,VRTX,vertex pharmaceutical incorporate vrtx free report partner crispr therapeutic ag crsp free report announce fda have place clinical hold company investigational new drug ind application ctx company have file ind application last month start phase ii study ctx sickle cell disease unite state part review ind fda put forward certain question company vertex crispr therapeutic plan work rapidly fda resolve issue so clinical hold be lift study initiate december part strategic research collaboration form vertex crispr therapeutic select ctx move clinical development gene edit treatment sickle cell disease thalassemia develop used crispr therapeutic proprietary crispr cas technology back then company have opted toco develop co commercialize ctx equally share cost profit worldwide vertex have right license new gene editing treatment include ctx develop used crispr cas technology emerge joint research deal application have also be submit begin phase ii study thalassemia europe plan begin study second half year be intact unaffected hold sickle cell disease study share crispr therapeutic be more hour trading wednesday response negative pipeline update vertex stock do not show movement fact so far year crispr therapeutic share have gain vertex be compare industry decline genomic editing technology used crispr technology repair defective genetic material cause disease be probably most promising exciting healthcare innovation decade be several method use crispr target genetic defect cause specific disease most promising be use enzyme call cas deliver crispr affected cell other crispr therapeutic intellium therapeutic ntla free report edita medicine inc edit free report also plan carry clinical study used crispr cas address disease share intellium therapeutic edita medicine be more hour wednesday crispr therapeutic currently have zack rank strong buy vertex have zack rank hold see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
676,VRTX,recently document potential genome editing technology revolutionize treatment many serious disease company be position use specific method gene therapy call cirspr cas repair genetic disease crispr therapeutic crsp free report intellium therapeutic ntla free report edita medicine edit free report read article here spectacular runup share crispr hit snag recently late wednesday crsp announce fda have place clinical hold company investigational new drug ind application use technology phase ii study sickle cell disease patient begin later market pummeled crsp share trade almost hour trading wednesday night have re-cover somewhat remain lower wednesday close intraday trading determine recent selloff represent buy opportunity investor get recently red hot stock more attractive price let take quick look fda ind process clinical hold actually mean fda processbefore researcher conduct human clinical trial investigational drug submit application fda address key safety efficacy issue application be require contain information broad area animal pharmacology toxicology study manufacturing information clinical protocol investigator information applicant not initiate clinical trial day fda reviews ind safety ensure research subject not be subject unreasonable risk be review period crsp receive notice fda clinical hold meaning not proceed trial fda have perform further review ground clinical hold stage encompass wide range possibility most serious include possibility application be intentionally erroneous mislead investigator be not qualify perform trial be significant risk illness injury participant least serious be ind application simply do not contain sufficient information need assess risk subject propose study more list ground be sufficient imposition clinical hold day impose clinical hold fda send applicant letter describe detail reason hold applicant be expect respond issue detailed hold letter specific time limit presumably have impetus respond expediently possible then fda have more day address response choose extend lift clinical hold fda do not make detail proceed public period crispr applicationin statement wednesday cirspr therapeutic joint venture partner vertex pharmaceutical vrtx free report say only crispr vertex expect obtain additional information fda question future plan work rapidly fda solution so point investor be somewhat dark reason clinical hold mean future trial company possible application be simply not thorough enough crispr append relevant information continue plan little delay possible fda be simply proceed extreme caution subject particular application additional scrutiny gene therapy be so new want be aware potential risk let proverbial genie bottle possible fda see serious risk trial factual inconsistency application threaten doom project altogether base language crispr press release odd be first reason more information impossible know point investor probably avoid add position reason hold be clearer continue monitor situation more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
677,VRTX,turn be notable year pharma biotech industry fda give nod novel drug well several biological license application bla include path breaking cancer treatment kymriah yescarta number compare favorably not only just novel drug be approve earlier year well other key approval last year include lilly verzenio advanced metastatic breast cancer gilead vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron regn free report sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin bmrn free report brineura treatment specific form batten disease other many drug have blockbuster potential drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst here be look few important regulatory event schedule month february fda decision amag makena feraheme amag pharmaceutical amag free report be seek fda approval subcutaneous auto injector version makena drug device combination product approve pdufa date february offer convenience used ready administer subcutaneous auto injector provide patient alternative option intramuscular injection makena be currently available intramuscular injection reduce risk preterm birth woman be pregnant baby spontaneously deliver preterm baby past approval product help amag extend patent life makena be schedule lose orphan drug exclusivity february amag be ready launch authorize generic partner february company do not expect generic competitor enter market later drug device combination product be approve company apply orange book list patent device meanwhile fda be expect issue decision regard label expansion feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida priority review gilead hiv treatment gilead science gild free report be also await decision fda month new drug application nda investigational fix dose combination bictegravir mg bic integrase strand transfer inhibitor emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv infection nda be priority review decision expect february company hepatitis virus hcv franchise see decline sale gilead be focuse hiv franchise growth company hiv portfolio include drug genvoya truvada atripla descovy odefsey complera stribild contribute approximately total sale first month gilead taf base product genvoya descovy odefsey remain key growth driver vertex boost cf portfolio fda approval month vertex pharmaceutical vrtx free report be key player cystic fibrosis cf market product orkambi kalydeco cf portfolio company be look strengthen position area further potential approval tezacaftor ivacaftor combination treatment be priority review decision fda expect february combination treatment be review use cf patient year older have copy del mutation del mutation residual function mutation be responsive treatment approval combination be major boost vertex cf portfolio be expect deliver revenue range currently patient be eligible treatment company cf portfolio number expect grow back eu reimbursement orkambi label expansion drug potential approval tezacaftor ivacaftor combination vertex share be last year outperform rally industry belong vertex be zack rank hold stock see complete list today zack rank strong buy stock here valeant pharmaceutical international inc vrx free report also expect hear fda approval status plenvu bowel cleanser used preparation colonoscopy fda action date february moreover company kempharm apricu expect response fda month resubmit ndas kempharm have pdufa date february apadaz immediate release abuse deterrent hydrocodone acetaminophen combination product candidate apricu get know approval status resubmit vitaro topically deliver treatment erectile dysfunction nda february meanwhile fda anesthetic analgesic drug product advisory committee be meeting february discuss pacira pharmaceutical pcrx free report supplemental new drug application snda exparel bupivacaine liposomal injectable suspension produce local analgesia nerve block produce regional analgesia hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
678,VRTX,fourth quarter earning season be full swing financial figure member index already jan latest earning preview total earning index member jump year quarter drive improvement revenue beat ratio be bottom line top line positive note ongoing earning phase seem have begin well drug biotech sector major large cap player johnson johnson jnj free report kick season earning beating estimate sale slightly miss same few other large pharma company release earning result last week picture look quite encourage pharma bigwig have report last week be novartis nvs free report abbvie abbv free report surpass earning sale estimate quarter review novartis raise sale guidance abbvie increase previously issue earning expectation year major player biotech sector biogen biib free report announce mixed performance report period earning lag estimate sale exceed same however celgene corp celg free report outpaced metric expectation fourth quarter drug biotech stock remain growth trajectory courtesy slew fda approval rise demand new product sale successful innovation product line expansion strong clinical report well continue robust performance legacy product moreover impressive factor regular acquisition be expect drive sector growth well also earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning period discussion pharma biotech giant be schedule report earning number jan let see thing be shape company upcoming release eli lilly company lly free report lilly be schedule release fourth quarter earning market open company deliver positive surprise last quarter lilly earning performance have be modest earning miss expectation last quarters beating same remain thus bring average beat proven model show lilly be likely beat earning quarter combination lilly zack rank increase predictive power esp solid zack rank positive earning esp make confident earning beat impending report zack consensus estimate quarter be report be peg share uncover best stock buy sell re report earning esp filter expect sturdy uptake new product trulicity taltz basaglar cyramza jardiance lartruvo upside be likely make decline sale establish product zyprexa alimta ciali strattera effient fourth quarter read more lilly report earning card vertex pharmaceutical inc vrtx free report vertex be slate release fourth quarter earning market close company track record have also be impressive so far deliver positive surprise trail quarters average beat third quarter vertex come positive surprise however proven model do not conclusively show vertex be likely beat earning quarter company favorable zack rank hold increase predictive power esp earning esp leave surprise prediction inconclusive zack consensus estimate be peg cent share see complete list today zack rank strong buy stock here vertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect uptrend be reflect result soon be report quarter read more vertex report earning card don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
679,VRTX,vertex pharmaceutical inc vrtx free report be schedule report fourth quarter result jan market close vertex share have soar past year industry have record increase vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi perform consistently first quarters expect positive trend be reflect result soon be report quarter approval line extension kalydeco unite state have increase eligible patient population drug kalydeco be approve use patient older have residual function mutation cftr gene be follow approval person have mutation responsive kalydeco include splice mutation august expansion patient population certainly boost sale drug zack consensus estimate kalydeco fourth quarter be vertex expect kalydeco revenue be range december vertex announce kalydeco meet endpoint phase iii study patient age year have mutation cftr gene regulatory application label expansion be plan be file first quarter also note regulatory application label expansion kalydeco be review application seek approval kalydeco tezacaftor patient age older have copy del mutation del mutation residual function mutation expect vertex provide updateson earning call company have not be so successful agreement europe related orkambi drug have do well so far year june july vertex strike re imbursement agreement ireland italy respectively consensus estimate orkambi fourth quarter be january vertex announce extension marketing application orkambi be approve europe approval orkambi marketing label eu now include use child cf age year have copy del mutation expand patient population investor focus call be triple combination cf regimen be crucial long term growth vertex however operate expense be likely be higher side vertex expand pipeline conduct multiple study evaluate candidate model proven model do not conclusively show vertex be likely beat earning quarter stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand uncover best stock buy sell re report earning esp filter zack rank vertex zack rank increase predictive power esp however need have positive esp be confident earning surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate quotestock warrant lookhere be biotech stock want consider model show have right combination element post earning beat quarter alexion pharmaceutical inc alxn free report be schedule release result feb company have earning esp zack rank see complete list today zack rank stock here anthera pharmaceutical inc anth free report be expect release result feb company have earning esp zack rank exelixis inc exel free report be expect release result feb have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
680,VRTX,have be month last earning report vertex pharmaceutical incorporate vrtx free report share have lose time frame recent negative trend continue lead next earning release be vrtx due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst vertex earning beat strong cf product salesvertex report first quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter vertex report revenue first quarter beating zack consensus estimate however sale be year year due significantly lower collaborative revenue company have receive upfront payment merck kgaa year period licensing oncology program be miss first quarter cf franchise sale strongvertex first quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be first quarter year year continue label expansion kalydeco orkambi launch symdeko pull cf sale quarter kalydeco sale surge follow approval treat expand population orkambi lumacaftor ivacaftor deliver sale year year due higher sale unite state well international market symdeko contribute top line quarter reflect initial week sale call company say symdeko launch be strong start unite state approval eu be expect second half cost riseadjust research development expense increase first quarter due higher cost related phase iii development triple combination cf regimen adjust selling general administrative sg expense increase mainly drive worldwide investment support drug kalydeco orkambi cost incur prepare launch symdeko guidancevertex provide guidance cf revenue range midpoint range represent approximately growth combine adjust research development selling general administrative sg expense guidance be maintain range increase operate expense reflect anticipate cost related pivotal study triple combination regimen investment support launch symdeko company be optimistic operate margin earning expand increase revenue exceed increase cost have estimate be move then turn fresh estimate have trend upward past month have be revision higher current quarter compare lower vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate quotevgm scoresat time vrtx have strong growth score be lag lot momentum front stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable growth investor momentum investor outlookestimate have be broadly trend upward stock magnitude revision look promising notably vrtx have zack rank hold expect line return stock next few month
681,VRTX,most promising exciting healthcare innovation decade be genomic editing technology used crispr technology repair defective genetic material cause disease crispr be acronym cluster regularly interspaced short palindromic repeat crispr research be offshoot human genome project map gene human body arm knowledge genetic material be suppose be structure researcher then endeavore devise way fix be incorrect breakthrough come field bacterium research certain bacterium have develop immune response retain piece dna invade virus reminder then dna be encounter again bacterium use crispr render virus innocuous thousand scientist be currently research way use same mechanism human dna cut defective portion sequence replace correct code many disease be cause genetic factor include alzheimer hemophilia sickle cell disease al many cancer ability identify fix faulty gene make many disease effectively curable research have deliver several method use crispr target genetic defect cause specific disease most promising point used enzyme call cas deliver crispr affected cell company currently have plan do study year human subject used crispr cas address disease crispr therapeutic crsp free report have be best perform stock nearly ytd already radar trader analyst stock get additional boost minute piece technology april favorable response company presentation lynch healthcare conference last week crsp be begin trial crispr cas treatment related genetic blood disorder human thalassemia sickle cell disease approach internally name ctx have have clinical trial application cta grant thalassemia study europe have investigational new drug ind application pending study sickle cell disease crsp potential therapy be still developmental stage company have yet turn profit promising result animal trial joint venture vertex pharmaceutical vrtx free report casebia therapeutic have analyst turn more bullish potential technology day turn potential blockbuster drug crsp be zack rank strong buy also focuse genetic therapy used crispr cas system intellium therapeutic ntla free report recently announce first cell therapy target be acute myeloid leukemia other potential hematological malignancy well solid tumor intellium have diversify strategy select disease target used various type genetic edit used vivo ex vivo delivery insulate company possibility disappointing result specific category intellium have partner regeneron regn free report vivo delivery specifically liver disease novartis nvs free report ex vivo delivery treat various cancer analyst upward revision past day quarterly earning suggest increase optimism future ntla crispr therapy share be versus return genetic therapy industry whole ntla be zack rank hold cambridge base edita medicine inc edit free report be discovery phase company apply crispr csa genetic therapy treatment leber congenital amaurosis degenerative debilitating eye disease result human primate trial be encourage test subject tolerate inject treatment immunity bacterial infection not impact pharmacological activity drug immuno response destroy active property drug be sometimes concern crispr cas therapy edita also have drug pipeline treat cancer muscular dystrophy cystic fibrosis company be bolster strong balance sheet cash equivalent have thus far retain commercial right pipeline program edit be zack rank buy obviously investing development stage company carry significant risk only be small part diversify strategy real home run potential genetic editing be extremely promising sector wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
682,VRTX,biotech space remain key area investor focus several bigwig announce quarterly result alexion alxn free report report solid result gilead gild free report report dismal number other development week regeneron regn free report sanofi announce plan lower price praluent amgen amgn free report receive positive opinion prolium recap important story progress report company alexion gilead vertex vrtx free report other report first quarter result last trading session alexion vertex deliver solid result quarter gilead earning sale miss estimate wider expect decline hcv franchise follow result alexion raise guidance also report positive datum long act complement inhibitor alxn show patient pnh be effectively safely switch treatment soliris week treatment alxn week tentative approval bode well alexion read more alexion earning beat estimate guidance vertex first quarter result be drive stellar performance cf product read more vertex earning beat strong cf product sale gilead be zack rank buy stock see complete list today zack rank strong buy stock here amgen get positive opinion prolium amgen announce committee medicinal product human use chmp european medicine agency ema have adopt positive opinion marketing authorization prolium treatment bone loss associate long term systemic glucocorticoid therapy adult patient increase risk fracture chmp opinion now be review european commission meanwhile company supplemental biologic license application prolium expand indication be also review unite state prescription drug user fee act action date note drug be already approve unite state treatment postmenopausal woman osteoporosis high risk fracture addition chmp have adopt positive opinion recommend label variation kyproli carfilzomib include final overall survival datum phase iii trial aspire demonstrated addition kyproli lenalidomide dexamethasone krd reduce risk death versus lenalidomide dexamethasone alone rd extend os month patient relapse refractory multiple myeloma regeneron partner sanofi cut praluent price regeneron partner sanofi announce company lower net price pcsk inhibitor praluent alirocumab injection more affordable patient access express script consequently praluent become exclusive pcsk inhibitor therapy express script national formulary agreement effective jul provide praluent lower net price enable streamline patient access base physician attestation meanwhile fda have accept priority review company biologic license application cemiplimab treatment patient metastatic cutaneous squamous cell carcinoma cscc patient locally advanced cscc be not candidate surgery candidate be grant breakthrough therapy designation status fda september target action date be oct biogen negotiate agreement neurimmune biogen biib free report neurimmune announce former have exercise option further reduce previously negotiate royalty rate payable potential future sale alzheimer disease candidate aducanumab candidate be currently phase iii result biogen make time payment neurimmune exchange reduction original royalty rate potential commercial sale aducanumab company have earlier announce reduction royalty rate reduce royalty rate potential commercial sale aducanumab be high single digit low teen biogen license worldwide right aducanumab neurimmune biomedical genetic industry yr return medical biomedical genetic industry yr return nasdaq biotechnology index gain last trading session major biotech stock alexion gain last month regeneron lose vertex gain see last biotech stock roundup here biotech stock roundup prta amgn revise view biib miss sale next biotech stay tune more earning regulatory update look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
683,VRTX,biotech industry be expect witness continuation last year favorable trend last year industry benefit number fda approval new product sale ramp success innovation strong clinical study result continue strength legacy product be first time approval innovative game change treatment option noteworthy be approval novartis nvs free report kymriah first cell base gene therapy know car therapy be innovative treatment option cancer be follow car approval kite pharma yescarta spark therapeutic luxturna first gene therapy treat rare inherited form childhood blindness be also approve last year nasdaq biotechnology index gain moreover medical biom genetic industry increase same time frame pricing pressure rise competition pipeline setback slowdown growth mature product generic competition certain key drug be headwind mentioned factor continue contribute sector growth december tax overhaul be sign law slash corporate tax rate boost profit large drug biotech company meanwhile change tax code also allow company bring back huge cash hold overseas time tax rate also tax cut be expect prevent inversion be rampant drug industry change definitely leave more cash hand drug biotech company cash be invest merger acquisition have be few bullish outlook sector look biotech stock have see share price rise more year so far look well position rest stock have witness upward estimate revision have favorable zack rank zack rank strong buy buy plc alk free report be focuse development marketing treatment central nervous system cns disease year be expect be year development pipeline key event line year include fda review alk new drug application nda treatment major depressive disorder phase iii datum readout alk schizophrenia nda filing alk first half be be evaluate treatment multiple sclerosis company also gain fda approval new initiation product aristada aripiprazole lauroxil nanocrystal dispersion treatment schizophrenia jun zack rank stock have see share gain year date compare rally industry belong see complete list today zack rank stock here company have see zack consensus estimate earning be revise upward last day vertex pharmaceutical inc vrtx free report vertexsport zack rank earning share estimate have moved last day company deliver positive earning surprise last quarters average beat share price company have increase year date year be tremendous year vertex positive datum read out regulatory approval lead increase eligible patient population cystic fibrosis cf product kalydeco orkambi trend continue orkambi get eu approval pediatric use consistent expansion patient population vertex cf product revenue increase company be optimistic positive trend cf sale continue additional reimbursement approval orkambi ex market approval launch tezacaftor vx ivacaftor combination medicine vertex cf pipeline be also quite strong broad portfolio next generation cf corrector vertex also make decent clinical progress multiple cf study have meaningful pipeline catalyst investor focus be triple combination cf regimen be crucial long term growth have potential treat cf patient vertex plan initiatepivotal phase iii study triple combination regimen first half inc agen free report agenuscarry zack rank loss estimate company narrow last day share price company have increase year date have form collaboration merck mrk free report incyte develop multiple checkpoint antibody october fda grant marketing authorization glaxosmithkline gsk free report herpes zoster vaccine shingrix contain proprietary immune adjuvant qs stimulon be good news shingrix have blockbuster potential increase sale impact business positively earlier month company announce dilutive royalty financing transaction healthcare royalty partner hcr significantly boost cash position use part proceed redeem royalty bond fund pivotal pipeline program company also announce new leadership appointment enhance team advance ongoing pivotal program ctla pd support plan bla filing second half today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
684,VRTX,vertex pharmaceutical incorporate vrtx free report report first quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter vertex report revenue first quarter beating zack consensus estimate however sale be year year due significantly lower collaborative revenue company have receive upfront payment germany base merck kgaa year period licensing oncology program cf drug sale remain strongvertex first quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi symdeko collaborative royalty revenue cf product revenue be first quarter year year due continuous expansion patient population kalydeco sale surge orkambi lumacaftor ivacaftor deliver sale year year growth be support continue approval expand population uptake globally quarter vertex receive approval third cf drug symdeko unite state drug have contribute top line cost riseadjust research development expense increase first quarter due higher cost related phase iii development triple combination cf regimen adjust selling general administrative sg expense increase mainly drive worldwide investment support treatment cf patient revenue guidancevertex provide guidance revenue primarily drive cf drug sale company expect revenue be range guidance combine adjust research development selling general administrative sg expense be maintain range pipeline regulatory updatesvertex remain focuse develop triple combination regimen treatment cf company have advanced next generation cftr corrector vx vx phase iii stage february fda approve symdeko treatment cf patient age older have copy del mutation have least mutation be responsive symdeko drug be review eu similar indication ongoing phase iii study be evaluate symdeko child age year similar mutation label expansion kalydeco include patient age year be review unite state well europe decision fda be expect august meanwhile vertex be also evaluate drug phase ii study treatment infant month similarly vertex be also seek approval orkambi patient age year regulatory application be review unite state europe decision expect august unite state phase iii study be initiate second half evaluate drug patient age month less month moreover january european commission approve line extension orkambi include use child cf age year have copy del mutation apart cf vertex be also develop treatment sickle cell disease thalassemia influenza pain management first quarter vertex announce positive datum phase ii proof concept study evaluate pain candidate vx acute pain follow bunionectomy surgery other phase ii study be evaluate candidate neuropathic pain pain osteoarthritis knee phase iii study pimodivir combination standard care treatment patient influenza be be conduct collaboration janssen pharmaceutical subsidiary johnson johnson jnj free report takevertex first quarter result reflect strong performance cf product help beat estimate count share rise almost hour trading response strong quarterly result robust increase share price last year vertex share price have increase so far year decrease industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector approval symdeko further strengthen franchise triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be express interest cf vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotezack rank key picksvertex carry zack rank buy couple better top rank stock biotech sector be ligand pharmaceutical lgnd free report protagonist therapeutic ptgx free report company sport zack rank strong buy see complete list today zack rank stock here ligand earning share estimate moved last day company deliver positive earning surprise trail quarters average beat company share have rally year date protagonist therapeutic loss estimate narrow cent last day company deliver positive earning surprise trail quarters average beat look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
685,VRTX,earning season have start gather steam latest earning preview member accounting index have already release financial figure apr total earning member have report result already be same period last year higher revenue beating ep estimate beating revenue estimate proportion company beating ep revenue estimate be ongoing earning phase seem have also begin encouragingly drug biotech sector major large cap player johnson johnson jnj free report kick season strong note beating zack consensus estimate earning well sale large cap player report earning last week be novartis nvs free report also surpass earning revenue expectation quarter also biogen inc biib free report release result week surpass earning miss sale expectation higher demand be expect boost new product sale also innovation successful product line expansion positive clinical study result fda approval consistent performance key product grow demand drug especially rare treat disease agee population well increase healthcare expenditure be factor keep sector growth trajectory also accord earning preview broader medical sector inclusive drug biotech well medical device company be likely record year year growth revenue rise earning quarter review pharma biotech giant be schedule report earning result apr let see thing be shape company upcoming release abbvie inc abbv free report be slate releaseresult market open company deliver positive earning surprise last report quarter moreover company performance have be impressive recent past earning surpass expectation trail quarters average positive earning surprise proven model show abbvie be likely beat earning be report quarter have right combination key ingredient positive earning esp zack rank hold zack consensus estimate company earning quarter review be peg share company key drug humira be likely remain key growth driver first quarter backed strong demand trend drug abbvie expect humira sale reflect rise low teen band imminent earning release internationally growth rate be project mid single digit range operationally other drug namely duopa creon be also likely maintain encourage performance soon be report quarter read more be beat card abbvie earning abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quote alexion alxn free report be slate report result open bell company deliver positive earning surprise last report quarter company track record be excellent have consistently top estimate last quarters average positive earning surprise alexion be likely beat earning be report quarter have positive earning esp zack rank buy zack consensus estimate quarterly earning be peg share see complete list today zack rank strong buy stock here alexion blockbuster drug soliris continue perform well company be work expand soliris label additional indication alexion recently announce acquire sweden base wilson therapeutic transaction be expect close second quarter acquisition add late stage candidate wtx alexion pipeline candidate be currently phase iii treatment wilson disease rare genetic disorder alexion be look diversify portfolio reduce dependence blockbuster drug soliris deal strengthen alexion rare disease pipeline late stage candidate read more be beat store alexion earning season alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quote bristol myer squibb bmy free report be slate report result open bell company deliver positive earning surprise last quarter company deliver positive earning surprise trail quarters average beat model show bristol myer be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share bristol myer blockbuster immuno oncology drug opdivo be expect remain main sale driver first quarter follow several line extension soon be report quarter company announce encourage result phase iii study evaluate opdivo first line small cell lung cancer label expansion leukemia drug sprycel approve november bring more sale drug moreover continue strong performance yervoy orencia have favorable impact read more be beat store bristol myer earning bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quote vertex pharmaceutical incorporate vrtx free report be slate report result market close vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex deliver positive earning surprise model show vertex be likely beat estimate quarter combination bristol myer zack rank positive earning esp make confident earning beat upcoming report consensus mark quarter be report be peg cent share uncover best stock buy sell re report earning esp filter vertex cystic fibrosis cf drug kalydeco orkambi perform well sale rise almost expect positive trend continue soon be report quarter also boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february expect company provide update symdeko plan initial uptake company be also likely provide full year revenue guidance include symdeko sale call read more be beat store vertex earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quote investor alert breakthrough pending medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
686,VRTX,expect vertex pharmaceutical inc vrtx free report beat expectation report first quarter result apr market close vertex share have increase so far year industry have record decrease vertex track record have be impressive so far company deliver positive earning surprise last quarters average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi perform consistently sale rise almost expect positive trend continue soon be report quarter however company announce last quarter earning call first quarter revenue be unfavorably impact higher gross net revenue adjustment buildup channel inventory fourth quarter january vertex announce extension marketing application orkambi be approve europe approval orkambi marketing label eu now include use child cf age year have copy del mutation expand patient population expand patient population be expect boost sale drug zack consensus estimate orkambi sale first quarter be kalydeco receive approval line extension include patient year older certain residual mutation cftr gene drug generate significant sale last year due rapid uptake expand patient population expect trend continue zack consensus estimate first quarter kalydeco sale be peg millionin boost vertex cf franchise fda approve vertex third cf drug symdeko be combination tezacaftor ivacaftor february drug be review europe however expect new drug contribute minimally first quarter sale expect company provide update symdeko plan initial uptake company remain focuse development triple combination regimen quarter vertex advanced vx vx phase iii development also phase iii study be initiate evaluate vx combination tezacaftor kalydeco ivacaftor cf patient investor focus call be triple combination cf regimen be crucial long term growth vertex company be also likely provide full year revenue guidance include symdeko sale call however operate expense be likely be higher side due initiation pivotal study launch symdeko likely positive surprise proven model indicate vertex be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate cent zack consensus estimate cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock considerhere be biotech stock also want consider model show have right combination element post earning beat quarter celgene corporation celg free report be schedule release result company have earning esp zack rank see complete list today zack rank stock here amgen inc amgn free report be schedule release result apr company have earning esp zack rank gilead science inc gild free report be schedule release result company have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
687,VRTX,share concert pharmaceutical inc cnce free report plunge more follow announcement patent trial appeal board ptab patent trademark office have refuse grant company post grant review petition dispute related incyte corporation incy patent however share company have gain past year significantly outperform industry gain period patent protect incyte jak inhibitor ruxolitinib be sell tradename jakafi treat myelofibrosis polycythemia vera concert pharma pipeline candidate ctp be modify version ruxolitinib be be develop treatment alopecia areata alopecia areata be auto immune disease result partial complete hair losson scalp body however company say challenge validity patent future federal court also continue develop ctp separate press release concert pharma announce fda have grant fast track designation ctp treatment moderate severe alopecia areata fda grant fast track designation expedite candidate development faster review treat serious unmet medical condition designation candidate be expect be grant priority review once file new drug application candidate be currently be evaluate phase iia study apart ctp concert pharma be also develop avp treat agitation associate alzheimer disease jzp collaboration jazz pharmaceutical plc jazz free report narcolepsy ctp collaboration celgene corporation celg free report inflammatory disease however asset purchase agreement company sell cystic fibrosis candidate ctp vertex pharmaceutical incorporate vrtx free report july last year zack rankconcert pharma carry zack rank hold see complete list today zack rank strong buy stock here wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
688,VRTX,year have be better expect biotech sector nasdaq biotechnology index be drug pricing issue competition slowdown growth key drug be expect remain hangover well approval new drug strategic acquisition several big wig be likely boost investor sentiment thus needless say hold promise generate stellar return slowdown mature product compel bigwig gilead science gild free report undertake acquisition bolster pipeline gilead acquire erstwhile kite pharma add yescarta kitty company also inked agreement acquire cell design lab gilead currently carry zack rank hold see complete list today zack rank strong buy stock here recently celgene inc celg free report inked deal acquire impact biomedicine upfront amount acquisition add late stage candidate fedratinib highly selective jak kinase inhibitor celgene pipeline candidate be be develop treatment myelofibrosis polycythemia vera celgene be look new deal acquisition give lacklustre have suffer few pipeline setback weakness otezla sale celgene currently carry zack rank acquisition merger keep investor focuse space addition new drug approval label expansion exist drug boost top line prominent biotech company amgen inc amgn free report look poise growth several blockbuster drug portfolio amgen new drug prolium xgeva vectibix nplate sensipar be perform well company recently win fda approval supplemental biologic license application sbla xvega expand drug label treatment multiple myeloma amgen carry zack rank exelixis inc exel free report be biotech look poise growth recent fda approval label expansion lead drug cabometyx treatment previously untreated advanced renal cell carcinoma be expect drive growth drug have perform impressively approval exelixis currently carry zack rank alexion pharmaceutical inc alxn free report blockbuster drug soliris continue perform well fda approval drug generalized myasthenia gravis further boost sale new product strensiq be gain momentum company redefine strategy kanuma alexion carry zack rank investor also keep eye key upcoming pdufa date regeneron pharmaceutical inc regn free report be look expand label newly approve drug dupixent drug be already approve treatment adult moderate severe atopic dermatitis company be also evaluate drug treat asthma adult liberty asthma quest study sbla same be expect be file shortly regeneron be work expand lead ophthalmology drug eylea label additional indication fda have accept review company sbla label expansion eylea injection company be seek approval week dose interval eylea injection patient wet age related macular degeneration wet amd base physician assessment action date set fda be aug regeneron carry zack rank big biotech vertex pharmaceutical incorporate vrtx free report be take measure strengthen already dominant position cystic fibrosis market cf vertex have cf drug kalydeco orkambi portfolio blockbuster potential company have develop cf corrector tezacaftor vx combination ivacaftor regulatory application be review unite state pdufa date feb eu potential approval further bolster demand vertex currently carry zack rank medical biomedical genetic industry yr return medical biomedical genetic industry yr threat biosimilar loom large key drug most company expect investor remain focus dynamic sector eye new drug approval important datum read out wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
689,VRTX,investor be always look stock be poise beat earning season vertex pharmaceutical incorporate vrtx free report be such company firm have earning come pretty soon event be shape quite nicely report be vertex pharmaceutical be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface vrtx report fact most accurate estimate current quarter be currently cent share vrtx compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate vrtx give stock zack earning esp head earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give vrtx have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead vertex pharmaceutical beat be card upcoming report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
690,VRTX,current year begin widespread optimism predict significant increase drug biotech merger acquisition activity mainly buoy new tax law enact december purchasing newer technology tax reform have lower tax rate provide low tax window bring back huge cash stash overseas certainly improve cash position company fuel activity struggle organic growth quarter year already go have see quite few dollar buyout deal be inked instance celgene corporation acquire juno therapeutic add car therapy pipeline approximately moreover company be process complete acquisition impact biomedicine upfront amount also sanofi bid strengthen blood disorder pipeline purchase bioverativ even offer buy belgian biotech company ablynx additionally pfizer be aggressively lookout buyer consumer healthcare unit british firm glaxo reckitt benckiser group withdraw discussion however glaxo announce acquisition novartis nvs free report stake healthcare joint venture meanwhile late last month takeda also confirm intention integrate dublin base shire portfolio boost core therapeutic area moreover week bore news couple more deal brief description deal be follow novartis buy avexisnovartis inked deal acquire base clinical stage gene therapy company avexis inc boost presence gene therapy neuroscience space avexis lead gene therapy candidate avxs be be develop treat spinal muscular atrophy sma disease accounting highest genetic cause death infant only approve treatment sma be biogen spinraza agreement novartis close acquisition cash deal company propose cash tender offer share avexis common stock deal be expect culminate second half read more novartis inks gene therapy deal buy avexis alexion wilson dealalexion pharmaceutical inc alxn free report announce consolidate sweden base wilson therapeutic portfolio add late stage candidate pipeline treatment wilson disease rare genetic disorder acquisition be line company strategy diversify portfolio lower dependence blockbuster drug soliris alexion have offer swedish krona cash outstanding share wilson therapeutic translate total transaction value buyout be expect get wrapped quarter read more alexion acquire wilson therapeutic article suggest drug biotech company logical acquisition target year parameter count buy drug biotech stock be current sale performance drug product prospect future sale growth quality company pipeline takeover small cap drug biotech company be very difficult forecast be quite frequent say space hence have be exclude discussion agio pharmaceutical inc agio free report agio pharmaceutical share price be witness rally week speculation company be buy other big player pharma biotech industry company receive fda approval idhifa enasidenib august treatment acute myeloid leukemia aml idh mutation lend huge boost immense commercial potential target market agio ivosidenib be review unite state therapy relapse refractory aml idh mutation candidate be also be develop address advanced hematologic malignancy agio pipeline also include mid stage genetic disease candidate consistent progress investigational candidate make company most lucrative takeover option other large player drug biotech space moment read more agio pharmaceutical share rise buyout speculation agio carry zack rank hold see complete list today zack rank stock here biomarin pharmaceutical inc bmrn free report company product pipeline portfolio comprise rare disease drug be great demand be less competition concern space expensive treatment garner huge profit biomarin be such drug developer market cap biomarin key orphan disease drug vimizim kuvan be do well backed strong underlie patient demand trend also orphan drug brineura earlier expect approval year treatment child cln disease be likely be huge boost biomarin potential approval pegvaliase be expect next month biomarin have already be target takeover speculation company gilead amgen roche be interested buy biomarin biomarin carry zack rank vertex pharmaceutical inc vrtx free report vertex consistent expansion patient population raise revenue quarter quarter moreover approval third cystic fibrosis cf drug symdeko tezacaftor ivacaftor combination further drive company sale company be hopeful positive trend cf sale continue gain additional reimbursement approval orkambi ex company be focuse triple combination therapy treat cf further expand patient population market cap vertex be more vertex carry zack rank incyte corporation incy free report incyte strong oncology portfolio make attractive pick company namely gilead amgen bristol myer incyte market cap be also primary reason incyte be ready buyout be encourage performance market product such jakafi iclusig jakafi be see strong sale performance drive solid patient demand approve indication company be also work further label expansion meanwhile incyte pipeline boast candidate immune therapy epacadostat be be study combination other drug cure cancer rheumatoid arthritis incyte carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
691,VRTX,proteostasis therapeutic inc pti free report share surge more dec announcement positive result study evaluate cystic fibrosis cf pipeline candidate candidate include pti cystic fibrosis transmembrane conductance regulator cftr amplifier pti cftr corrector pti cftr potentiator pti pti be evaluate patient be background therapy vertex pharmaceutical incorporate vrtx free report orkambi share company be past month outperform industry decline period most advanced candidate pti be evaluate phase ii study cf patient background orkambi therapy datum show addition pti orkambi have mean absolute improvement ppfev measure lung function used disease baseline compare placebo also show mean relative improvement datum demonstrate pti amplify effect orkambi respond patient ppfev baseline dose range phase study evaluate pti show mean improvement ppfev approximately baseline moreover phase study evaluate pti show candidate be well tolerate patient population proteostasis be also evaluate combination pti pti pti cf patient early stage study preliminary analysis show combination be well tolerate patient have potential be develop once daily dose proteostasis therapeutic inc price proteostasis therapeutic inc price proteostasis therapeutic inc quotezack rank stock carry zack rank hold couple better rank stock pharma sector include acadium pharmaceutical inc acad free report therapeutic inc cort free report stock carry zack rank buy see complete list today zack rank strong buy stock here acadium loss estimate narrow last day company come positive earning surprise trail quarters average beat company share have return so far year earning share estimate have increase cent cent last day company deliver positive earning surprise trail quarters average beat company stock be so far year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
692,VRTX,make debut smart beta exchange trade fund powershare dynamic biotechnology genome portfolio pbe free report provide investor broad exposure health care etfs category equity market be smart beta etfs market cap weight index be create reflect market specific segment market etf industry have traditionally be dominate product base strategy investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way be investor rather invest smart beta fund fund track cap weight strategy be strong option prefer choose great stock order beat market index attempt select stock have better chance risk return performance base certain fundamental characteristic combination such characteristic even space provide many choice investor think simplest methodology equal weighting more complicate one fundamental volatility momentum base weighting not have be able deliver first rate result fund sponsor indexpbe be manage invesco powershare fund have amassed make average size etfs health care etfs pbe fee expense seek match performance dynamic biotechnology genome intellidex index be comprise stock biotechnology genome company be company be principally engage research development manufacture marketing distribution various product service process company benefit significantly scientific technological advance biotechnology genetic engineering research cost other expenseswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive cousin long term other factor remain equal operate expense annual basis be pbe make par most peer product space fund have month trail dividend yield sector exposure top holdingseven etfs offer diversify exposure minimize single stock risk be still important look fund holding investing luckily most etfs be very transparent product disclose holding daily basis etf have heaviest allocation healthcare sector portfolio look individual holding illumina inc ilmn free report account fund total asset follow vertex pharmaceutical inc vrtx free report regeneron pharmaceutical inc regn free report top holding account approximately pbe total asset management performance etf have add roughly so far year be last year past week period have trade etf have beta standard deviation trail year period make high choice space holding have more concentrated exposure peer dynamic biotechnology genome portfolio be excellent option investor seek outperform health care etfs segment market be other etfs space investor consider well spdr biotech etf xbi free report track biotechnology select industry index ishare nasdaq biotechnology etf ibb free report track nasdaq biotechnology index spdr biotech etf have asset ishare nasdaq biotechnology etf have xbi have expense ratio ibb charge investor look cheaper lower risk option consider traditional market cap weight etfs aim match return health care etfs bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
693,VRTX,last year turn be pretty good pharma biotech stock far fda decision be concern regulatory body approve novel drug easily surpass total tally landmark decision last year include approval couple gene base therapy cancer novartis nvs free report kymriah gilead science gild free report yescarta therapy have potential change way look cancer treatment just quarter go year fda have already grant approval new treatment key approval include jnj free report next generation oral androgen receptor ar inhibitor erleada apalutamide pre metastatic prostate cancer crpc vertex pharmaceutical incorporate vrtx free report third medicine treat underlie cause cf symdeko be combination tezacaftor ivacaftor gilead once daily single tablet hiv regimen biktarvy novartis lutathera certain neuroendocrine tumor drug development process be lengthy time consume require utilization lot fund resource key pipeline event include datum readout regulatory update be paramount importance act major catalyst let take look few important regulatory event schedule month april note month fda have already approve pacira pharmaceutical exparel new indication nerve block regional analgesia clovis oncology parp inhibitor rubraca maintenance therapy recurrent ovarian cancer second indication novartis kymriah apr fda be expect give decision novartis supplemental biologic license application bla look approval kymriah second indication latest filing novartis be look get kymriah approve treatment adult patient relapse refractory diffuse large cell lymphoma dlblc most common form hodgkin lymphoma have fail more prior therapy kymriah be approve treatment deadly cancer call acute lymphoblastic leukemia last august accord company annual report dlblc patient do not respond initial therapy relapse month treatment indicate significant market potential kymriah dlblc indication fda decision mallinckrodt label expansion amitiza child mallinckrodt plc mnk free report supplemental new drug application snda look get constipation drug amitiza approve paediatric functional constipation year be review fda be expect give decision apr amtiza be add mallinckrodt portfolio february acquisition sucampo pharmaceutical amitiza be already approve chronic idiopathic constipation cic adult irritable bowel syndrome constipation ib adult woman opioid induced constipation oic patient chronic cancer pain accord company press release amitiza approve paediatric functional constipation be first only prescription medication specifically approve such patient have limit treatment option address disease fda panel back gw pharmaceutical epidiolex incyte lilly olumiant fda panel be expect give opinion gw pharmaceutical lead cannabinoid pipeline candidate epidiolex next week gw pharmaceutical be look get epidiolex approve adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy fda grant priority review epidiolex nda response fda be expect jun epidiolex represent blockbuster potential especially be approve possible indication fda panel be also expect give opinion month incyte lilly lly free report olumiant baricitinib treatment adult patient moderately severely active rheumatoid arthritis april company have receive complete response letter crl fda baricitinib fda require additional clinical datum thenda olumiant be re submit january olumiant have already be launch select european country japan fetch sale fda take recommendation panel advisory committe account review application be not bound follow same fda decision rigel tavalisse ultragenyx burosumab april fda be expect give decision rigel pharmaceutical nda tavalisse fostamatinib treatment chronic immune itp apr rigel be prepare launch oral spleen tyrosine kinase syk inhibitor second quarter approve exist therapy treat chronic itp include steroid blood platelet production booster tpos splenectomy however still disease remain inadequately treat many patient mean approve tavalisse enjoy significant market potential fda decision expect apr be ultragenyx pharmaceutical bla burosumab treat pediatric adult patient link xlh burosumab be approve treat xlh trade name crysvita eu february fda decide prometic ryplazim fda decision expect apr be canadian biotech prometic life science biologic license application bla ryplazim treatment congenital plasminogen deficiency ryplazim enjoy orphan drug fast track designation fda say indication bristol myer opdivo yervoy combo get fda approval bristol myer bmy free report have file sbla look get blockbuster drug opdivo approve combination cancer drug yervoy patient previously untreated advanced metastatic renal cell carcinoma rcc fda decision be expect apr clinical study combination have demonstrated superior overall survival os compare current standard care sunitinib intermediate poor risk patient bode well drug give potential target market pd inhibitor be presently approve several country include unite state eu japan several cancer indication label expansion boost opdivo sale further opdivo generate sale almost bristol myer be zack rank hold stock see complete list today zack rank strong buy stock here look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
694,VRTX,vertex pharmaceutical inc vrtx free report announce european commission have approve extension marketing application cystic fibrosis product orkambi approval orkambi marketing label eu now include use child cf age year have copy del mutation label expansion approval eu be base positive datum asix month phase iii efficacy study patient population datum study present november demonstrated treatment orkambi lead statistically significant improvement absolute change lung clearance index measure lung function early cf disease compare placebo week treatment approval age group expand target patient population patient ireland vertex already have reimbursement agreement use child other country country country reimbursement process now be initiate vertex please note unite state orkambi be already market patient population september year be tremendous vertex positive datum read out regulatory approval lead increase eligible patient population kalydeco orkambi consistent expansion patient population vertex cf product revenue increase latest label expansion approval eu look trend continue company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine stock have surge past year substantially outperform increase register industry estimate have also moved northward past day vertex cf pipeline be also quite strong broad portfolio next generation cf corrector vertex also make decent clinical progress multiple cf study have meaningful pipeline catalyst investor focus be triple combination cf regimen be crucial long term growth have potential treat cf patient vertex plan initiatepivotal phase iii study triple combination regimen first half vertex sport zack rank strong buy other biotech stock worth consider be exelixis inc exel free report xoma corporation xoma free report paratek pharmaceutical inc prtk free report exelixis have same rank vertex xoma paratek carry zack rank buy see complete list today zack rank stock here exelixis earning estimate have go last day share price company have soar past year xoma loss estimate have narrow cent cent last day share price company have sky-rocket past year paratek loss estimate have narrow last day share have rise past year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
695,VRTX,week focus be annual morgan healthcare conference several biotech pharma company provide preliminary look result have also provide pipeline update well outlook meanwhile celgene celg free report be news company announce intention acquire impact biomedicine recap week most important storiescelgene buy impact celgene have start year acquisition announcement company be acquire impact biomedicine be develop fedratinib myelofibrosis polycythemia vera deal term include upfront payment approximately contingent payment base achievement regulatory approval milestone myelofibrosis celgene make additional payment base approval label expansion achievement sale base milestone plan be submit new drug application fda mid celgene be look boost pipeline acquisition company have rough share decline last year issue pipeline setback well weak performance otezla have be weigh stock read more celgene acquire impact biomedicine boost pipeline key takeaway morgan healthcare conference several biotech company be present annual morgan healthcare conference most company provide preliminary look fourth quarter result outlook key update acorda acor free report start face generic competition flagship drug ampyra time jul company be currently seek fda approval inbrija response be february read more acorda share disappointing ampyra view vertex vrtx free report hold strong position cystic fibrosis cf market be look strengthen position further potential approval tezacaftor ivacaftor unite state decision fda be expect feb vertex also be company pursue acquisition deal year celgene also provide preliminary result outlook read more celgene provide preliminary result view vertex be zack rank strong buy stock see complete list today zack rank stock here axovant plunge intepirdine discontinuation axovant science axon free report share lose more value company announce disappointing result lead pipeline candidate intepirdine candidate fail meet primary efficacy endpoint study be conduct patient dementia lewy body dlb patient dementia gait impairment base axovant have decide discontinue development intepirdine be not first time axovant have face setback development effort intepirdine last year september company have say intepirdine fail meet co primary efficacy endpoint late stage study be conduct mild moderate alzheimer disease ad patient be receive background donepezil therapy time too company share have plunge significantly axovant share be last year compare decline record industry belong regeneron sanofi boost investment dupixent cemiplimab regeneron pharmaceutical regn free report partner sanofi have decide boost investment development cemiplimab pd antibody oncology dupixent il il pathway block antibody type allergic disease base decision investment cemiplimab shoot least increase approximately initial agreement company contribute equally cemiplimab be be study monotherapy well combination other therapy wide range cancer include advanced skin cancer small cell lung cancer cervical cancer lymphomas regulatory application cemiplimab advanced cutaneous squamous cell carcinoma be schedule be submit european union unite state first quarter meanwhile dupixent currently approve eczema have potential be evaluate additional indication include chronic obstructive pulmonary disease peanut allergy grass allergy patient have multiple allergic condition be addition ongoing development pediatric atopic dermatitis pediatric asthma eosinophilic esophagitis nasal polyposis regeneron sanofi be currently seek fda approval dupixent uncontrolled persistent asthma patient least year old candidate benefit additional investment be regn il antibody potential indication include atopic dermatitis asthma chronic obstructive pulmonary disease abbvie eczema drug get btd abbvie abbv free report investigational once daily oral jak selective inhibitor upadacitinib have be grant breakthrough therapy designation btd fda use adult patient moderate severe atopic dermatitis be candidate systemic therapy breakthrough therapy designation help fasten development review drug be be evaluate treatment serious condition preliminary clinical evidence indicate drug be substantially better exist treatment clinically significant endpoint upadacitinib be schedule move late stage program atopic dermatitis first half year read more abbvie upadacitinib gain breakthrough therapy designation biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron decline gilead gild free report gain last month biogen be regeneron lose see last biotech stock roundup here gwph submit epidiolex eu sangamo inks deal pfizer next biotech world watch usual regulatory pipeline update well preliminary result announcement outlook ahead release fourth quarter result look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
696,VRTX,earning season pharma biotech sector be scatter few small biotech company yet report release so far provide clear picture sector performance overall sector perform reasonably well biotech pharma bigwig gilead gild free report celgene celg free report vertex vrtx free report beat earning revenue estimate meanwhile biogen biib free report announce mixed result earning beating estimate sale lag same however amgen amgn free report have rather weak quarter miss expectation earning sale also issue lower expect sale guidance drug biotech stock remain growth trajectory ramp new product sale successful innovation product line expansion favorable clinical study result frequent fda approval strong performance key product grow demand drug especially rare treat disease age population increase health care spending be factor keep drive sector faster drug approval process propose removal outdated regulation push cost slowdown innovation also prove beneficial year start expectation pick activity new tax law cut corporate tax rate encourage company bring back huge cash hold overseas time tax rate be expect spur merger activity year sanofi sny free report earlier year announce deal buy belgian biotech company ablynx haemophilium focuse biotech firm bioverativ banking positive trend impressive performance be perfect time cash bountiful prospect grow market here have picked biotech stock see positive estimate revision post earning release also flaunt zack rank strong buy buy see complete list today zack rank stock here earning estimate revision have greatest impact stock price stock rise estimate have significantly outperformed index year year hence investor safely bet stock have be see upward movement earning estimate company have also see steady rally share price post result ligand pharmaceutical incorporate lgnd free report san diego base biotechnology company ligand carry zack rank stock witness positive estimate revision last day company release fourth quarter earning feb have see zack consensus estimate earning rise company surpass earning revenue estimate fourth quarter mainly higher royalty revenue additionally share company have rally post earning release regeneron pharmaceutical inc regn free report tarrytown ny base company regeneron witness positive estimate revision last day company release fourth quarter earning feb zack rank stock have see zack consensus estimate earning rise respectively regeneron fourth quarter result be impressive earning sale beat estimate strong sale company key market drug eylea share company have rally release earning release horizon pharma plc hznp free report base dublin ireland horizon pharma carry zack rank company have see zack consensus estimate earning move last day company release fourth quarter earning feb share company have gain post earning announcement horizon pharma also beat earning sale estimate fourth quarter backed strong performance orphan unit company sale guidance be encourage well outlookwhile be strong year be expect be vital biotech sector company continue invest pipeline build global business drive new product growth zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
697,VRTX,car stock be news week key biotech player gilead science gild free report announce intention acquire kite pharma most advanced player car therapy market moreover fda approve novartis kymriah yesterday make first car therapy gain approval recap week most important storiesgilead look boost oncology pipeline kite deal gilead have finally announce deal company say acquire kite pharma share cash approximately gilead have be lot pressure utilize huge pile cash major acquisition deal give dwindle sale erstwhile top selling hepatitis virus hcv franchise kite acquisition slate close fourth quarter place gilead top player emerge field cell therapy kite expertise lie develop engineer cell therapy express chimeric antigen receptor car engineer cell receptor tcr depend type cancer kite already have car therapy axicabtagene ciloleucel axi cel priority fda review response expect nov eu approval come next year axi cel be review treatment refractory aggressive hodgkin lymphoma nhl include diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl other candidate kite pipeline include target hematologic cancer well solid tumor also read gilead fly high kite pharma acquisition axi cel have blockbuster potential novartis be currently first company gain approval car treatment fda approve company kymriah kite share be follow acquisition news year date stock have gain substantially outperform rally industry belong kite gilead deal be announce other company involved car treatment see share shooting hope more deal be announce segment market juno shot bluebird bio be gilead be zack rank buy stock see complete list today zack rank strong buy stock here incyte baricitinib regulatory update incyte incy free report partner eli lilly company provide update regard resubmission regulatory application experimental rheumatoid arthritis ra treatment baricitinib company have previously say expect delay least month resubmission regulatory application baricitinib announce be resubmit regulatory application jan new safety efficacy datum be include resubmission investor react positively news send incyte share medicine co vabomere get fda nod medicine company mdco free report get boost accelerate approval vabomere treatment adult patient complicate urinary tract infection include pyelonephritis drug address pathogen designate center disease control cdc urgent serious antimicrobial resistance threat pathogen cite world health organization critical need new antibiotic vabomere enjoy additional year exclusivity give status qualify infectious disease product qidp generate antibiotic incentive now gain act medicine company intend launch vabomere fourth quarter priority review biomarin drug biomarin pharmaceutical bmrn free report pegvaliase get priority review reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management mean response agency regard approval status pegvaliase be feb however fda ask company submit additional chemistry manufacturing control cmc information biomarin say expect review period be extend additional month also read biomarin pegvaliase bla grant priority review fda acorda inbrija regulatory update acorda therapeutic acor free report see share fall news fda have issue refusal file rtf letter inbrija agency have raise question rtf regard date manufacturing site be ready inspection other regard submission drug master production record fda have also ask additional information resubmission have not ask additional efficacy safety study acorda intend meet fda discuss rtf acorda be look get inbrija approve treatment symptom period person parkinson disease take carbidopa levodopa regimen company need add new product market product portfolio consider flagship drug ampyra be likely face generic competition post jul biomedical genetic industry yr return medical biomedical genetic industry yr returnit be good week biotech stock nasdaq biotechnology index gain last trading session major biotech stock gilead be biogen be alzheimer disease datum also read biogen alzheimer drug show promise long term study last month vertex vrtx free report be amgen slip see last biotech stock roundup here eu label expansion alexion biib face drug price probe next biotech world watch usual regulatory pipeline update simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
698,VRTX,month have go last earning report vertex pharmaceutical incorporate vrtx free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst vertex earning sale top strong cf salesvertex report second quarter adjust earning share cent beat zack consensus estimate cent meanwhile earning rise year year strong product revenue lead higher profit quarter vertex report revenue second quarter year year drive strong product revenue revenue also beat zack consensus estimate cf franchise sale strongvertex second quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be second quarter year year kalydeco sale rise gain inventory stocking ahead jul holiday orkambi lumacaftor ivacaftor deliver sale year year sequential basis orkambi sale rise almost second quarter support continue uptake globally further uptake pediatric indication approval be receive sep meanwhile pharmacy order approximately ahead jul holiday also benefit sale second quarter inventory stocking seasonal summer slowdown hurt revenue third quarter cost riseadjust include stock base compensation expense research development expense increase second quarter due higher cost related development triple combination cf regimen adjust include stock base compensation expense selling general administrative sg expense increase due increase investment support global launch orkambi maintain guidancevertex maintain guidance orkambi kalydeco sale raise guidance combine operate cost orkambi revenue be expect range kalydeco revenue be estimate range total cf product revenue be expect range management continue believe orkambi sale growth be dependent reimbursement discussion europe june july year vertex strike re imbursement agreement ireland italy respectively orkambi meanwhile reimbursement discussion be ongoing other country include france netherlands unite kingdom specifically company have mentioned gain reimbursement france year contribute significantly revenue growth combine adjust research development selling general administrative sg expense be anticipate range higher expect previously cost be expect be higher due accelerate development triple combination cf pipeline investment develop ctp have estimate be move then turn fresh estimate have trend upward past month have be revision higher current quarter vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate quotevgm scoresat time stock have great growth score be lag lot momentum front stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely growth base style score outlookestimate have be trend upward stock magnitude revision also look promising notably stock have zack rank hold be look inline return stock next few month
699,VRTX,vertex pharmaceutical incorporate vrtx free report announce regulatory application tezacaftor ivacaftor kalydeco combination have be accept fda european medicine agency ema review regulatory application have be file seek approval kalydeco combination tezacaftor vx treatment cystic fibrosis cf patient older copy del mutation note kalydeco be already approve treatment patient year cf have mutation cystic fibrosis transmembrane conductance regulator cftr gene meanwhile application have be grant priority review fda expect give decision feb share vertex be thursday fact vertex share price be massive so far year compare favorably increase industry come back latest news regulatory application eu be submit basis positive outcome phase iii study evolve expand datum study be announce march year study meet primary endpoint demonstrated statistically significant improvement lung function patient cf combination have also be grant orphan drug designation fda company press release approximately person north america europe australia suffer cf fact more person age year older have copy del mutation more person age have mutation hence approval drug provide company access huge base patient affected disease bring closer goal serve person disease fact vertex cf pipeline be quite strong broad portfolio next generation cf corrector vertex be evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study conduct cf patient have del mutation minimal function mutation del min be present july datum demonstrated combination lead pronounce improvement lung function fact be first datum show potential treat underlie cause cf patient have severe difficult treat type disease follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient cf future vertex carry zack rank hold stock considerbetter rank biotech stock include alexion pharmaceutical inc alxn free report ligand pharmaceutical incorporate lgnd free report regeneron pharmaceutical inc regn free report zack rank strong buy see complete list today zack rank stock here share alexion be year date estimate have rise past day share ligand have rise so far year estimate have rise respectively past day regeneron share year so far estimate have rise have go past day surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
700,VRTX,amgen inc amgn free report announce fda have approve supplemental biologic license application sbla expand label key drug xgeva xgeva be currently approve prevention skeletal related event sre solid tumor patient bone metastase latest fda approval label xgeva be expand include patient multiple myeloma fda decision come earlier pdufa date feb similar regulatory application be also review eu past year amgen share have return contrast decrease register industry fda approval be base safety efficacy pivotal phase iii study enrolled patient head head study compare xgeva novartis ag nvs free report zometa zoledronic acid meet primary endpoint inferiority drug delay time first study sre patient multiple myeloma bone complication patient multiple myeloma be quite damage now bisphosphonate be only treatment option available bone protection multiple myeloma patient however bisphosphonate cause renal toxicity lead renal impairment xgeva be not clear kidney offer better treatment option such patient xgeva be key revenue driver amgen generate revenue first month year year expect approval expand patient population help further boost sale drug amgen carry zack rank hold better rank biotech stock be vertex pharmaceutical inc vrtx free report exelixis inc exel free report zack rank strong buy see complete list today zack rank stock here vertex stock have return past year earning estimate have go almost past day earning estimate exelixis have moved north past day stock price have increase past year medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
701,VRTX,week focus be datum present annual conference american society hematology ash december company emerge winner other lose ground disappointing datum recap week most important storiesash roundup several company be ash datum approve pipeline drug company soar datum other be hit disappointing result company score be bluebird blue free report partner celgene celg free report announce update result ongoing phase study bb bcma car cell therapy patient late stage relapse refractory multiple myeloma company say overall response rate orr be patient active dose cohort complete response cr rate observed patient active dose cohort bluebird share shot celgene gain read more bluebird share jump strong datum car therapy bluebird be zack rank hold stock see complete list today zack rank strong buy stock here kite gilead gild free report company be also ash update result ongoing phase ii zuma study kte car cell therapy treatment adult patient relapse refractory acute lymphoblastic leukemia high rate response be observed patient kte achieve complete tumor remission long term datum be also present yescarta pivotal zuma study patient refractory large cell lymphoma patient continue respond therapy include complete remission median follow month yescarta be approve unite state recently be currently review eu potential approval expect first half read more gilead post update datum car therapy yescarta juno therapeutic major name car category provide additional datum transcend study jcar patient relapse refractory aggressive cell hodgkin lymphoma datum look good share decline reflect investor expectation better result company expect finish submit regulatory application unite state second half approval expect early end read more juno report additional datum car therapy share drop company be hit ash datum be spark therapeutic once free report see share plunge preliminary datum investigational hemophilia treatment spk read more spark therapeutic stock plunge hemophilia therapy datum gilead buy cell design lab strengthen cellular therapy effort gilead announce next acquisition deal come few month company acquire kite pharma approximately time round gilead be acquire cell design lab inc deal expect add new technology platform gilead portfolio gilead shell include upfront payment approximately additional payment be make occurrence certain event include achievement development approval milestone acquisition gilead be look enhance effort cellular therapy read more gilead science acquire cell design lab vertex select first gene edit treatment crispr collaboration vertex pharmaceutical vrtx free report announce selection ctx first gene edit treatment be co develop co commercialize agreement crispr therapeutic company split cost profit worldwide plan be commence phase ii study europe thalassemia investigational new drug ind application be submit unite state support commencement phase ii study sickle cell disease meanwhile cystic fibrosis cf front vertex say kalydeco meet primary endpoint open label phase iii study child year age cf vertex expect file approval unite state eu patient population first quarter read more vertex kalydeco study successful child age year vertex share be year date compare gain record industry belong repro be acquire allergan repro therapeutic see share gain news be acquire allergan cash payment cent share acquisition be expect close first quarter acquisition allergan be look boost woman health pipeline however repro proellex run trouble program be place partial clinical hold fda ask large pre approval safety datum base support future development biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock celgene gain amgen decline last month biogen be regeneron regn free report lose see last biotech stock roundup here fda nod amgen pcsk inhibitor revance rt datum next biotech world watch usual pipeline regulatory update make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
702,VRTX,biotech stock amgen amgn free report intercept pharmaceutical icpt free report be news amgen provide update impact hurricane marium intercept continue be impact ocaliva safety concern recap week most important storiesamgen maintain outlook amgen provide update impact hurricane marium impact company manufacturing facility puerto rico maintain outlook company say product process inventory be lose company have enough stock meet patient demand time release second quarter result amgen have guide earning share total revenue ocaliva safety issue continue hit intercept intercept continue be impact safety issue surround sole market product ocaliva company share be initially hit dear doctor letter earlier month see share fall almost drug safety communication issue fda last week communication layer emphasis importance use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva be approve use primary biliary cholangitis pbc patient company be work fda ensure appropriate safe use ocaliva ocaliva approve bring sale second quarter intercept share be year date compare industry rally infinity bristol myer clinical trial collaboration expand infinity pharmaceutical infi free report exist clinical collaboration bristol myer squibb ipi pi gamma inhibitor opdivo pd immune checkpoint inhibitor have be expand include patient triple negative breast cancer tnbc have not be previously expose pd pd therapy ipi be currently phase ib study patient advanced solid tumor abbvie bristol myer clinical trial collaboration abbvie abbv free report be collaborate bristol myer squibb evaluate combination abbvie investigational antibody drug conjugate abbv bristol myer immunotherapy opdivo meet overexpressing small cell lung cancer nsclc phase ib study be ongoing cancer remain challenge medical condition several company be enter clinical trial collaboration evaluate different combination address disease abbvie be zack rank hold stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock gilead gild free report be vertex lose last month vertex vrtx free report be see last biotech stock roundup here fda nod first cancer biosimilar halo deal raise outlook next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
703,VRTX,key development week be fda approval first cancer biosimilar amgen amgn free report allergan mvasi biosimilar version roche blockbuster cancer drug avastin other update include important datum presentation company nabriva therapeutic nbrv free report abbvie abbv free report recap week most important storiesfirst cancer biosimilar get fda nod fda approve amgen allergan mvasi biosimilar version roche blockbuster cancer drug avastin bevacizumab mvasi be used eligible indication reference product approval be line expectation consider favorable vote biosimilar get fda advisory panel recently approval be quite boost company well effort lower drug price so far biosimilar be yet make significant dent reference product sale unite state mvasi be review eu read more amgen allergan avastin biosimilar secure fda approval nabriva positive antibiotic datum nabriva get major boost company post positive top line result oral lefamulin patient community acquire bacterial pneumonia cabp lead cause infectious death unite state leap study first pivotal late stage study be conduct lefamulin meet fda primary endpoint inferiority compare moxifloxacin adjunctive linezolid early clinical response european medicine agency ema criterium be also meet nabriva be look position lefamulin first line empiric monotherapy second pivotal study be currently enrolling topline result expect next year spring positive result allow company file fda approval second half nabriva have gain year date significantly outperform industry rally read more nabriva lefamulin positive pivotal study stock surge fda advisory panel meeting biomarin drug biomarin pharmaceutical bmrn free report know strong presence market serious life threaten rare disorder say fda be not look hold advisory panel meeting company biologic license application bla pegvaliase biomarin be look get pegvaliase approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management pegvaliase be currently priority review response fda expect feb however well be push month agency have ask biomarin additional chemistry manufacturing control cmc information read more biomarin say fda not plan adcom pegvaliase bla tesaro zejula step closer eu nod cancer focuse tesaro tsro free report get good news ema committee medicinal product human use chmp issue positive opinion zejula niraparib monotherapy maintenance treatment adult patient platinum sensitive relapse high grade serous epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy give positive opinion chance gain eu approval look high approval make zejula first oral once daily parp inhibitor europe use patient regardless brca mutation biomarker status zejula be already approve unite state read more tesaro ovarian cancer drug zejula get positive chmp opinion abbvie roche cancer drug positive late stage study abbvie partner roche be look expand label cancer therapy venclexta venclyxto result late stage study murano help effort venclexta rituxan meet primary endpoint prolong progression free survival compare treanda bendamustine rituxan patient relapse refractory chronic lymphocytic leukemia cll murano study independent datum monitoring committee have recommend unblind study base positive result label expansion indication expand patient population venclexta significantly boost commercial potential read more roche announce positive datum leukemia drug halozyme sign deal raise view halozyme therapeutic halo free report share shot company announce deal roche bristol myer squibb enhanze drug delivery technology raise outlook year roche agreement halozyme stand receive upfront achievement specify development regulatory sale base milestone company also receive tiered mid single digit royalty sale commercialize product bristol myer deal see company get upfront future milestone royalty payment base licensing deal halozyme up revenue guidance expect exit year cash balance more previous guidance read more bristol myer collaborate halozyme enhanze halozyme be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock celgene be biogen lose last month vertex vrtx free report be see last biotech stock roundup here alexion cut job streamline operation kura cancer datum next biotech world watch usual regulatory pipeline update more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
704,VRTX,key highlight week include fda refusal file letter celgene corp celg free report ozanimod gilead science inc gild free report collaboration sangamo therapeutic inc used latter technology positive chmp opinion amgen inc amgn free report xgeva incyte corp incy free report beat revenue strong jakafi sale fourth quarter recap week most important storiesfda refuse ozanimod nda follow announcement receipt refusal file letter fda regard new drug application nda multiple sclerosis candidate ozanimod share celgene be pre market trading candidate be be develop treatment patient relapse form multiple sclerosis however fda determine nonclinical clinical pharmacology section nda be inadequate allow complete review hence celgene request type meeting fda ascertain additional information need resubmission nda news come great disappointment investor celgene be take desperate attempt bolster portfolio reduce overdependence lead drug revlimid company recently obtain antitrust clearance impending juno acquisition celgene be zack rank hold stock see complete list today zack rank strong buy stock here gilead collaborate sangamo gilead kite have enter collaboration agreement sangamo therapeutic inc agreement kite use sangamo zfn technology modify gene develop next generation cell therapy autologous allogeneic use oncology lieu sangamo receive upfront payment potential milestone payment sangamo be also entitle receive tiered royalty sale potential future product result collaboration other hand kite be responsible development manufacturing product collaboration sangamo share sky-rocket high news collaboration investor have lot cheer give gilead expertise biotech field chmp positive amgen xgeva label expansion committee medicinal product human use chmp european medicine agency have give positive opinion expand current indication amgen xgeva include skeletal related event patient multiple myeloma give positive result phase iii study candidate get approval aforementioned indication study result show xgeva successfully meet primary endpoint demonstrate inferiority zoledronic acid delay time first study skeletal related event patient multiple myeloma fda already approve company supplemental biologic license application xgeva expand currently approve indication prevention skeletal related event patient bone metastase solid tumor include patient multiple myeloma january vertex initiate phase iii triple combination study cf vertex pharmaceutical inc vrtx free report leader cystic fibrosis cf market announce initiation phase iii study vx tezacaftor kalydeco investigational triple combination regimen patient suffering cf have del mutation minimal function mutation study be be conduct support submission nda unite state used datum week primary efficacy endpoint together safety datum week treatment earlier month fda approve symdeko treatment underlie cause cf patient age older have copy del mutation cystic fibrosis transmembrane conductance regulator gene have least mutation be responsive tezacaftor ivacaftor biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex gain last month regeneron lose amgen gain see last biotech stock roundup here biotech stock roundup abbvie result impress ablynx be acquire sanofi next biotech world stay tune more regulatory pipeline update approach last leg earning season wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
705,VRTX,vertex pharmaceutical incorporate vrtx free report announce fda have grant approval cystic fibrosis cf corrector tezacaftor vx combination ivacaftor kalydeco brand name symdekotm combo therapy be approve treat underlie cause cf patient age year certain mutation cf transmembrane conductance regulator gene approval mark company third treatment underlie cause cf company say be ready launch product market week nod regulatory agency vertex address significantly larger cf patient population unite state notably combination regime be also review eu decision expect second half vertex share price have soar year time compare favorably industry decrease aforementioned approval be support positive datum phase iii study tezacaftor ivacaftor combination evolve expand trial meet primary endpoint demonstrated statistically significant improvement lung function different cf patient population combination treatment be find be well tolerate case company presently market cf drug kalydeco orkambi also boast strong cf pipeline broad portfolio next generation cf corrector bring multus dollar sale company approve notably vertex be evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination program present july show combo lead marked improvement lung function company be also develop fourth next generation corrector vx phase ii study datum expect early meanwhile company be look buy cf candidate be put together tezacaftor ivacaftor create triple combination last july vertex buy concert pharmaceutical inc cnce free report cf pipeline candidate vx ctp company be develop candidate promising once daily triple combination compile other pipeline drug treat underlie cause cf remind investor cf market represent huge commercial potential be rare life threaten disease estimate affect person north america europe australia cf combination regimen approve further strengthen market position translate higher revenue vertex pharmaceutical incorporate price vertex pharmaceutical incorporate price vertex pharmaceutical incorporate quote zack rank key picksvertex carry zack rank hold better rank stock health care sector be xoma corporation xoma free report exelixis inc exel free report xoma sport zack rank strong buy exelixis carry zack rank buy see complete list today zack rank stock here xoma loss share estimate have narrow cent cent last day company come average beat stock have sky-rocket last month exelixis earning share estimate have be revise upward cent cent last day company pull positive surprise trail quarters average beat share price company have rally year time hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
706,VRTX,fourth quarter earning season have crossed halfway mark so far result reflect favorable trend average proportion company beating top bottom line expectation latest earning preview total earning member have release result be year quarter rise revenue beat ratio bottom line be top line be proportion company beating ep revenue estimate be biotech company alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report be expect report number feb let take look biotech company have edge other ahead release however look number let have look biotech industry glance biotech industry be see significant pickup merger acquisition deal late year start celgene celg free report announce plan acquire impact biomedicine company reveal plan acquire juno therapeutic approximately french pharma giant sanofi sny free report also announce buy biopharma company bioverativ january same month sanofi also announce plan acquire belgian biotech company ablynx fourth quarter biotech sector be well poise major player biotech sector biogen biib free report put mixed show report period earning lag estimate sale exceed same however celgene vertex vrtx free report outpaced metric expectation alexion new haven ct base alexion blockbuster drug soliris continue perform well alexion continue identify treat high number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus soliris country operate platform alexion be work expand soliris label additional indication fda recently approve drug treatment refractory gmg patient be acetylcholine receptor antibody positive drug be approve europe indication label expansion additional indication give soliris access higher patient population increase commercial potential drug significantly company also announce restructure initiative context alexion plan focus rare disease business core area hematology nephrology neurology metabolic disorder enhance productivity zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year alexion track record be excellent have top estimate last quarters average positive earning surprise alexion have earning esp most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc price ep surprise alexion pharmaceutical inc quoteregeneron regeneron key growth driver eylea be likely continue contribute company top line growth regeneron be work expand eylea label additional indication phase iii study panorama be evaluate eylea treatment moderately severe severe proliferative diabetic retinopathy patient dme phase iii study japan be evaluate neovascular glaucoma label expansion additional indication give eylea access higher patient population increase commercial potential drug apart eylea investor remain focuse uptake new drug kevzara dupixent fda also approve dupixent dupilumab injection treatment adult moderate severe atopic dermatitis initial uptake drug be encourage drug be approve europe also company be also evaluate drug treat asthma adult liberty asthma quest study hence focus be company performance particularly eylea dupixient uptake fourth quarter earning call investor be also expect await update company pipeline earning esp regeneron be company currently carry zack rank sell zack consensus estimate fourth quarter revenue be peg mark increase year year zack consensus estimate fourth quarter earning be peg share mark increase year year company performance have be mixed so far last quarters surpass earning estimate occasion miss average positive surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc price ep surprise regeneron pharmaceutical inc quoteour takedure fourth quarter alexion price decline compare regeneron fall however alexion zack rank combine positive esp make reasonably confident earning beat see complete list today zack rank strong buy stock here regeneron caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision therefore proprietary model believe alexion be poise better performance upcoming quarter zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
707,VRTX,galapago nv glpg free report announce positive top line datum phase ib study evaluate osteoarthritis oa candidate glpg candidate reduce level args neoepitope cartilage breakdown biomarker more half highest dosage share company have rise past year outperform industry decline period phase ib study evaluate dose glpg versus placebo period week glpg reduce level args neoepitope low medium high dose respectively compare placebo glpg work target adamts cartilage degrading enzyme meanwhile galapago be work design phase ii program further evaluate candidate oa study be expect start end year apart glpg galapago be also develop candidate filgotinib sjogren syndrome infectious uveitis ankylose spondylitis psoriatic arthritis company have global collaboration gilead science inc gild free report development filgotinib inflammatory indication moreover galapago be develop glpg cystic fibrosis cf patient be long term stable treatment vertex pharmaceutical incorporate vrtx free report cf drug kalydeco november last year galapago announce positive top line datum phase ii study demonstrate improvement lung function compare baseline company have cf candidate include glpg be be develop partnership abbvie inc abbv free report galapago nv price galapago nv price galapago nv quotegalapago carry zack rank hold see complete list today zack rank strong buy stock here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
708,VRTX,blog highlight large cap biotech stock vertex pharmaceutical inc vrtx free report alexion pharmaceutical inc alxn free report attract investor attention last year likely remain focus new year well vertex alexion enjoy dominant position medical area cystic fibrosis cf vertex ultra rare disorder alexion be not very competitive put company advantageous position peer face rise competitive pressure vertex vertex market cf drug kalydeco orkambi year be tremendous year vertex positive datum read out regulatory approval lead increase eligible patient population kalydeco orkambi consistent expansion patient population vertex cf product revenue increase company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine stock surge substantially outperform increase register industry estimate have also moved northward past day drive company positive earning surprise vertex cf pipeline be also quite strong broad portfolio next generation cf corrector vertex have also make decent clinical progress multiple cf study year have meaningful pipeline catalyst investor focus be triple combination cf regimen be crucial long term growth have potential treat cf patient vertex plan initiate pivotal phase iii study triple combination regimen first half alexionalexion be focuse development life transform drug treatment patient ultra rare disorder key drug soliris approve severe ultra rare blood disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus have be consistently do well meanwhile alexion be work expand drug label include additional indication approve boost further sale growth october fda approve soliris treat refractory generalized myasthenia gravis gmg be acetylcholine receptor achr antibody positive have other drug rare disease call strensiq kanuma be emerge growth driver alexion also have robust pipeline several candidate development include soliris follow candidate alxn datum key study alxn be expect be present year alexion share price decline slightly last year estimate moved northward past day company consistently deliver positive earning surprise strong product portfolio consistently successful pipeline development vertex alexion likely attract investor attention year industry struggle increase pricing competitive pressure also company be view attractive acquisition target larger company company have zack rank hold see complete list today zack rank strong buy stock here investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
709,VRTX,alexion pharmaceutical alxn free report get boost eu approve key revenue driver soliris additional indication meanwhile biogen biib free report be news investigation be launch rise price multiple sclerosis ms drug investigation have be launch rep elijah cumming rep peter welch letter be send company include biogen request information pricing strategy ms drug recap week most important storieseu label expansion alexion soliris alexion flagship product soliris gain eu approval treatment patient refractory generalized myasthenia gravis gmg make first only complement base therapy approve eu ultra rare subset gmg alexion launch soliris indication initially germany be evaluate additional eu launch gmg indication represent incremental growth opportunity soliris enable company enter neurology therapeutic area soliris be currently review japan response expect early next year gmg indication eu grant approval look soliris gain approval well decision be expect oct accord information provide company person suffer myasthenia gravis mg alexion target population be approximately total mg patient population result late stage study regain conduct company indicate refractory gmg patient respond treatment soliris soliris be alexion key growth driver drug bring sale first half company expect soliris revenue assume identification steady number new patient paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus globe also read alexion soliris label expansion approve europe alexion be zack rank strong buy stock see complete list today zack rank stock here biogen other face ms drug price probe biogen hold strong position ms market have be ask submit information ms drug avonex tysabri tecfidera plegridy zinbryta co promote abbvie accord letter drug have see least double digit price increase approval price drug have increase almost moreover zinbryta be introduce price annum price biogen other ms drug be hike match zinbryta price biogen have respond letter aug also read biogen other multiple sclerosis drug stock focus here pipeline setback ultragenyx ultragenyx pharmaceutical rare free report company focuse develop treatment rare ultra rare disease suffer pipeline setback candidate fail late stage study aceneuramic acid extend release ace fail meet primary well key secondary endpoint phase iii study patient gne myopathy gnem ultragenyx have decide discontinue development ace ultragenyx currently have investigational treatment fda review vestronidase alpha mps decision expect nov be look file fda approval burosumab link shortly fda nod ironwood gout drug ironwood pharmaceutical irwd free report once daily gout treatment gain fda approval duzallo have be approve treatment hyperuricemia associate gout patient have not achieve target serum uric acid level medically appropriate daily dose allopurinol alone make duzallo first fda approve fix dose combination treatment available single pill address cause hyperuricemia gout production excretion serum uric acid ironwood expect launch product fourth quarter ironwood expect duzallo drive sale gout franchise be expect deliver total annual peak sale more note duzallo label include box warning acute renal failure also read ironwood pharma combination gout drug get fda approval start roll nda submission mdd drug alk free report have start roll submission new drug application nda investigational major depressive disorder mdd drug alk roll nda submission once daily oral medicine novel mechanism action adjunctive treatment mdd be slate complete year end also read initiate roll submission depression drug alk have fast track designation have lose value year date versus growth industry biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index inched slightly last trading session major biotech stock alexion be celgene lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here regeneron drop rsv antibody gilead hiv drug get priority review next biotech world watch usual regulatory pipeline update amgen amgn free report be present new datum pcsk inhibitor repatha european society cardiology esc congress surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
710,VRTX,earning season draw close focus be back pipeline regulatory update regeneron pharmaceutical regn free report have several pipeline catalyst line second half year report datum late stage pipeline candidate gilead science gild free report get priority review investigational hiv treatment recap week most important shelve rsv antibody study failure regeneron investigational antibody suptavumab regn respiratory syncytial virus rsv fail meet primary endpoint late stage study conduct infant regeneron have decide not continue development candidate regeneron have several pipeline catalyst line second half year later quarter company expect report top line phase iii datum dupixent asthma positive datum allow company go ahead filing fourth quarter important datum readout schedule second half year be company pd antibody regn cutaneous squamous cell carcinoma cscc second most common skin cancer basal cell carcinoma second deadliest skin cancer melanoma meanwhile eylea be be evaluate combination nesvacumab top line datum phase ii study wet age related macular degeneration diabetic macular edema expect fourth quarter year regeneron be zack rank strong buy stock see complete list today zack rank stock here priority review gilead hiv drug gilead gain priority review investigational fix dose combination bictegravir mg bic novel investigational integrase strand transfer inhibitor insti emtricitabine tenofovir alafenamide mg ftc taf dual nrti backbone treatment hiv gilead have used priority review voucher time filing regulatory application combination gain priority review response fda be feb combination be review eu well gilead hiv franchise be major contributor sale approve drug genvoya truvada atripla stribild descovy odefsey complera bring sale first half gilead share be year date lag industry rally also read gilead nda hiv combo regimen get priority review late stage failure ophthotech eye drug ophthotech opht free report be focuse development treatment eye disease announce fovista fail meet primary endpoint late stage study superiority study be evaluate fovista pdgf therapy combination eylea avastin bevacizumab vegf therapy compare eylea avastin monotherapy treatment wet age related macular degeneration amd study fail achieve primary endpoint company have anyway attribute low likelihood success study give fovista earlier failure phase iii study well failure mid stage study conduct competitor pdgf inhibitor vegf inhibitor combination amd ionis retain full right inotersen ionis fb lrx ionis pharmaceutical ion free report say glaxo have decline option drug inotersen ionis fb lrx keep decision reprioritize pipeline review rare disease business company however continue collaborate ionis ionis hbvrx ionis hbv lrx be be evaluate hepatitis virus hbv infection ionis retain right investigational drug company layer plan say be filing approval inotersen follow launch initial indication inotersen have be design treat patient ttr amyloidosis attr be expect be treatment patient polyneuropathy due hereditary ttr amyloidosis hattr pn ionis say be consider set commercial subsidiary commercialize co commercialize inotersen north america company be evaluate other option well include partnership deal meanwhile ionis fb lrx be slate move mid stage study patient dry age related macular degeneration amd later year also read ionis pharmaceutical retain right inotersen stock galapago ipf datum galapago nv glpg free report share be positive datum mid stage study company investigational idiopathic pulmonary fibrosis ipf drug glpg halter disease progression ipf patient study be first autotaxin inhibitor show effect ipf study galapago now intend move candidate late stage study be already discussion regulator regard study design galapago datum come shortly fibrogen investigational ipf drug pamrevlumab fared well mid stage study well combination safety sub study pamrevlumab be connective tissue growth factor ctgf antibody ipf market represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer currently approve ipf drug include esbriet ofev biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron be slightly celgene celg free report lose last month vertex vrtx free report be biogen slip see last biotech stock roundup here earning regeneron kite more fibrogen ipf datum next biotech world second quarter earning season come end watch usual regulatory pipeline update hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
711,VRTX,regeneron regn free report several mid small cap biotech stock report earning result company dynavax dvax free report abbvie abbv free report provide regulatory update recap week most important storiesa look earning result regeneron report strong quarter company surpass earning revenue estimate back eylea sale company raise outlook eylea well read more regeneron beat earning sale raise view immuno oncology focuse company juno read more juno therapeutic loss widen revenue surpass kite also report second quarter result kite have key regulatory event come later year fda expect respond approval status company car treatment axicabtagene ciloleucel nov investigational treatment have be submit review eu well treatment relapse refractory diffuse large cell lymphoma dlbcl transform follicular lymphoma tfl primary mediastinal cell lymphoma pmbcl patient be ineligible autologous stem cell transplant regeneron be zack rank strong buy stock see complete list today zack rank stock here dynavax hepatitis vaccine pdufa date push back month dynavax get favorable vote fda advisory panel investigational hepatitis vaccine heplisav be face delay get vaccine approve fda ask detailed information company propose post marketing study treatment advisory panel have vote favor safety datum heplisav have comment design dynavax propose post marketing study base company fda agree more time be need finalize key detail post marketing study result fda action date be push back month nov company still expect launch heplisav early dynavax share be whopping year date significantly outperform industry rally abbvie new hcv treatment get fda nod abbvie week pan genotypic ribavirin free once daily hepatitis virus hcv treatment mavyret gain fda approval use hcv patient cirrhosis be new treatment approval competition hcv market be go heat further accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history company say american be chronically infected hcv mavyret gain eu approval recently fibrogen hit week high ipf drug datum fibrogen fgen free report share shot positive datum company investigational idiopathic pulmonary fibrosis ipf drug pamrevlumab mid stage study well combination safety sub study proprietary first class connective tissue growth factor ctgf antibody be be evaluate fibrotic disease cancer ipf indication represent huge commercial potential ipf abnormal scarring lung be rare serious lung disease survival rate comparable deadliest cancer approve pamrevlumab bring significant sale fibrogen currently approve ipf drug include esbriet ofev read more do fibrogen stock hit time high today biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene celg free report vertex vrtx free report record minimal gain gilead lose reflect impact approval abbvie new hcv drug last month vertex be see last biotech stock roundup here earning gilead celg more dynavax panel vote next biotech world watch earning report small mid cap biotechs well usual regulatory pipeline update more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
712,VRTX,week shaky trading wall street continue second largest bull run dodge list wo include geopolitical tension washington turmoil elevated valuation aftermath hurricane harvey irma well round downbeat economic datum particular be spotlight index breach milestone first time bring year date gain nearly accord bloomberg rally overtake increase index bull run add almost value american equity journey point come less month suggest strong complacency stock market renew hope trump tax reform end year be main catalyst drive stock market new high additionally steady economic fundamental strong corporate earning add strength upward trend be likely continue month ahead read etf asset report equity rule give enthusiasm investor be flock etf ishare core etf ivv free report let take closer look fundamental ivv performance ivv focusivv be top asset creator year pull nearly capital track index hold stock basket security hold more total asset suggest nice balance security prevent heavy concentration however product be slightly tilt information technology sector share health care financial consumer discretionary industrial account double digit exposure etf be low cost choice space charge bps fee year investor trade solid volume share day average fund have gain year date time frame have zack etf rank buy medium risk outlook most stock fund portfolio have deliver impressive return few be real star gain more read etf industry face regulatory oversight have highlighted best perform stock etf respective position fund basket best perform stock ivvvertex pharmaceutical vrtx free report stock have surge so far year carry zack rank hold vgm style score company have see positive earning estimate revision cent year past month expect earning growth rate compare industry average stock have solid zack industry rank top account just share ivv align technology inc algn free report stock make allocation fund basket have deliver incredible return so far year stock have see solid earning estimate revision cent past month year reflect year year earning growth much higher industry average growth further align technology have zack rank vgm style score have dismal zack industry rank bottom nrg energy inc nrg free report stock have gain year date time frame nrg have see positive earning estimate revision cent past month year earning be expect decline annually compare industry average growth nrg energy currently have zack rank vgm style score stock have ugly zack industry rank bottom make share ivv read trade oil rally etfs stock activision blizzard inc atvi free report stock have surge so far year have exposure fund basket have see solid earning estimate revision cent past month year earning be expect decline year year compare industry average growth activision blizzard have zack rank strong buy vgm style score belong solid zack industry rank top centene corporation cnc free report stock account asset fund basket have gain year date time frame have see solid earning estimate revision cent past month year however earning be expect grow well industry average centene corporation have zack rank vgm style score belong robust zack industry rank top want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
713,VRTX,be quite few major development week alexion pharmaceutical alxn free report announce restructure plan see company cut job streamline operation meanwhile datum be present company regeneron pharmaceutical regn free report abbvie abbv free report kura oncology kura free report other recap week most important storiesalexion cut job shift headquarters alexion announce restructure plan see company cut global workforce close several site include rhode island manufacturing facility certain regional country base office shift headquarters boston mid effort company expect generate annual pre tax saving saving be used growth opportunity optimization alexion be guide operate margin growth expect reinvest year start alexion be focuse grow maximize presence rare disease business core area focus include hematology nephrology neurology metabolic disorder result restructure company expect incur pre tax cost be record year alexion be zack rank strong buy stock see complete list today zack rank stock here company have gain year date outperform industry rally regeneron sanofi asthma drug positive phase iii regeneron partner sanofi announce positive top line result late stage study dupixent dupilumab uncontrolled persistent asthma dupixent be find reduce severe asthma attack improve lung function overall result be good less activity be observed patient lower eosinophilic cell regeneron sanofi intend file fda approval year end asthma market be huge person unite state live uncontrolled persistent asthma be treat standard therapy dupixent have blockbuster potential be currently approve eczema be be evaluate additional indication pediatric atopic dermatitis nasal polyp eosinophilic esophagitis read more regeneron sanofi dupixent asthma study meet endpoint abbvie upadacitinib positive study abbvie come positive datum company say experimental oral jak selective inhibitor upadacitinib meet primary rank secondary endpoint late stage study moderate severe rheumatoid arthritis read more abbvie ra candidate meet primary endpoint phase iii company also present promising datum upadacitinib atopic dermatitis eczema phase iib study read more abbvie upadacitinib meet primary endpoint phase iib upadacitinib be be evaluate additional indication include psoriatic arthritis crohn disease ulcerative colitis ankylose spondylitis intercept hit dear doctor letter intercept pharmaceutical icpt free report share be dear doctor letter issue company related use sole market product ocaliva letter layer emphasis use recommend dosage label liver injury liver decompensation liver failure death be report ocaliva be dose more frequently recommend ocaliva approve primary biliary cholangitis pbc patient moderate severe hepatic impairment child pugh bring sale second quarter intercept share be company say recent call do not expect label change box warning sage drug disappoint late stage study sage therapeutic sage free report share be disappointing top line datum late stage study brexanolone sage treatment super refractory status epilepticus srse study fail meet primary endpoint brexanolone be currently late stage development treatment postpartum depression ppd kura soar promising cancer study datum kura share jump more positive topline result mid stage study lead pipeline candidate tipifarnib patient hra mutant relapse refractory squamous cell carcinoma head neck hnscc primary endpoint be achieve completion enrollment biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock amgen be regeneron lose last month vertex vrtx free report be see last biotech stock roundup here cellectis clinical hold insm soar positive datum next biotech world watch usual regulatory pipeline update response fda regard approval status amgen allergan biosimilar version roche cancer drug avastin bevacizumab be shortly company get favorable vote fda advisory panel recently more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
714,VRTX,biotech sector be go roof right now spdr biotech etf xbi free report add month sep plenty factor be power sector breakthrough food drug administration fda approval success immune oncology field merger acquisition be forefront biotech stock vertex pharmaceutical vrtx free report receive new fda approval cystic fibrosis drug kalydeco early september fda approve novartis ag breakthrough gene transfer treatment kymriah suspension treatment patient year age cell precursor acute lymphoblastic leukemia be refractory second later relapse source investor note car be fresh immunocellular therapy many company be eyee fact gilead science gild announce buyout kite pharma kite late august read biotech etfs soar gilead kite deal kite pharma be expect receive approval car therapy axicabtagene ciloleucel axi cel shortly acquisition gilead step new arena oncology treatment know car target body own immune system fight tumor month clovis oncology clvs share also sky-rocket follow company positive cancer drug datum company then say clinical trial datum ovarian cancer drug treatment indicated substantially help more patient expect read stock etfs buy clovis positive drug datum be not enough teva pharmaceutical teva share surge sep appoint former nordisk nvo ceo new recruitment follow teva last full time ceo month term resignation bribery scandal compelling valuation biotech stock be most hurt member last year have probably make space cheap help be back bang biotech etf xbi add last month sep spdr etf spy free report be fund xbi have relative strength index mean fund be yet enter overbought territory also fear price gouge be ebb substantially trump administration nutshell space be ride research development log more return ahead etfs tap highlight few biotech etfs benefit investor solid gain see health care etfs here direxion daily biotech bull labu free report ultrapro nasdaq biotechnology proshare ubio free report proshare ultra nasdaq biotechnology bib free report ishare nasdaq biotech etf ibb free report bioshare biotech clinical trial bbc free report vaneck vector biotech etf bbh free report bioshare biotech product bbp free report loncar cancer immunotherapy etf cncr free report alp medical breakthrough etf sbio free report want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
715,VRTX,be relatively slow week biotech sector key pipeline update be provide company cellectis cll free report insm insm free report insm sky-rocket positive datum lead pipeline candidate cellectis be hit clinical hold couple phase study recap week most important hit fda clinical hold cellectis share be hit clinical hold place fda couple early stage study be conduct ucart study be acute myeloid leukemia aml other be blastic plasmacytoid dendritic cell neoplasm bpdcn hold come place company report death bpdcn study cellectis be focuse develop immunotherapy base gene edit allogeneic car cell ucart say be work fda investigator resumption study amend protocol include lower dosage share be clinical hold cellectis have gain year date significantly outperform industry rally insm shoot alis datum insm share shot positive top line datum late stage study convert treatment refractory nontuberculous mycobacterial ntm lung disease cause mycobacterium avium complex mac result show addition alis amikacin liposome inhalation suspension guideline base therapy gbt eliminate evidence ntm lung disease cause mac sputum sixth month patient compare patient gbt alone base datum insm intend seek accelerate approval priority review alis subpart alis have breakthrough therapy designation fast track status unite state be also qualify infectious disease product qidp generate antibiotic incentive now gain act provide additional year exclusivity alis be lead candidate insm pipeline accord company patient be diagnosed ntm lung disease be treat ntm lung disease cause mac akcea ionis submit fcs drug fda approval akcea therapeutic akca free report ionis pharmaceutical ion free report announce submission new drug application nda volanesorsen treatment familial chylomicronemia syndrome fcs severe rare disorder characterize extremely high level triglyceride company be look launch volanesorsen globally provide gain timely approval efficacy datum volanesorsen be promising concern remain safety profile candidate give injection site reaction fall platelet count volanesorsen be currently be evaluate late stage study familial partial lipodystrophy fpl topline datum expect ligand diabetes drug fare well mid stage study ligand pharmaceutical lgnd free report announce positive top line result mid stage study investigational type ii diabetes treatment lgd oral small molecule glucagon receptor antagonist gra addition show robust statistically significant dose dependent reduction baseline hemoglobin week treatment lgd be find be safe well tolerate be several diabetes treatment available market remain significant need additional treatment consider diabetes be grow global epidemic affect million world ligand be zack rank strong buy stock see complete list today zack rank stock here amgen mimpara eu label expand amgen amgn free report gain approval eu pediatric formulation mimpara treatment secondary hpt child age year end stage renal disease esrd maintenance dialysis therapy approval be largely expect committee medicinal product human use chmp european medicine agency ema have adopt positive opinion pediatric formulation earlier year june also read amgen get eu nod expand drug label biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock alexion be last month vertex vrtx free report be amgen slip see last biotech stock roundup here car focus gilead kite deal incyte baricitinib update next biotech world watch usual regulatory pipeline update surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
716,VRTX,second quarter report cycle have almost end only stock left report aug sector exclude auto conglomerate have record earning growth quarter total earning increase second quarter back revenue growth year period pharma biotech sector have perform well first half sector be turmoil due drug pricing controversy bring forward presidential candidate hillary clinton campaign however defy odd uncertainty surround obamacare sector have turn year drug pricing risk still persist investor be seemingly comfortable scenario be focuse fundamental nyse arca pharmaceutical index have rise almost year date ytd decline almost last year nasdaq biotechnology index be ytd slide fact zack drug sector be ytd however have rise period impressive rise medical sector have record earning growth revenue growth first quarter second quarter company have report so far earning have grow revenue growth look beat ratio show earning beat revenue beat second quarter sector biotech stock perform particularly well most key player beat earning revenue expectation few company sub sector have also raise outlook sale new drug be also impressive be expect offset impact genericization key drug extent moreover pipeline candidate have progressed well evident positive result announce first half company be also focuse newer category gene editing nash parkinson disease base present trend be expect see far more approval agency have already approve total drug so far year compare whole meanwhile tax reform cash repatriation policy give pharma biotech company more cash flexibility pursue acquisition deal however many company fight bring therapy market competition be intensify loss exclusivity certain key drug high profile pipeline setback drug pricing issue still remain concern sector nonetheless rest be expect be eventful quite few company expect announce datum pipeline candidate be develop wide range therapeutic area note first half be rather quiet term merger acquisition collaboration deal however be chance pick second half begin gilead acquisition kite pharma almost stock favorable scenario many biotech stock have show impressive run here be biotech company share price have more double so far year puma biotechnology inc pbyi free report los angele base puma first market drug neratinib be approve fda treatment advanced breast cancer july subsequently launch august brand name nerlynx drug be review eu response expect early nerlynx fda approval be major boost puma give immense commercial potential target market share pumahave surge so far year outperform gain industry company have zack rank hold see complete list today zack rank strong buy stock here alnylam pharmaceutical inc alny free report cambridge base company have make major progress pipeline first half july alnylam advanced hemophilia candidate fitusiran phase iii study patisiran demonstrated potential halt improve neuropathy progression patient hattr amyloidosis phase ii study datum phase iii study be expect year new drug application expect be file year end givosiran develop acute hepatic porphyria june show potential prevent porphyrium attack patient acute intermittent porphyrium aip suffering recurrent attack phase study company expect initiate phase iii study year end company share be so far year significantly outperform industry gain alnylam carry zack rank kite pharma inc company share be so far year significantly outperform industry gain car therapy axicabtagene ciloleucel be near approval however kite pharma have agree be acquire gilead approximately deal be expect close fourth quarter also give major push share ciloleucel treat aggressive hodgkin lymphoma nhl be priority review decision fda be expect nov believe solid efficacy profile demonstrated pivotal zuma study axicabtagene ciloleucel be likely support drug approval year europe regulatory application be file july approval launch expect next year kite pharma carry zack rank vertex pharmaceutical inc vrtx free report share boston base company have increase so far year compare industry gain vertex cf drug kalydeco orkambi have perform well combine sale increase almost year year cf pipeline be quite strong broad portfolio next generation cf corrector company be evaluate next generation cftr corrector vx vx vx vx part triple combination kalydeco datum vx vx phase ii vx phase triple combination study be present july datum demonstrated combination lead pronounce improvement lung function fact be first datum show potential treat underlie cause cf patient have severe difficult treat type disease follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half triple combo regime be successful vertex address significantly larger cf patient population almost patient cf future vertex carry zack rank do zack investment idea come be welcome download full minute list zack rank strong buy stock free charge be better place start own stock search access full list avoid zack rank strong sell other private research see stock free
717,VRTX,investor be always look stock be poise beat earning season vertex pharmaceutical incorporate vrtx free report be such company firm have earning come pretty soon event be shape quite nicely report be vertex pharmaceutical be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface vrtx report fact most accurate estimate current quarter be currently cent share vrtx compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate vrtx give stock zack earning esp head earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give vrtx have zack rank hold esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead vertex pharmaceutical beat be card upcoming report today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
718,VRTX,celgene corporation celg free report be schedule report third quarter result oct open bell celgene stock have moved year date compare industry gain celgene have excellent track record company beating earning estimate last trail quarters last quarter company beat expectation overall company have deliver average positive surprise expect company beat estimate once again back strong performance key drug revlimid likely positive surprise proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quoterevlimid drive second quarter earning result celgene raise guidance company anticipate earning range share compare previous guidance share net product sale be project zack consensus estimate product sale third quarter currently stand revlimid oral drug be currently approve several indication include mm myelodysplastic syndrome mantle cell lymphoma drug perform well first half combat challenge uneven buy pattern coverage gap market share gain key market longer treatment duration be contribute drug growth meanwhile celgene be work expand revlimid label further revlimid receive fda approval use maintenance treatment ndmm patient receive autologous stem cell transplant ndmm market share continue grow outside unite state positive uptake eu japan continue momentum core indication label expansion global launch help product keep contribute top line zack consensus estimate revlimid currently stand third quarter other key product pomalyst imnovid abraxane otezla continue perform well pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be update unite state europe include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function pomalyst combination darzalex dexamethasone relapse refractory myeloma be approve unite state propel sale further approval idhifa treatment adult patient relapse refractory aml aml further boost celgene portfolio drug be develop collaboration agio pharmaceutical agio free report otezla achieve blockbuster status drive solid demand unite state trend be expect continue increase contribution european country also impact sale positively be currently be evaluate phase iii study behet disease atopic dermatitis expand indication psoriatic arthritis plaque psoriasis company be keen expand oncology franchise abraxane label geographical expansion approve drug additional indication increase commercial potential further abraxane sale be estimate be pomalyst revenue be project same otezla be estimate third quarter earning call investor be expect remain focuse company performance label expansion effort update pipeline front other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical inc vrtx free report have earning esp zack rank company be schedule release third quarter result oct see complete list today zack rank stock here glaxosmithkline plc gsk free report have earning esp zack rank company be schedule release third quarter result oct make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
719,VRTX,leader hepatitis virus hcv space gilead science inc gild free report be expect beat expectation report third quarter result oct market close gilead track record be pretty mixed company beating estimate last miss last quarter company beat expectation overall company record average positive earning surprise gilead stock have gain year date industry strong performance third quarter boost share price performance further likely positive surprise proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg penny lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quote factor playconcurrent second quarter earning call gilead update annual guidance base better expect performance first half specifically unite state company raise guidance gilead now expect net product sale range provide earlier hcv product sale be project earlier projection hcv product sale be project earlier projection adjust expense adjust sg expense be now project range respectively adjust product gross margin be expect range earning share be now project cent earlier projection cent strong hiv performance other antiviral product sale be be drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey expect trend continue third quarter well genvoya have already become most prescribe regimen treatment nave switch patient launch drive hcv product sale taf base regimen now represent total gilead hiv prescription volume follow launch genvoya odefsey descovy specifically genvoya be now company bestselling hiv product treatment nave patient share zack consensus estimate genvoya stand strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside unite state impact sale meanwhile hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie inc abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely company increase guidance hcv franchise zack consensus estimate lead hcv drug sovaldi harvoni currently stand third quarter hcv portfolio receive major boost epclusa gain approval fda also approve vosevi tablet single tablet regimen str re treatment chronic hcv infection adult other hand expect company increase guidance further incremental contribution recent kite pharma acquisition fda recently approve chimeric antigen receptor cell car therapy yescarta axicabtagene ciloleucel treatment refractory aggressive hodgkin lymphoma include dlbcl transform follicular lymphoma primary mediastinal cell lymphoma expect management throw more light same third quarter call investor be also likely keep eye other pipeline update other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release third quarter result oct see complete list today zack rank stock here glaxosmithkline plc gsk free report have earning esp zack rank company be schedule release third quarter result oct make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
720,VRTX,vertex pharmaceutical incorporate vrtx free report report fourth quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter lower operate expense ratio year year vertex report revenue fourth quarter almost year year drive strong product revenue revenue also beat zack consensus estimate fourth quarter sale strongvertex fourth quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be fourth quarter year year kalydeco sale surge follow approval treat expand population kalydeco be approve use cf patient year older have residual function mutation cftr gene august kalydeco be approve cf patient year older have residual function mutation result splice defect cftr gene line extension increase eligible patient population kalydeco orkambi lumacaftor ivacaftor deliver sale year year growth be support continue uptake globally especially pediatric patient unite state cost riseadjust research development expense increase fourth quarter due higher cost related development triple combination cf regimen adjust selling general administrative sg expense increase resultsvertex full year revenue increase year year mainly drive upfront payment earn germany base merck kgaa strong cf portfolio sale upfront payment be part collaboration agreement vertex license oncology program merck kgaa adjust earning be year year share adjust expense increase year year however exclude upfront payment related acquisition cftr potentiator vx concert pharmaceutical inc cnce free report adjust sg expense increase year year include cost related potential launch tezacaftor ivacaftor combination unite state increase be also due increase investment support global orkambi kalydeco stock repurchase earning release vertex announce board have authorize share repurchase program buy back common stock tune guidancevertex provide guidance combine operate cost combine adjust research development selling general administrative sg expense be anticipate range increase operate expense reflect anticipate cost related development triple combination treat cf plan launch tezacaftor ivacaftor combination pipeline regulatory updatesin december vertex announce datum phase iii study arrival evaluate kalydeco child age year have mutation cftr gene show improvement multiple endpoint include measure pancreatic function base datum vertex plan file regulatory application approval kalydeco child age year first quarter january european commission approve line extension orkambi include use child cf age year have copy del mutation approval increase target patient population patient company have plan file regulatory application approval orkambi child age cf have copy del mutation first quarter vertex be also seek approval combination tezacaftor kalydeco ivacaftor cf patient age older have copy del mutation have least residual function mutation regulatory application be review unite state europe decision be expect unite state feb europe second half company be also develop triple combination regimen treat cf be capable treat almost patient vertex have select next generation corrector vx vx advance separate phase iii triple combination study candidate evaluate combination tezacaftor kalydeco apart cf vertex be also develop treatment sickle cell disease thalassemia influenza pain management fourth quarter company initiate phase iii study pimodivir combination standard care treatment patient influenza study be be conduct collaboration janssen pharmaceutical subsidiary johnson johnson jnj free report takevertex fourth quarter result reflect strong performance cf product company beat estimate count sale cf drug rise share rise hour trading response strong quarterly result past year vertex share price have increase massive compare favorably increase industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be express interest cf vertex carry zack rank hold see complete list today zack rank strong buy stock here vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotewall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
721,VRTX,acquisition once again remain focus week ablynx agree be acquire sanofi sny free report deal worth approximately seattle genetic sgen free report also announce intention acquire cascadian therapeutic meanwhile earning result be focus abbvie abbv free report report strong quarter provide upbeat outlook recap week most important storiesa look earning result company celgene celg free report abbvie biogen vertex vrtx free report report fourth quarter result last trading session celgene read more celgene earning sale beat solid revlimid vertex top earning well revenue estimate biogen top revenue miss earning read more biogen earning miss sale top view upbeat vertex also announce have select next generation corrector vx vx move late stage development part different triple combination regimen person cystic fibrosis cf last year vertex share be compare gain record industry belong abbvie share jump follow release better expect fourth quarter result upbeat outlook result be drive performance humira imbruvica mavyret read more abbvie soar result key takeaway earning call abbvie be zack rank buy stock see complete list today zack rank strong buy stock here ablynx be acquire sanofi belgium base biopharma company ablynx have agree be acquire french pharma giant sanofi price share cash approximately announcement come just few week nordisk have announce interest acquire ablynx deal value approximately ablynx have reject nordisk offer company board say proposal fundamentally undervalue ablynx growth prospect look ablynx pipeline show company well be position launch first product caplacizumab vwf acquire thrombotic purpura attp year caplacizumab be currently review eu regulatory application be file unite state first half estimate annual market opportunity attp life threaten blood clot disease be expect be company also have broad range partnership potential generate more milestone royalty other pipeline candidate also address significant market opportunity company have more program pipeline nanobody clinical development acquisition be expect close end second quarter read more sanofi buyout spree month buy ablynx bellicum fda clinical hold bellicum pharmaceutical share be almost follow company announcement fda have place clinical hold study be conduct bpx hold be place case encephalopathy be deem possibly connect bpx company say case be complex certain factor prior fail transplant prior history concurrent infection administration rimiducid combination other medication bellicum be now wait receive formal notice fda step need be take resumption study clinical hold not impact ongoing registration study europe seattle genetic boost pipeline cascadian acquisition seattle genetic announce be acquire cascadian therapeutic share cash acquisition slate close first quarter seattle be add tucatinib pipeline tucatinib be investigational oral small molecule tyrosine kinase inhibitor tki be highly selective growth factor receptor be overexpressed several cancer include breast colorectal ovarian gastric candidate be currently pivotal phase ii program metastatic breast cancer complement seattle exist pipeline biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion decline gilead gild free report gain last month biogen be regeneron lose next biotech world watch amgen amgn free report fourth quarter result be market close today read more amgen benefit growth drug earning meanwhile fda be expect issue decision regard label expansion amag pharmaceutical feraheme february amag be look expand label current chronic kidney disease ckd indication include eligible adult patient iron deficiency anemia ida wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
722,VRTX,last week issue article mentioned merger acquisition be quite lean pick significantly propose tax reform be finally approve reform aim cut corporate tax rate boost profit large drug biotech company change tax code also allow company bring back huge cash hold overseas time tax rate change definitely leave more cash hand drug biotech company also focus drug pricing take backseat large drug biotech company struggle organic growth be lot chatter possible increase large give take several year million dollar develop new therapeutic scratch large pharmaceutical company sit huge pile cash prefer buy innovative small mid cap biotech company build pipeline article discuss mid large cap name be logical acquisition target next year company pfizer pfe free report merck mrk free report johnson johnson jnj free report other matter buy drug biotech stock be current sale performance drug product prospect future sale growth quality pipeline company discuss have most factor go favor acquisition small cap drug biotech company be very difficult predict quite frequent hence have be exclude discussion biomarin pharmaceutical inc bmrn free report company product pipeline portfolio include rare disease drug be great demand be less competitive space expensive treatment bring huge profit biomarin be such drug developer market cap be biomarin key orphan disease drug vimizim kuvan continue do well backed strong underlie patient demand trend biomarin expect sustain growth drug brineura earlier expect approval year treatment child cln disease form batten disease be also huge boost biomarin impressive rare disease pipeline be also progress well approval pegvaliase treatment expect pipeline believe late stage candidate vosoritide achondroplasia most common form dwarfism bmn hemophilia have blockbuster potential biomarin have already be target takeover speculation company gilead gild amgen amgn roche be interested buy biomarin vertex pharmaceutical inc vrtx free report vertex so far have be tremendous year positive datum read out regulatory approval lead increase eligible patient population approve cystic fibrosis cf kalydeco orkambi cf be vertex main area focus consistent expansion patient population vertex cf product revenue have increase quarter quarter company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine meanwhile company have also make decent clinical progress multiple cf study year have meaningful pipeline catalyst market cap vertex be incyte corporation incy free report incyte strong oncology portfolio make lucrative target company gilead amgen bristol myer market cap incyte be more primary reason incyte be ripe buyout be product market jakafi iclusig jakafi jak inhibitor be first only product be approve polycythemia vera pv myelofibrosis mf rare blood cancer jakafi be see strong sale performance drive strong patient demand indication order expand patient population increase commercial potential drug company be work expand label further iclusig be approve chronic myeloid leukemia acute lymphoblastic leukemia meanwhile incyte pipeline boast candidate immune therapy epacadostat be study combination pd agent merck bristol myer other olumiant rheumatoid arthritis approve europe regulatory application be file unite state january alexion pharmaceutical inc alxn free report biomarin alexion be also focuse development life transform drug treatment patient ultra rare disorder key drug be soliris approve severe ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus have be consistently do well meanwhile alexion be work expand drug label include additional indication approve boost further sale growth have other drug rare disease call strensiq kanuma be emerge growth driver alexion also have robust pipeline several candidate development include soliris follow candidate alxn roche pfizer novartis be interested buy alexion market cap alexion be more today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
723,VRTX,vertex pharmaceutical incorporate vrtx free report announce phase iii study evaluate key cystic fibrosis cf drug kalydeco child age year meet primary safety endpoint kalydeco ivacaftor be presently market treatment patient year cf have mutation cystic fibrosis transmembrane conductance regulator cftr gene arrival study be conduct young child less year age have mutation cftr gene not only do reveal kalydeco be well tolerate child young year study also show improvement multiple endpoint include measure pancreatic function base datum vertex plan file regulatory application approval kalydeco child age year first quarter study however continue infant less year age approve use additional patient population sale kalydeco improve further please note kalydeco sale rise first month year date vertex share have gain outperform increase industry vertex so far have be tremendous year positive datum read out regulatory approval lead increase eligible patient population approve cf medicine kalydeco orkambi consistent expansion patient population vertex cf product revenue have increase quarter quarter vertex raise guidance orkambi once kalydeco be up twice year company be optimistic positive trend cf sale continue gain additional reimbursement approval orkambi ex market get approval launch tezacaftor vx ivacaftor combination medicine meanwhile company have also make decent clinical progress multiple cf study year meaningful pipeline catalyst lie ahead vertex carry zack rank hold better rank stock biotech genetic sector include emergent biosolution inc ebs free report xoma corporation xoma free report myriad genetic inc mygn free report zack rank strong buy see complete list today zack rank stock here emergent biosolution earning estimate have moved last day share price company have rise year date myriad genetic share have rise year date earning estimate have rise past day xoma share have rise massive year date loss estimate have narrow almost past day wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
724,VRTX,key highlight week include announcement couple acquisition agreement well pipeline news biogen biib free report celgene celg free report announcement relate acquisition ignyta roche sucampo pharmaceutical mallinckrodt recap week most important storiescelgene revlimid combo datum celgene share be disappointing datum combination evaluate company blockbuster cancer drug revlimid treatment nave follicular lymphoma patient late stage relevance study evaluate revlimid rituxan follow maintenance compare standard care rituxan chemotherapy chop bendamustine cvp follow rituxan maintenance treatment arm fail achieve superiority co primary endpoint complete response unconfirmed complete response cr cru week progression free survival read more celgene discourage datum revlimid celgene share be year date compare gain record industry belong acquisition agreement announce couple acquisition deal be announce week first agreement see ignyta be acquire swiss pharma giant roche cash deal value share ignyta be focuse develop precisely target therapeutic guide diagnostic patient rare cancer acquisition slate close first half roche add entrectinib portfolio entrectinib be currently mid stage development second agreement see sucampo be acquire mallinckrodt share approximately acquisition mallinckrodt get source term net sale earning accretion amitiza boost rare disease pipeline vts cpp sulindac deal be expect close first quarter sucampo be zack rank strong buy stock see complete list today zack rank stock here biogen share alzheimer datum biogen share decline datum ongoing alzheimer disease study ban be be develop collaboration eisai independent datum monitoring committee say ban do not meet criterium success base bayesian analysis month primary endpoint phase ii study study fail show early positive result company say blind study be be conduct patient prodromal mild alzheimer disease collectively know early alzheimer disease continue comprehensive final analysis be conduct month result be expect be obtain second half study datum come disappointment positive datum have be major boost moreover result have raise concern candidate chance success give high rate failure experience other company bring alzheimer disease treatment market read more biogen alzheimer drug miss goal interim analysis biomarin pdufa date extend fda have extend prescription drug user fee act pdufa goal date biomarin pharmaceutical bmrn free report pegvaliase month biomarin be look get investigational therapy approve reduction blood phenylalanine phe level adult patient pku have uncontrolled blood phe level exist management extension be expect agency have ask company submit additional chemistry manufacturing control cmc information company say due memorial day weekend action goal date be read more biogen alzheimer drug miss goal interim analysis agio submit ivosidenib nda agio pharmaceutical agio free report have submit new drug application nda seek fda approval ivosidenib ag investigational oral treatment patient relapse refractory acute myeloid leukemia aml isocitrate dehydrogenase idh mutation company have ask priority review cut review period month agio also announce have receive permission fda move pipeline candidate ag clinical study company intend commence phase study first quarter biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex vrtx free report gain biogen decline last month biogen be regeneron lose see last biotech stock roundup here label expansion exelixis cabometyx fda nod spark gene therapy next biotech world watch usual pipeline regulatory update wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
725,VRTX,key highlight week include fda approval luxturna first gene therapy genetic disease first only pharmacologic treatment inherited retinal disease ird first adeno associate virus aav vector gene therapy earlier expect label expansion exelixis exel free report cabometyx recap week most important storiesearlier expect label expansion exelixis cabometyx exelixis receive boost earlier expect fda approval cabometyx first line treatment advanced renal cell carcinoma rcc patient cabometyx be previously approve use advanced rcc patient have receive angiogenic therapy approval first line indication expand patient population significantly approval be base result show cabometyx demonstrated clinically meaningful statistically significant reduction rate disease progression death median progression free survival pfs cabometyx be month compare month sunitinib accord information provide company press release patient country need first line treatment advanced kidney cancer year almost many patient second third line take together represent significant opportunity company grow cabometyx sale exelixis share be year date compare gain record industry belong spark gene therapy get fda nod spark therapeutic once free report gain fda approval time gene therapy luxturna patient confirm biallelic rpe mutation associate retinal dystrophy make luxturna first gene therapy genetic disease first only pharmacologic treatment ird first aav vector gene therapy be approve unite state accord fda biallelic rpe mutation associate retinal dystrophy affect approximately patient unite state approval be expect consider favorable fda advisory panel vote october decision come ahead jan prescription drug user fee act pdufa date spark be yet provide information pricing be key factor influence treatment uptake company say luxturna be available administration treatment center late first quarter pricing other detail be provide early january spark also get rare disease priority review voucher be used gain priority review subsequent drug application be not eligible priority review company also sell voucher million dollar other company want fasten review process candidate biomarin unite therapeutic knight therapeutic be company sell priority review voucher million dollar new sma collaboration biogen ionis biogen biib free report have enter new collaboration agreement ionis pharmaceutical inc ion free report new antisense oligonucleotide drug candidate be identify treatment spinal muscular atrophy sma new agreement allow biogen license therapy arise collaboration company be responsible development biogen make upfront payment well payment achievement development regulatory milestone tiered royalty company already have sma treatment spinraza market be develop collaboration agreement inception september ionis have receive collaboration agreement biogen biogen ionis be zack rank hold stock see complete list today zack rank strong buy stock here regeneron sign isa immuno oncology collaboration regeneron pharmaceutical inc regn free report be collaborate isa pharmaceutical clinical stage immunotherapy company evaluate isa immunotherapy target human papillomavirus type hpv induced cancer combination cemiplimab regn pd antibody company jointly fund conduct study evaluate combination cervical cancer head neck cancer regeneron make upfront payment well equity investment isa gain option exclusive global license isa regeneron decide exercise option be liable make milestone well royalty payment isa regeneron be develop cemiplimab sanofi read more regeneron strategic immuno oncology collaboration isa clinical hold lift alnylam sanofi fitusiran fda have lift clinical hold be place study be conduct alnylam pharmaceutical alny free report sanofi fitusiran company expect resume dose year end study include phase ii open label extension ole study atla phase iii program dose have be suspend follow observation fatal thrombotic serious adverse event sae patient hemophilia inhibitor be receive fitusiran ole study read more sanofi alnylam say fda lift clinical hold fitusiran alnylam sanofi also announce have submit regulatory application eu approval patisiran treatment adult hereditary transthyretin mediate amyloidosis read more alnylam sanofi submit maa europe rnai candidate biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock vertex vrtx free report gain celgene decline last month biogen be regeneron lose see last biotech stock roundup here ash datum focus gilead buy cell design lab next biotech world watch usual pipeline regulatory update medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
726,VRTX,higher hope tax reform be pass have act latest catalyst drive wall street new high particular nasdaq composite index gain day outperform other benchmark dow jone hit major milestone first time surge technology sector account nearly half index well broad bullish sentiment help nasdaq lead higher gain year compare gain dow jone read tech etfs crushed fang etfs combination factor improve global fundamental strong corporate earning rise interest rate scenario emergence cut edge technology be act key catalyst stock consumer discretionary industrial stock index be also gain accelerate economic growth rise consumer confidence rise oil price pick activity most part world well improve global sentiment have add strength result powershare qqq qqq serve proxy index have climb nearly year so far let take closer look fundamental qqq qqq etf provide exposure largest domestic international financial company list nasdaq tracking nasdaq index be largest most popular etf large cap space aum average daily volume share charge investor bps annual fee fund have zack etf rank buy medium risk outlook see large cap etfs here most stock fund portfolio deliver strong return few be real star have gain more have highlighted best perform stock etf respective position fund basket top perform stock qqqalign technology inc algn free report stock make just allocation fund basket have deliver incredible return nearly year have see solid earning estimate revision cent year past day expect earning growth rate align technology have zack rank strong buy vgm style score additionally belong solid industry have zack rank top read sector etf stock winner year great recession mercadolibre inc meli free report stock have surge nearly year currently carry zack rank strong sell vgm style score stock have see negative earning estimate revision cent year past month expect earning decline further mercadolibre have ugly zack industry rank bottom stock account share qqq micron technology inc mu free report stock have gain year have see solid earning estimate revision past month year expect earning growth rate micron technology currently have zack rank top vgm style score also boast solid zack industry rank top stock make share fund basket vertex pharmaceutical vrtx free report stock have surge year carry zack rank hold vgm style score company have see solid earning estimate revision cent year past month expect earning growth stock belong industry have zack rank top account just share qqq read value biotech etfs buy now wynn resort limit wynn free report stock have gain so far year have exposure fund basket have see solid earning estimate revision cent past month year expect earning growth rate wynn resort have zack rank vgm style score additionally have solid industry rank top want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
727,VRTX,biotech sector have have great year spdr biotech etf xbi free report add dec ebb tension price gouge issue hope ease regulation positive clinical trial fda approval drug success immune oncology field lead rally top performer space virtus lifesci biotech clinical trial etf bbc free report be year date frame dec however steep price rise result overvaluation concern many fear high beta sell space next year highlight few factor power rally likely tax reformwith tax reform few hurdle away enactment be reason cheer biotech stock reform seek lower corporate tax rate boost drug biotech company change tax code also permit company bring back huge cash hold overseas time tax rate read senate pass tax bill etfs buy now upbeat clinical trial fda clinical trial new drug be also act tailwind space notable improvement be note cancer drug datum clovis oncology clvs free report say june clinical trial datum ovarian cancer drug treatment indicated substantially help more patient expect news act catalyst entire space read stock etfs buy clovis positive drug datum month impressive clinical datum blood disorder medication be release breakthrough food drug administration fda approval vertex pharmaceutical vrtx free report new fda approval cystic fibrosis drug novartis ag breakthrough gene transfer treatment be notable merger acquisition perk tax reform cash repatriation lead rise biotech merger acquisition case merger acquisition last few year have be great biotech company reduce competition same kind offering attain synergy tax reform leave company more cash pursue dream deal expectation be rife big player sanofi pfizer merck announce deal etfs tap say note overvaluation come way rally so better bet etfs still have low valuation highlight few biotech etfs have considerably low sector benefit investor solid gain see health care etfs here spdr biotech etf xbi free report xvaneck vector biotech etf bbh free report xloncar cancer immunotherapy etf cncr free report xishare nasdaq biotechnology etf ibb free report xwant key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
728,VRTX,major biotech stock gilead gild free report celgene celg free report alexion abbvie abbv free report vertex vrtx free report report second quarter result last few day company gilead amgen amgn free report also provide regulatory update recap week most important storiesa look earning result gilead result be strong company hiv franchise putt strong performance hepatitis virus hcv franchise perform better expect company raise revenue outlook include hcv franchise read more gilead top earning revenue estimate stock celgene also top estimate raise earning guidance year read more celgene beat earning sale estimate up view do alexion read more alexion top earning revenue up view vertex read more vertex earning top solid cystic fibrosis sale abbvie too top expectation read more abbvie top earning revenue outlook intact earlier expect fda approval celgene agio cancer drug celgene partner agio agio free report gain fda approval idhifa enasidenib treatment adult patient relapse refractory acute myeloid leukemia aml idh mutation detected fda approve test approval come ahead fda action date aug make idhifa first only fda approve therapy patient population represent aml patient information provide company more new case aml be detected year majority patient see disease relapse eventually prognosis aml be poor overall survival patient population estimate be less month idhifa come box warning regard differentiation syndrome uptake be strong give significant unmet medical need be third time lucky dynavax heplisav dynavax dvax free report share shot favorable recommendation fda vaccine related biological product advisory committee vrbpac heplisav vaccine immunization hepatitis infection adult positive vote expectation be high company finally gain approval vaccine have previously receive complete response letter nov other feb decision agency be expect aug approve dynavax plan launch vaccine early next year dynavax share be whopping year date significantly outperform industry rally read more dynavax share jump fda committee approval vertex up cf outlook kalydeco label expansion vertex cystic fibrosis cf drug kalydeco label have be expand now be used more cf patient year older have residual function mutation result splice defect cystic fibrosis transmembrane conductance regulator cftr gene label expansion vertex up sale guidance drug old guidance vertex now expect total cf product revenue old guidance include orkambi sale unchanged regulatory update amgen gilead amgen provide quite few regulatory update last few day company say have submit regulatory application seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop prolium bring sale first half amgen partner allergan also say have file fda approval abp biosimilar candidate roche herceptin trastuzumab herceptin be approve treatment adjuvant breast cancer metastatic breast cancer metastatic gastric cancer meanwhile amgen pcsk inhibitor repatha get priority review inclusion fourier cardiovascular outcome study datum reduction risk cardiovascular event decision agency be expect dec amgen say second application expansion lipid lower indication include additional patient population study be also accept agency gilead also have update regulatory front company say hcv drug epclusa label be update include use patient co infected hiv epclusa initially gain approval jun be oral pan genotypic once daily single tablet regimen label expansion provide co infected patient convenient pill day regimen work hcv genotype be compatible widely used antiretroviral regimen epclusa sale crossed first half moreover gilead latest hcv offer vosevi gain approval eu treatment genotype marketing authorization harvoni eu be also extend allow use adolescent population vosevi be approve few week back july gilead be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock alexion gain regeneron lose last month vertex be see last biotech stock roundup here amgen biogen top estimate update incyte ra drug next biotech world watch earning report company biomarin regeneron other more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
729,VRTX,pharma sector have be moderate performer year nyse arca pharmaceutical index add so far year nov underperform nasdaq do not eat issuer enthusiasm direxion recently launch triple leverage pharmaceutical fund name daily pharmaceutical medical bull share pill free report let delve little deeper find cause issuer shoot leverage fund apparently underperform current level space fund look track performance dynamic pharmaceutical intellidex index underlie index comprise common share company be research development manufacturing distribution pharmaceutical drug type abbvie ord shs bristol myer squibb ord pfizer ord be top holding fund pharmaceutical stock occupy portfolio biotechnology stock account rest fund charge annually do fit portfolio price gouge have be nagging space threat have subside lot trump era more vocal protest democratic opponent hillary clinton campaign day sector still face risk price controversy still long term prospect space appear bright however progress close pharma sector continue perform well breakthrough food drug administration fda approval success immune oncology field merger acquisition read keep portfolio healthy biotech etfs third quarter biotech stock vertex pharmaceutical vrtx free report receive new fda approval cystic fibrosis drug kalydeco early september fda approve novartis ag breakthrough gene transfer treatment gilead science gild free report gild free report
730,VRTX,index hasn logged fall least nov article publish marketwatch marked longest winning streak north korea induced geopolitical tension hurricane political entanglement europe fed rate hike uncertainty trump tax plan come way index read etf strategy benefit north korea tension rather hope deregulation tax cut well improve global economy keep push market higher bar occasional blip index be nov highlight few etfs stock gain record run trump bump improve economy proshare ultra etf sso free report be most popular liquid etfs leverage space aum more fund seek deliver twice return index charge investor expense ratio fund have gain nov read hit mark trade etfs direxion daily bull share etf offer exposure index charge just bps annual fee have accumulate asset base have add nov direxion daily bull share spuu free report product also provide time exposure index charge lower fee bps have aum fund have add nov proshare ultrapro etf upro free report investor have more bullish view higher risk appetite find upro interesting fund provide time exposure index etf charge slightly higher fee bps year have amassed asset base so far be nov stock picksalign technology inc algn free report align technology manufacture market invisalign system proprietary method treat malocclusion vgm value growth momentum score stock be time writing stock be nov nrg energy inc nrg free report company own operate portfolio power generate facility primarily unite state vgm score stock be time writing stock be nov vertex pharmaceutical incorporate vrtx free report company market small molecule drug address major unmet medical need stock have vgm sore be nov micron technology inc mu free report company business segment include computer networking business unit cnbu mobile business unit mbu storage business unit sbu embed business unit ebu vgm score stock be now nov want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
731,VRTX,galapago nv glpg free report announce positive top line datum phase ii study albatross evaluate cystic fibrosis transmembrane conductance cftr corrector candidate glpg cystic fibrosis cf patient lead improvement lung function so far year galapago share have outperformed industry stock have gain compare increase register industry phase ii study evaluate once daily dose mg mg candidate cf patient have gate mutation del mutation be long term stable treatment vertex pharmaceutical incorporate vrtx free report cf drug kalydeco treatment kalydeco be continue course study study achieve primary objective safety be well tolerate patient population datum also show improvement mean percent predict fev measure lung function compare baseline mg arm study meanwhile vertex be also develop combination therapy tezacaftor kalydeco similar indication apart glpg galapago be also develop glpg cftr regulator phase study glpg cftr potentiator phase ii study cf patient candidate be be develop partnership abbvie inc abbv free report company have diverse pipeline candidate be develop several other indication include atopic dermatitis psoriatic arthritis uveitis lupus membranous nephropathy other galapago nv price galapago nv price galapago nv quotezack rank stock carry zack rank hold sucampo pharmaceutical inc be better rank health care stock sporting zack rank strong buy see complete list today zack rank stock here sucampo earning share estimate have increase last day company deliver positive earning surprise trail quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
732,VRTX,biotech industry turn year drug pricing issue cripple performance last year have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product play pivotal role bring sector track year however rise first month year january september medical biotech genetic industry have decline so far fourth quarter oct date macro industry specific factor result sudden downfall uncertain macro picturea big component sell be confusion pass tax reform reform aim bring corporate tax stimulate economic well employment growth propose tax reform approve leave more cash hand biotech company cash be invest merger acquisition have be relatively fewer year compare last go say significant uncertainty regard timely pass tax reform have cast shadow future biotech sector october president trump once again criticize high drug price come time investor have start expect trump action drug price not be onerous previously fear send health care stock lower tepid resultscome industry specific factor most big biotechs beat estimate earning sale however share most company decline post earning release various reason gilead gild free report top earning revenue estimate third quarter witness continue decline sale hcv drug harvoni sovaldi result competitive pricing pressure amgen amgn free report also beat expectation earning sale raise earning guidance however sale decline year year result share price decline post earning call sale pcsk inhibitor repatha be also disappointing celgene celg free report share plunge follow release third quarter result celgene earning top estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook biogen biib free report third quarter result be better expect share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza alexion alxn free report top earning estimate miss revenue third quarter vertex vrtx free report abbvie abbv free report be only outperformer conclusionwe believe biotech space be back track be more certainty regard timing tax reform be fundamental sector remain strong meanwhile earning season now stock start pick positive datum key clinical study drive sector share price biotechs be correlated success key study major biotech player need infusion new growth driver pipeline product portfolio internal development buy asset outside strategic deal sign biotechs also push stock higher look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
733,VRTX,second quarter report cycle be full swing quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig eli lilly company lly free report biogen inc biib free report release second quarter result week company beat earning revenue estimate raise sale earning expectation full year moreover vertex pharmaceutical incorporate vrtx free report amgen inc amgn free report report encourage second quarter result jul beating estimate count however glaxosmithkline plc gsk free report report mixed second quarter result same day beating earning miss sale let take look large cap pharma company be set report second quarter result jul abbvie inc abbv free report abbvie be schedule release earning market open have deliver positive earning surprise last quarter abbvie earning performance have be mixed earning beating expectation last quarters meeting same remain result average positive surprise quarter abbvie have earning esp zack rank hold do not conclusively show abbvieis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter abbvie inc price ep surprise abbvie inc price ep surprise abbvie inc quoteabbvie key drug humira be perform well be expect continue do well second quarter imbruvica have be record strong sale past few quarters expect trend continue however hcv franchise continue be pricing pressure read more abbvie earning disappointment store merck co inc mrk free report merck be also schedule announce result open bell merck have beaten estimate last quarters result average positive surprise last report quarter merck deliver positive surprise merck company inc price ep surprise merck company inc price ep surprise merck company inc company have earning esp zack rank buy thus do not look poise deliver beat time see complete list today zack rank strong buy stock here merck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter however company be expect face headwind form genericization increase competition negative impact currency exchange read more merck pull surprise earning season more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
734,VRTX,vertex pharmaceutical incorporate vrtx free report report second quarter earning share cent include impact stock base compensation expense beat zack consensus estimate cent notably company have post loss cent year quarter strong product revenue lead higher profit quarter exclude stock base compensation expense second quarter adjust earning be cent share compare year figure cent vertex report revenue second quarter year year drive strong product revenue revenue also beat zack consensus estimate cf franchise sale strongvertex second quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be second quarter year year kalydeco sale rise gain inventory stocking ahead jul holiday year kalydeco be approve use cf patient year older have residual function mutation cftr gene more person have mutation expand indication boost sale drug future quarters orkambi lumacaftor ivacaftor deliver sale year year sequential basis orkambi sale rise almost second quarter support continue uptake globally further uptake pediatric indication approval be receive sep meanwhile inventory stocking ahead jul holiday also benefit sale second quarter cost riseadjust include stock base compensation expense research development expense increase second quarter due higher cost related development triple combination cf regimen adjust include stock base compensation expense selling general administrative sg expense increase due increase investment support global launch orkambi maintain guidancevertex maintain guidance orkambi kalydeco sale raise guidance combine operate cost orkambi revenue be expect range kalydeco revenue be estimate range remind investor follow approval additional indication kalydeco revenue guidance be up total cf product revenue be expect range combine adjust research development selling general administrative sg expense be anticipate range higher expect previously cost be expect be higher due accelerate development triple combination cf pipeline investment develop ctp focus triple combination cf regimensvertex be evaluate next generation cftr corrector vx vx vx vx part triple combination withvx tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study conduct cf patient have del mutation minimal function mutation del min be present last week datum demonstrated combination lead pronounce improvement lung function fact be first datum show potential treat underlie cause cf patient have severe difficult treat type disease follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half other cf pipeline updatein march positive datum phase iii study evolve expand evaluate kalydeco combination vx tezacaftor cf patient copy del mutation be also announce study meet primary endpoint demonstrated statistically significant improvement lung function base positive outcome study company recently submit regulatory application eu encouragingly combination be also grant orphan drug designation fda june earlier week vertex announce have close previously announce agreement buy concert pharmaceutical inc cnce free report cf pipeline candidate ctp vertex plan develop ctp potential use future once daily regimen combination other pipeline drug treat underlie cause cf takevertex second quarter result be encourage top estimate count sale cf drug rise share decline slightly hour trading probably response hike operate cost expectation year however so far year vertex share priceis massive compare favorably increase industry meanwhile vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient cf future however forget potential competition vertex triple combo belgian company galapago nv glpg free report abbvie inc abbv free report be also develop triple cftr combination therapy cf vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotevertex sport zack rank strong buy see complete list today zack rank stock here more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
735,VRTX,efficiency ability transform input output be potential indicator company financial health company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance ratio evaluate efficiency levelswe have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough patch term sale dwindle level indicate company run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be possibility company be utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have ratio higher respective industry average screening parametersin addition mentioned ratio have add favorable zack rank zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average higher value ratio industry average indicate efficiency level company be greater peer use criterium have narrow universe stock only here be top stock farmer merchant bancorp inc fmao free report operate bank hold company farmer merchant state bank provide commercial banking retail banking other financial service individual small business northwest ohio northeast indiana zack rank company have average quarter positive earning surprise advanced energy industry inc aeis free report be provider engineer precision power conversion measurement control solution zack rank company have average quarter positive earning surprise nvr inc nvr free report be engage construction sale single family detach home townhome condominium building zack rank company have average quarter positive earning surprise see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report be engage discover develop manufacturing commercialize medicine serious disease zack rank company have average quarter positive earning surprise sanderson farm inc safm free report be poultry process company company be engage production process marketing distribution fresh frozen chicken also preparation process marketing distribution processed minimally prepared chicken zack rank company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
736,VRTX,just handful biotech company left report third quarter result focus be back regulatory pipeline update major news week dynavax technology dvax free report finally gain fda approval hepatitis vaccine loxo oncology loxo free report be news collaboration agreement bayer recap week most important storiesloxo bayer deal worth loxo be focuse development highly selective medicine patient genetically defined cancer see share lose ground announcement collaboration agreement bayer be worth company be collaborate global development loxo highly selective trk inhibitor larotrectinib loxo patient trk fusion cancer agreement term include upfront payment loxo receive achievement certain regulatory commercial milestone additional milestone related loxo development cost be split equally company company co promote unite state loxo receive tiered double digit royalty net sale sale milestone totale ex territory larotrectinib be schedule be file fda approval late early loxo share be news investment community express disappointment sharing profit unite state well absence acquisition deal fda nod dynavax hepatitis vaccine turn be third time lucky dynavax company finally gain fda approval hepatitis vaccine heplisav regulatory action make heplisav first new hepatitis vaccine unite state more year only dose hepatitis vaccine adult hepatitis highly infectious potentially deadly virus affect wide range adult unite state infection rise give absence cure however hepatitis be prevent vaccination heplisav be first fda approve product dynavax company expect launch vaccine first quarter achillion slip secondary offer news achillion pharmaceutical inc achn free report be news shareholder johnson johnson innovation jjdc inc jjdc be selling whole equity positon achillion approximately share achillion not receive part proceed offer remind investor achillion have agreement johnson johnson janssen pharmaceutical hepatitis virus hcv treatment time announce hcv agreement achillion have also announce equity transaction jjdc invest achillion get approximately newly issue unregistered share achillion share be significantly company have announce termination hcv agreement september read more achillion hcv partnership terminate stock fall year date achillion share be compare industry rally zymework inks deal company zymework inc clinical stage company announce licensing agreement janssen biotech company development next generation bispecific antibody therapeutic deal janssen get worldwide royalty bearing license research develop commercialize bispecific antibody used zymework azymetric efect platform zymework be entitle upfront payment development milestone commercial milestone payment well tiered royalty potential sale janssen also have option add more bispecific program deal mean additional money zymework deal be boost zymework already have partnership agreement several other large company merck lilly celgene glaxo daiichi sankyo include deal zymework have potential earn milestone worth total agreement zymework be zack rank buy stock see complete list today zack strong buy rank stock here chmp positive amgen drug amgen amgn free report partner allergan get positive opinion european union committee medicinal product human use chmp abp biosimilar version roche blockbuster cancer drug avastin bevacizumab abp be already approve unite state trade name mvasi amgen also get positive opinion chmp effort expand use nplate pediatric patient chronic immune purpura read more amgen get positive chmp opinion expand nplate label chmp positive vertex orkambi label expansion vertex vrtx free report also get positive opinion chmp label expansion cystic fibrosis cf drug orkambi use child cf year age group copy del mutation approval age group expand target patient population patient decision be month orkambi be already approve age group unite state be expect bring revenue meanwhile company expect seek regulatory approval use orkambi child cf year age group have copy del mutation first quarter read more vertex get chmp recommendation orkambi label expansion biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock regeneron lose alexion be last month vertex be celgene be see last biotech stock roundup here regeneron deliver strong result cellectis clinical hold lift next biotech world clinical stage company ultragenyx pharmaceutical inc rare free report well gain fda approval first product week fda expect give response november approval status vestronidase alpha rhgus mps also know sly syndrome patient world be afflict disease be rarest form mps currently be approve treatment mps hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
737,VRTX,vertex pharmaceutical inc vrtx free report announce committee medicinal product human use chmp have recommend approval label expansion orkambi europe company be seek extension marketing authorization orkambi include use child cystic fibrosis cf be age year have copy del mutation note european commission generally follow recommendation chmp be not bound decision be typically expect month recommendation remind investor orkambi be currently approve eu treatment cf patient age year have copy del mutation cf transmembrane conductance regulator cftr gene vertex stock have outperformed industry so far year share be compare industry gain period company believe label expansion increase eligible patient population europe drug be already approve unite state indication orkambi generate net sale first month grow year period potential label expansion further boost drug sale meanwhile company have complete part phase iii study evaluate orkambi cf patient year age have copy del mutation cftr gene last month company announce study meet primary endpoint safety vertex expect file application expand orkambi label patient population regulatory authority unite state europe first quarter cf rare life threaten disease be estimate affect approximately person unite state europe australia vertex currently have cf drug kalydeco portfolio company generate cf product revenue more include sale kalydeco orkambi first month moreover boost cf portfolio curb competition vertex buy concert pharmaceutical inc cnce free report cf candidate ctp july cf market have be attract lot interest several company develop candidate potential therapy patient vertex pharmaceutical incorporate price vertex pharmaceutical incorporate price vertex pharmaceutical incorporate quotezack rank stock considervertex carry zack rank hold couple better rank health care stock include ophthotech corporation opht free report ligand pharmaceutical inc lgnd free report ophthotech sport zack rank strong buy ligand carry zack rank buy see complete list today zack rank stock here ophthotech earning share estimate have moved cent last day company deliver positive earning surprise trail quarters average beat ligand earning share estimate have moved last day company pull positive earning surprise trail quarters average beat share price company have increase year date make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
738,VRTX,key highlight biotech sector past week include earning result company regeneron pharmaceutical inc regn free report lift clinical hold impose fda couple study be conduct cellectis cll free report ucart recap week most important storiessolid result regeneron regeneron third quarter result be strong company surpass earning revenue expectation flagship product eylea continue perform well third quarter call regeneron say diabetic macular edema dme indication represent significant growth opportunity consider only patient dme unite state be currently treat vegf agent regeneron be look expand eylea label diabetic retinopathy expect file regulatory approval second half result late stage study be positive supplementary biologic license application bla week dose eylea wet age related macular degeneration amd be set be file year end dupixent launch atopic dermatitis be ongoing regeneron partner sanofi expect file approval asthma indication year end meanwhile datum odyssey outcome study pcsk inhibitor praluent be first quarter regulatory application pd inhibitor cemiplimab be also slate first quarter read more regeneron beat earning sale share regeneron have gain year date outperform industry rally dicerna boehringer ingelheim work together nash treatment dicerna pharmaceutical drna free report be focuse development investigational rna interference rnai therapeutic have sign boehringer ingelheim discovery development novel rnai therapeutic base dicerna proprietary technology platform galxc treatment chronic liver disease initial focus be nonalcoholic steatohepatitis nash chronic liver disease treatment option currently approve several company be conduct research area agreement see dicerna receive more boehringer include upfront payment development commercial milestone payment reimbursement galxc candidate address undisclosed nash target dicerna also receive stagger royalty double digit worldwide net sale dicerna share jump follow announcement deal keryx auryxia label expansion keryx inc kerx free report be focuse develop medicine renal disease gain fda approval label expansion auryxia auryxia now be used treatment patient iron deficiency anemia dialysis dependent chronic kidney disease ckd however approval indication significantly expand patient population auryxia be positive company share be disappointing third quarter result read more keryx loss wider expect stock decline fda lift clinical hold cellectis study fda lift clinical hold previously announce sep couple early stage study be conduct cellectis ucart acute myeloid leukemia aml blastic plasmacytoid dendritic cell neoplasm bpdcn hold be place company have report death bpdcn study cellectis have agree several change study protocol hold be lift include lower cohort dose level well dose lympho deplete regimen include specific criterium day ucart infusion ensure next patient be treat protocol be age ensure enrollment be stagger ucart protocol aml abc least day elapse enrollment patient study lift clinical hold come several restriction be relief company be focuse develop immunotherapy base gene edit allogeneic car cell ucart cellectis be zack rank buy stock see complete list today zack rank strong buy stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index gain last trading session major biotech stock regeneron be reflect strong third quarter result gilead gild free report be last month vertex vrtx free report be celgene lose see last biotech stock roundup here celgene amgen gilead hit result vertex beat front next biotech world several small mid cap company be report result next few day moreover company dynavax technology corporation dvax free report heron therapeutic inc get response fda regulatory application file be third time lucky dynavax be await approval hepatitis vaccine heplisav fda expect respond today heron be await decision fda cinvanti be review prevention chemotherapy induced nausea vomit cinv fda be expect give decision november today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
739,VRTX,expect vertex pharmaceutical inc vrtx free report beat expectation report third quarter result oct market close year date vertex share have soar industry have record increase vertex track record have be impressive so far company deliver positive earning surprise last quarters miss expectation average positive earning surprise last quarters be last report quarter vertex come positive surprise let see thing be shape quarter factor playvertex cystic fibrosis cf drug kalydeco orkambi do well second quarter expect positive trend continue second well kalydeco gain fda approval use patient year older have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene person unite state have mutation august kalydeco receive approval cf patient have residual function mutation cause splice defect cftr gene person unite state have mutation follow approval label expansion vertex up kalydeco revenue guidance zack consensus estimate kalydeco third quarter be orkambi sale growth be dependent reimbursement discussion europe june july year vertex strike re imbursement agreement ireland italy respectively orkambi thereby make medicine more accessible country expand accessibility be expect bring more sale drug first quarter company have also mentioned gain reimbursement france year contribute significantly revenue growth however company be yet sign agreement consensus estimate orkambi third quarter be vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor investor focus call be triple combination cf regimen be crucial long term growth vertex however operate expense be likely shoot vertex expand pipeline model proven model show vertex be likely beat estimate quarter have right combination key ingredient stock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex currently have zack rank combination positive earning esp favorable zack rank make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quoteother stock warrant lookhere be biotech stock also want consider model show have right combination element post earning beat quarter clovis oncology inc clvs free report be expect release result nov company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result oct company have earning esp zack rank trevena inc trvn free report be expect release result nov have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
740,VRTX,facebook inc fb free report operate social networking worldwide zack rank strong buy stock growth score have ample growth catalyst not least be earning estimate continue rise strong balance sheet significant cash flow also make attractive investor vertex pharmaceutical inc vrtx free report discover develop market small molecule drug address major unmet medical need company have cystic fibrosis drug portfolio blockbuster potential company also have strong history beating consensus earning estimate not only zack rank strong buy have growth momentum score more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
741,VRTX,be enter peak period second quarter report cycle week quarter undoubtedly be strong start jul member accounting index total market capitalization report result accord earning preview beat revenue earning estimate compare first quarter total earning index member be year quarter improvement revenue beat ratio be earning revenue earning momentum be expect continue season report total earning company second quarter be expect grow year year higher revenue follow earning growth first quarter increase revenue highest almost year pharma bigwig johnson johnson jnj free report report mixed second quarter result beating earning miss sale other hand novartis nvs free report second quarter result be encourage company top earning sale estimate jul lilly lly free report biogen inc biib free report release second quarter result company beat earning revenue estimate lilly raise previously issue adjust earning sale outlook biogen also raise earning sale outlook let take look pharma giant be set report second quarter result jul let see thing be shape quarter gilead science inc gild free report gilead be schedule release earning close bell have deliver positive earning surprise last quarter gilead earning performance have be mixed earning miss expectation last quarters beating remain result average positive surprise quarter gilead have earning esp zack rank hold indicate likely beat quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter hiv other antiviral product be expect boost sale however hcv franchise continue be pricing pressure read more be gilead poise beat earning season gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotevertex pharmaceutical inc vrtx free report vertex be also schedule announce result close bell vertex average positive earning surprise last quarters be last report quarter vertex post positive surprise company have earning esp zack rank strong buy be thus expect beat earning estimate quarter see complete list today zack rank stock here investor focus vertex second conference call be triple combination cystic fibrosis cf regimen be crucial long term growth vertex datum vx vx phase ii vx phase triple combination study present last week have show combination lead pronounce improvement lung function read more be beat card vertex earning vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate plc gsk free report company be expect report market hour glaxosmithkline report line earning last quarter glaxo performance have be pretty impressive company report positive surprise consistently average earning beat last quarters be company have earning esp zack rank glaxo pharmaceutical vaccine segment be expect drive sale second quarter well meanwhile consumer healthcare segment have slow due impact general sale tax continue slowdown nutrition category india challenge economic condition other international market nigerian beverage business divestment factor impact second quarter result well read more lie store glaxo earning season glaxosmithkline plc price ep surprise glaxosmithkline plc price ep surprise glaxosmithkline plc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
742,VRTX,geron corporation gern free report be expect report second quarter result next week company earning come line zack consensus estimate last report quarter let see thing be shape upcoming announcement geron share outperformed industry rise so far year industry witness gain focus imetelstat geron have approve product portfolio top line solely comprise license fee royalty such scenario investor focus remain company sole pipeline candidate imetelstat geron collaboration johnson johnson jnj free report janssen biotech be develop candidate treat patient hematologic myeloid malignancy myelofibrosis mf myelodysplastic syndrome mds acute myelogenous leukemia aml april geron provide positive update late stage study imetelstat imbark phase ii treatment myelofibrosis mf imerge phase ii iii treatment myelodysplastic syndrome mds owing favourable update trial be continue unmodified geron inform janssen have complete second internal review datum study imbark imerge imetelstat janssen say benefit risk profile imetelstat treat patient support continue development lower risk mds indication imbark latest clinical benefit potential overall survival benefit observed support continuation trial modification trial assess safety efficacy imetelstat treatment relapse refractory mds also include assessment overall survival also datum suggest mg kg be appropriate start dose studyjanssen be expect take decision regard initiation phase iii stage imerge study later year decision regard continue development imetelstat relapse refractory mf indication next year expect company provide update path forward imetelstat development program second quarter conference call surprise historygeron performance last quarters have be mixed company surpass expectation thrice meeting same once average positive surprise last quarters be geron corporation price ep surprise geron corporation price ep surprise geron corporation quoteearning whispersour proven model do not conclusively show geron be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate zack consensus estimate stand loss cent uncover best stock buy sell re report earning esp filter zack rank geron zack rank increase predictive power esp esp make surprise prediction difficult quarter note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be couple health care stock want consider model show have right combination element post earning beat quarter arena pharmaceutical inc arna free report be expect release result aug company have earning esp zack rank see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
743,VRTX,company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance efficiency be ability transform input output be potential indicator company financial health key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank buy screen objective make strategy more profitable see complete list today zack rank strong buy stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium narrow universe stock only here be stock make screen vertex pharmaceutical incorporate vrtx free report be engage discover develop manufacturing commercialize medicine serious disease company have average quarter positive earning surprise lululemon athletica inc lulu free report be designer distributor retailer athletic apparel company operate segment company operated store direct consumer have average quarter positive earning surprise sanderson farm inc safm free report be integrate poultry process company produce process market distribute fresh frozen prepared chicken product unite state company have average quarter positive earning surprise farmer merchant bancorp inc fmao free report operate bank hold company farmer merchant state bank provide commercial banking retail banking other financial service individual small business northwest ohio northeast indiana company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
744,VRTX,swiss pharmaceutical company novartis ag nvs free report be schedule report third quarter result oct novartis stock have rally year date compare industry gain last quarter novartis deliver positive earning surprise company post average positive earning surprise trail quarters let see thing be shape announcement factor playconcurrent second quarter result novartis reiterate guidance net sale be expect be broadly line level include impact continue genericization gleevec glivec unite state europe novartis operate segment innovative medicine pharmaceutical alcon sandoz generic novartis have strong oncology portfolio drug afinitor exjade jakavi zykadia tasigna jadenu recently approve kisqali recent approval kymriah acute lymphoblastic leukemia be major boost novartis give potential car therapy space meanwhile fda have recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer new product cosentyx entresto be expect boost top line cosentyx have be strong company have grab market share rival abbvie inc abbv free report humira amgen inc amgn free report enbrel cosentyx achieve blockbuster status record sale entresto be expect record revenue sale cosentyx be project reach additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure be expect impact third quarter result also loss exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition unite state eu japan gleevec lose exclusivity unite state february eu december thereby lead generic competition exforge be also face generic competition unite state eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company negative esp make highly unlikely earning beat quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quote stock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result oct see complete list today zack rank stock here hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
745,VRTX,investor be always look stock be poise beat earning season vertex pharmaceutical incorporate vrtx free report be such company firm have earning come pretty soon event be shape quite nicely report be vertex pharmaceutical be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface vrtx report fact most accurate estimate current quarter be currently cent share vrtx compare broader zack consensus estimate cent share suggest analyst have very recently bump estimate vrtx give stock zack earning esp head earning season vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give vrtx have zack rank strong buy esp positive territory investor want consider stock ahead earning see complete list today zack rank stock here clearly recent earning estimate revision suggest good thing be ahead vertex pharmaceutical beat be card upcoming report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
746,VRTX,exelixis inc exel free report be schedule report second quarter result aug market close exelixis track record be outstanding company have surpass expectation trail quarters average positive earning surprise exelixis share price have increase year date compare zack classify industry gain factor likely impact resultsexelixis receive major boost fda approval cabometyx tablet apr treatment patient advanced renal cell carcinoma rcc initial uptake drug be encourage be expect propel top line forthcoming quarters sequential increase cabometyx sale be also positive moreover cabometyx be also approve eu meanwhile exelixis be develop cabozantinib broad development program oct company announce positive result phase ii cabosun study cabozantinib versus sunitinib formerly untreated advanced rcc be present esmo base cabosun result company have plan submit supplemental new drug application snda cabozantinib treat first line advanced rcc third quarter company present further positive analysis trial jun potential label expansion drug further boost result early exelixis collaborate bristol myer squibb bmy free report evaluate cabozantinib combination opdivo alone combination yervoy phase iii trial first line rcc potentially other tumor type include hcc bladder cancer exelixis also evaluate cabometyx combination tecentriq pd antibody patient advanced rcc bladder cancer jun exelixis initiate dose escalation stage phase ib trial cabozantinib combination tecentriq drug be evaluate patient suffering locally advanced metastatic urothelial carcinoma uc rcc collaboration allow exelixis earn milestone payment royalty boost top line however expense continue increase exelixis expect total cost operate expense range exelixis inc price ep surprise exelixis inc price ep surprise exelixis inc quoteearning whispersour proven model do not conclusively show exelixis be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat earning be not case here see zack esp earning esp represent difference most accurate estimate zack consensus estimate be most accurate be cent zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank exelixis sport zack rank be favorable however combine negative esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
747,VRTX,celgene corporation celg free report be schedule report second quarter result jul open bell last quarter company beat expectation celgene have outperformed zacksclassify industry year so far stock have gain period industry gain celgene track record have be pretty decent company beating earning estimate thrice trail quarters overall company have deliver average positive surprise let see thing be shape company ahead announcement earning whispersour proven model show celgene be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg lower uncover best stock buy sell re report earning esp filter zack rank celgene currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision factor playconcurrent first quarter earning result celgene update outlook company now expect earning compare earlier forecast share net product sale be expect celgene key product revlimid continue be main growth driver first quarter drive share gain important market longer treatment duration newly diagnosed multiple myeloma mm revlimid sale be project currently celgene be work expand revlimid label further fda approve use maintenance treatment ndmm patient receive autologous stem cell transplant drug be also approve eu same ndmm market share continue grow outside positive uptake eu japan label expansion drug be expect boost sale further meanwhile broad phase iii program evaluate revlimid hodgkin lymphoma nhl be underway other key product pomalyst imnovid abraxane otezla continue perform well otezla pomalyst achieve blockbuster status record sale otezla sale first quarter be impact manage care dynamic lead lower total marketplace prescription psoriasis therapy pressure be expect ease year go pomalyst imnovid be be evaluate multiple combination study relapse refractory mm drug label be recently update eu include datum pooled pharmacokinetic analysis patient relapse refractory mm impair renal function pomalyst combination darzalex dexamethasone relapse refractory myeloma be fda review abraxane sale be estimate be pomalyst revenue be project same otezla be estimate meanwhile expense percentage revenue be expect increase year second quarter call investor be expect remain focuse company performance label expansion effort update pipeline front celgene have submit new drug application fda idhifa relapse refractory aml nda idhifa be grant priority review prescription drug user fee act pdufa action date aug note celgene have inked agreement agio pharmaceutical agio free report idhifa celgene corporation price ep surprise celgene corporation price ep surprise celgene corporation quotestock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
748,VRTX,major biotech company report earning result last trading day company amgen amgn free report vertex vrtx free report top expectation be mixed quarter company celgene celg free report alexion read more alexion top earning lag sale view biomarin read more biomarin loss narrow profit guidance raise recap week most important storiesa look earning result be earning week several key name report third quarter result amgen top expectation witness year year decline revenue company also announce not be develop oral cetp inhibitor amg be explore licensing opportunity candidate read more amgen earning top sale decline stock fall meanwhile celgene plunge follow release third quarter result celgene top earning estimate revenue fall short moreover company lower outlook otezla sale well total revenue earning outlook reflect impact discontinuation ged crohn disease market dynamic impact otezla opportunity risk associate late stage datum read out schedule read more celgene top earning sale miss update view vertex have strong presence cystic fibrosis cf market report strong quarter earning revenue surpass expectation company also raise guidance cf franchise sale read more vertex beat earning sale raise view vertex have gain year date outperform industry rally abbvie abbv free report top earning estimate revenue be line read more abbvie earning top revenue line view gilead surpass expectation company hepatitis virus hcv franchise remain immense pressure read more gilead weak hcv sale earning beat incyte epacadostat be study early lung cancer imfinzi incyte corporation incy free report report strong third quarter result also announce expansion clinical trial collaboration astrazeneca company say evaluate efficacy safety incyte investigational selective ido enzyme inhibitor epacadostat combination astrazeneca pd inhibitor imfinzi compare imfinzi alone company conduct late stage study patient locally advanced stage iii unresectable small cell lung cancer nsclc disease have not progressed follow platinum base chemotherapy concurrent radiation therapy crt study be co funded company be conduct astrazeneca patient enrolment schedule commence first half note incyte have clinical trial collaboration merck well bristol myer squibb epacadostat incyte be zack rank hold stock see complete list today zack strong buy rank stock here voyager sanofi exit parkinson disease program voyager therapeutic inc vygr free report share be sanofi exit company vy aadc program advanced parkinson disease deal sign february sanofi have exclusive option ex development commercial right vy aadc deal term include upfront payment well future potential development sale milestone payment tiered royalty product sale accord voyager sanofi decide exit deal option do not include right unite state voyager gain global right vy aadc program advanced parkinson disease company say remain track dose first patient second quarter gw finish roll drug submission epilepsy drug gw pharmaceutical plc gwph free report announce have complete roll submission new drug application nda unite state epidiolex cannabidiol adjunctive treatment seizure associate lennox gastaut syndrome lgs dravet syndrome lgs dravet syndrome be highly treatment resistant form childhood onset epilepsy gw have rare pediatric disease orphan drug designation indication unite state dravet syndrome indication have fast track status well fda timely approval allow company launch product biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow release third quarter result alexion be last month vertex be celgene be see last biotech stock roundup here biogen top earning gilead car drug get fda nod next biotech world focus remain earning result several mid small cap biotech company more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
749,VRTX,vertex pharmaceutical incorporate vrtx free report report third quarter earning share cent beat zack consensus estimate cent come ahead year earning cent strong product revenue lead higher profit quarter vertex report revenue third quarter almost year year drive strong product revenue revenue also beat zack consensus estimate cf franchise sale strongvertex third quarter revenue consist sale cystic fibrosis cf product kalydeco orkambi collaborative royalty revenue cf product revenue be third quarter year year kalydeco sale rise follow approval treat expand population kalydeco be approve use cf patient year older have residual function mutation cftr gene more person unite state have mutation expand indication boost sale drug future quarters august kalydeco be approve cf patient year older have residual function mutation result splice defect cftr gene occur more patient orkambi lumacaftor ivacaftor deliver sale year year growth be support continue uptake pediatric patient unite state additional revenue european country vertex have sign reimbursement agreement cost riseadjust research development expense increase third quarter due higher cost related development triple combination cf regimen adjust selling general administrative sg expense increase due increase investment support global orkambi kalydeco guidance raisedvertex increase guidance orkambi kalydeco sale however maintain guidance combine operate cost orkambi revenue be expect range previously kalydeco revenue be estimate range previously total cf product revenue be expect range note increase orkambi sale projection be base strong demand see so far year projection kalydeco be increase follow strong demand newly approve indication combine adjust research development selling general administrative sg expense be still anticipate range focus next generation cf regimensvertex tezacaftor ivacaftor combination treat cf patient be review unite state europe company be seek approval person cf age older have copy del mutation del mutation residual function mutation decision be expect february next year unite state approval europe be expect second half concurrent press release company announce datum phase iii study evaluate combination cf patient copy del mutation copy gate mutation study have fail meet primary endpoint absolute change percent predict force expiratory volume second ppfev measure lung function vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination vx tezacaftor ivacaftor follow discussion regulatory agency vertex initiate pivotal phase iii study triple combination regimen first half other cf pipeline updatevertex epithelial sodium channel enac inhibitor candidate vx be be evaluate phase ii study cf patient be be treat orkambi press release study do not meet primary endpoint change ppfev phase ii study be develop vx treat patient primary ciliary dyskinesia takevertex third quarter result be encourage company beat estimate count sale cf drug rise share decline slightly hour trading probably due failure pivotal tezacaftor ivacaftor study however so far year vertex share price be massive compare favorably increase industry vertex cf pipeline be quite strong broad portfolio next generation cf corrector triple combination cf regimen be consider crucial long term growth triple combo regime be successful vertex address significantly larger cf patient population almost patient future however competition be increase several major company be develop interest cf belgian company galapago nv glpg free report abbvie inc abbv free report be also develop triple cftr combination therapy cf threat vertex triple combo regimen vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate price consensus ep surprise vertex pharmaceutical incorporate quotevertex carry zack rank hold better rank stock health care sector be adaptimmune therapeutic plc adap free report carry zack rank buy see complete list today zack rank strong buy stock here adaptimmune loss estimate narrow cent cent last day company deliver positive earning surprise trail quarters average beat company share be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
750,VRTX,intercept pharmaceutical inc icpt free report be schedule report second quarter result jul last report quarter company beat expectation let see thing be shape announcement intercept share price movement year so far reveal stock outperformed industry company share have rally period compare industry gain surprise track record have be decent so far company surpass expectation last quarters company have post average positive earning surprise period likely positive surprise proven model show intercept be likely beat estimate quarter have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be peg loss zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank intercept currently carry zack rank combination zack rank positive esp make confident earning beat upcoming release conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision factor receive major boost fda approval lead drug ocaliva combination ursodeoxycholic udca treatment primary biliary cholangitis pbc adult inadequate response udca monotherapy adult unable bear udca dec european commission also grant conditional approval ocaliva same indication ocaliva generate sale last quarter initial uptake ocaliva have be encourage sale drug be expect topick further meanwhile ocaliva be be evaluate other indication include alcoholic steatohepatitis nash primary sclerosing cholangitis psc intercept expect operate expense range support continue ocaliva pbc unite state other market sustain clinical development oca pbc nash continue advancement int other pipeline program company initiate phase iii study regenerate ocaliva treatment cirrhotic nash patient advanced liver fibrosis fda approve redesign regenerate trial safety efficacy treat nash patient liver fibrosis company now need achieve only co primary endpoint fibrosis improvement nash resolution compare earlier target achieve sample size trial have also be reduce approximately patient patient arm company plan complete enrolment interim analysis cohort regenerate trial soon datum readout intercept also initiate phase ii study control combination oca andstatin monitoring lipid oca enrolment study be complete third quarter top line datum expect shortly company also plan initiate phase iii trial ocaliva nash patient cirrhosis second half company also expect top line result phase ii trial aesop primary sclerosing cholangitis psc expect investor remain focuse sale ramp ocaliva pipeline update call intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc price ep surprise intercept pharmaceutical inc quotestock warrant lookhere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report schedule release result jul have earning esp zack rank see complete list today zack rank stock here gilead science inc gild free report have earning esp zack rank company be schedule release result jul alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
751,VRTX,radius health inc rdus free report be schedule report second quarter financial result aug radius health share have outperformed industry year so far stock have gain time period industry gain radius health have disappointing track record so far company have miss estimate trail quarters negative average surprise let see thing be shape quarter factor playradius health focus development therapeutic treatment osteoporosis oncology endocrine disease company new drug tymlos be approve apr drug be instrumental treat postmenopausal woman osteoporosis high risk fracture defined history osteoporotic fracture multiple risk factor fracture drug be also used patient have fail be intolerant other available osteoporosis therapy drug be review eu drug be price annualize wholesaler acquisition cost pen hence expect investor focus impending launch upcoming earning call osteoporosis market have great potential approximately postmenopausal woman experience osteoporotic fracture year tymlos be expect face significant competition forteo prolium meanwhile committee medicinal product human use chmp issue second day list outstanding issue request additional datum analysis related safety efficacy abaloparatide sc process ongoing regulatory review company expect chmp issue opinion regard maa abaloparatide sc prior end company be plan file supplemental new drug application tymlos base activextend study result activextend trial show statistically significant fracture risk reduction year sequential therapy tymlos follow antiresorptive jun company announce encourage result ongoing phase study pipeline candidate elacestrant rad patient suffering estrogen receptor positive breast cancer candidate oral selective estrogen receptor serd be be evaluate potential use oral steroidal treatment estrogen receptor positive breast cancer high dose first quarter earning call company state plan discuss next step program fda expect company throw more light same radius health inc price ep surprise radius health inc price ep surprise radius health inc quoteearning whispersour proven model do not conclusively show radius health be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp radius health be currently peg be most accurate estimate zack consensus estimate be peg loss uncover best stock buy sell re report earning esp filter zack rank radius health have zack rank sell note caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision stock considerhere be few pharma company consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report be schedule release result jul company have earning esp zack rank see complete list today zack rank stock here intercept pharmaceutical inc icpt free report have earning esp zack rank company be expect release result aug gilead science inc gild free report have earning esp zack rank company be schedule release result jul more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
752,VRTX,gigamon inc be schedule report second quarter result jul last quarter company post positive earning surprise let see thing be shape announcement factor considergigamon be engage provide intelligent traffic visibility solution enterprise datum center service provider believe gigamon result be poise benefit rapidly grow network security solution market worth more ongoing transition cloud fast adoption internet thing iot technology present significant growth potential company further company product launch be expect drive growth gigasmart gigavue hc gigavue hc platform continue witness increase adoption moreover company be add client boost financial result however company face pricing challenge intensify competition juniper network inc jnpr free report cisco gigamon inc price ep surprise gigamon inc price ep surprise gigamon inc quoteearning whispersour proven model do not conclusively show gigamonis likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate zack consensus estimate be peg loss cent share hence difference be uncover best stock buy sell re report earning esp filter zack rank gigamoncarry zack rank zack rank increase predictive power esp company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision stock considerhere be couple company model have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report earning esp zack rank see complete list today zack rank stock here allegiant travel company algt free report earning esp zack rank more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
753,VRTX,dst system inc be set report second quarter result jul last quarter company deliver positive earning surprise notably dst zack consensus estimate trail quarters average positive earning surprise let see thing be shape prior announcement factor considerdst system report encourage first quarter result earning revenue surpass zack consensus estimate grow year year be still opinion dst system business volume massive scale operation financial service attract new customer moreover expect steady contribution acquisition support revenue growth continue share buyback dividend payment be other encourage factor however persistent decline register account ongoing consolidation financial service market stiff competition international business machine corporation ibm free report fiserv inc put fundamental pressure additionally high debt burden remain major concern dst system inc price ep surprise dst system inc price ep surprise dst system inc quoteearning whispersour proven model do not conclusively show dst systemsis likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate zack consensus estimate be peg cent share hence difference be uncover best stock buy sell re report earning esp filter zack rank dst systemscarry zack rank zack rank increase predictive power esp company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision stock considerhere be couple company model have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report earning esp zack rank see complete list today zack rank stock here allegiant travel company algt free report earning esp zack rank more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
754,VRTX,quest diagnostic inc dgx free report be schedule report third quarter earning result open bell oct last quarter company surpass zack consensus estimate cent deliver positive earning surprise also quest diagnostic outperformed zack consensus estimate trail quarters average beat let take look thing be shape prior announcement factor playafter several quarters sustain drag company revenue requisition performance last quarter see slight rebound however still remain be see improvement be here stay not company professional lab service pls engagement wj barnabas health healthone system hca holding inc hca carry lower revenue requisition due nature work overall believe low level employment slow growth commercially insure life continuously impact company volume measure number requisition environment economy turn better quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate apart unit price headwind be less bps previously report second quarter unit price headwind hover moderate range approximately last few year company continue expect same rest too also last year quest diagnostic have face several reimbursement issue affected revenue company be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure be reflect overhang company performance soon be report quarter too notably company have not positively take latest center medicare medicaid service cms publication propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf however leave impact yet be report quarter revenue number positive note quest diagnostic seem be determine repeat well meaning effort second quarter stimulating company performance point growth strategy accelerate growth drive operational excellence be also optimistic company successful execution strategy grow esoteric testing business drive profitable growth additionally quest diagnostic have recently witness significant growth infectious disease testing prescription drug monitoring industry lead wellness business expect growth driver remain active third quarter well drive same metric precede quarter strongly believe recent development significantly contribute company top line third quarter company currently expect full year revenue range annualize growth current zack consensus estimate revenue be peg just lower end guide range addition company adjust ep range remain zack consensus estimate be range earning whispersour proven model do not conclusively show quest diagnostic be likely beat earning quarter be stock need have positive earning esp favorable zack rank strong buy buy hold happen be not case here see zack esp quest diagnostic have earning esp be most accurate estimate be peg lower zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank quest diagnostic have zack rank sell decrease predictive power esp combine negative esp quest diagnostic chance earning beat not be conclusively predict caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be few stock worth consider same space proven model show comprise right combination element beat estimate quarter cooper company inc coo free report have earning esp zack rank see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report have earning esp zack rank humana inc hum free report have earning esp zack rank well trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
755,VRTX,expect abbott free report surpass expectation report third quarter result oct market open last quarter abbott deliver positive earning surprise abbott strong impressive earning track record reflect estimate beat past quarters deliver average also company share have surge so far year compare favorably industry register rally same period likely positive surprise proven model conclusively show abbott be likely beat earning quarter have right combination key ingredient stock need have positive earning esp favorable zack rank strong buy buy hold likely positive surprise zack esp abbott have earning esp indicative be confident earning surprise uncover best stock buy sell re report earning esp filter zack rank abbott currently carry bullish zack rank increase predictive power esp higher chance beating estimate conversely sell rate stock be caution go earning announcement be drive better expect earning abbott have be healthy growth trajectory establish pharmaceutical division epd business deliver encourage operational sale growth trail few quarters major part growth be stimulate series strategic action include abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quote company also continue expect strong growth epd upcoming quarters particularly china russia several market latin america include brazil back abbott strong position lie competitive edge geography also be chance certain revamp epd sale india third quarter follow business loss abbott have incur due implementation good service tax gst country second quarter have be slew development medical device space well market be upbeat abbott freestyle libre flash glucose monitoring system recent reimbursement approval unite kingdom company have recently announce receipt health canada license freestyle libre flash glucose monitoring system positive place abbott freestyle libre system stand partially fully cover country include france germany japan expect uptrend further stimulate growth diabetes care sale segment medical group improve second quarter continue consumer acceptance freestyle libre international arena cardiac arrhythmia heart failure business recent fda approval abbott full maglev heartmate left ventricular assist system be expect boost company sale third quarter be also encourage ongoing synergy acquisition st jude medical jan earlier year comprehensive combine portfolio appear quite promising notably abbott project annual pre tax synergy include revenue expansion opportunity well operational sg efficiency third quarter company forecast adjust earning share cent comparable operational sale growth quarter be project mid single digit other stock considerhere be few other company worth consider same space proven model show too have right combination element come earning beat quarter qiagen qgen free report have earning esp zack rank see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report have earning esp zack rank humana inc hum free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
756,VRTX,company amgen amgn free report regeneron regn free report be news amgen provide pipeline regulatory update regeneron partner sanofi get good news appeal court ruling favor pcsk inhibitor lawsuit amgen recap week most important storiesphase ii combination datum amgen imlygic publish positive datum amgen oncolytic viral therapy imlygic used combination bristol myer squibb yervoy be publish journal clinical oncology result mid stage study show objective response rate orr more double imlygic be used combination yervoy compare yervoy alone patient unresectable stage iiib iv melanoma versus moreover complete response rate be almost double combination arm compare yervoy alone versus response be observed inject uninjected lesion include visceral lesion advanced melanoma be highly aggressive most dangerous type skin cancer be need multiple treatment approach course disease datum be encourage open new avenue revenue imlygic eventually gain approval use combination checkpoint inhibitor sale imlygic approve october be yet pick meanwhile amgen say fda have accept regulatory application seek label expansion use prolium glucocorticoid induced osteoporosis most common form secondary osteoporosis response agency be prolium bring sale second quarter be important growth driver amgen company work improve diagnosis treatment rate duration order drive access greater number patient read more amgen label expansion application prolium accept fda amgen be zack rank buy stock share amgen have gain year date significantly outperform industry rally see complete list today zack rank strong buy stock here breather amgen neulasta biosimilar approval delay amgen get bit breather fda issue complete response letter crl mylan biocon biosimilar version amgen blockbuster drug neulasta pegfilgrastim agency do not raise query regard biosimilarity pharmacokinetic pharmacodynamic datum clinical datum immunogenicity myl crl relate pending update regulatory application certain cmc datum facility requalification activity post recent plant modification note mylan biocon be not only company get crl fda biosimilar version neulasta novartis sandoz have receive crl last year coherus be issue crl year june regeneron sanofi score pcsk inhibitor litigation regeneron partner sanofi get major boost court appeal federal circuit order new trial related amgen claim regard patent pcsk inhibitor court also vacated permanent injunction lawsuit mean sanofi regeneron continue selling pcsk inhibitor praluent unite state read more regeneron sanofi get favorable ruling amgen abbvie immuno oncology deal abbvie abbv free report have enter research option license agreement clinical stage immuno oncology company turnstone biologic deal provide abbvie exclusive option license turnstone next generation oncolytic viral immunotherapy turnstone ad mg magea therapy be couple phase ii study different solid tumor indication alone well combination approve pd checkpoint inhibitor promising new datum biogen spinraza new phase iii datum present biogen biib free report spinraza show earlier initiation treatment therapy improve motor function outcome infant child spinal muscular atrophy sma biogen ionis spinraza be first approve medicine treatment sma spinraza be promising start unite state bring sale second quarter clovis seek label expansion parp inhibitor clovis oncology clvs free report have file label expansion parp inhibitor rubraca unite state company be look get drug approve maintenance treatment patient recurrent epithelial ovarian fallopian tube primary peritoneal cancer be complete partial response platinum base chemotherapy company have present impressive late stage datum earlier year june rubraca show treatment significantly improve progression free survival ovarian cancer patient population evaluate ariel study rubraca have gain accelerate fda approval december use advanced ovarian cancer patient have be treat more chemotherapy have deleterious germline somatic brca mutation broader label boost rubraca sale potential read more clovis submit snda ovarian cancer drug rubraca biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen gain celgene celg free report lose last month vertex vrtx free report be see last biotech stock roundup here endocyte shoot deal amgen abbvie settle humira litigation next biotech world sector gear third quarter earning watch usual regulatory pipeline update spark therapeutic voretigene neparvovec be review fda cellular tissue gene therapy advisory committee ctgtac october spark be seek fda approval treatment patient vision loss due confirm biallelic rpe mutation associate retinal dystrophy wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
757,VRTX,amgen inc amgn free report announce fda have accept regulatory application unite state seek label expansion prolium treatment patient glucocorticoid induced osteoporosis giop fda be expect give decision next year prolium be presently market unite state treatment postmenopausal woman osteoporosis high risk fracture well increase bone mass man osteoporosis high risk fracture supplemental biologic license application sbla be submit july year sbla be base phase iii study evaluate safety efficacy prolium compare risedronate patient receive glucocorticoid medication giop be most common form secondary osteoporosis serious condition be presently treat glucocorticoid treatment increase fracture risk first month begin treatment prolium approve treatment giop cater expand patient population drive sale higher prolium be key revenue generator amgen be witness market share gain unite state international market first half drug generate sale year year amgen share have rally year so far better industry growth so far year currently amgen hold zack rank buy see complete list today zack rank strong buy stock here key pickssome other top rank biotech stock include vertex pharmaceutical incorporate vrtx free report pdl biopharma inc pdli free report celgene corporation celg free report vertex pdl biopharma sport zack rank strong buy celgene have same zack rank amgen vertex have witness zack consensus estimate current year earning climb past day company share have increase year so far pdl biopharma earning estimate have go share have rise year so far celgene earning estimate inched go past day stock have rally so far year outperform industry today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
758,VRTX,biogen biib free report third quarter result surpass top bottom line expectation meanwhile gilead gild free report car therapy gain earlier expect fda approval alexion alxn free report also get regulatory boost fda expand label company flagship product soliris recap week most important storiesbiogen beat front biogen third quarter result be better expect company surpass earning revenue expectation share be concern regard company multiple sclerosis franchise sale well sale recently launch spinal muscular atrophy sma treatment spinraza spinraza sale be third quarter more less flat second quarter sale company report increase number patient therapy unite state compare end second quarter however second quarter sale include inventory buildup read more biogen top earning sale spinraza sale biogen have gain year date outperform industry rally gilead car therapy yescarta approve gilead yescarta become part company portfolio follow kite pharma acquisition gain fda approval treatment adult patient relapse refractory large cell lymphoma more line systemic therapy make yescarta first chimeric antigen receptor cell car therapy gain approval use patient population yescarta be second gene therapy gain approval unite state first be novartis kymriah treatment come box warning regard risk cytokine release syndrome crs neurologic toxicity yescarta approval be major boost gilead be currently face decline sale hepatitis virus hcv franchise accord information provide company diffuse large cell lymphoma dlbcl be most common aggressive hodgkin lymphoma nhl patient refractory dlbcl be eligible car therapy year yescarta represent new treatment option patient have run treatment option face poor prognosis yescarta be launch list price unite state be currently review eu response be expect first half read more gilead car therapy yescarta clinch fda approval gilead also announce phase ii result investigational treatment nonalcoholic steatohepatitis nash company say higher dose mg gs oral acc inhibitor achieve significant reduction buildup fat liver noninvasive marker fibrosis timp compare placebo however statistical significance be not achieve other parameter liver stiffness fibroscan mre serum alt piii np serum marker fibrogenesis meanwhile difference lower dose mg gs placebo be not statistically significant celgene hit crohn disease study discontinuation celgene celg free report share be news company be discontinue study phase iii revolve study extension study sustain be conduct investigational crohn disease drug ged mongersen decision be base recommendation datum monitoring committee october follow interim futility analysis meaningful safety imbalance be observed analysis celgene also say review full dataset phase ii ulcerative colitis study ged decide path forward company not be initiate phase iii define study crohn disease read more celgene discontinue crohn disease drug study abbvie announce immuno therapy focuse deal abbvie abbv free report announce couple deal week deal be focuse immuno neurology other be focuse immuno oncology immuno neurology deal see abbvie collaborate alector use latter immuno neurology discovery platform innovative new therapy alzheimer disease other neurological disorder immuno neurology rapidly evolve scientific area be focuse harness power immune system attack disorder alzheimer disease development cost well profit be share equally company alector get upfront payment potential future equity investment meanwhile immuno oncology deal see abbvie team harpoon therapeutic use harpoon tri specific cell activate construct tritac platform abbvie research stage immuno oncology target develop cancer therapeutic read more abbvie inks immuno oncology deal harpoon therapeutic label expansion alexion soliris fda grant approval alexion use flagship product soliris eculizumab adult patient generalized myasthenia gravis gmg be achr antibody positive soliris already approve unite state serious ultra rare disorder paroxysmal nocturnal hemoglobinurium pnh atypical hemolytic uremic syndrome ahus bring sale first half year gmg indication represent incremental growth opportunity soliris alexion be zack rank hold stock see complete list today zack strong buy rank stock here biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index decline last trading session major biotech stock celgene lose reflect sell follow crohn disease update biogen be last month vertex vrtx free report be celgene be see last biotech stock roundup here exelixis soar priority review fda panel support spark drug next biotech world week company amgen amgn free report vertex alexion gilead celgene abbvie be report third quarter result zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
759,VRTX,third quarter report cycle be full swing corporate earning have be reassure so far quarter expect momentum continue go ahead oct member accounting index total market capitalization have report result accord earning preview total earning index member be year quarter improvement revenue growth revenue be impressive ahead previous quarter growth significantly higher quarter average beat ratio be earning revenue more half company have beaten ep revenue estimate report total earning company third quarter be expect grow year year higher revenue meanwhile broader medical sector include drug biotech well medical device company be expect record year year growth revenue earning only big name biotech pharma sector have report thus far johnson johnson jnj free report swiss base novartis ag nvs free report result be better expect company raise sale profit outlook year well novartis also beat estimate revenue earning quarter let take look pharma biotech company be set report third quarter result oct amgen inc amgn free report amgen be schedule release earning market close have deliver positive earning surprise last quarter amgen beat expectation last quarters average positive surprise quarter amgen have earning esp zack rank hold do not conclusively show amgenis likely beat estimate quarter zack consensus estimate be peg share uncover best stock buy sell re report earning esp filter higher demand amgen new drug be expect offset lower sale mature brand company key drug neulasta be face competition newer cancer therapy threat biosimilar also lurk several company be look launch generic version drug read more card amgen earning season glaxosmithkline plc gsk free report london base glaxo be schedule announceresult open bell tomorrow glaxo have beaten estimate last quarters meet same result average positive surprise last report quarter glaxo deliver positive surprise company have earning esp zack rank indicate be poise deliver beat time see complete list today zack rank strong buy stock here glaxo hiv product be expect drive sale pharmaceutical segment quarter moreover newly launch respiratory drug be expect offset decline sale seretide advair avodart meanwhile slowdown consumer segment due market condition impact divesture be expect continue read more glaxo earning deliver beat yet again vertex pharmaceutical incorporate vrtx free report company specially focus cystic fibrosis cf report result tomorrow market close last quarter vertex deliver positive earning surprise company come average positive earning surprise trail quarters company have earning esp zack rank indicate likely positive surprise zack consensus estimate be peg cent share approval label expansion cf drug kalydeco unite state august have broaden patient population drive sale drug moreover re imbursement agreement ireland italy orkambi be also positive read more be beat card vertex earning today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
760,VRTX,equifax inc efx free report be schedule report second quarter result jul last quarter company post positive earning surprise notably equifax outperformed zack consensus estimate trail quarters average positive earning surprise let see thing be shape announcement factor considerequifax post better expect result first quarter earning revenue record year year growth recent development equifax enter definitive agreement acquire id watchdog further company expand strategic alliance bizequity global leader business valuation knowledge big datum move be aim boost equifax capability serve customer better believe management effort such strategic initiative product innovation expansion datum asset acquisition continuous share gain north america act tailwind moreover company strong correlation consumer financial market exposure europe be likely propel growth move ahead however expect company investment new initiative weigh upcoming quarterly earning additionally uncertainty surround spending strengthen dollar be concern moreover increase competition like fiserv fisv free report total system service be other factor likely affect earning term equifax inc price ep surprise equifax inc price ep surprise equifax inc quoteearning whispersour proven model do not conclusively show equifax be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate zack consensus estimate be peg share hence difference be uncover best stock buy sell re report earning esp filter zack rank equifax carry zack rank zack rank increase predictive power esp company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision stock considerhere be couple company model have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report earning esp zack rank see complete list today zack rank stock here allegiant travel company algt free report earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
761,VRTX,network inc ffiv free report be set report third quarter result jul last quarter company post negative earning surprise notably network outperformed zack consensus estimate trail quarters average positive earning surprise let see thing be shape prior announcement factor considerf network report dismal second quarter fiscal result bottom line top line miss zack consensus estimate however year year comparison count be favorable be worth mention company gbb pricing strategy big iq platform remain tailwind revenue growth seem be steady be positively impact strength business segment higher software revenue believe company product refresh boost revenue go forward moreover initiative be expect expand total addressable market result client win better execution focus enterprise service provider have place network well application delivery controller market nevertheless volatile spending atmosphere competition juniper network inc jnpr free report remain concern network inc price ep surprise network inc price ep surprise network inc quoteearning whispersour proven model do not conclusively show networksis likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate zack consensus estimate be peg share hence difference be uncover best stock buy sell re report earning esp filter zack rank network carry zack rank zack rank increase predictive power esp company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision stock considerhere be couple company model have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report earning esp zack rank see complete list today zack rank stock here allegiant travel company algt free report earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
762,VRTX,expect vertex pharmaceutical inc vrtx free report beat expectation report second quarter result jul market close year date vertex share have soar industry have record increase vertex track record have be impressive so far company deliver positive earning surprise miss expectation last quarters average positive earning surprise last quarters be last report quarter vertex post positive surprise vertex pharmaceutical incorporate price ep surprisevertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotelet see thing be shape quarter factor playsale vertex cystic fibrosis cf drug kalydeco orkambi rise first quarter expect positive trend continue second well kalydeco gain fda approval use patient older have residual function mutation cystic fibrosis transmembrane conductance regulator cftr gene person have mutation follow approval vertex up kalydeco revenue guidance expect expand indication boost kalydeco sale second quarter orkambi sale growth be dependent reimbursement discussion europe last week vertex announce have strike re imbursement agreement italy orkambi thereby make medicine more accessible country reimbursement agreement not be beneficial second quarter contribute sale second half year first quarter company have also mentioned gain reimbursement france year contribute significantly revenue growth year vertex be also evaluate next generation cftr corrector vx vx vx vx part triple combination tezacaftor ivacaftor datum vx vx phase ii vx phase triple combination study present earlier week have show combination lead pronounce improvement lung function phase ii study vx be expect be initiate early aug phase ii study fourth next generation corrector vx triple combination tezacaftor ivacaftor be already go datum vx vx phase ii study be expect early thereafter discussion regulatory agency vertex initiate pivotal study more triple combination regimen first half triple combo regime be successful vertex address significantly larger cf patient population investor focus call be triple combination cf regimen crucial long term growth vertex however operate expense be likely shoot vertex expand pipeline model proven model show vertex be likely beat estimate quarterbecause have right combination key ingredient astock need have positive earning esp zack rank strong buy buy hold happen zack esp earning esp represent difference most accurate estimate earning cent zack consensus estimate earning cent stand be lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank vertex currently flaunt zack rank strong buy so desirable combination make reasonably confident earning beat conversely caution sell rate stock go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter gilead science inc gild free report be schedule release result jul company have earning esp zack rank see complete list today zack rank stock here celgene corp celg free report be schedule release result jul company have earning esp zack rank proteostasis therapeutic inc pti free report be expect release result aug have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
763,VRTX,xilinx inc xlnx free report be slate report first quarter result jul last quarter company post positive earning surprise notably xilinx outperformed zack consensus estimate precede quarters average positive earning surprise let see thing be shape prior announcement factor considerkeep earning streak alive successive quarter xilinx report better expect fourth quarter result surpass zack consensus estimate count further top line bottom line increase year year rise demand nm nm nm node drive higher wireless deployment strength wire communication segment be expect remain growth driver company product launch be likely further aid revenue be also encourage xilinx endeavor return shareholder value continue share buyback dividend investor friendly initiative not only boost earning also increase investor confidence loyalty however slowdown chinese economy economic weakness europe asia pacific region adversely affect xilinx term result competition like lattice semiconductor corporation lscc free report be headwind xilinx inc price ep surprise xilinx inc price ep surprise xilinx inc quoteearning whispersour proven model do not conclusively show xilinxis likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp most accurate estimate zack consensus estimate be peg cent share hence difference be uncover best stock buy sell re report earning esp filter zack rank dst systemscarry zack rank zack rank increase predictive power esp company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be witness negative estimate revision stock considerhere be couple company model have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report earning esp zack rank see complete list today zack rank stock here allegiant travel company algt free report earning esp zack rank more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
764,VRTX,bristol myer squibb company bmy free report be schedule report first quarter result jul open bell last quarter company beat earning estimate bristol myer squibb company price ep surprise bristol myer squibb company price ep surprise bristol myer squibb company quotebristol myer stock have lose past year underperform industry remain flat period bristol myer have decent track record so far company earning beat estimate trail quarters average positive surprise bristol myer surpass expectation time well let see thing be shape quarter factor impact quarterbristol myer high profile immuno oncology drug opdivo continue drive company top line be report quarter opdivo sale be drive melanoma second line small cell lung cancer renal cell carcinoma indication recent label expansion classical hodgkin lymphoma head neck cancer indication boost drug sale however lung cancer market become more competitive due entry tecentriq bristol myer expect second line lung cancer business be competitive pressure result sale drug market be project be flat first quarter see stability second line lung cancer recent fda approval merck mrk free report keytruda first line treatment metastatic nonsquamous nsclc further impact sale other hand virology business be expect decline significantly due competition epclusa hiv business continue face competitive pressure recent launch other company same space be expect further impact sustiva franchise bristol myer be also look diversify portfolio development bms nash positive note bristol myer raise earning expectation concurrent first quarter result company now project earning range share old guidance revenue be expect grow mid single digit range due strong trend business particularly key product opdivo eliquis yervoy gross margin be project decline year progress be estimate range expense be expect increase low double digit range second quarter earning call investor be expect focus company performance label expansion effort opdivo update business development activity earning whispersour proven model do not conclusively show bristol myer be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen unfortunately be not case here elaborate zack esp earning esp bristol myer be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank bristol myer currently carry zack rank increase predictive power esp however esp make unlikely stock beat earning quarter be caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be health care stock want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp carry zack rank company be schedule release result jul see complete list today zack rank stock here gilead science inc gild free report have earning esp carry zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
765,VRTX,pharma biotech stock start strong note part market remain favor year progress so far year nasdaq biotechnology index nyse arca pharmaceutical index be respectively investor be more comfortable drug pricing scenario focus have shift fundamental sector drug pricing issue remain headwind expectation be step take trump administration drive drug price not be draconian previously expect deregulation increase competition seem be way be used control drug price fda be work lower healthcare cost speeding development next generation treatment especially rare disease target cancer therapy be also work clear backlog orphan drug application fda have approve far more drug year do whole key approval year include novartis nvs free report kymriah first gene therapy unite state lilly verzenio advanced metastatic breast cancer gilead gild free report vosevi hepatitis virus puma nerlynx reduce risk breast cancer return tremfya moderate severe plaque psoriasis regeneron sanofi kevzara rheumatoid arthritis roche multiple sclerosis treatment ocrevus regeneron sanofi eczema treatment dupixent tesaro parp inhibitor zejula biomarin brineura treatment specific form batten disease other quite few drug have blockbuster potential meanwhile other factor continue have positive impact pharma biotech stock be new product sale ramp success innovation strong result higher number fda approval continue strong performance legacy product accord zack earning trend report medical sector have be better perform sector last several quarters be expect record earning growth revenue growth third quarter give scenario medical sector earning round corner make sense look pharma biotech stock be expect report positive earning surprise quarter investing such stock prove beneficial investor earning beat usually lead significant share price appreciation drug stock keep eye earning help zack stock screener have zero pharma biotech stock sport zack rank strong buy buy hold have positive earning esp earning esp be very valuable tool investor look stock be most likely beat earning estimate moreover add zack rank have produce positive surprise time see complete list today zack rank stock here uncover best stock buy sell re report earning esp filter pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product company have surpass earning expectation first quarters key revenue driver include ibrance eliquis xeljanz pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential company be report third quarter result october have earning esp eli lilly company lly free report lilly have strong presence pharmaceutical well animal health segment be slate report third quarter result october zack rank stock have earning esp third quarter lilly surpass earning expectation first quarters company be face challenge include generic competition new product drive result lilly have several important pipeline catalyst line come quarters well estimate earning growth current year be lilly have gain year date compare rally industry belong vertex pharmaceutical vrtx free report vertex key player cystic fibrosis cf market surpass earning expectation last quarters average surprise company hold strong position cf market product orkambi kalydeco portfolio early august vertex have say expect cf franchise deliver revenue include orkambi revenue company be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong company be expect report third quarter result october have earning esp quarter biogen inc biib free report biogen be key name multiple sclerosis ms market several approve product tecfidera tysabri avonex portfolio company also have spinal muscular atrophy product spinraza portfolio be work develop treatment disease alzheimer parkinson amyotrophic lateral sclerosis biogen earning track record be good company surpass earning expectation last quarters average surprise company be schedule report third quarter result october have earning esp last day stock have see zack consensus estimate third quarter current year earning be revise respectively biogen zack rank stock have gain year date outperform rally industry belong merck mrk free report merck zack rank stock have consistently surpass earning expectation last quarters average surprise company be report earning october earning esp be company do have challenge form generic competition well safety issue related study be conduct keytruda new product keytruda strong performance base business provide support merck also have deep pipeline bode well long term growth today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
766,VRTX,look stock be good position beat earning next report consider vertex pharmaceutical incorporate vrtx free report firm medical biomedical genetic industry be great candidate beat company have see nice streak beating earning estimate especially look previous report fact report vrtx have beaten estimate least case suggest have nice short term history crush expectation earning quarters vrtx be expect post cent share actually produce cent share beat meanwhile most recent quarter company look deliver cent share actually see cent share instead represent positive surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate price ep surprise vertex pharmaceutical incorporate quotethank part history recent estimate have be move higher vertex pharmaceutical fact earning esp vrtx be positive be great sign come beat zack earning esp compare most accurate estimate broad consensus look find stock have see big revision late suggest analyst have recently become more bullish company earning prospect be case vrtx firm currently have zack earning esp so beat be corner be particularly true consider vrtx have great zack rank strong buy be harbinger outperformance signal strong earning profile see complete list today zack rank stock here add solid zack rank positive earning esp positive earning surprise happen nearly time so seem pretty likely vrtx see beat next report especially recent trend be guide today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
767,VRTX,deal sear amazon weigh home improvement retailer thursday turn drag dow lower nasdaq however buck decline trend post first day winning streak feb such stellar rally be support microsoft rise ahead result broad base gain biotech stock also help tech laden index hit record close high look issue currently face market make sure read today ahead wall street article dow jone industrial average dji decline close also drop meagre finish other hand tech heavy nasdaq composite index increase close advance issue meanwhile outnumber decliner nyse see complete list today zack rank strong buy stock here sear amazon deal home improvement retailer bleedsear holding corp share climb have launch kenmore appliance amazon com inc amzn free report sear have be deal consistently slumping sale year now have access amazon massive customer base largest potential pool outside own brick mortar store company also announce be integrate amazon alexa technology new line appliance sear ceo eddie lampert say continuously look opportunity enhance reach iconic brand more customer create additional value asset add launch kenmore product amazon com significantly expand distribution availability kenmore brand read more be sear skyrocket today news drag other appliance retailer home depot inc hd free report lowe company inc low free report best buy co inc bby free report lower appliance maker whirlpool corporation whr free report wasn spare close red put drag dow jone nasdaq continue winning nasdaq close higher straight day help gain microsoft corporation msft free report biotech stock microsoft be due report result close bell share tech behemoth gain momentum expectation better expect quarterly result banking strong cloud performance tax benefit meantime ishare nasdaq biotechnology etf ibb close also help nasdaq move north sector be verge next major leg higher key catalyst be vertex pharmaceutical inc vrtx free report company have already report positive phase result treatment patient cystic fibrosis stock make headlinesab inbev expand organic space hiball buyoutanheuser busch inbev sa nv bud free report be track acquire hiball order widen organic product assortment read more gatx corp earningstop revenue lag view intactgatx corporation gatx free report report better expect earning share lower expect revenue second quarter read more encana earning revenue top estimate yencana corporation eca free report report second quarter operate earning share ahead zack consensus estimate read more make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
768,VRTX,merck co inc mrk free report be report second quarter earning jul market open last quarter company deliver positive earning surprise merck performance have be pretty impressive company exceed earning expectation consistently average positive earning surprise last quarters be merck share rise year so far compare unfavourably increase industry factor considermerck new product keytruda cancer zepatier hcv bridion sugammadex injection drive top line quarter believe keytruda sale likely be drive strong uptake launch new country expansion additional indication especially first line nsclc mar apr keytruda receive fda eu approval refractory classical hodgkin lymphoma chl first keytruda approval hematologic malignancy indication keytruda be approve first line combination therapy lung cancer first fda approval combination therapy expand indication especially combination therapy add keytruda sale quarter apart continue strength melanoma indication rapid penetration head neck cancer indication boost keytruda sale last couple month be series regulatory approval label expansion keytruda advanced bladder cancer expect update management plan same conference call first quarter conference call management have say be work secure reimbursement keytruda first well second line nsclc indication outside lung cancer sale become much larger contributor outside country year progress expect update conference call meanwhile ongoing launch globally be likely support zepatier sale however company continue face headwind form genericization increase competition negative impact currency exchange sale remicade lose exclusivity europe face stiff biosimilar competition region nasonex generic version launch mar cubicin lose patent protection jun zetia lose market exclusivity dec likely decline quarter sluggish growth integrase class continue competitor dynamic europe continue affect isentress sale investor focus remain performance merck dpp inhibitor januvia pricing pressure hurt sale januvia janumet franchise first quarter remain be see trend improve second quarter vaccine animal health franchise also boost sale quarter earning whispersour proven model do not conclusively show merck be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be most accurate estimate well zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank merck zack rank increase predictive power esp however need have positive esp be confident earning beat caution sell rate stock zack rank go earning announcement especially company be see negative estimate revision merck company inc price ep surprise merck company inc price ep surprise merck company inc quotestock considerstock pharmaceutical sector also have positive earning esp favorable zack rank be nordisk nvo free report schedule release result aug have earning esp zack rank see complete list today zack rank stock here pfizer inc pfe free report have earning esp zack rank company be schedule release result aug vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
769,VRTX,sere therapeutic inc mcrb free report be big mover last session company see share rise little day move come solid volume too far more share change hand normal session break recent trend company stock be now trading volatile price range past month time frame company have see positive estimate revision past day also zack consensus estimate moved higher same timeframe so make sure keep eye stock go forward see recent jump turn more strength road sere therapeutic currently hold zack rank buy earning esp be negative sere therapeutic inc price sere therapeutic inc price sere therapeutic inc quoteanother top rank stock medical biomedical genetic industry be vertex pharmaceutical incorporate vrtx free report sport zack rank strong buy see complete list today zack rank stock here be mcrb go predict see other think downwill make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
770,VRTX,tap stock come solid earning be common practice instead pick post earning investing be beat market expectation increase gain manifold be positive earning surprise so important historically stock company solid quarterly earning nominal basis fall miss just come line market expectation earning rise look good apparently doesn tell earning growth have be exhibit decelerate trend be case company fundamental be serious question be also factor seasonal fluctuation company be seasonally weak be strong then be likely report sequential earning decline such case growth rate be ambiguous judge company true health other hand wall street analyst study company financial initiative forecast earning fact club insight company guidance derive earning estimate so outperform estimate be almost equivalent beating company own expectation well market perception company manage surpass earning wide margin typically drife stock higher right release find gem be hard predict company beat miss upcoming earning season investor check earning surprise history notable track record generally act tailwind rev chance beating estimate next release too investor expect company use same old trick come ahead expectation be smart enough pull beat next release winning strategyin order shortlist stock be likely come earning surprise choose follow primary screening parameter last ep surprise greater equal stock deliver positive surprise last quarter tend surprise again average ep surprise last quarters greater lift bar outperformance slight higher set average earning surprise last quarters average ep surprise last quarters greater point more consistent surprise history make case surprise even stronger addition place few other criterium push chance positive surprise zack rank less equal only company zack rank strong buy buy rating get earning esp greater stock need have positive earning esp zack rank earning beat happen proven model order have long term growth potential high trading liquidity have add follow parameter too next year estimate ep growth year greater solid expect earning growth exhibit stock long term growth prospect average day volume greater high trading volume imply stock have adequate liquidity handful criterium have narrow universe stock here be stock pass screen vertex pharmaceutical incorporate vrtx free report company be developer marketer small molecule drug stock belong zack industry rank top have zack rank agco corporation agco free report company be engage manufacturer distribution farm equipment machinery replacement part unite state canada stock belong zack industry rank be top carry zack rank owen corning oc free report world leader build material system composite solution sport zack rank zack industry rank stock be top inc fivn free report provider cloud software contact center hold zack rank zack industry rank stock be top axcelis technology inc acls free report be lead producer ion implantation equipment used fabrication semiconductor stock have zack rank zack industry rank be top get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
771,VRTX,sarepta therapeutic inc srpt free report report narrower expect loss second quarter biotech also increase sale outlook exondys treatment duchenne muscular dystrophy dmd only market drug share be almost hour trading so far year sarepta share be compare favorably increase register zack classify biom genetic industry period narrower losssarepta incur loss cent share second quarter narrower year loss well zack consensus estimate loss cent loss share exclude restructure cost gain asset sale include impact share base compensation expense quarterly detailssarepta receive huge boost fda approval exondys only market drug also first dmd treatment gain approval drug be review eu second quarter sarepta record revenue sequentially primarily attributable sale exondys revenue beat zack consensus estimate prior year quarter sarepta have recognize revenue adjust research development expense be second quarter year year due lower manufacturing expense owing capitalization inventory follow approval exondys fda be partly offset increase expense preclinical study ppmo platform other follow exon increase patient enrollment ongoing clinical study however exclude time payment summit therapeutic plc smmt free report complete enrolment phase ii study evaluate modulator ezutromid adjust selling general administrative sg expense be year year due increase legal fee commercial initiative compensation other personnel expense sg expense exclude impact restructure cost share base compensation expense subsequent quarter jul sarepta launch manage access program uk base clinigen ensure availability exondys dmd patient certain geography outside company also appoint dougla ingram new president ceo moreover also sign gene therapy research collaboration agreement genethon jointly develop treatment dmd earlier week company announce hassettle global patent litigation biomarin pharmaceutical inc bmrn free report regard exclusive license patent pertain exon skip technology used dmd therapy sarepta hadn settle biomarin latter have prevent sarepta commercialize exondys several jurisdiction outlookbased sale trend witness second quarter sarepta update guidance exondys sale higher prior guidance zack consensus estimate sale be peg biotech company raise outlook exondys base increase market penetration start form physician additional new patient second quarter meanwhile sarepta be look build own dmd pipeline exondys develop other exon skip treatment sarepta have exon skip candidate pipeline treat dmd population company expect present datum study end sarepta therapeutic inc price consensus ep surprise sarepta therapeutic inc price consensus ep surprise sarepta therapeutic inc quotezack rank stock considersarepta therapeutic carry zack rank hold better rank stock health care sector be vertex pharmaceutical incorporate vrtx free report sporting zack rank strong buy see complete list today zack rank stock here vertex earning estimate increase cent cent last day company post positive earning surprise trail quarters average beat company share be so far year top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
772,VRTX,vertex pharmaceutical incorporate vrtx free report share surge drug maker declare positive result clinical study cystic fibrosis treatment share discovery communication inc disca free report gain company be talk merge scripps network interactive inc sni share unite continental holding inc ual free report decline total operate expense exclude special item grow year year share crown castle international corp cci free report increase company be acquire lightower fiber network cash
773,VRTX,gilead science inc gild free report be schedule report second quarter result jul market close last quarter company beat expectation gilead science inc price ep surprise gilead science inc price ep surprise gilead science inc quotegilead track record be pretty mixed company beating estimate last miss other overall company record average positive earning surprise share gilead have moved year so far underperform zack classify medical biomedical genetic industry gain let see thing be shape biotech major announcement earning whispersour proven model show gilead be likely beat earning estimate quarter be have right combination key ingredient positive earning esp zack rank strong buy buy hold zack esp earning esp represent difference most accurate estimate zack consensus estimate be be most accurate estimate be zack consensus estimate be peg lower uncover best stock buy sell re report earning esp filter zack rank gilead currently carry zack rank combination zack rank positive esp make confident earning beat conversely sell rate stock zack rank never be consider go earning announcement especially company be see negative estimate revision factor playconcurrent first quarter earning call gilead reiterate guidance annual guidance gilead expect net product sale range hcv product sale be project hcv product sale be project strong performance hiv other antiviral product sale drive continue uptake tenofovir alafenamide taf base product genvoya descovy odefsey continue boost sale expect trend continue second quarter well genvoya have already become most prescribe regimen treatment nave switch patient launch end first quarter taf base regimen make gilead hiv prescription volume treatment market strong uptake truvada use pre exposure prophylaxis set be also expect boost sale however gilead lose exclusivity viread country outside impact sale however hcv franchise continue be competitive pricing pressure lead massive decline harvoni sovaldi sale harvoni sovaldi have be face competition abbvie abbv free report viekira pak viekira xr other higher discount payer mix continue impact sale adversely total hcv treatment start be estimate approximately less company expect further decline patient start positive note hcv portfolio receive major boost epclusa gain approval become first only oral pan genotypic str consist sovaldi velpatasvir ns inhibitor treatment adult genotype chronic hcv infection initial uptake epclusa have be encourage formulary reviews be track recently approve hbv drug vemlidy be also expect start contribute top line fda recently approve vosevi sovaldi velpatasvir mg voxilaprevir mg tablet single tablet regimen str re treatment chronic hepatitis virus hcv infection adult genotype previously treat ns inhibitor contain regimen genotype previously treat sovaldi contain regimen ns inhibitor second quarter call investor be likely keep eye gilead performance pipeline update also be keenly await focus also be performance epclusa taf base regimen other stock poise beat estimateshere be other health care stock want consider model show too have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here alexion pharmaceutical inc alxn free report have earning esp zack rank company be schedule release result jul top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
774,VRTX,share vertex pharmaceutical incorporate vrtx free report soar morning trading wednesday company release positive result cystic fibrosis treatment pharmaceutical company say yesterday hour cystic fibrosis treatment improve lung function more patient condition surpass expectation result come trial consist different triple drug combination order determine best strategy treat cystic fibrosis combination include vx vx vx trial be successful vertex have bigger market opportunity person world have genetic disease cystic fibrosis cause accumulation mucus lung other organ vertex have now develop medicine target person company rally hold price stock gain add vertex market capitalization vrtx remain zack rank strong buy consensus estimate show company have extremely strong year year earning growth current year vertex be expect report next quarterly earning july market close look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
775,VRTX,israel base generic drug maker teva pharmaceutical industry limit teva free report see share decline last week company suffering fresh setback form fda approval generic version company top selling brand drug copaxone multiple sclerosis mylan nv myl free report gain fda approval generic version mg thrice weekly dosage well once daily mg formulation copaxone mylan be first applicant challenge mg patent company enjoy day exclusivity mylan have launch product mylan also gain approval mg dose eu fda approval generic copaxone be major blow teva be currently face whole lot challenge teva issue statement say launch mg formulation final resolution pending patent infringement lawsuit mylan be treat risk launch mean mylan have pay significant damage court uphold patent protect drug copaxone bring total sale first half end second quarter copaxone mg account more total copaxone prescription unite state entry mg formulation entry second generic version mg formulation sandoz momenta have be market quite glatopa generic version mg dose be expect cut teva earning least cent share additional detail be company announce third quarter result november entry generic copaxone just add exist list problem be face teva generic pricing erosion remain huge issue generic company teva sharp decline generic drug price blessing patient be prove be major challenge generic drugmaker well drug distributor consolidation industry have increase ability negotiate lower price generic drug lead increase price erosion decrease volume moreover fda be speeding approval generic drug mean more competition increase price cut decrease volume teva say price erosion be second quarter be expect increase high single digit remainder year headwind persist generic unit future result lower revenue profit segment potentially meanwhile company say do not expect earning contribution business venezuela give significant devaluation venezuelan currency teva also cut dividend teva have many challenge ahead pay debt divest core business increase focus core area generate cash deliver pipeline get generic business back track company have be work address issue recently announce appointment new ceo read more do teva pharmaceutical stock soar today teva have also make significant progress divestment core business however entry copaxone mg be major setback company well be teva be able get back track teva be zack rank sell stock company have see zack consensus estimate current year earning be revise downward last day zack consensus estimate have be revise downward last day teva have lose value year date versus decline industry teva deal challenge here be look drug company sport strong zack rank look well position celgene corporation celg free report celgene be focuse discovery development innovative therapy treatment cancer inflammatory disease company have several blockbuster product portfolio include revlimid pomalyst otezla celgene have rich promising pipeline well key datum readout line next year celgene zack rank buy stock have gain year date outperform rally industry belong company also have vgm score vgm score be useful tool allow investor gain insight stock strength weakness research show stock vgm score combine zack rank offer best upside potential see complete list today zack rank strong buy stock here pfizer inc pfe free report pfizer be focuse development wide range medicine vaccine well consumer health care product first half year company paid dividend share buyback shareholder include accelerate share repurchase program pfizer expect revenue be affected due loss exclusivity loe be work bring new product market make lose sale company have potential blockbuster line next year half potentially focus also remain grow new product ibrance eliquis xeljanz meanwhile impact loe continue decline come year well less pfizer zack rank stock carry vgm score amgen amgn free report amgen most well know name biotech industry have presence oncology hematology inflammation nephrology bone health cardiovascular disease market key product include enbrel neulasta aranesp prolium xgeva epogen kyproli repatha blincyto other most product be blockbuster have blockbuster potential amgen have deep pipeline company work bring new product market combat impact potential biosimilar competition mature product franchise company have be return value shareholder form share buyback dividend amgen be also zack rank stock vgm score stock have gain year date outperform rally industry belong vertex pharmaceutical vrtx free report vertex be key player cystic fibrosis cf market company hold strong position market market product orkambi kalydeco vertex be work expand cf portfolio be currently seek fda ema approval tezacaftor ivacaftor combination fda grant priority review response be feb vertex zack rank stock have gain year date substantially outperform rally industry belong ligand pharmaceutical incorporate lgnd free report ligand business model be base develop acquire royalty revenue generate asset couple lean corporate cost structure company be focuse development licensing asset ligand captisol formulation technology have allow enter several licensing deal generate royalty company partner include big name amgen novartis other ligand also have licensing deal base omniab technology ligand recent decision acquire crystal bioscience leader avian genetic generation fully human therapeutic antibody be expect boost company revenue least earning least cent share ligand zack rank stock have gain year date substantially outperform rally industry belong look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
776,VRTX,company amgen amgn free report endocyte ecyt free report be news amgen signing deal abbvie abbv free report related entry biosimilar version humira endocyte signing licensing deal prove be company recap week most important storiesendocyte soar licensing deal endocyte share have shot whopping follow company announcement have get exclusive worldwide license psma abx gmbh endocyte say quickly move lu psma phase iii development lu psma be radioligand therapeutic rlt target prostate specific membrane antigen psma present patient metastatic castration resistant prostate cancer mcrpc deal provide endocyte most advanced target radioligand therapy development prostate cancer represent market opportunity more company hope start phase iii development first half complete program early term deal include upfront payment well issuance share abx warrant purchase additional share endocyte common stock abx also stand receive milestone payment tiered royalty start mid teen endocyte bear future development expense read more endocyte inks deal prostate cancer candidate share abbvie amgen sign deal delay humira biosimilar entry abbvie have gain breathe space enter settlement agreement amgen related biosimilar competition abbvie multus dollar drug humira amgen gain fda approval amjevita biosimilar version humira have acknowledge validity abbvie extensive intellectual property portfolio humira accord deal exclusive license humira commence jan unite state different date other market include oct most country eu amgen also pay royalty agreement have remove major overhang abbvie share company be still face patent challenge boehringer ingelheim gain approval biosimilar version humira cyltezo august humira generate sale first half include unite state remain key market drug humira continue perform well remain major contributor top line come year moreover agreement give abbvie ample time focus develop pipeline launch new product help make loss revenue once biosimilar humira enter market expectation be high abbvie boehringer ingelheim announce similar settlement agreement dismiss patent litigation abbvie be zack rank hold stock amgen be zack rank buy stock see complete list today zack rank strong buy stock here ablynx positive phase iii result ablynx share shot positive topline result late stage study caplacizumab company von factor vwf nanobody be be develop treatment acquire thrombotic purpura attp ablynx be currently seek approval caplacizumab eu expect submit regulatory application unite state first half caplacizumab have fast track designation unite state treatment attp timely approval make first therapeutic specifically indicated treatment attp acute life threaten autoimmune blood clot disorder cytomx immuno oncology deal amgen cytomx therapeutic ctmx free report have enter immune oncology focuse strategic collaboration amgen development cytomx probody cell engage bispecific epidermal growth factor receptor egfr early development be lead cytomx amgen lead later development company share global late stage development cost deal see cytomx get upfront payment issue common stock amgen cytomx also earn development regulatory commercial milestone egfr program global commercial activity be lead amgen cytomx have option opt profit share unite state receive tiered double digit royalty net product sale outside unite state agreement also cover additional undisclosed target amgen decide pursue target cytomx get additional upfront milestone payment high single digit mid double digit royalty payment cytomx also receive right undisclosed preclinical cell engage bispecific program amgen make milestone royalty payment result product arrangement expect investor react favorably deal regeneron sanofi eczema drug get eu nod regeneron regn free report partner sanofi gain eu approval eczema treatment dupixent make dupixent first target biologic be approve use adult moderate severe atopic dermatitis ad be candidate systemic therapy dupixent approve unite state earlier year have blockbuster potential be be investigate other indication well include asthma eosinophilic esophagitis nasal polyp share regeneron have gain year date significantly outperform industry rally biomedical genetic industry yr returnmedical biomedical genetic industry yr nasdaq biotechnology index gain almost last trading session major biotech stock regeneron be gilead gild free report lose last month vertex vrtx free report be see last biotech stock roundup here amgen reiterate outlook intercept hit ocaliva safety issue next biotech world watch usual regulatory pipeline update hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
777,VRTX,vertex pharmaceutical incorporate vrtx free report announce datum study different triple combination regimen be evaluate treatment cystic fibrosis cf lead pronounce improvement lung function share company surge more hour trading follow announcement positive datum so far year vertex share have significantly outperformed zack classify medical biom genetic industry stock have gain compare increase register industry phase ii study evaluate vx mg vx mg phase study evaluate vx combination kalydeco tezacaftor treatment cf patient del mutation minimal function mutation del min primary endpoint study be improvement lung function measure percent predict force expiratory volume second ppfev measure volume air exhale second study meet primary endpoint study evaluate vx show mean absolute improvement point ppfev baseline week versus placebo study vx show absolute change point ppfev baseline average week measurement versus placebo vx regimen achieve mean improvement point baseline compare placebo datum demonstrated potential regimen treat underlie cause cf patient severe difficult treat type disease rather treat symptom also different regimen be well tolerate patient most adverse event be mild moderate severity company be also evaluate vx vx patient copy del mutation be already receive tezacaftor kalydeco combination initial datum show improvement mean absolute ppfev point vertex fourth next generation corrector development be vx phase ii triple combination combination kalydeco tezacaftor study vx be ongoing company expect initiate phase ii study vx early next month datum study be expect early thereafter discussion regulatory agency vertex initiate pivotal study more triple combination regimen first half remind investor vertex remain focuse cf treatment company have cf drug kalydeco orkambi market orkambi kalydeco together be approve treat approximately cf patient north america europe australia generate revenue first quarter together be higher year period successful completion triple combination study subsequent approval cf patient minimal function mutation also be eligible treatment vertex portfolio cf drug significantly boost vertex sale vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate price consensus vertex pharmaceutical incorporate quotezack rank key picksvertex currently carry zack rank strong buy other top rank stock health care sector be enzo inc exelixis inc exel free report therapeutic incorporate cort free report stock sport zack rank see complete list today zack rank stock here enzo loss estimate have narrow cent cent cent cent last day company come positive earning surprise last quarters average beat share price be so far year exelixis earning estimate remain stable cent moved cent cent last day company deliver positive earning surprise last quarters average beat stock be so far year earning remain stable cent moved cent cent last day company deliver positive earning surprise last quarters average beat stock be so far year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
778,VRTX,key highlight week include impressive datum vertex vrtx free report cystic fibrosis cf pipeline company gilead gild free report puma pbyi free report get fda approval hepatitis virus hcv breast cancer treatment respectively recap week most important storiesvertex cf datum impress vertex get major boost positive datum different triple combination regimen person cystic fibrosis cf have del mutation minimal function mutation del min be first datum show potential treat underlie cause cf patient have severe difficult treat type disease company be look start pivotal program first half vertex share be significantly pre market trading crl amgen ucb osteoporosis drug amgen amgn free report partner ucb get complete response letter crl fda evenity romosozumab investigational treatment postmenopausal woman osteoporosis however crl doesn come surprise consider emergence new safety signal late stage study arch evenity meet primary endpoint key secondary endpoint study company say imbalance positively adjudicate cardiovascular serious adverse event be observed fda have ask company include datum arch study resubmission well datum bridge study man osteoporosis read more amgen get crl osteoporosis drug evenity bla amgen be zack rank hold stock see complete list today zack rank strong buy stock here fda nod gilead hcv drug gilead have add drug hepatitis virus hcv portfolio fda grant approval vosevi single tablet regimen re treatment adult chronic hcv vosevi provide physician new therapeutic option hardest treat patient however vosevi come box warning regard risk hepatitis virus hbv reactivation hcv hbv co infected patient limit uptake gilead hcv franchise be major revenue generator be considerable strain due new competition pricing pressure company have underperform zack categorize medical biomedical genetic industry so far share gain industry be puma fda approval nerlynx puma gain fda approval breast cancer treatment nerlynx neratinib have blockbuster potential nerlynx first approve drug puma portfolio be indicated extend adjuvant treatment early stage breast cancer aggressive type tumor mean nerlynx be take initial treatment so risk cancer come back be reduce further nerlynx approval be line expectation consider favorable advisory panel vote earlier year puma share be news year date ytd puma share be whopping sarepta biomarin settle patent dispute sarepta srpt free report biomarin settle patent dispute regard use sarepta exondys future exon skip product treatment duchenne muscular dystrophy dmd company sign licensing agreement provide sarepta global exclusive right biomarin dmd patent estate exondys future exon skip product biomarin have option convert license co exclusive right decide proceed exon skip therapy dmd term deal include time payment sarepta well certain milestone base payment royalty sarepta share be biomedical genetic industry yr return medical biomedical genetic industry yr nasdaq biotechnology index be last trading session major biotech stock biogen biib free report be almost last month vertex be alexion alxn free report be see last biotech stock roundup here arena shoot study datum celg inks immuno oncology deal next biotech world watch earning report company biogen sarepta look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
779,VRTX,biotech industry have witness great turnaround year drug pricing issue cripple performance last year decline last year medical biotech genetic industry have rise year so far outpace gain same time frame nasdaq biotechnology index be almost year date slide zack industry rank be zack industry medical biom genetic indicate bright outlook sector go forward biotech sector have number thing go favor strong quarterly result new product sale ramp rise demand successful innovation product line expansion strong clinical study result more frequent fda approval continue strong performance legacy product have play pivotal role bring sector track year factor have contribute sector surge be president trump expect action drug price not be onerous previously fear factor continue drive sector rest year probably next well challenge rise competition pipeline setback slowdown growth mature product generic competition certain key drug broader macro front propose tax reform approve leave more cash hand company cash be invest merger acquisition have be relatively fewer year compare last biotech stock tear here have picked biggest biotech company look well poise growth be add portfolioamgen inc amgn free report amgen be lead biotechnology company world several blockbuster drug portfolio amgen newer drug prolium xgeva vectibix nplate sensipar be perform well amgen be also progress pipeline include biosimilar drug last month receive fda approval mvasi biosimilar version roche cancer drug avastin mvasi be first biosimilar approve unite state treatment cancer other recent positive pipeline regulatory development amgen include eu approval pediatric formulation mimpara positive long term datum kyproli endeavor study regulatory filing label expansion prolium kyproli other support positive development amgen share have outperformed industry so far year share have rise compare favorably industry gain amgen carry zack rank buy see complete list today zack rank strong buy stock here earning estimate have rise have go past day celgene corporation celg free report celgene key growth driver multiple myeloma drug revlimid continue drive revenue company meanwhile celgene label expansion effort revlimid bode well further sale growth drug other key product pomalyst imnovid abraxane otezla be also perform well recent positive development celgene be fda approval idhifa treatment adult patient relapse refractory acute myeloid leukemia aml celgene also carry zack rank earning estimate have rise past day stock have go year outperform industry biogen inc biib free report biogen have strong position multiple sclerosis market backed wide range product biogen be try diversify be look strengthen alzheimer disease ad other disorder pipeline newly launch spinraza spinal muscular atrophy be also promising start spinraza have witness faster expect adoption unite state biogen be ramp launch effort internationally recent key positive pipeline regulatory development biogen include promising long term dataon alzheimer disease candidate aducanumab eu approval imraldi biogen biosimilar version abbvie top selling blockbuster drug humira biogen have make several new executive appointment bring management team back track several key executive depart past couple year include ceo george scango cfo paul clancy biogen also rank stock have see earning estimate rise past day share have rise year other biotech company smaller mentioned company be worth mention vertex pharmaceutical incorporate vrtx free report have see share price shoot year so far earning estimate rise stock be ride high success cystic fibrosis cf pipeline particularly triple combination cf regimen have potential treat cf patient regeneron pharmaceutical inc regn free report see launch key pipeline candidate dupixent atopic dermatitis kevzara rheumatoid arthritis unite state year drug be also approve eu meanwhile regeneron key growth driver eylea continue drive revenue market share gain company be expand drug label additional indication regeneron share have rise year earning estimate have go vertex regeneron have be sporting zack rank strong buy quite time soon join league big biotech stock make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
780,VRTX,mallinckrodt plc mnk free report announce have acquire privately hold infacare pharmaceutical corporation specialty pharmaceutical company focus development proprietary pharmaceutical neonatal pediatric patient infacare product candidate stannsoporfin be expect become first only pharmacologic option treatment neonate severe severe jaundice approve company make upfront payment mallinckrodt be also require pay milestone payment acquisition be dilutive bottom line cent cent modestly higher estimate total number term birth be estimate year approximately infant be treat jaundice large number be unresponsive phototherapy hence be unmet need treatment infant combine potential patient treatment require annually unite state severe jaundice be approximately note mallinckrodt be currently focuse reshape product portfolio strategic acquisition core asset divestiture transform portfolio become high perform specialty pharmaceutical company acquisition diversify pediatric pipeline strengthen brand business company generic segment continue face weakness various product category be witness stiff competition be hurt volume price company expect double digit decline revenue segment addition continue expect weakness segment adversely impact gross profit margin also company sell nuclear imaging business due persistent challenge condition company also sell intrathecal therapy business focus key area acthar sale continue be strong back increase formulary position access appropriate patient commercial public environment sale therakos be expect decline investor interested healthcare sector consider stock stock include alexion pharmaceutical inc alxn free report regeneron pharmaceutical inc regn free report vertex pharmaceutical incorporate vrtx free report valuable pick make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
781,VRTX,swiss pharmaceutical company novartis ag nvs free report be schedule report second quarter result jul look novartis share price movement year date show stock have outperformed zack classify large cap pharma industry share have rally compare industry gain last report quarter novartis deliver positive earning surprise company have post average positive earning surprise trail quarters let see thing be shape announcement factor impact quarternovartis operate segment innovative medicine pharmaceutical alcon sandoz generic new product cosentyx entresto boost top line cosentyx have be strong company have grab market share rival abbvie abbv free report humira amgen amgn free report enbrel cosentyx achieve blockbuster status record sale novartis have broaden oncology portfolio acquisition fda recent approval kisqali use combination inhibitor first line treatment postmenopausal woman hormone receptor positive human epidermal growth factor receptor negative hr advanced metastatic breast cancer further boost company oncology portfolio meanwhile fda have also recently approve label expansion zykadia first line treatment patient metastatic small cell lung cancer additionally novartis generic arm sandoz be make effort strengthen biosimilar portfolio company plan launch biosimilar major oncology immunology biologic key geography company be however face significant pricing pressure due delay launch glatopa mg be expect impact second quarter result also exclusivity key drug novartis portfolio be hurt company top line company blockbuster drug diovan be face stiff generic competition eu japan gleevec lose exclusivity feb eu dec thereby lead generic competition exforge be also face generic competition eu furthermore oncology drug be face new competition form immuno oncology therapy negative impact generic competition be expect impact sale company ophthalmologic division alcon continue face challenge due lower surgical equipment sale stiff competition face intraocular lens slowdown demand equipment purchase continue act dampener do not expect improve trend division sale be report quarter earning whispersour proven model do not conclusively show novartis beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate unfortunately be not case here see zack esp earning esp novartis be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank novartis currently carry zack rank rank be favorable company esp make surprise prediction difficult note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision novartis ag price ep surprise novartis ag price ep surprise novartis ag quotestock considerhere be stock healthcare sector want consider model show have right combination element post earning beat quarter vertex pharmaceutical incorporate vrtx free report have earning esp zack rank company be schedule release result jul see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
782,VRTX,approach begin earning season be important remember earning estimate revision projection be extremely important determine zack rank quarterly earning report have ability greatly affect stock financial outlook company future potential zack customer utilize stock screener search company have consistently surprised beaten earning projection recent quarters company be constantly able defeat earning projection usually exhibit effective management stronger upward momentum more impressive future outlook many earning report begin be release check stock be project beat earning estimate once again quarter crescent point energy corporation cpg free report crescent point energy corporation be engage acquisition exploration development oil natural gas property western canada notably crescent point have demolish earning estimate past operational quarters whopping average not surprisingly company feature grade growth grade value style score system essence crescent point exhibit ample opportunity growth company be currently view undervalue crescent point pay shareholder impressive dividend yield be intriguing investor seek income stock furthermore crescent point hold project ep growth cash flow share compare favorably industry average respectively additionally company possess solid price sale ratio fare well industry average crescent point energy be recently promote zack rank strong buy vertex pharmaceutical incorporate vrtx free report vertex pharmaceutical incorporate discover develop market small molecule drug address major unmet medical need company have defeat earning estimate past operational quarters average additionally firm feature current earning esp mean vertex pharmaceutical be more likely surprise earning season also day vertex have witness full year ep estimate increase impressive vertex pharmaceutical possess grade growth grade momentum mean company hold excellent growth prospect share price have perform well recently fact vertex share price have increase past year vertex also boast astronomical project ep growth respectable project sale growth vertex pharmaceutical currently sit zack rank strong buy sodastream international ltd soda free report sodastream international be engage manufacture home beverage carbonation system enable consumer transform ordinary tap water carbonate soft drink sparkling water sodastream have beaten earning projection past operational quarters average additionally sodastream operate discretionary consumer product industry currently sit top zack industry rank company sport grade growth mean firm be anticipate continue expand sodastream feature current cash flow growth net margin defeat industry average respectively furthermore company boast excellent current ratio cash price ratio demolish industry average sodastream international be recently promote zack rank strong buy prior earning season commercial vehicle group inc cvgi free report commercial vehicle group inc supply interior system vision safety solution other cab related product global commercial vehicle market commercial vehicle group have defeat earning projection past operational quarters astounding average nevertheless company sport beta rating firm also belong group business top zack sector rank commercial vehicle share price have perform well recently increase whopping past year additionally company hold project ep growth price book ratio fare well industry average respectively finally commercial vehicle group support solid price sale ratio commercial vehicle group possess zack rank strong buy melco crown entertainment limit mlco free report melco crown entertainment limit be developer owner operator casino gaming entertainment casino resort facility primarily asia similarly melco crown have be consistent beating earning estimate have accomplish feat past operational quarters average also day melco crown full year ep estimate be revise increase melco crown pay shareholder respectable dividend yield company boast project sale growth cash flow share compare favorably industry average respectively melco crown entertainment limit be recently promote zack rank strong buy more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
